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Ten years ago, I started my medical training with the intention of becoming a neurologist. 
I was intrigued by the mysterious function of the brain. Sometimes however, our actual life 
paths differ from our expectations. During the second year of my medical training, my dad 
was diagnosed with pancreatic cancer. Cancer. Metastatic. Incurable. Hearing that diagnosis 
changed my life path. I was determined to become a medical oncologist.
 This thesis combines my interest in neurology, my passion for oncology, and my love 
for science. During my dad his illness, his cognition was influenced by the cancer, the 
chemotherapy, the pain killers, and all psychological factors that accompanied his cancer 
diagnosis and disease process. During this period, he painted the illustration that I used as the 
cover of this thesis. This painting is based on a photograph of me horse riding on the beach 
of Texel. The first horse rider is the leader of the group that is shown at the end of the original 
painting. I am the second horse rider, the one who is not completely painted yet. I am just a 
sketch. He did not have enough time left to finish the painting.
 Throughout this thesis you will find more of his illustrations. Although the illustrations do 
not complement the text of this thesis, sometimes – just like in research – you have to work 
with what you have.







Oncology – the study ‘logos’ of the tumour ‘ónkos’
‘A bulging tumour of the breast. Treatment: none.’
These words mark the first description of cancer that originates from Ancient Egypt 3000 
years Before Christ. For many years, prominent historical physicians including Hippocrates – 
who introduced the term ‘karkinos’ (Latin: cancer) based on the shape of a crab – and Galenus 
– who proposed the term ‘ónkos’ (Latin: onco) – have been intrigued by tumours.1 Also famous 
artists such as Rubens and Rembrandt were probably fascinated by this disease, because 
they spent many hours illustrating the appearance of tumours on their canvas.2,3 Despite 
many efforts, it took almost five thousand years after this first known description before the 
first effective cancer-specific treatment – apart from mutilating surgery – was discovered: 
radiotherapy.4 Since this discovery, the options of cancer treatment have further been 
expanded with chemotherapy,5 hormonal therapy,6,7 and more recently with immunotherapy.8 
Improvements in cancer treatments are necessary, because the number of cancer patients is 
growing considerably due to ageing populations worldwide.
 In 2017, 16.8 million persons worldwide were diagnosed with cancer and 9.6 million 
persons died of cancer, making cancer the second leading cause of death.9 Advances in 
screening methods and improvements in treatments have ensured longer survival of cancer 
patients, which in turn has led to higher rates of long-term and late side effects, both of cancer 
itself as well as of the aggressive treatments.10 Such side effects include fatigue, infertility, 
secondary tumours, and cardiovascular diseases. In addition, cognitive problems are amongst 
the most frequently reported complaints by cancer patients and survivors that can negatively 
impact their quality of life and daily life functioning.11-13
Neurology – the study ‘logos’ of the nerve ‘neûron’
Many persons have been intrigued by the complexity of the brain and its relation with behaviour, 
including Hippocrates, who referred to the brain as ‘the organ of the intellect’, the centre of 
all mental functions.14 Diseases of the brain and spinal cord, i.e., the central nervous system 
(CNS), can manifest in different ways, such as epilepsy, multiple sclerosis, stroke, Parkinson’s 
disease, and cognitive problems. Cognitive problems refer to disruptions in mental functions, 
including memory, learning, attention, concentration, executive functioning, and information 
processing speed. 
 Cognitive function declines gradually during brain ageing. Accelerated decline in 
cognitive function can result in cognitive impairment and may reflect the preclinical phase 
of neurodegenerative diseases, including dementia. The increase in life expectancy has not 
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only resulted in a higher number of cancer patients, but has also led to a growing number 
of patients with dementia. At present, around 50 million persons worldwide are living with a 
dementia diagnosis, and almost 10 million persons are diagnosed with dementia every year.15 
 Although many studies have shown that cancer patients often have impaired cognitive 
function, their trajectory of change in cognitive function and their risk of dementia remain poorly 
understood. It has been proposed that cognitive function declines shortly after diagnosis and 
treatment and then parallels the trajectory of cognitive function in persons without a history of 
cancer (phase shift hypothesis) or that decline in cognitive function is accelerated in comparison 
to cognitive function in persons without a history of cancer (accelerated ageing hypothesis). 
Longitudinal, population-based studies are needed to explore these hypotheses.16 
Epidemiology – the study ‘logos’ of what is upon ‘epi’ the people ‘demos’
Although modern epidemiology has been established from the 1980s onwards, Hippocrates 
already contributed to the foundation of epidemiology by studying the frequency of diseases 
and the causes of variation in this frequency. He focused however on the individual patient, 
rather than studying a group of patients. This touches upon an important epidemiological 
principle, i.e., group thinking.17 Group thinking is a mode of conceptualising issues for a 
whole group of persons, i.e., the population. At a population-level, we can compare groups by 
contrasting what is observed in the group in presence of the exposure to what is occurred in 
the group that has not been exposed.
 The aim of this thesis is to understand the origin and course of cognitive decline in 
cancer patients and survivors, their risk of dementia, and the mechanisms underlying these 
cognitive problems and dementia. The focus will be on comparing the cognitive function in 
cancer patients and survivors (exposed persons) to that in persons without a history of cancer 
(unexposed persons) at a population-level. In order to do so, the work presented in this thesis 
studies participants from the Rotterdam Study, a prospective population-based cohort study 
that was established in 1989 to study the occurrence and determinants of common diseases 
in the elderly. This thesis is divided into five Parts, which I will introduce in more detail.
Part I – Cancer registration
Before investigating cognitive function in cancer patients, it needs to be determined whether 
data on cancer events in the Rotterdam Study is complete and accurate. Lack of perfection 
in data collection may lead to an incorrect estimate of the true effect.18 The Rotterdam Study 
collects data on cancer events using medical records of general practitioners and through 
linkage with the national hospital discharge registry and histology and cytopathology registries. 
To determine the completeness and accuracy of cancer registration in the Rotterdam Study, 
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Chapter 2 compares the registered cancer events in the Rotterdam Study to those in the 
Netherlands Cancer Registry. The Netherlands Cancer Registry is the oncological hospital 
registry in the Netherlands that collects data about all cancer patients. Cancer events in the 
Rotterdam Study were updated according to the results of this comparison in order to achieve 
accurate and complete cancer registration and to minimise measurement error. Chapter 3 
subsequently focuses on a specific group of cancers that are often missed by cancer registries: 
cancers that are not confirmed by pathology. Apart from pathological confirmation, patients 
with non-pathology-confirmed cancers have undergone the same extensive diagnostic work-
up as patients with pathology-confirmed cancers. To estimate whether missing data on these 
cancer events may influence cancer statistics and may bias aetiological studies, this Chapter 
determines the characteristics and survival of patients with non-pathology-confirmed cancers.
Part II – Cancer and cognition
We have known for many years that patients with CNS cancer can develop cognitive 
problems.19 These cognitive problems can be caused by local damage due to the tumour itself 
or by the harmful effects of cancer treatment on healthy brain tissue. In the early nineties, 
several neuropsychologists and oncologists noticed that also patients with cancer outside 
the brain – non-CNS cancer – experienced cognitive problems. Since then, the number of 
scientific publications on cognitive function in cancer patients has increased substantially 
(Figure 1). These studies have shown that about 20% to 30% of all non-CNS cancer patients 
have cognitive problems, with a subgroup of non-CNS cancer survivors having long-term 
















































Figure 1 Number of scientific publications per year on cognition and cancer. 
Numbers are obtained from the PubMed library using the search terms “cancer” and (“cognition” or 
“chemobrain”) not (“brain tum*” or “glioma” or “mening*” or “brain met*”).
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 Research has primarily been directed to chemotherapy as the driving force behind 
disturbances in the normal function of the brain, dubbed by some cancer survivors as 
‘chemobrain’. Different mechanisms for chemotherapy-induced cognitive problems have 
been suggested and revealed, including toxicity to neural progenitor cells, DNA damage 
in post-mitotic neurons and telomere shortening, deregulation of cytokines, and hormonal 
changes.21,22 However, studies that have examined the consequences of chemotherapy on 
brain function were often cross-sectional and could therefore not provide information about 
the baseline cognitive function in cancer patients.23
 More recent longitudinal studies have incorporated baseline assessments of cognitive 
function after surgery and before initiation of systemic adjuvant treatment. These studies have 
revealed that chemotherapy may not be the only cause of cognitive problems, because some 
patients had lower than expected cognitive function before they received chemotherapy.24-27 In 
addition, imaging studies have shown that before patients received chemotherapy, some had 
altered brain structure and function, including lower white matter integrity and hyperactivation 
of different brain regions, in particular the frontal and parietal lobes.28-32 Hyperactivation is often 
seen as a compensatory mechanism to maintain adequate levels of test performance during 
inadequate functioning of the brain.33 Changes in brain functions were not fully explained by 
anxiety, depression, or fatigue. However, the time of study entry may not be appropriate, as 
the impact of anaesthesia and side effects of surgery could also induce changes in cognitive 
function. 
 Less is known about cognitive function in cancer patients prior to surgery. Thus far, seven 
studies have assessed cognitive function in newly diagnosed cancer patients.34-40 Interestingly, 
these patients also showed worse neuropsychological test performance than cancer-free 
controls and had alterations on brain magnetic resonance imaging (MRI) scans. Preclinical 
support for this observation comes from studies that have shown that immunodeficient mice 
engrafted with patient tumour tissue had molecular changes in the brain similar to those 
seen in neurodegeneration and brain ageing.41,42 This suggests that cancer itself may induce 
changes in the normal function of the brain, although clinical studies cannot fully exclude 
psychological factors that accompany a new cancer diagnosis. 
 Besides the role of cancer itself, cognitive problems in newly diagnosed cancer patients 
could also be explained by a shared pathology. For instance, genetic susceptibility, 
inflammation, and oxidative stress are processes related to cancer and cognitive decline.43,44 
Furthermore, shared risk factors such as ageing, smoking, lack of physical activity, and a 
poor diet, could also play a role in the development of both conditions. The potential different 











Figure 2 Overview of the potential causes of cognitive problems in cancer patients.
 In this Part, Chapter 4 first describes the change of cognitive function in the general 
population between the ages of 45 and 90 years. Understanding the natural course of 
cognitive function during ageing is necessary to identify persons who deviate from the mean 
trajectory of decline. This standard could therefore be used to contrast the trajectory of 
cognitive function in patients with cancer. Chapter 5 subsequently delineates the change in 
cognitive function in cancer patients before they are diagnosed with cancer. In the Rotterdam 
Study, participants are invited to visit the research centre every three to six years to undergo 
several examinations including cognitive function assessments. Some of these participants 
will eventually be diagnosed with cancer. This enables us to investigate their cognitive function 
before the clinical manifestation of cancer, thereby excluding the psychological effects of a 
new cancer diagnosis. The underlying hypothesis is that if the cancer itself can affect cognitive 
function, cognitive function would already be altered before the diagnosis of cancer, because 
the time between the first cancer cell and clinical manifestation of the disease ranges between 
five and forty years for solid tumours (Figure 3).45 Also based on this hypothesis, Chapter 
6 investigates the brain structure of patients before their cancer diagnosis using brain MRI. 
Lastly, Chapter 7 investigates the change of cognitive function from before cancer diagnosis 




Figure 3 Preclinical phase of cancer.
Cancer cells can be present in the body years before the cancer is diagnosed (i.e., latency period). During 
this period, cancer cells can produce different factors that may affect the brain. Therefore, cognitive 
function and brain structure might already be affected before a person is diagnosed with cancer.
Part III – Cancer and dementia
Since a shared pathology between cognitive problems and cancer has been hypothesised 
and given that dementia is preceded by cognitive decline, a logical question emerges whether 
cancer and cancer treatment are also associated with a higher risk of dementia. Cancer and 
dementia share different biological processes, including inflammation, oxidative stress, DNA 
damage, and angiogenesis which may support a higher risk of dementia in cancer patients 
and survivors.46 In contrast to these expectations, a substantial body of literature suggests 
an inverse link between cancer and dementia, i.e., in comparison with healthy persons, 
cancer patients have a lower risk of dementia, and patients with dementia have a lower risk of 
subsequently being diagnosed with cancer.46-62 
 The first study on the link between cancer and dementia originates from 1990, in which 
Yamada et al. investigated risk factors for dementia in atomic-bomb survivors.60 They have 
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observed that the odds of having cancer prior to Alzheimer’s disease (AD), the most common 
type of dementia, was 70% lower in patients with AD than in persons without AD. More than 
a decade later, longitudinal studies have confirmed that cancer patients had a lower risk of 
developing dementia than persons without a history of cancer. These studies have also shown 
that patients with dementia were less likely to be diagnosed with cancer than persons without 
dementia. These findings suggest an inverse association between cancer and dementia 
in both directions. This inverse association was observed for most cancer types, including 
non-melanoma skin cancer, and was consistent across different studies. An overview of 
the individual studies investigating this association is provided in Table 1 at the end of this 
Chapter. 
 In addition to the role of cancer itself, few retrospective studies have evaluated the effect 
of chemotherapy on dementia in breast cancer survivors.63-66 All these studies have used data 
from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database. 
For this reason, the outcomes cannot be interpreted as independent. Nevertheless, these 
studies have demonstrated contrasting results with only one study showing a higher incidence 
of dementia in patients treated with chemotherapy than in patients without chemotherapy 
treatment.65 Comparison of the risk of dementia in cancer survivors after chemotherapy with 
the dementia risk in cancer-free controls showed again an inverse association.64
 Multiple biological mechanisms have been proposed supporting this inverse association 
between cancer and dementia in both directions. Promotion of genetic pathways involved 
in cell proliferation and survival could result in an increased cancer risk, while dementia is 
associated with increased cell death. For instance, the expression of the tumour suppressor 
protein p53 is often decreased in cancer, whilst elevated in AD brains.67 Furthermore, the 
enzyme pin1 is involved in protein folding and cell cycle regulation, and is often overexpressed 
in tumours whereas it is depleted in AD. Other candidate processes are opposite disturbances 
of the epigenome and ultraviolet radiation exposure.58,68
 Despite consistent results and suggested biological mechanisms, several methodological 
issues potentially driving this inverse association have not completely been ruled out. 
Therefore, careful interpretation and critical evaluation of the observed link is needed. Cancer 
and dementia are accompanied by multiple symptoms, which can mask symptoms of other, 
yet undiagnosed diseases. Additionally, physicians could be less willing to refer diseased 
patients, resulting in surveillance bias. Also, studying diseases in the older population may be 





Box 1 Surveillance bias.
Surveillance bias arises when patients with a certain disease undergo more or less 
intensive disease screening, resulting in a respectively higher or lower probability to be 
diagnosed with the studied outcome.69 Patients with cancer or dementia may be less likely 
to be screened and diagnosed with other diseases. Several observations support this 
conception.
 Firstly, patients with dementia are not always able to communicate symptoms such as 
pain.70 This is supported by the finding that cancer in dementia patients is often diagnosed 
in a more advanced stage than in persons without dementia, since pain is an important 
symptom of a variety of cancers.71 In turn, symptoms of comorbid diseases in cancer 
patients may be attributed to cancer, leaving the other underlying disease unrecognised.72 
Secondly, when a patient has a serious illness with a limited life expectancy, physicians 
may be less prepared to start a diagnostic work-up for new symptoms. In the case of 
dementia, patients undergo less often screening for cancer.73,74 Also, it can be difficult for 
these patients to understand the risks and benefits of screening and the benefits may not 
outweigh the harms such as overdiagnosis and overtreatment.75 A study under elderly care 
physicians in nursing homes has shown that end stage dementia was the primary reason 
not to refer patients with suspected breast cancer.76 In cancer patients, cognitive problems 
remain often unrecognised, because cognitive assessment is not standard practice.77 
Thirdly, when a dementia patient is suspected to have cancer, pathological confirmation 
through biopsies is often omitted since it does not have therapeutic consequences.78 
Several studies have demonstrated that patients with dementia and cancer often do not 
receive cancer treatment.71 Since many cancer registries only register pathology-confirmed 
tumours, these tumours will remain unnoticed.79
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Box 2 Survival bias.
Survival bias is considered as a special case of selection bias and may occur when the 
studied exposure is associated with survival.80 When the exposure negatively influences 
survival, those exposed persons who will survive are likely to have some other, protective 
characteristics helping them to survive. This results in a lower frequency of the exposure 
among the survivors, which can be observed as an inverse association between the 
exposure and outcome. Figure 4 shows an illustration of non-medical survival bias.81
 Both cancer and dementia are potentially fatal diseases and can affect survival. 
Survival rates for patients with cancer differ per cancer type and depend on the stage at 
diagnosis.82 For dementia, the median overall survival depends on the age of the patient 
and ranges between 6.0 years for persons aged below 75 years, and 3.5 years for those 
aged over 85 years.83 Importantly, patients who have developed both cancer and dementia 
have a higher overall mortality and disease-specific mortality than patients with only one of 
these conditions.84 This suggests that survival bias could affect estimates of the association 
between cancer and dementia, resulting in lower exposure rates among the diseased (i.e., 
lower numbers of prevalent cancer diagnosis in patients with dementia, and less diagnoses 
of dementia before cancer development).
Figure 4 Illustration of survivor bias during World War II.
During World War II, researchers studied the damage done to army planes that had returned from 
missions. To reinforce the planes, they recommended to add additional armour on those places that 
showed most damage: the wings and tail (pink dots). The statistician Abraham Wald noticed that the 
researchers only investigated planes that had returned from their missions (survivors). The planes that 
had been lost during the missions were not observed (non-survivors). Therefore, the unscathed parts – 
the engines – instead of the damaged parts needed to be reinforced (image shows hypothetical data).
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 Different studies have tried to overcome surveillance and survival bias. For instance by 
restricting the analyses to persons who survived to at least the age of eighty years,48,49 by 
studying the relation between cancer and negative control diseases such as automobile injuries 
and stroke,49-51 and by focussing on different cancer types and stages.46-48,50-53 Despite these 
strategies, the potential effects of surveillance and survival bias have not been satisfactory 
ruled out. 
 This thesis provides an alternative approach to elucidate the biological link between 
cancer and dementia. First, Chapter 8 studies AD as a multistep process using multistage 
models. These models have frequently been used in cancer research to gain more insight in 
the number of steps (mutations) needed before manifestation of the cancer. If AD complies 
with the multistep process, this could support that AD and cancer follow a similar biological 
process. Next, the Chapters 9, 10, and 11 focus on the preclinical stages of one disease – 
either cancer or dementia – and link it to the other disease. Preclinical stages of the disease 
share often the same biological underpinnings as the clinically manifested disease. If there is 
a biological link between cancer and dementia, this should extent across all preclinical stages 
of the diseases. Persons who have a preclinical stage of one of these diseases have often a 
longer life expectancy than those with clinically manifested disease. Therefore, studying the 
preclinical stage of one disease and linking it to the other disease can provide more insight in 
the biological relation between cancer and dementia by circumventing the effects surveillance 
and survival bias. Chapter 9 describes the relation between mild cognitive impairment – a 
preclinical stage of dementia – and the risk of cancer. Chapter 10 subsequently determines 
the relation between plasma amyloid-β – one of the earliest detectable changes in preclinical 
dementia – and the risk of cancer. Next, Chapter 11 examines the relation between the tumour 
marker carcinoembryonic antigen as proxy for preclinical cancer and the subsequent risk of 
dementia. Lastly, Chapter 12 presents alternative methods that can deal with selection bias 
to further examine the relation between cancer and dementia.
Part IV – Underlying mechanisms
To be able to develop prevention and intervention strategies for cognitive problems in cancer 
patients, it is necessary to understand the mechanisms by which cancer and cancer treatment 
can lead to disruptions in cognitive function. Proposed underlying mechanisms are the 
release of extracellular vesicles, inflammation, oxidative stress, vascular changes, changes in 
hormonal levels, and telomere shortening (Figure 5).21,85 These mechanisms are partly based 
on the biological similarities between cancer and dementia.86 As yet, it is unknown whether 
these mechanisms have already a role before clinical manifestation of cancer, and whether 
these mechanisms underlie late cognitive problems and dementia in cancer patients. This 
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thesis explores the role of the following two proposed mechanisms: inflammation and vascular 
factors. 
 Exact quantification of chronic systemic inflammation is often challenging. Well-known 
markers of inflammation have different limitations. For instance, C-reactive protein is not 
only elevated during chronic inflammation, but also during acute inflammatory processes, 
and the erythrocyte sedimentation rate is a non-specific measure of inflammation. Cytokines 
are more specific, but exact quantification is limited because of the wide variety of cytokine 
panels and the high costs. Recent evidence has suggested the use of easily obtainable 
measures of blood cells that can capture chronic systemic inflammation and have reliable 
prognostic and predictive value in cancer patients.87-92 These blood cells are the neutrophils, 
lymphocytes, and platelets. In cancer, higher levels of neutrophils and platelets are associated 
with promotion of tumour growth and metastasis, whereas higher levels of lymphocytes are 
associated with tumour growth inhibition.93,94 The measurements of these blood cells can be 
combined into ratios, i.e., the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and 
systemic immune-inflammation index. Chapter 13 studies the levels of these inflammatory 
ratios in relation to cognitive function in breast cancer survivors who were treated with surgery, 
radiotherapy, and chemotherapy on average twenty years ago. Chapter 14 subsequently 
focuses on the same inflammatory markers in preclinical stage of dementia. In these studies, 
the granulocyte count is used as proxy for the neutrophil count.
 Next to inflammation, cancer and cancer treatment can induce vascular changes such as a 
hypercoagulable state, atherosclerosis, and injury to cardiac myocytes.95,96 Because of these 
vascular changes, cancer patients are often at a higher risk of developing thromboembolic 
complications and cardiovascular diseases than persons without a history of cancer.97-99 
Less is known about vascular changes before cancer diagnosis. Chapter 15 contributes 
to this understanding by studying the presence of atherosclerotic calcification in the aortic 
arch – as proxy for systemic atherosclerosis – and the subsequent risk of cancer. Vascular 
changes might result in altered brain perfusion, which in turn can lead to long-term cognitive 
problems.100,101 Chapter 16 therefore evaluates atherosclerotic carotid disease and brain 
perfusion in breast cancer survivors on average twenty years after cancer treatment. 
Part V – General discussion
In this last Part, I summarise the main findings of this thesis in the context of current 
knowledge on cognitive problems and dementia in non-CNS cancer patients. In addition, I 
discuss methodological considerations, define the implications of these findings, and provide 























Effects of cancer treatment
Figure 5 Overview of different mechanisms underlying cognitive problems in cancer patients. 
Cancer might lead to differences in extracellular vesicles (blue background). Inflammation, oxidative 
stress, and vascular changes can be induced by both cancer and cancer treatment (green background). 
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Background Complete and accurate registration of cancer is needed to provide data on 
cancer incidence and to investigate aetiology. Such data can be retrieved from national 
registries, but also from large population-based cohort studies. Yet, the concordance and 
discordance between these data sources remain unknown.
Methods We evaluated completeness and accuracy of cancer registration by studying the 
concordance between the population-based Rotterdam Study and the Netherlands Cancer 
Registry between 1989 and 2012 using the independent case ascertainment method. We 
compared all incident cancers in participants of the Rotterdam Study (aged 45 years and 
older) to registered cancers in the Netherlands Cancer Registry in the same persons based 
on the date of diagnosis and the International Classification of Diseases (ICD) code.
Results In total, 2977 unique incident cancers among 2685 persons were registered. Two 
hundred eighty-eight cancers (9.7%) were coded by the Rotterdam Study that were not 
present in the Netherlands Cancer Registry. These were mostly non-pathology-confirmed 
lung and haematological cancers. In addition, 116 cancers were coded by the Netherlands 
Cancer Registry, but not by the Rotterdam Study (3.9%), of which 20.7% were breast cancers. 
Regarding pathology-confirmed cancer diagnoses, completeness was more than 95% in both 
registries. Eighty percent of the cancers registered in both registries was coded with the same 
date of diagnosis and ICD code. Of the remaining cancers, 344 (14.5%) were misclassified 
with regard to date of diagnosis and 72 (3.0%) with regard to ICD code.
Conclusions Our findings indicate that multiple sources on cancer are complementary and 
should be combined to ensure reliable data on cancer incidence.
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INTRODUCTION
With an estimated number of 3.9 million new diagnoses and 1.9 million deaths from cancer 
in Europe in 2018, cancer poses a huge burden on societies.1 Optimal cancer registration is 
not only crucial to provide reliable estimations of incidence and mortality,2 but is also pivotal 
to better understand risk factors of cancer.3 Extensive quality checks are performed before 
cancer registry data are accepted in Cancer Incidence in Five Continents, the reference 
source of data on international cancer incidence.4 However, the number of validation studies 
of cancer registries is limited.
 Methods to assess completeness and accuracy of cancer registries can be classified 
into two categories, i.e., qualitative and quantitative methods.5 Qualitative methods include 
comparison of performance of a cancer registry with other registries, such as comparison with 
historical data or other populations. In contrast to qualitative methods, quantitative methods 
including independent case ascertainment, flow method, or capture-recapture methods 
provide a numerical evaluation of the extent to which all eligible events are registered and are 
therefore more appealing.
 Several studies have compared cancer registries in Europe using quantitative methods.6-17 
In the Netherlands, the Netherlands Cancer Registry managed by the Netherlands 
Comprehensive Cancer Organisation (IKNL) registers cancers nationwide and provides 
information regarding cancer incidence, prevalence, risk, mortality, and survival of cancer.18 
Completeness of registration by the Netherlands Cancer Registry has been estimated at 
98.7% in 1990 based on cancers registered by general practitioners.6 A second evaluation 
in 1993 has shown completeness of 96.2%.7 However, the potential added value of a large 
prospective population-based cohort study to the completeness and accuracy of cancer 
registration by the national cancer registry has not been evaluated. 
 Therefore, in this study, we investigated the concordance of cancer registration by the 






This study is embedded within the Rotterdam Study, an ongoing population-based cohort 
study in Rotterdam, the Netherlands, designed to study the occurrence and determinants 
of diseases in the elderly population. Besides cancer, the Rotterdam Study focuses on the 
aetiology, prediction, and prognosis of cardiovascular, endocrine, hepatic, neurological, 
ophthalmologic, psychiatric, dermatological, otolaryngologic, locomotor, and respiratory 
diseases. The Rotterdam Study started in 1989 with 7983 participants (response of 78%) 
aged 55 years and older and residing in the district Ommoord, a suburb of Rotterdam. This first 
subcohort (RS-I) was extended with a second subcohort (RS-II) in 2000, consisting of 3011 
participants (response of 67%) and with a third subcohort (RS-III) in 2006, composed of 3932 
participants aged 45 years and older (response of 65%). The design of the Rotterdam Study 
has been described in detail.19 In total, the Rotterdam Study comprises 14 926 participants 
aged 45 years and older at study entry. 
 The Rotterdam Study has been approved by the Medical Ethics Committee of Erasmus 
Medical Centre and by the board of The Netherlands Ministry of Health, Welfare, and Sports. 
A written informed consent was obtained from all participants. 
Assessment of cancer
The Rotterdam Study
Diagnosis of incident cancer is based on medical records of general practitioners (including 
hospital discharge letters) and furthermore through linkage with the national hospital 
discharge registry (Landelijke Medische Registratie [LMR]) hosted by Dutch Hospital Data 
and histology and cytopathology registries in the region (part of the nationwide network 
PALGA). Cancer diagnosis is coded independently by two physicians and classified according 
to the International Classification of Diseases, 10th revision (ICD-10). In case of discrepancy 
between sources, consensus is sought through consultation with a physician specialised in 
internal medicine. Date of diagnosis is based on the pathology date, or – if unavailable – 
date of hospital admission or hospital discharge letter. Level of uncertainty of diagnosis is 
established as: certain (pathology-confirmed), probable (e.g., based on imaging features or 
elevated tumour markers without pathological confirmation), and possible (e.g., based on 
symptoms and physical examination, or suspicion based on imaging features or elevated 
tumour markers without pathological confirmation). Possible cancers were not included in the 
current study. Registration of cancer diagnoses is completed up to January 1st, 2013. 
Concordance of cancer event registration
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The Netherlands Cancer Registry
The Netherlands Cancer Registry is a population-based cancer registry with nationwide 
coverage since 1989. Cancer diagnoses are notified by the nationwide network and registry 
of histology and cytopathology (PALGA) and in addition through linkage with the LMR 
hosted by Dutch Hospital Data. Each cancer is coded by trained registration clerks (internal 
education of one year) according to the International Classification of Diseases for Oncology, 
3rd edition (ICD-O-3) based on information gathered from medical files at the hospital. Date 
of diagnosis is coded according to international coding rules and mostly based on the date of 
first pathological confirmation, or – if unavailable – date of first hospital admission. In addition, 
information about tumour histology, tumour stage, and primary treatment was retrieved.
Linkage
All persons from the Rotterdam Study (N=14 926) were linked with patients in the Netherlands 
Cancer Registry based on the following characteristics: date of birth, sex, birth name, initials, 
zip code, and – if applicable – date of death. If a participant had multiple zip codes due 
to moving, historical zip codes were also included. All data were pseudonymised using a 
double-pass procedure beforehand. Data exchange took place between secured encrypted 
data servers. All cancers diagnosed between 1989 and 2012 were included. To make an 
equal comparison between the two cancer registries, we excluded the following cancers: 
cancers diagnosed before entry in the Rotterdam Study or after January 1st, 2013, cancers 
solely coded as cause of death, skin cancers (due to different registration methods), benign 
or borderline tumours, and carcinomas in situ other than ductal carcinoma in situ of the breast 
(Figure 1). 
 If a cancer was only coded by the Rotterdam Study or the Netherlands Cancer Registry 
(unmatched cancers), we performed a second linkage with previously excluded cancers (i.e., 
for instance, date of diagnosis prior to study entry or cancer solely registered as cause of 
death). In case of multiple cancers per patient, we included all different cancers.
 We were interested in (i) the completeness and; (ii) the accuracy of both registries. Since 
we do not know the true number of cancers in the study population, we defined completeness 
as the proportion of cancers in one registry in relation to the total number of cancers coded 
by at least one of the registries. Completeness was determined for pathology-confirmed 





Figure 1 Flowchart of matched and unmatched cancers after linkage between Rotterdam Study 
and Netherlands Cancer Registry.
* Cancer as cause of death corresponds to cancer solely coded as cause of death, without a date of 
incident cancer diagnosis. † Five cancers were both misclassified with regard to date >1 month and <1 
year and with regard to ICD code. Therefore, the number of matched cancers is lower than the total 
number of cancers in the different misclassification categories. ‡ A second linkage was performed to 
preclude whether unmatched cancers were present in both databases, but were excluded prior to the 
linkage of cancers based on the exclusion criteria. 
DCIS = ductal carcinoma in situ, ICD = International Classification of Diseases.
 
Cancers in Rotterdam Study
(n=6162)
Excluded:
• Date of diagnosis before study entry (n=840)
• Date of diagnosis after January 1st, 2013 (n=735)
• Skin cancer (n=640)
• Carcinoma in situ except DCIS (n=149)
• Benign/borderline tumours (n=73) 
Included cancers (n=2806)




• Date of diagnosis before study entry (n=1057)
• Cancer as cause of death* (n=136)
• Skin cancer (n=2163)
Linkage of cancers
Matched cancers† (n=2376) Unmatched cancers (n=601)
• Only in Rotterdam Study (n=430)
• Only in Netherlands Cancer registry (n=171)
• Only in Rotterdam Study (n=288)
• Only in Netherlands Cancer registry (n=116)
Second linkage with excluded cancers‡
• Date of diagnosis before study entry (n=12)
• Cancer as cause of death* (n=29)
• Misclassification of skin cancer (n=18)
• Misclassification of carcinoma in situ (n=119)
• Misclassification of benign tumour (n=19)
Rotterdam Study
(N=14 926)
Linkage of participants 
Rotterdam Study Netherlands Cancer Registry
• Matched date and ICD code (n=1965)
• Misclassification date >1 month and <1 year 
(n=324)
• Misclassification date >1 year (n=20)
• Misclassification ICD code (n=72)
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 Accuracy of the date of cancer diagnosis and ICD code was investigated for cancers that 
were present in both registries (matched cancers). We digitally converted the ICD-O-3 codes 
into ICD-10 codes. These matched cancers were classified into the following categories: 
matched date of diagnosis (difference in date of diagnosis of one month or less) and ICD 
code, misclassification of date of diagnosis (two categories: (i) difference in date of diagnosis 
of more than one month but less than one year; and (ii) difference of more than one year), or 
misclassification of ICD code (different ICD code and different organ system). An overview 
of the different ICD-10 codes used for the categorisation into different organ systems is 
presented in Supplementary Table 1.
 Unmatched cancers only coded by the Rotterdam Study and cancers misclassified with 
regard to date of diagnosis or ICD code were reassessed through evaluation of the patient’s 
original medical files collected by the Rotterdam Study.
Statistical analyses
Differences in patient characteristics were evaluated using an independent samples t test 
(continuous variables) or a chi-square test (categorical variables). Two-sided P<.05 was 
considered statistically significant. Statistical analyses were performed using SPSS and the 
‘UpSetR’ package from R software Version 3.3.2.20
RESULTS
In the same source population based on 14 926 participants of the Rotterdam Study, 2806 
incident cancers among 2579 persons were coded by the Rotterdam Study and 2547 cancers 
among 2342 persons were coded by the Netherlands Cancer Registry (Figure 1). Linkage of 
the two registries resulted in a total of 2977 unique cancers among 2685 persons.
 
Completeness of registries
After the first linkage, 2376 cancers among 2227 persons were coded by both registries. The 
remaining 601 unmatched cancers were coded solely by one of the two registries, of which 
197 cancers could eventually be matched after a second linkage with previously excluded 
cancers. This resulted in 288 cancers (9.7%) among 284 persons coded solely by the 
Rotterdam Study, of which 105 cancers (36.5%) were pathology-confirmed. Furthermore, 116 
cancers (3.9%) among 115 persons were coded solely by the Netherlands Cancer Registry, of 
which 109 cancers (94.0%) were pathology-confirmed. Taking only cancers after the second 
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linkage into account, the Rotterdam Study had a completeness of 95.8% (2664 out of 2780 
cancers) and the Netherlands Cancer Registry of 89.6% (2492 out of 2780 cancers) of all 
cancers. Regarding pathology-confirmed cancers (2475 cancers), completeness was 95.3% 
in the Rotterdam Study and 95.2% in the Netherlands Cancer Registry. Completeness of non-
pathology-confirmed cancers (305 cancers) was 97.7% in the Rotterdam Study and 40.0% in 
the Netherlands Cancer Registry.
 Persons with matched cancer diagnoses were significantly younger at baseline and at 
first cancer diagnosis than those coded solely by the Rotterdam Study (P<.001 and P<.001, 
respectively) or by the Netherlands Cancer Registry (P<.001 and P<.001, respectively, Table 
1). 
 Cancer sites that were most frequently registered by both registries were gastric and 
oesophagus (93.4% of all these cancers were included in both registries), head and neck 
(91.0%), and male genital organs (90.0%, Table 2). Lung and mesothelioma was the most 
common cancer site among cancers coded solely by the Rotterdam Study (20.5% of all cancer 
cases solely coded by the Rotterdam Study). 
 Haematological cancer represented the second most frequent diagnosis that was coded 
solely by the Rotterdam Study (16.0%), of which chronic lymphocytic leukaemia was the most 
common diagnosis (39.1%). The distribution of different cancer sites among cancers coded 
solely by the Netherlands Cancer Registry was comparable to the distribution among the 
matched cancers, with breast as the most frequently diagnosed cancer site (20.7%). One-
third of all cancers solely coded by the Netherlands Cancer Registry were second primary 
cancers of the same cancer site, with the highest numbers for breast (75.0%) and colon 
cancers (56.3%).
Accuracy of registries
One thousand nine hundred sixty-five cancers out of 2376 matched cancers (82.7%) were 
coded with the same date of diagnosis and ICD code by both registries. Cancer sites that were 
often correctly classified were colorectal (91.9% of all matched colorectal cancers), breast 
(88.3%), and oesophagus and gastric (87.9%). The remaining cancers were misclassified 
with regard to date of diagnosis (344 cancers [14.5%]) or ICD code (72 cancers [3.0%]).
 Misclassification of date was further divided into a difference in date of diagnosis more 
than one month and less than one year (324 cancers), and more than one year (20 cancers, 
Table 3). Male genital cancer with prostate cancer as most frequent cancer was the most 
common cancer site among cancers with a difference in date of diagnosis of more than one 
month (24.4%) and the second among cancers misclassified for more than one year (25.0%), 
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Table 1 Characteristics of persons with matched and unmatched cancers in the Rotterdam Study 











Age at study entry, years, median 
(IQR) 65.1 (60.3 to 71.8) 71.5 (64.8 to 77.7) 69.0 (63.6 to 75.3)
Women, No. (%) 1081 (48.5) 151 (53.2) 61 (53.0)
Educational level*, No. (%)
 Primary 395 (17.7) 69 (24.3) 22 (19.1)
 Lower 897 (40.3) 104 (36.6) 43 (37.4)
 Intermediate 647 (29.1) 89 (31.3) 33 (28.7)
 Higher 261 (11.7) 19 (6.9) 15 (13.0)
Age at first cancer diagnosis, 
years, mean (SD) 74.0 (8.5) 80.5 (8.6) 78.2 (9.1)
 45-65 years 355 (15.9) 16 (5.6) 10 (8.7)
 65-75 years 856 (38.4) 50 (17.6) 27 (23.5)
 75-85 years 794 (35.7) 126 (44.4) 51 (44.3)
 >85 years 222 (10.0) 92 (32.4) 27 (23.4)
Persons in Rotterdam Study or Netherlands Cancer Registry do not sum up to total number of persons 
with unmatched cancers since some persons with unmatched cancers overlap. Missing values of 
educational level are not imputed and therefore numbers do not always sum up to 100%.
* Educational levels were assessed during home interviews according to the following categories: 
primary: primary education, lower: lower or intermediate general education, or lower vocational education, 
intermediate: intermediate vocational education or higher general education, or higher: higher vocational 
education or university.
IQR = interquartile range, SD = standard deviation.
after haematological malignancies (40.0%). Date of diagnosis was more often accurately 
registered by the Netherlands Cancer Registry than by the Rotterdam Study based on 
evaluation of the original medical files (Supplementary Table 2).
 Misclassification regarding ICD code was less common, with 72 cancers (3.0%) classified 
as misclassification of ICD code and organ system (Supplementary Figure 1). Most 
differences in ICD code were found for lung cancers or cancers coded as tumour of unknown 
primary origin (Supplementary Figure 1).
Chapter 2
52
Table 2 Cancer sites according to matched and unmatched cancers. 







Head and neck 71 (91.0) 4 (5.1) 3 (3.8)
Oesophagus and gastric 141 (93.4) 5 (3.3) 5 (3.3)
Colorectal 393 (89.1) 30 (6.8) 18 (4.1)
Hepato-pancreato-biliary 121 (81.2) 26 (17.4) 2 (1.3)
Lung and mesothelioma 351 (82.4) 59 (13.8) 16 (3.8)
Bone and soft tissue 15 (71.4) 2 (9.5) 4 (19.0)
Breast 366 (89.5) 19 (4.6) 24 (5.9)
Female genital organs 101 (87.8) 10 (8.7) 4 (3.5)
Male genital organs 380 (90.0) 27 (6.4) 15 (3.6)
Unitary tract 176 (80.7) 28 (12.8) 14 (6.4)
Central nervous system 19 (73.1) 7 (26.9) 0
Haematological 165 (76.7) 46 (21.4) 4 (1.9)
Other 21 (67.7) 4 (12.9) 6 (19.4)
Unknown primary origin 56 (71.8) 21 (26.9) 1 (1.3)
Numbers are displayed in total number of cancer site (percentage per row).
DISCUSSION
In this study, we investigated the concordance of cancers in a prospective population-based 
cohort study, the Rotterdam Study, with the Netherlands Cancer Registry. There was a high 
concordance with regard to pathology-confirmed cancers (>95%), but the Rotterdam Study 
registered a higher number of non-pathology-confirmed cancers. Furthermore, there was a 
high accuracy with regarding to cancer site, but the accuracy with regard to date of diagnosis 
was lower in the Rotterdam Study than in the Netherlands Cancer Registry. These findings 
can help to identify the reasons for inaccurate cancer registration and emphasise that cancer 
registration by national cancer registries may complement population-based cohort studies 
and vice versa. 
 Completeness varying between 90 and 100% is considered as acceptable to estimate 
optimal cancer incidence, provided that there are no large differences regarding cancer site 
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More than one 
year (n=20)
Head and neck 52 (73.2) 19 (26.8) 0 0
Oesophagus and gastric 124 (87.9) 13 (9.2) 0 4 (2.8)
Colorectal 361 (91.9) 25 (6.4) 1 (0.3) 6 (1.5)
Hepato-pancreato-biliary 88 (72.1) 24 (19.7) 1 (0.8) 9 (7.4)
Lung and mesothelioma 291 (82.2) 41 (11.6) 2 (0.6) 20 (5.6)
Bone and soft tissue 10 (66.7) 5 (33.3) 0 0
Breast 323 (88.3) 37 (10.1) 2 (0.5) 4 (1.1)
Female genital organs 89 (88.1) 9 (8.9) 1 (1.0) 2 (2.0)
Male genital organs 296 (77.9) 79 (20.8) 5 (1.3) 0
Unitary tract 136 (76.8) 38 (21.5) 0 3 (1.7)
Central nervous system 15 (78.9) 3 (15.8) 0 1 (5.3)
Haematological 130 (78.8) 27 (16.4) 8 (4.8) 0
Other 10 (47.6) 1 (4.8) 0 10 (47.6)
Unknown primary origin 40 (71.4) 3 (5.4) 0 13 (23.2)
Numbers are displayed in total number per cancer site (percentage per row). Cancers misclassified with 
regard to ICD code are classified according to the different cancer groups based on the ICD code of the 
Rotterdam Study.
* Five cancers were both misclassified with regard to date >1 month and <1 year and with regard to ICD 
code. Therefore, the number of misclassified cancers is lower than the total number of cancers in the 
different misclassification categories. † Difference in date of diagnosis more than one month and less 
than one year. 
ICD = International Classification of Diseases.
or age at cancer diagnosis between registered and unregistered cancers.3 Completeness 
of pathology-confirmed cancers was comparable between the Rotterdam Study and the 
Netherlands Cancer Registry, but we found that the number of non-pathology-confirmed 
cancers, with lung and haematological cancers in particular, were underreported in the 
Netherlands Cancer Registry. This can be explained by the use of different sources of cancer 
registration, with the Rotterdam Study having access to the medical records of general 
practitioners in addition to notification of cancer diagnoses through the pathology database. 
Regarding the cancers missed by the Rotterdam Study, we observed that one-third of these 
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cancers were second primary cancers. It is often not well documented in discharge letters 
whether a second tumour is a recurrent cancer, metastasis, or second primary cancer, in 
contrast to the documentation in medical files in hospitals to which the Netherlands Cancer 
Registry has access. Although under-registration of second primary cancers within the same 
organ will not affect cancer statistics, because these cancers are not included in cancer 
incidence and survival estimations,21 it may impact aetiological research questions.
 Furthermore, we found that cancers coded by solely one registry occurred often in older 
persons, which has been observed in previous studies as well.2,6,22 This observation can be 
explained because, compared to younger patients, pathological confirmation through biopsies 
can be limited in elderly patients due to poor clinical condition and prognosis.23-25 Harms 
caused by histological tissue acquisition for pathological confirmation without consequences 
for cancer treatment may outweigh the benefit of knowing the diagnosis in these patients. 
Furthermore, older patients are less often referred to the hospital and are more likely to be 
treated (in nursing homes) by their general practitioner.26 Such cancers will remain unnoticed 
in the Netherlands Cancer Registry, because there is no linkage with general practitioners. 
 Although the Rotterdam Study had a higher degree of completeness of non-pathology-
confirmed cancers, the accuracy of calendar date of cancer diagnosis was lower than 
that of the Netherlands Cancer Registry. The Rotterdam Study aims to register the date 
of cancer diagnosis based on the date of biopsy (solid cancers) or laboratory assessment 
(haematological cancers). However, this information is not always documented in the hospital 
discharge letters and other medical files obtained from general practitioners. If the date 
of pathological confirmation is unavailable, a proxy is taken based on the date of hospital 
admission or the date of the medical letter. Most discrepancies regarding date of diagnosis 
were found for male genital organ cancer, mostly represented by prostate cancer, and 
haematological cancer. Prostate cancer is frequently detected by elevated prostate-specific 
antigen (PSA) levels. Since the long-term benefit of invasive treatment for prostate cancer is 
questionable,27 treatment options such as watchful waiting and active surveillance are often 
applied for indolent localised prostate cancer. Monitoring of patients by measuring PSA levels 
limits the need for pathological confirmation of the cancer in contrast to cancer at other sites. 
Pathology can be obtained in case of cancer progression, which may occur months after 
the initial clinical diagnosis. The dates across these different clinical stages are not always 
accurately documented in medical letters, resulting in misclassification of the date of first 
diagnosis. Differences in the date of diagnosis of haematological cancers were explained by 
the different diagnostic examinations on which the date of diagnosis was based (peripheral 
blood versus bone marrow biopsy).
 In addition, we showed that few of the registered cancers were misclassified with regard to 
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ICD code. We considered cancers with a different ICD code within the same organ system as 
correctly classified, because part of the misclassification is due to different coding rules. These 
different coding rules also explain the misclassified cancers with the ICD code for ‘tumour of 
primary origin’, with the Rotterdam Study being more lenient in coding cancers according to 
the most probably primary origin. Moreover, cancer diagnoses in the Rotterdam Study are 
coded independently by two physicians, whereas cancers in the Netherlands Cancer Registry 
are coded by one trained registration clerk, which could affect the accuracy of registered 
cancers as well.28 
 The main strength of this study is the independent case ascertainment method used to 
study the concordance between a large population-based cohort study and the nationwide 
cancer registry. Although the flow method may outperform the independent case ascertainment 
by having the advantage of measuring completeness during the registration process,5 it 
does not appropriately describe the data when cancer registration begins with a delay, and 
is therefore not used in the Netherlands Cancer Registry. Data on cancer diagnoses were 
collected independently, partly from different sources, and with different aims, i.e., determining 
statistics on cancer incidence, prevalence, and survival by the Netherlands Cancer Registry 
while investigating aetiology by the Rotterdam Study. Although these aims are different, 
optimal cancer registration is fundamental for both purposes. However, it should be noted that 
the current study is conducted within persons aged 45 years and older and that these findings 
may differ among a younger population. Furthermore, we cannot rule out that cancers without 
pathological confirmation are actually benign. However, we classified cancers based on all 
available medical information, thereby limiting the number of false-positive diagnoses. 
 Based on our findings, we have identified the main limitations of both registries, which 
opens avenues for improvements. Date of diagnosis was misclassified in 11.8% in the 
Rotterdam Study compared to 4.8% in the Netherlands Cancer Registry. Since this information 
is not always documented in the medical files, we can improve the accuracy by standardised 
linkage with the Netherlands Cancer Registry. Regarding the Netherlands Cancer Registry, it 
is of the utmost importance to investigate the reason why some pathology-confirmed cancers 
are not captured. Therefore, continuous improvement of registration quality is necessary, 
especially regarding cancers in elderly and at specific cancer sites such as pancreas, lung, 
and haematological cancers. In addition, many non-pathology-confirmed cancers were not 
registered by the Netherlands Cancer Registry. Cancer diagnoses in the Netherlands Cancer 
Registry are primarily notified by the pathology laboratories and the national hospital discharge 
registry. However, outpatients are included in the national hospital discharge registry as 
of 2015, which is expected to improve notification of non-pathology-confirmed cancers to 
the Netherlands Cancer Registry. This effect is mainly visibly in lung cancer, for which the 
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proportion of non-pathology-confirmed cancers increased from 8% between 1989 and 2012 
(the inclusion period of this study) to 13% between 2015 and 2017. Since this misclassification 
could result in an underestimation of cancer incidence, inclusion of these clinically diagnosed 
cancers may provide more accurate cancer statistics. However, cancers diagnosed by general 
practitioners or nursing home physicians without further diagnostics that include pathology or 
referral to a hospital are still not be captured by the Netherlands Cancer Registry.
 In conclusion, our findings indicate that linkage of different cancer registries is needed 
to improve registration by identifying the reasons of inaccurate cancer registration. Cancer 
registration by national cancer registries may complement cancer registration by population-
based cohort studies and vice versa. Combination of different sources is needed to provide 
reliable data on cancer incidence.
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Supplementary Figure 1 Intersection plot of misclassified cancers with regard to ICD code. 
The connecting dots represent the mismatched ICD codes per organ system. Tumour of unknown primary 
origin was the most common misclassified cancer type, especially in the match with cancers of the lung 
and mesothelioma. The term ‘other’ represents other and unspecified. 
ICD = International Classification of Diseases. 
Chapter 2
60
Supplementary Table 1 Overview of the used ICD-10 codes per organ system.
Organ system Corresponding ICD-10 code
Head and neck C01-C14, C30, C32, C69, C73
Oesophagus and gastric C15, C16
Colorectal C18-C20
Hepato-pancreato-biliary C22-C25
Lung and mesothelioma C34, C45
Bone and soft tissue C40, C41, C49
Breast C50
Female genital organs C51-C57
Male genital organs C60-C63
Unitary tract C64-C68
Central nervous system C70-C72
Haematological C81-C96
Other C17, C21, C26, C37-C39, C48, C75, C76
Unknown primary origin C80
ICD = International Classification of Diseases.
Supplementary Table 2 Overview of accuracy of misclassified cancers.
Registry Misclassified cancers
Date of diagnosis 
more than one month 
difference (n=324)*
Date of diagnosis more 
than one year difference 
(n=20)
Date correctly classified by
 Rotterdam Study 57 (17.6) 6 (30.0)
 New Rotterdam Study† 48 (14.8) 3 (15.0)
 Netherlands Cancer Registry 219 (67.6) 11 (55.0)
Numbers are displayed in total number (percentage per column).
Original medical files were evaluated to determine the correct date of diagnosis.
* Difference in date of diagnosis more than one month and less than one year. † New Rotterdam Study 
indicates that date of diagnosis was originally not accurately registered in both registries, and was 
changed after evaluation of the original medical files of the corresponding participant.
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Background Cancer diagnoses which are not confirmed by pathology are often under-
registered in cancer registries compared to pathology-confirmed diagnoses. It is unknown 
how many patients have a non-pathology-confirmed cancer diagnosis, and whether their 
characteristics and survival differ from patients with a pathology-confirmed diagnosis.
Methods Participants from the prospective population-based Rotterdam Study were followed 
between 1989 and 2013 for the diagnosis of cancer. Cancer diagnoses were classified into 
pathology-confirmed versus non-pathology-confirmed (i.e., based on imaging or tumour 
markers). We compared participant characteristics and the distribution of cancers at different 
sites. In addition, we investigated differences in overall survival using survival curves adjusted 
for age and sex. 
Results During a median (interquartile range) follow-up of 10.7 years (6.3 to 15.9), 2698 out 
of 14 024 participants were diagnosed with cancer, of which 316 diagnoses (11.7%) were 
non-pathology-confirmed. Participants with non-pathology-confirmed diagnoses were older, 
more often women, and had a lower education. Most frequently non-pathology-confirmed 
cancer sites included central nervous system (66.7%), hepato-pancreato-biliary (44.5%), 
and cancers of unknown primary origin (31.3%). Survival of participants with non-pathology-
confirmed diagnoses after one year was lower than survival of participants with pathology-
confirmed diagnoses (32.6% versus 63.4%; risk difference of 30.8% [95% confidence interval 
= 25.2% to 36.2%]).
Conclusions Pathological confirmation of cancer is related to participant characteristics 
and cancer site. Furthermore, participants with non-pathology-confirmed diagnoses have 
worse survival than participants with pathology-confirmed diagnoses. Missing data on non-
pathology-confirmed diagnoses may result in an underestimation of cancer incidence and 
in an overestimation of survival in cancer registries, and may introduce bias in aetiological 
research.
Burden of tumours not confirmed by pathology
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INTRODUCTION
With ageing populations worldwide, the incidence of cancer is rising. In 2018, 17 million 
people were diagnosed with cancer and 9.6 million people died from cancer.1 Accurate and 
complete registration of incident cancers is pivotal for cancer statistics. However, most cancer 
registries primarily rely on pathology databases. Although this limits the risk of false-positive 
diagnoses, it may result in under-registration of cancers that are diagnosed purely on the 
basis of other sources than pathology, such as imaging features or tumour markers.2,3 This 
may lead to an underestimation of cancer incidence and to inaccurate estimates of survival. 
Furthermore, aetiological studies often only include patients with a pathology-confirmed 
cancer diagnosis, which may induce bias if pathological confirmation is related to patient or 
cancer characteristics. 
 Several studies have investigated characteristics of patients with unstaged cancer based 
on the Surveillance, Epidemiology and End Results (SEER) database4-6 or state cancer 
registries in the United States.7-9 It has been found that unstaged cancer occurs more often in 
patients with older age and in patients residing in nursing homes. Also, unstaged cancers were 
often cancers with a poor survival such as cancer in the oesophagus, liver, or pancreas.6,10 
Missing cancer stage was explained by different reasons such as failure of the registry 
system, refusal for diagnostic testing, or absence of therapeutic consequences of staging. 
However, tumour grade was known in the majority of the unstaged cancers, which suggests 
that the studied cancer population is a combination of patients with missing cancer stage, but 
with pathological confirmation of the cancer, and patients with missing both cancer stage and 
pathology. Therefore, the incident number of patients with a cancer diagnosis based on other 
sources than pathology and their characteristics remain largely unknown. 
 Patients with suspected cancer undergo an extensive diagnostic work-up that includes 
physical examination, laboratory assessments, imaging features, and pathology. In some 
patients, pathology is not included in the diagnostic work-up of cancer. In this study, we will 
refer to these cancer diagnoses as ‘non-pathology-confirmed’ diagnoses. If pathology is used 
to confirm the cancer diagnosis, we will use the term ‘pathology-confirmed’ diagnosis. 
 We hypothesised that pathology is more often omitted in older, vulnerable patients with 
impaired survival. Insight into the number of non-pathology-confirmed cancer diagnoses and 
identification of the reasons for omitting pathology in the diagnostic work-up of cancer could 
stimulate and facilitate cancer registries and aetiological research studies to capture these 
cancer diagnoses. In the current study, we therefore determined the number of participants 
with a non-pathology-confirmed cancer diagnosis, their characteristics, and their overall and 
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cancer-specific survival in the population-based Rotterdam Study.
METHODS
Study population
This study is embedded within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of age-related diseases in the general 
population. The objectives and design have been described in detail previously.11 In 1989, 
all residents aged 55 years and over of the district Ommoord in Rotterdam, the Netherlands, 
were invited to participate. This initial cohort comprised 7983 participants (response of 78%) 
and was extended with a second subcohort in 2000 with 3011 participants (response of 67%) 
who had become 55 years of age or moved into the study district. In 2006, the cohort was 
further extended with 3932 participants (response of 65%) aged 45 years and over. In total, 
the Rotterdam Study comprises 14 926 participants aged 45 years and over. The current 
study includes all participants who provided informed consent for follow-up data collection 
without a history of cancer at study entry (N=14 024). 
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and 
Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam 
Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.
nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/
network/primary/en/) under shared catalogue number NTR6831. All participants provided 
written informed consent to participate in the study and to have their information obtained 
from treating physicians.
Assessment of incident cancer
Diagnosis of incident cancer was based on medical records of general practitioners (including 
hospital discharge letters) and furthermore through linkage with Dutch Hospital Data (Landelijke 
Basisregistratie Ziekenhuiszorg), histology and cytopathology registries in the region 
(PALGA), and the Netherlands Cancer Registry. Using different sources of cancer diagnoses, 
the Rotterdam Study aims to capture also the non-pathology-confirmed diagnoses. Incident 
cancer was defined as any primary malignant tumour, excluding non-melanoma skin cancer. 
Each primary malignant tumour was registered, so that participants could have been diagnosed 
with multiple cancers. Cancer diagnoses were coded independently by two physicians and 
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classified according to the International Classification of Diseases, 10th revision (ICD-10). In 
case of discrepancy, consensus was sought through consultation with a physician specialised 
in internal medicine. Level of uncertainty of diagnosis was established as: certain (pathology-
confirmed), probable (e.g., based on imaging features or elevated tumour markers without 
pathological confirmation), and possible (e.g., based on symptoms and physical examination, 
without further analysis and without pathological confirmation). Date of diagnosis was based 
on date of biopsy (solid tumours), laboratory assessment (haematological tumours), or – if 
unavailable – date of hospital admission or hospital discharge letter. For non-pathology-
confirmed cancers, we used the date of imaging, date of laboratory assessment, date of 
physical examination, or – if unavailable – the date of hospital admission or hospital discharge 
letter. Follow-up was completed up to January 1st, 2014. In case of multiple cancers within one 
participant, we only included the first diagnosis for analyses. 
Assessment of mortality
Information on vital status was updated continuously. Date of death was obtained and verified 
through notification by the municipal administration. Cause of death was obtained through 
follow-up of records of general practitioners and hospital discharge letters, and was classified 
according to the ICD-10 by two research physicians independently. Thereafter, a medical 
expert in the field reviewed all coded events. Cancer-specific mortality was defined as mortality 
attributed to malignant neoplasms (ICD-10, C00 to C97). 
Assessment of characteristics
During home interviews at study entry, participants provided information on marital status, 
educational level, smoking status, and alcohol use. Marital status was categorised as living 
with or without partner. Educational level was classified into primary education, lower (lower 
or intermediate general education, or lower vocational education), intermediate (intermediate 
vocational education or higher general education), or higher (higher vocational education or 
university). Smoking habits were categorised as never, current, or former smoker. Alcohol use 
was classified into any use or no use of alcohol. At the research centre, height and weight 
were measured from which the body mass index (BMI, kg/m2) was computed. Hypertension 
was defined as a resting blood pressure exceeding 140/90 mm Hg or the use of blood 
pressure lowering medication.12 Diabetes was defined as a fasting serum glucose level ≥7.1 
mmol/L, random serum glucose level ≥11.1 mmol/L, or the use of antidiabetic medication.13 
History of stroke, coronary heart disease (myocardial infarction, percutaneous coronary 
intervention, or coronary artery bypass grafting), chronic obstructive pulmonary disease, and 
neurodegenerative disease (dementia and parkinsonism) was assessed by interview and 
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verified by reviewing medical records.14-17
Statistical analyses
We used the independent samples t test (for continuous variables with a normal distribution), 
the Wilcoxon signed-rank test (for continuous variables with a skewed distribution), or 
the chi-square test (for categorical variables) to investigate differences in characteristics 
between participants with pathology-confirmed diagnoses (certain cancer) and those with 
non-pathology-confirmed diagnoses (probable and possible cancer). Furthermore, we 
compared cancer site specific percentages. An overview of the different ICD-10 codes used 
for categorisation into different cancer sites is presented in Supplementary Table 1.
 Next, we explored a potential trend of pathological confirmation of cancer diagnoses 
over the years by plotting the number of incident pathology-confirmed and non-pathology-
confirmed diagnoses per calendar year. We formally tested the association between year of 
diagnosis and source of diagnosis (with or without pathological confirmation) using logistic 
regression models. This analysis was performed for all cancer sites combined and for the five 
most frequent non-pathology-confirmed cancer sites separately. We constructed two nested 
models: Model I was unadjusted; Model II was adjusted for age at diagnosis (continuous).
 We used two different methods to estimate overall survival. First, time to event was defined 
as follow-up time starting from date of diagnosis until date of death or date of censoring (loss 
to follow-up or end of the study period [January 1st, 2014]), whichever came first). Second, 
differences in overall survival between participants with and without pathological confirmation 
of the cancer diagnosis were visualised by Kaplan-Meier curves and tested with a log-rank 
test. We additionally computed standardised survival curves to remove the influence of 
different distributions in age at diagnosis and sex between the groups.18,19 
 Standardised survival curves were created using a pooled logistic regression model for 
death including the following covariates: time (years), time squared (years), pathological 
confirmation of the diagnosis, age at diagnosis (continuous), and sex. Interactions between 
time and time squared with source of diagnosis were added to the model to allow for a flexible 
estimation of the baseline hazard. After fitting the pooled logistic model, we estimated the 
probability of death if all participants with cancer had a pathology-confirmed diagnosis, and the 
probability of death if all participants with cancer had a non-pathology-confirmed diagnosis at 
each time point. Subsequently we calculated the difference in survival probability at each time 
point by taking the cumulative product as with Kaplan-Meier method. Confidence intervals 
(CIs) were obtained by bootstrapping. In sensitivity analyses, we repeated the analyses for 
cancer-specific survival and explored effect modification by median age, sex, education, and 
marital status.
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 Statistical analyses were performed using IBM SPSS Statistics Version 24.020 and the 
packages ‘survival’21 and ‘survminer’22 from R software Version 3.3.2.
RESULTS
During a median (interquartile range) follow-up of 10.7 (6.3 to 15.9) years, 2698 out of 14 024 
participants were diagnosed with cancer. The majority had a pathology-confirmed diagnosis 
(n=2382 [88.3%]). Of the participants with a non-pathology-confirmed diagnosis, 257 (9.5%) 
had a probable diagnosis and 59 (2.2%) had a possible diagnosis.
 Characteristics of participants categorised into three groups, i.e., without cancer, with 
pathology-confirmed diagnosis, and with non-pathology-confirmed diagnosis, are presented 
in Table 1. Participants with non-pathology-confirmed diagnoses were older at diagnosis than 
participants with pathology-confirmed diagnoses (median age of 83.2 versus 74.2 years, 
P<.001). Furthermore, they were more often women (55.7% versus 47.6%, P=.007), lived 
more often without a partner (37.3% versus 25.1%, P<.001), and had lower educational 
levels (P=.002). Lastly, participants with non-pathology-confirmed diagnoses had more 
often hypertension (71.8% versus 49.8%, P<.001) and more frequently a history of stroke 
(12.0% versus 6.9%, P=.001), coronary heart disease (15.8% versus 12.7%, P<.001), chronic 
obstructive pulmonary disease (19.0% versus 13.7%, P=.011), and neurodegenerative 
disease (30.4% versus 14.8%, P<.001) at diagnosis than participants with pathology-
confirmed diagnoses. 
 Most frequently diagnosed cancer sites that were non-pathology-confirmed included 
central nervous system (66.7% of all central nervous system cancers), hepato-pancreato-
biliary (44.5%), cancers of unknown primary origin (31.3%), lung and mesothelioma (19.7%), 
and urinary tract (17.5%, Table 2). There was no statistically significant relation between 
pathological confirmation of these cancer sites with calendar year after adjustment for age at 
diagnosis, indicating that the number of participants with a pathology-confirmed diagnosis did 
not increase or decrease during the study period (Supplementary Figure 1 and Table 3).
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Age, years, median (IQR) 62.4 (57.7 to 72.7) 65.0 (60.2 to 72.0) 72.0 (66.1 to 78.1)
Women, No. (%) 6912 (61.0) 1135 (47.6) 176 (55.7)
Living without partner, No. (%) 3036 (26.8) 597 (25.1) 118 (37.3)
Educational level, No. (%)
 Primary 2081 (18.4) 423 (17.8) 76 (24.1)
 Lower 4393 (38.8) 948 (39.8) 131 (41.5)
 Intermediate 2886 (25.5) 700 (29.4) 82 (25.9)
 Higher 1718 (15.2) 283 (11.9) 20 (6.3)
Body mass index, kg/m2, mean (SD) 26.9 (4.2) 26.7 (3.8) 26.3 (3.7)
Smoking, No. (%)
 Never 3838 (33.9) 629 (26.4) 104 (32.9)
 Former 4950 (43.7) 1106 (46.4) 109 (34.5)
 Current 2313 (20.4) 608 (25.5) 90 (28.5)
Alcohol use, No. (%) 7843 (69.2) 1683 (70.7) 188 (59.5)
Age at cancer diagnosis, No. (%)
 45-65 years 372 (15.6) 8 (2.5)
 65-75 years 897 (37.7) 42 (13.3)
 75-85 years 870 (36.5) 136 (43.0)
 >85 years 243 (10.2) 130 (41.1)
 Median (IQR) 74.2 (68.0 to 80.3) 83.2 (78.0 to 88.0)
Comorbidities at cancer diagnosis, 
No. (%)
 Stroke 164 (6.9) 38 (12.0)
 Coronary heart disease 302 (12.7) 50 (15.8)
 Hypertension 1186 (49.8) 227 (71.8)
 Diabetes 324 (13.6) 37 (11.7)
 Chronic obstructive pulmonary  
 disease 326 (13.7) 60 (19.0)
 Neurodegenerative disease 353 (14.8) 96 (30.4)
Characteristics are measured at entry in the Rotterdam Study except for age at cancer diagnosis and 
comorbidities. Missing values are not imputed and therefore numbers do not always sum up to 100%. 
IQR = Interquartile range, N = number of participants, SD = standard deviation.
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Head and neck 83 (94.3) 5 (5.7) 88
Oesophagus and gastric 140 (97.9) 3 (2.1) 143
Colorectal 397 (96.6) 14 (3.4) 411
Hepato-pancreato-biliary 81 (55.5) 65 (44.5) 146
Lung and mesothelioma 314 (80.3) 77 (19.7) 391
Bone and soft tissue 19 (90.5) 2 (9.5) 21
Breast 341 (96.6) 12 (3.4) 353
Female genital organs 112 (94.9) 6 (5.1) 118
Male genital organs 387 (95.6) 18 (4.4) 405
Unitary tract 165 (82.5) 35 (17.5) 200
Central nervous system 9 (33.3) 18 (66.7) 27
Haematological 188 (90.0) 21 (10.0) 209
Other 80 (88.9) 10 (11.1) 90
Unknown primary origin 66 (68.8) 30 (31.3) 96
Numbers are displayed in total number (percentage per row).










Model I Model II
OR (95% CI) OR (95% CI)
All cancer sites 2382 316 1.01 (1.00 to 1.03) 1.01 (0.99 to 1.03)
Hepato-pancreato-biliary 81 65 0.97 (0.92 to 1.02) 0.95 (0.89 to 1.02)
Lung and mesothelioma 314 77 1.05 (1.01 to 1.09) 1.03 (0.99 to 1.08)
Unitary tract 165 35 0.96 (0.91 to 1.02) 0.96 (0.90 to 1.03)
Central nervous system 9 18 1.05 (0.93 to 1.19) 1.06 (0.94 to 1.21)
Unknown primary 66 30 1.06 (0.99 to 1.14) 1.05 (0.98 to 1.13)
Model I = unadjusted. Model II = adjusted for age at diagnosis (continuous).
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Figure 1 Kaplan-Meier curves for overall survival of participants with a 
pathology-confirmed diagnosis (blue) or a non-pathology-confirmed diagnosis (yellow). 
Participants with a non-pathology-confirmed diagnosis had worse overall survival than those with a 
pathology-confirmed diagnosis (P of log-rank test <.0001). Participants were censored if they were lost to 
follow-up or at the end of the study period (January 1st, 2014), whichever came first.
 Of the 2382 participants with a pathology-confirmed diagnosis, 1154 participants (48.4%) 
died from cancer and 455 participants (19.1%) died due to other causes, such as heart failure, 
dementia, and cardiac arrest. Among participants with non-pathology-confirmed diagnoses, 
231 (73.1%) died from cancer, and 63 participants (19.9%) died from other causes. The 
overall survival of participants with non-pathology-confirmed diagnoses was lower than the 
overall survival of participants with pathology-confirmed diagnoses (P for log-rank test <.0001, 
Figure 1). After adjusting for age at diagnosis and sex, the overall survival of participants with 
non-pathology-confirmed diagnosis was 30.8% (95% CI = 25.2% to 36.2%) lower one year 
after diagnosis than the overall survival of participants with pathology-confirmed diagnoses 
(survival probability was 32.6% versus 63.4%, respectively, Figure 2). Two and five years 
after diagnosis, the difference in survival was respectively 29.3% (95% CI = 24.2% to 33.9%) 
and 22.5% (95% CI = 17.7% to 26.4%). Cancer-specific survival probability was comparable 
to overall survival probability, with a lower cancer-specific survival in participants with non-
pathology-confirmed diagnoses (37.2%) than in participants with pathology-confirmed 
diagnoses (67.4%, Supplementary Figure 2). No significant effect modification was observed 
across different strata of median age, sex, education, and marital status.




















Figure 2 Standardised survival curves for overall survival of participants with a pathology-
confirmed diagnosis (blue) or a non-pathology-confirmed diagnosis (yellow). 
Dashed lines represent 95% confidence intervals. Survival curves are adjusted for age at diagnosis and 
sex. The risk difference of overall survival between participants with a non-pathology-confirmed and a 
pathology-confirmed diagnosis was 30.8% after one year, 29.3% after two years, and 22.5% after five 
years.
DISCUSSION
In a large population-based cohort study, we showed that non-pathology-confirmed diagnoses 
of cancer represent an additional ten percent of cancer diagnoses besides pathology-confirmed 
diagnoses. Pathological confirmation of cancer was associated with multiple participant 
characteristics, comorbidities, cancer site, and survival. The proportion of participants with 
pathology-confirmed diagnoses did not change over time.
 In line with previous studies investigating characteristics of patients with unstaged 
cancer,4-9 we found that participants with a non-pathology-confirmed diagnosis were on 
average older than those with a pathology-confirmed diagnosis. There are different reasons 
for this observation. First, older patients have more comorbidities that may be of greater health 
concern than a potential cancer diagnosis.23 Therefore, the diagnostic cancer work-up may be 
partly omitted. Furthermore, older patients are sometimes more vulnerable, limiting the ability 
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to obtain pathology material for diagnosis through invasive procedures, such as endoscopic 
retrograde cholangiopancreatography (ERCP) for pancreatic cancer. In addition, age and 
comorbidities are associated with potentially less intensive treatment assignment including 
palliative radiotherapy and hormonal therapy.24,25 Although pathological confirmation of the 
cancer is often preferred, it may not always be mandatory for these treatment regimens.23,26
 Lack of therapeutic consequences of pathological confirmation may explain why cancers 
with a poor survival in particular, such as cancer of central nervous system, hepato-pancreato-
biliary tract, and lung were often diagnosed without pathological confirmation. Cancers at 
these organ sites are often detected in a more advanced stage, limiting treatment options 
to palliative treatments. In addition, we found that participants with cancer of unknown 
primary origin often had no pathological confirmation, suggesting that these participants had 
metastatic disease and did not undergo further diagnostic testing.27 Another explanation for 
this finding is that cancers at these sites are less accessible for obtaining tumour tissue, 
in particular regarding cancers of the central nervous system. Lastly, cancers in the urinary 
tract including renal cell carcinoma were often non-pathology-confirmed. These cancers can 
be diagnosed non-invasively with imaging modalities (renal cell carcinoma). Also, prostate 
cancer is sometimes diagnosed non-invasively based on tumour markers. Watchful waiting 
is increasingly being considered as an option for older, vulnerable patients with regard to 
prostate cancer,28 which may result in a lower number of pathology-confirmed diagnoses. 
 Interestingly, we showed that participants with a non-pathology-confirmed diagnosis of 
cancer had worse overall and cancer-specific survival than participants with a pathology-
confirmed diagnosis. Although the number of cancers with a poor survival was more 
frequently represented among non-pathology-confirmed diagnoses, this difference in cancer 
type distribution cannot completely explain the observed difference in survival. Therefore, 
the difference in survival may indicate that pathological confirmation is more often omitted 
in patients with a ‘worse’ cancer prognosis. In contrast, previous studies have found a better 
survival in patients with unstaged cancer. For instance, the survival of patients with unstaged 
colorectal cancer was higher than the survival of patients with distant-staged cancer.5 
Furthermore, non-pathology-confirmed early stage lung cancer patients had a better cancer-
specific survival than patients with a pathology-confirmed diagnosis, due to the occurrence of 
benign lung nodules among the diagnosed cancers without pathological confirmation.29 This 
misclassification of benign tumours may partly explain the discrepancy in survival between 
previous studies and the current study. Although we cannot exclude that we also classified 
benign tumours as non-pathology-confirmed cancers, the number of misclassified tumours is 
expected to be low because of the persistent poor cancer-specific survival of participants with 
a non-pathology-confirmed diagnosis.
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 We have previously shown that cancer registries primarily rely on pathology databases 
as signalling source of cancer diagnoses, resulting in under-registration of non-pathology-
confirmed diagnoses.30 The findings of our current study indicate that under-registration of 
such cancers may result in underestimation of the cancer incidence, and in overestimation 
of cancer survival. In addition, non-pathology-confirmed diagnoses were related to multiple 
characteristics including age, sex, smoking status, and education, and to cancer site. Most 
aetiological studies only include patients with a pathology-confirmed diagnosis, which may 
induce information bias and result in inaccurate estimates of association.31 For these reasons, 
our results suggest that registries and research studies should also include patients with non-
pathology-confirmed diagnoses for potential sensitivity analyses.
 The main strength of this study is the unique setting of the Rotterdam Study in which 
cancer registration relies on medical letters and medical records from the general practitioners 
in addition to signalling of diagnoses through the nationwide pathology database as well 
as linkage to the Netherlands Cancer Registry. This allowed us to investigate also non-
pathology-confirmed diagnoses not registered through the pathology database. Furthermore, 
we estimated survival by computing standardised survival curves in addition to the unadjusted 
Kaplan-Meier curves. Unfortunately, we could not adjust these survival curves for frailty. 
Although the Rotterdam Study started to collect data on frailty from 2009 onwards, including 
weight loss, physical activity, weakness, slowness, and fatigue to calculate the Fried frailty 
index,32 this was not available for the majority of the participants (<20%), or – if available – was 
measured several years after cancer diagnosis. Another limitation is that the date of diagnosis 
is determined differently for non-pathology-confirmed and pathology-confirmed diagnoses. It 
is plausible that participants with non-pathology-confirmed diagnoses were diagnosed sooner, 
resulting in a slightly longer cancer-specific survival. Lastly, we cannot rule out that non-
pathology-confirmed diagnoses are benign tumours. However, we classified cancers based 
on all the available information from medical letters and medical records, limiting the number 
of false-positive diagnoses. In addition, we showed that participants with non-pathology-
confirmed diagnoses had worse cancer-specific survival persistent over time, suggesting that 
these cancers were malignant.
 In conclusion, we show that purely non-pathology-confirmed diagnoses represent ten 
percent of the total number of diagnosed cancers, besides pathology-confirmed diagnoses. 
Pathological confirmation is associated with several characteristics and with worse overall 
and cancer-specific survival. Our findings suggest that missing data or exclusion of non-
pathology-confirmed diagnoses may result in underestimation of the true cancer incidence, 
overestimation of survival, and potentially in biased aetiological research findings.
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Supplementary Figure 1 Trends in cancer diagnoses per calendar year of cancer diagnosis. 
Number of pathology-confirmed diagnoses (blue) and non-pathology-confirmed diagnoses (yellow) are 
shown as the total number of cancer diagnoses.




























Supplementary Figure 2 Standardised survival curves of individuals with a pathology-confirmed 
diagnosis (blue) or a non-pathology-confirmed diagnosis (yellow). 
Dashed lines represent 95% confidence intervals. Survival curves are adjusted for age at diagnosis and 
sex. The risk difference of cancer-specific survival between participants with a non-pathology-confirmed 




Supplementary Table 1 Overview of the used ICD-10 codes per organ system.
Organ system Corresponding ICD-10 code
Head and neck C01-C14, C30, C32, C69, C73
Oesophagus and gastric C15, C16
Colorectal C18-C20
Hepato-pancreato-biliary C22-C25
Lung and mesothelioma C34, C45
Bone and soft tissue C40, C41, C49
Breast C50
Female genital organs C51-C57
Male genital organs C60-C63
Unitary tract C64-C68
Central nervous system C70-C72
Haematological C81-C96
Other C17, C21, C26, C37-C39, C43, C48, C75, C76
Unknown primary origin C80







Trajectories of cognitive and motor function between ages 45 and 90 
years
van der Willik KD*, Licher S*, Vinke EJ, Knol MJ, Darweesh SK, 
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Background To establish trajectories of cognitive and motor function, and to determine the 
sequence of change across individual tests in community-dwelling individuals aged 45 to 90 
years.
Methods Between 1997 and 2016, we repeatedly assessed cognitive function with five 
tests in 9514 participants aged 45 to 90 years from the population-based Rotterdam Study. 
Between 1999 and 2016, we measured motor function with three tests in 8297 participants. 
All participants were free from dementia, stroke, and parkinsonism. We assessed overall and 
education-specific cognitive and motor trajectories using linear mixed models with age as time 
scale. Next, we determined the sequence of change across individual tests.
Results The number of assessments per participant ranged between one and six (mean 
[standard deviation [SD]] interval was 5.1 years [1.4]) for cognitive function, and one and four 
(5.4 years [1.4]) for motor function. Cognitive and motor trajectories declined linearly between 
ages 45 and 65 years, followed by steeper declines after ages 65 to 70 years. Lower educated 
participants had lower cognitive function at age 45 years (baseline), and declined faster on 
most cognitive, but not on motor tests than higher educated participants. Up to a 25-year age 
difference between the fastest and slowest declining test scores was observed.
Conclusions At a population-level, cognitive and motor function decline similarly. Compared 
to higher educated individuals, lower educated individuals had lower cognitive function at 
baseline, and a faster rate of decline thereafter. These educational-effects were not seen for 
motor function. These findings benefit the understanding of the natural course of cognitive 
and motor function during ageing, and highlight the role of education in the preservation of 
cognitive but not motor function.
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INTRODUCTION
Understanding the natural course of cognitive and motor function during brain ageing is pivotal 
to determine deviations in function that may signal early stages of clinical neurodegenerative 
diseases.1,2 Decline in both cognitive and motor function has been associated with an increased 
risk of dementia, Parkinson’s disease, and stroke.1-3 In addition, we have recently shown that 
individuals in whom decline in motor function precedes decline in cognitive function are at 
an increased risk of dementia.3 Numerous studies have quantified the temporal relation of 
cognitive and motor function with advancing age,4-17 yet little is known about the sequence 
of individual cognitive and motor tests in a population free from neurodegenerative diseases 
and stroke.
 Comparing trajectories of cognitive and motor tests in the general population reveals 
whether decline in motor function precedes decline in cognitive function. In addition, it 
identifies the specific individual tests that have the earliest signs of decline. Such findings 
could inform clinicians about which cognitive and motor tests are most sensitive to detect 
change in cognitive or motor function. These trajectories can also be used to signal vulnerable 
patient groups that deviate from their expected course based on several key characteristics, 
such as age, sex, educational level, or genes. These characteristics significantly influence 
cognitive function and the rate of cognitive decline, but their effects on motor function beyond 
gait speed are less understood.18,19 
 Alike changes in brain structure, we hypothesise that change in cognitive and motor function 
accelerates with advancing age.20 To model this non-linear change, we present trajectories 
of cognitive and motor function. In addition, we assess the effects of key determinants of 
cognitive and motor function, namely age, sex, education, and apolipoprotein E genotype 
(APOE) on these trajectories. Finally, we determine the sequence of change of individual 
cognitive and motor function tests. 
METHODS 
Study design
This study was embedded within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of age-related diseases in the general 
population.21 In 1989, all inhabitants aged at least 55 years from Ommoord, a well-defined 
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district in Rotterdam, the Netherlands received an invitation to participate. This initial cohort 
comprised 7983 participants. In 2000, 3011 participants who had become 55 years of age 
or moved into the study district since the start of the study were additionally included in the 
cohort. In 2006, a further extension of the cohort was initiated in which 3932 participants aged 
at least 45 years participated. In total, the Rotterdam Study comprises 14 926 participants 
aged at least 45 years. The overall response rate across all three recruitment waves was 72%.
Standard protocol approvals, registrations, and patient consents
The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and 
Sport (Population Screening Act WBO, license number 1071272-159521-PG). All participants 
provided written informed consent to participate in the study and to have their information 
obtained from treating physicians.
Study population
Of a total of 14 926 participants, we excluded those with a history of dementia (n=907), stroke 
(n=846), Parkinson’s disease (n=300), or parkinsonism (n=20) at time of their first cognitive or 
motor assessment. Next, we excluded participants with insufficient data to determine whether 
they had a history of one or multiple of these diseases (n=1800). Baseline and follow-up 
ascertainment methods for dementia, stroke, Parkinson’s disease, and parkinsonism have 
previously been described in detail.22 In addition, five participants were excluded because 
they did not provide informed consent to access medical records and hospital discharge 
letters during follow-up. From the remaining 11 048 participants, 1494 participants were 
excluded because they did not have data available on any cognitive or motor test. Finally, 
we excluded assessments from participants after they had reached age 90 years in order to 
minimise the influence of leverage points on the trajectories of cognitive and motor function. 
This resulted in an additional exclusion of 33 participants who did not have any cognitive or 
motor function assessment at all before the age of 90 years, leaving 9521 participants with 
at least one cognitive or motor assessment. During follow-up, we excluded assessments of 
participants after the age of 90 years (n=1266) and of participants after a dementia, stroke, 
or Parkinson’s disease diagnosis (n=3175). All of the included participants were thus free 
from neurodegenerative diseases and stroke at time of their test assessments. In total, 
155 347 cognitive function assessments from 9514 participants and 62 545 motor function 
assessments from 8297 participants were available for analyses. 
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Assessment of cognitive function
Between 1997 and 2016, participants underwent cognitive assessments at the research centre 
using a neuropsychological test battery every three to six years.6,21 This battery included the 
Word Fluency Test,23 Letter-Digit Substitution Test,24 and Stroop Test (Reading, Naming, and 
Interference subtask).25 In 2002, the 15-Word Learning Test (Immediate recall, Delayed recall, 
and Recognition) was added to the test protocol.26 This test protocol was further expanded with 
the Design Organisation Test in 2006.27 Assessments of these cognitive tests have previously 
been validated and have a reasonable to good test-retest reliability.28-31
Word Fluency Test
In the Word Fluency Test, participants were asked to mention as many animals as possible 
within sixty seconds, thereby measuring semantic fluency.23 The total number of correct 
answers was used as test score, with a maximum score of thirty in our study protocol. 
Letter-Digit Substitution Test
The Letter-Digit Substitution Test is a modified version of the Symbol Digit Modalities Test for 
which participants were asked to write down as many numbers underneath the corresponding 
letters as possible within sixty seconds, following a key that shows correct combinations.24 
This test captures both information processing speed and aspects of executive function. The 
total number of correct answers was used as test score with a maximum attainable score of 
125.
Stroop Test
The Stroop Test consists of three different subtasks, i.e., Reading, Naming, and Interference.25 
In the Stroop Reading subtask, participants were asked to read the printed colour names. For 
the Stroop Naming subtask, participants were asked to name the printed colour blocks. In 
the Interference subtask, participants were asked to name the ink colour of colour names 
printed in incongruous ink colours (information processing on an interference subtask). The 
time taken to complete the subtask was used as the outcome for each subtask separately 
and was adjusted for failures, i.e., total time plus for each failure the total time divided by the 
number of items, multiplied with 1.5.32 Thus, a higher score indicates a worse performance. 
The Stroop Test assesses information processing speed and executive function.
Word Learning Test 
The Word Learning Test comprises three subtasks: Immediate recall, Delayed recall, and 
Recognition.26 For Immediate recall, participants were three times visually presented with 
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a sequence of 15 words and were subsequently asked to recall as many of these words 
as possible, measuring verbal learning. Free Delayed recall was tested approximately ten 
minutes after visual presentation, evaluating retrieval from verbal memory. Recognition was 
tested by visually presenting the participants a sequence of 45 words, followed by correctly 
recognising the 15 words presented during the Immediate recall while mixed with 30 other 
words. Outcome variables were the mean number of words of three trials immediately recalled 
(as a summary score for Immediate recall), after the delay of ten minutes (as a score for free 
Delayed recall), and the mean number of correctly recognised words during the recognition 
trial (as a score for Recognition), with a maximum score of 15 per subtask.
Design Organisation Test 
The Design Organisation Test consists of square black-and-white grids with visual patterns, 
of which participants were asked to reproduce as many designs as possible in two minutes 
using a numerical code key. It measures visuospatial abilities and is based on and highly 
correlated to WAIS-III block design,27 but is less dependent on motor skills. Test score on 
the Design Organisation Test has a range from 0 to 56 points for each individual, with higher 
scores indicating better performance.
Assessment of motor function
Participants repeatedly underwent motor tests every three to six years at the research centre 
between 1999 and 2016. This motor test battery included two tests to assess fine motor function 
and a quantitative gait assessment to assess gross motor function. From 1999 onwards, the 
Purdue Pegboard Test was implemented into the study protocol to assess manual dexterity. 
Assessment of fine motor function was further expanded in 2008 with the implementation 
of the Spiral Archimedes Test to assess manual precision. In 2009, a quantitative gait 
assessment using an electronic walkway at the research centre was implemented in the core 
study protocol.
Purdue Pegboard Test 
For the Purdue Pegboard Test, participants were asked to place as many as possible cylindrical 
metal pegs into one of the 25 holes in a pegboard in thirty seconds in three separate trials, 
using their left hand only, right hand only, and both hands simultaneously, measuring fine 
motor function.33 The test-retest reliability of assessments has been established previously. 
The outcome variable was the sum-score of Purdue Pegboard Test score of these three trials, 
with a maximum of 75 points. 
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Archimedes Spiral Test
The Archimedes Spiral Test measures fine motor function by requiring participants to trace a 
picture of a spiral template that was printed on paper attached to an electronic drawing board 
(WACOM Graphire Wireless Pen Tablet, model CTE-630BT).7 Participants were instructed to 
trace the spiral as accurately and as fast as possible using a special pen with their dominant 
hand, starting in the middle (Supplementary Figure 1). Automatic quantitative analyses were 
done using custom-made software written in MatLab (version 8.1, The Mathworks, Natick, 
MA, USA), and processed and visually inspected by two trained physicians (S.L., S.K.L.D.) 
for analyses (intraclass correlation coefficient for interrater reliability for all test components 
>.95). A smoothly drawn spiral would have a length of drawing about 56 cm (the length of the 
template) with little deviation from the template, a low variability in speed, and no crossings 
(Supplementary Figure 1). The mean amplitude in deviation from the template to spiral 
drawing (cm) was used as outcome, since it is sensitive to capture small differences in fine 
motor function.7 A higher deviation indicates worse performance.
Gait assessment
Gait was evaluated using a 5.79m long walkway (GAITRite Platinum, CIR systems, Sparta, 
NJ: 4.88m active area, 120-Hz sampling rate).21 The reliability and validity of assessments 
obtained with this device have previously been established.34 The standardised gait protocol 
comprises three walking conditions: normal walk, turning, and tandem walk. In the normal 
walk, participants walked at their usual pace across the walkway. In turning, participants 
walked at their usual pace, turned halfway, and returned to the starting position. In the tandem 
walk, participants walked heel-to-toe on a line across the walkway. Based on the recorded 
footfalls, the walkway software calculated thirty parameters, including 25 from the normal 
walk, two from turning, and three from the tandem walk. In Supplementary Table 1, we 
provide descriptions of the thirty gait parameters.
 To summarise these thirty gait parameters into several independent domains, we log-
transformed skewed gait parameters to obtain a normal distribution, and subsequently 
standardised all continuous gait parameters. Next, we conducted a principal component 
analysis with Varimax rotation to derive gait domains, as previously described.35 This yielded 
seven gait domains with an eigenvalue > 1, which we labelled in accordance with the gait 
parameter that had the highest correlation coefficient with the corresponding domain: rhythm 
(step time), variability (standardised step length), phases (double support), pace (velocity), 
tandem (sum of step distance), turning (turning time), and base of support (stride width).35 
These gait domains are illustrated in Supplementary Figure 2. Higher values of the gait 
domains except ‘pace’, represent worse gait performance. Based on these seven gait 
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domains, the Purdue Pegboard Test and the Archimedes Spiral Test, a total of nine different 
facets of motor function were available for analysis.
Assessment of study population characteristics 
During home interviews, educational level was assessed and categorised as primary 
education (‘primary’), lower or intermediate general education, or lower vocational education 
(‘lower’), intermediate vocational education or higher general education (‘intermediate’), 
and higher vocational education or university (‘higher’). Smoking and alcohol habits were 
assessed during the same home interviews. Participants were categorised as current, former, 
or never smokers. Alcohol habits were classified into any use or no use of alcohol. At the 
research centre, height and weight were measured from which the body mass index (BMI, 
kg/m2) was computed. Blood pressure was measured twice in sitting position on the right arm 
using a random-zero sphygmomanometer, and the average of two measurements was used. 
In addition, non-fasting blood samples were collected and glucose levels were determined. In 
the initial subcohort, diabetes mellitus was defined as a random or post-load serum glucose 
concentration ≥11.1 mmol/L, or the use of drugs to lower blood glucose. In the first and second 
extension subcohorts, diabetes mellitus was defined as a fasting serum glucose concentration 
≥7.0 mmol/L, a non-fasting serum glucose concentration ≥11.1 mmol/L (only if fasting serum 
was unavailable), or usage of blood glucose lowering drugs. APOE genotype was determined 
using polymerase chain reaction on coded DNA samples in the initial cohort and with a bi-
allelic TaqMan assay in the two extensions.36,37 APOE ε4 carrier status was defined as carrier 
of one or two APOE ε4 alleles.
Statistical analysis
We assessed trajectories of cognitive and motor function using linear mixed models with 
random intercepts and slopes. If models did not converge with both random intercepts and 
slopes, only a random intercept was used. Age of the participant at time of cognitive or motor 
function assessment was used as underlying time scale. To capture possible non-linearity, 
we included natural cubic splines of age with one, two, or three knots, depending on model 
performance determined by a likelihood ratio test (P<.05). Knots were defined at the median, 
tertiles, or quartiles for respectively one, two, or three knots. We only reported P-values for 
each of the age intervals, since appropriate interpretation of effect estimates is hindered by 
the inclusion of natural cubic splines in the models. Skewed test outcomes (i.e., Stroop Tests, 
Word Learning Test: Recognition subtask, Archimedes Spiral Test, and gait domains ‘variability’ 
and ‘tandem’) were natural log-transformed to reach an approximate normal distribution, and 
were back-transformed for visualisation. In addition, we visualised trajectories of cognitive 
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and motor function by sex, education, or both, using interaction terms on the additive scale 
between age and sex, age and educational level, and age with sex and educational level. 
 Missing data on educational level (1.1%) were imputed by chained equations with five 
iterations. We generated one imputed dataset based on age at baseline and sex. Furthermore, 
we assessed trajectories for APOE ε4 carriers and non-carriers separately by including an 
interaction term between age and APOE ε4 status. This analysis was limited to the participants 
with known APOE ε4 status (N participants = 8986 for cognitive tests and N participants = 
7835 for motor tests).
 Next, we repeated these analyses by standardising the cognitive and motor test results to 
the test performance of the age of 45 years (study baseline) to investigate the temporal course 
of change across tests with ageing. Skewed test outcomes were natural log-transformed before 
standardisation. We depicted a threshold of decline in performance of 0.5 and 1.0 standard 
deviation (SD) compared to the test score at age 45 years. We subsequently assessed the 
age at which the test score had reached a decline of 0.5 and 1.0 SD compared to the test 
result at age 45 years. 
 Data were analysed with SPSS Statistics version 24.0 (IBM Corp., Armonk, NY) and R, 
CRAN version 3.4.3 ‘mice’ and ‘nlme’ packages.38,39
RESULTS
Characteristics of the study population at time of study entry are presented in Table 1. A total 
of 9514 participants contributed to the cognitive function assessments. The mean (SD) age 
at first cognitive assessment was 64.7 years (9.5) and 5442 (57.2%) of the participants were 
women. Of all participants, 2058 (21.6%) had a single cognitive assessment, 4362 (45.8%) 
had two, 1174 (12.3%) had three, and 1920 (20.2%) had at least four cognitive assessments. 
The mean interval between tests was 5.1 years (1.4). During follow-up up to January 1st, 2016, 
2977 out of 9514 participants (31.3%) died.
 A total of 8297 participants contributed to the motor function assessments with a mean 
(SD) age at first assessment of 64.6 years (10.0), of whom 4737 (57.1%) were women (Table 
1). Out of these participants, 2136 (25.7%) had a single motor function assessment, 4192 
(50.5%) had two, 1091 (13.1%) had three, and 878 (10.6%) had four motor assessments with 
a mean (SD) test interval of 5.4 years (1.4). Out of 8297 participants, 1903 died (22.9%) during 
follow-up. The number of participants per cognitive and motor test is shown in Supplementary 
Table 2. Supplementary Table 3 shows the characteristics of the excluded participants. 
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Overall, excluded participants were older at study entry, attained more often a lower level of 
education, and had a higher mean systolic blood pressure than included participants.
Trajectories of cognitive function
Performance on the cognitive tests declined with advancing age. Decline on cognitive tests 
was generally linear between ages 45 and 65 years, followed by a steeper, non-linear decline. 
Men had higher scores on most cognitive tests and generally declined less fast than women 
(P=.003 for Letter-Digit Substitution Test, P=.02 for Word Learning Test: Immediate recall, 
P=.05 for Word Learning Test: Delayed recall). These differences between men and women 
disappeared after assessing the trajectories per educational level, suggesting that sex-
differences were largely attributable to differences in the level of attained education between 
men and women. As such, results from here onwards are presented per educational level for 
men and women combined. 
 For each higher level of attained education, participants showed better performance on 
all cognitive tests at age 45 years (Figure 1). Differences in trajectories of cognitive function 
between participants with ‘primary’ educational level and participants with other educational 
levels became larger with advancing age, albeit not statistically significant. In addition, 
participants with ‘higher’ education declined slower than those with ‘primary’ education 
over time on the Interference subtask of the Stroop Test (P=.002, Figure 1E) and the Word 
Learning Test: Recognition subtask (P=.017, Figure 1H). However, they declined faster than 
participants with ‘primary’ education on the Word Fluency Test (P=.048, Figure 1A) and the 
Word Learning Test: Delayed recall subtask (P=.007, Figure 1G).
 Regarding APOE ε4 carrier status, carriers declined faster on all cognitive tests than 
non-carriers (P for interaction between age and APOE ε4 carrier status <.005), except on 
the Design Organisation Test that showed similar trajectories for carriers and non-carriers 
(Supplementary Figure 3).
Trajectories of motor function
Trajectories of decline in motor function varied across different motor tests (Figure 1) with 
the gait domain ‘phases’ and the Purdue Pegboard Test declining first at the age of 56 and 
60 years, respectively. Performance on the gait domains ‘rhythm’, ‘tandem’, and ‘base of 
support’ remained largely stable over time. Significant differences between men and women 
were only found for trajectories of the domain ‘tandem’ and ‘phases’, with women performing 
increasingly worse over age than men (P=.005 for ‘tandem’ and P<.001 for ‘phases’). 
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Table 1 Characteristics of the study populations.
Characteristic
Analysis of cognitive 
function
(N=9514)
Analysis of motor 
function
(N=8297)
Age at study entry, years, mean (SD) 62.0 (7.9) 60.9 (7.4)
Age at first assessment, years, mean (SD) 64.7 (9.5) 64.6 (10.0)
Women, No. (%) 5442 (57.2) 4737 (57.1)
Educational level, No. (%)
 Primary 1160 (12.2) 886 (10.7)
 Lower 3889 (40.9) 3375 (40.7)
 Intermediate 2751 (28.9) 2422 (29.2)
 Higher 1714 (18.0) 1614 (19.5)
Number of assessments*, No. (%)
 1 2058 (21.6) 2136 (25.7)
 2 4362 (45.8) 4192 (50.5)
 3 1174 (12.3) 1091 (13.1)
 ≥4 1920 (20.2) 878 (10.6)
Median number of assessments (range) 2 (1-6) 2 (1-4)
Test assessment interval, years, mean (SD) 5.1 (1.4) 5.4 (1.4)
Body mass index, kg/m2, mean (SD) 27.0 (4.1) 27.1 (4.2)
Systolic blood pressure, mm Hg, mean (SD) 136 (20.8) 136 (20.6)
Diabetes mellitus, No. (%) 865 (9.1) 735 (8.9)
Smoking, n (%)
 Never 2941 (30.9) 2522 (30.4)
 Former 4558 (47.9) 4063 (49.0)
 Current 1944 (20.4) 1663 (20.0)
 Alcohol use, No. (%) 7760 (81.6) 6928 (83.5)
APOE ε4 carrier, No. (%) 2539 (26.7) 2217 (26.7)
Characteristics were measured at study entry except for age at first assessment.
Missing values for all characteristics but educational level were not imputed and therefore numbers do 
not always sum up to 100%.
* Gait was considered as one assessment, because virtually all participants (95%) with an available gait 
assessment had complete values for all underlying gait parameters. Therefore, the presented number of 
motor assessments is independent from the number of underlying available gait parameters that were 
used to compute seven gait domains.
APOE = apolipoprotein E, N = number of participants, SD = standard deviation.
 In contrast to the effects of education on cognitive function, motor function trajectories 
were not associated with educational level (Figure 1), but those with a ‘primary’ educational 
level performed better over time on the Purdue Pegboard Test than participants with other 
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educational levels (P<.016, Figure 1J). In addition, they decreased less fast on the gait 
domains ‘rhythm’, ‘phases’, and ‘turning’ than participants with higher educational levels (P for 
all tests <.039, Figures 1L, 1N, and 1Q). 
 APOE ε4 carriers performed worse with advancing age than non-carriers on the Purdue 
Pegboard Test and on the gait parameters ‘phases’, and ‘turning’ (P for all tests <.034, 
Supplementary Figure 3).
Sequence of change in cognitive and motor function 
Before the age of 75 years, most cognitive and motor test scores had reached a decline 
of 0.5 SD in standardised test score compared to test scores at age 45 years (Figure 2). 
Considering both cognitive and motor tests, the decline of 0.5 SD was first reached for the 
Stroop Test: Interference subtask at the age of 58 years. This was followed by the Design 
Organisation Test at the age of 59 years and the Stroop Test: Naming subtask at the age of 64 
years. Of all motor tests, the gait domain ‘phases’ showed the fastest decline, reaching a 0.5 
SD decrease in test score at the age of 58 years. Across all tests, the average time between 
the age of 45 years and the age at which 0.5 SD decrease in test score was reached, was 
shorter for cognitive tests than for motor tests (20.0 versus 24.7 years, respectively, P=.039). 
By contrast, the time between 0.5 SD and 1.0 SD decrease in test scores was longer for 
cognitive than for motor tests (11.2 years versus 8.9 years, respectively, P<.001). 
DISCUSSION
In this population-based study, we showed that both cognitive and motor function generally 
decline linearly between the ages 45 and 65 years, followed by a steeper decline after the 
age of 65 to 70 years. Test scores for cognitive and motor function declined similarly, with high 
variation in the rate of decline across age for individual tests. Importantly, whereas a higher 
level of education was associated with higher cognitive function, there was no association 
between level of education and function on the majority of the motor tests.
 Various studies have reported changes in cognitive function with ageing, but evidence 
on the temporal relation between change in cognitive compared to motor function is limited. 
Most evidence has come from memory clinics,11 or from studies that have solely relied on gait 
speed to assess motor function.11,19,40-44 These studies have closely linked global cognitive 
function to gait speed. As yet, no studies have investigated differences in performance on 
specific cognitive tests nor studied other facets of motor function, such as fine motor skill. 
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These knowledge gaps remain unaddressed since prior studies have found that decline of 
cognitive and motor function may vary, or that one may predate the other.12,45-47 Most of these 
studies have been conducted in older participants (aged 70 years and older), with a limited 
sample size (varying between 488 and 2276 participants), or with relatively short follow-up 
(ranging from five to seven years). The current study is able to extend these findings by 
leveraging a detailed set of cognitive and motor tests among a broader age range (ages 45 to 
90 years) in a larger, population-based sample (N≥8297) with up to six repeated assessments 
during a maximum follow-up of 19.4 years.
 We did not find distinct patterns of an overall decline in cognitive function preceding motor 
function or vice versa, yet we observed large variability in test-specific decline. For instance, 
tendency to shuffle (‘phases’ gait domain) and fine motor function generally started to show 
initial signs of decline up to 25 years earlier than widely used cognitive (screening) tests, 
such as the Word Learning Tests: Delayed recall and Recognition.11,40-42,48 These findings may 
be explained by accelerating changes in brain structure during ageing, with loss of white 
matter preceding loss of grey matter.20,49 We indeed observed the earliest changes in cognitive 
and motor domains that depend on white matter integrity, including information processing 
speed, executive function, and the gait domain ‘phases’.20,50-52 In contrast, cognitive and motor 
domains related to alterations in grey matter volume (i.e., memory and the gait domain ‘base 
of support’) showed a later decline in function than those related to white matter integrity.20,51-53
 Variability in test-specific decline may also be explained by diseases and common 
comorbidities in these older adults, such as cardiovascular diseases, depression, respiratory 
diseases, cancer, or impairments in sensory organs.54-57 These may differentially influence 
cognitive compared to motor function in some individuals. As an example, presence of 
peripheral artery disease or arthrosis limits walking speed, but does not directly influence 
executive functioning as assessed by the Stroop Task.58 The contribution of these potentially 
modifiable determinants to sequence of test-specific decline and the shape of these trajectories 
was beyond the scope of the present study, and warrants further investigation using more 
advanced statistical models.
 As expected, we found that participants with a higher educational level had higher baseline 
scores (scores at age 45 years) for cognitive tests than participants with a lower educational 
level. Regarding the rate of change in cognitive function, we found that participants with a 
‘primary’ educational level declined faster on most tests than higher educated participants. 
The declines over time were largely similar among ‘lower’, ‘intermediate’, and ‘higher’ 
educated participants. This implies that higher educated individuals are generally older 
when they reach the same cognitive test performance than lower educated individuals. As 
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Figure 1 Trajectories of cognitive and motor function.
The thick black continuous line reflects the trajectory of performance for the total study population based 
on the results of the linear mixed model, the black dotted lines represent the 10th and 90th percentile 
curves. Test performance was visualised per educational level in red for cognitive tests and in blue for 
motor tests. 
* Higher scores indicate worse performance. † Percentile curves could not be calculated and are therefore 
not shown, since the majority of the test scores was equal to 0.
Figure 2 Sequence of decline of cognitive and motor function (right page). 
Decline was defined as reaching an average population test score of 0.5 or 1.0 SD below the population 
mean of the test score at age 45 years. The circle or triangle is displayed at the age at which 0.5 SD 
(opaque) or 1.0 SD (transparent) lower score was reached with cognitive tests depicted in red circles and 
motor tests in blue triangles. The dotted line represents time between mean population test score at age 
45 years and the age at which 0.5 SD decrease in that test score is reached. The continuous line denotes 
time between the age at which 0.5 SD decrease in the test score was reached and the age at which 1.0 
SD in the test score was reached. The Word Learning Test: Recognition subtask and the gait domains 
‘tandem’ and ‘base of support’ did not reach a score of 0.5 SD lower at a certain age than the score at age 
45 years and are therefore not shown. 
This sequence of decline was estimated based on the total study population. Note that not all participants 
had all cognitive and motor tests completed.
SD = standard deviation.
























































































































































































































































































































































































































Word Learning Test: Delayed recall subtask score, reveals that at age 45 years, the lowest 
educated individuals remembered on average eight of the 15 originally presented words after 
ten minutes. The highest educated individuals however attained this same score when they 
were on average 73 years. Yet, no association was found between educational level and 
motor function for the majority of the motor tests. These findings support emerging evidence 
that cognitive reserve, operationalised by for example educational attainment, could have 
long-lasting compensatory effects on cognitive but not on motor function, with the potential to 
postpone cognitive decline and thereby the clinical diagnosis of dementia.59-61 
 This study has several limitations. First, given that participants underwent most cognitive 
tests at the research centre, we cannot exclude that selection bias may have influenced our 
results, with those who are considered less healthy being less likely to participate. Therefore, 
the presented test scores on cognitive and motor function may be an overestimation of the 
true performance in the general population, especially for those at older ages.62 Second, 
repetitive administering of cognitive tests can lead to learning effects, which could have led to 
overestimating performance with increasing age. However, these effects are expected to be 
limited, since the median test interval was 5.1 years for cognitive assessments and 5.4 years 
for motor assessments. Third, in the early nineties, the completed level of education was 
determined by several factors including sex and social economic status. As such, educational 
attainment in this study may not be a proper proxy for cognitive reserve in women. Lastly, 
we estimated trajectories of cognitive and motor function at a population-level, yet deviations 
from this pattern on an individual level may signal an under recognised group at high risk for 
neurodegenerative diseases and stroke. Strengths of this study include the large sample size 
and the repeated and simultaneous assessments of cognitive and motor function in a single, 
community-dwelling population.
 In this study, we present trajectories of decline of both cognitive and motor functioning 
among individuals aged 45 to 90 years in the general population. Such data are essential to 
understand the natural course of cognitive and motor function during ageing. Cognitive and 
motor function decline similarly during ageing, characterised by a linear decline between the 
ages 45 and 65, and a steeper decline thereafter. Higher educational attainment was related 
to higher cognitive function at baseline and to a slower rate of subsequent decline, but it did 
not affect motor function. In the sequence of decline across individual tests, up to a 25-year 
age difference between the fastest and slowest declining test scores was observed.
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Supplementary Figure 1 Spiral test.
Example of a spiral-drawing quantification, showing an example of the calculation of quantitative measures 
of fine motor skills. The start and endpoint are indicated by a dot. The Figure explains how deviation from 




stride length double support percentage stride length
cumulative distance
of side steps turning time variability in step length
Pace Phases Rhythm
Turning Variability
Supplementary Figure 2 Gait domains. 
To summarise gait parameters into independent domains, we conducted a principal component analysis. 
This yielded seven independent gait domains: ‘base of support’, ‘pace’, ‘phases’, ‘rhythm’, ‘tandem’, 
‘turning’, and ‘variability’. For each gait domain, a single gait parameter that has high correlation with the 
domain is illustrated.
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Supplementary Figure 3 Trajectories of cognitive and motor function stratified by APOE ε4 carrier 
status. 
Test performance was visualised for APOE ε4 carrier status level in red for cognitive tests and in blue 
for motor tests. Participants with unknown APOE ε4 carrier status were excluded for analysis regarding 
APOE ε4 carrier status (528 out of 9514 participants for cognitive tests and 462 out of 8297 participants 
for motor tests).
* Higher scores indicate worse performance.
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Supplementary Table 1 Description of original gait parameters.





The time elapsed between the last contact of 
the opposite foot and the first contact of the 




The time elapsed between the last contact of 
the current footfall to the first contact of the 
next footfall on the same foot in seconds
Higher Rhythm
Step time
The time elapsed between the first contact of 




The elapsed time between the first contacts of 
two consecutive footfalls of the same foot in 
seconds
Higher Rhythm
Cadence The number of steps/minute Lower Rhythm
Stance time
The time elapsed between the first contact and 
the last contact of two consecutive footfalls on 
the same foot in seconds. It is initiated by heel 





The standard deviation in the stride length in 
centimetres Higher Variability
Step length SD The standard deviation in the step length in centimetres Higher Variability
Stride velocity 
SD
The standard deviation in the stride velocity 
(stride length/stride time) in centimetres/
second
Higher Variability
Stride time SD The standard deviation in the stride time in seconds Higher Variability
Step time SD The standard deviation in the step time in seconds Higher Variability
Stance time 
SD
The standard deviation in the stance time in 
seconds Higher Variability
Swing time SD The standard deviation in the swing time in seconds Higher Variability
Single support 
time SD
The standard deviation in the single support 
time in seconds Higher Variability
Double support 
time SD
The standard deviation in the double support 
time in seconds Higher Variability
Single support 
(%GC)
The single support time as a percentage of the 
stride time Lower Phases
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Supplementary Table 1 Description of original gait parameters (continued).
Parameter Description Indication of “worse” gait 
Main underlying 
domain
Swing (%GC) The swing time as a percentage of the stride time Lower Phases
Stance (%GC) The stance time as a percentage of the stride time Higher Phases
Double support 
(%GC)
The double support time as a percentage of 
the stride time Higher Phases
Double support 
time
The amount of time that two feet are on the 




The distance between the heel points of two 
consecutive footprints of the same foot on the 
line of progression in centimetres
Lower Pace
Step length
The distance between the heel points of two 
consecutive opposite footprints on the line of 
progression in centimetres
Lower Pace
Velocity The velocity in centimetres/second Lower Pace
Sum of feet 
surface
The sum of the surfaces of the side steps* as a 
percentage of the surface of a normal step Higher Tandem
Sum of step 
distance
The sum of the distances of the side steps* 
from the line on the walkway in centimetres Higher Tandem
Double step
A double-step was a step with one foot, 
followed by a step with the same foot, where 




The number of steps used within the turning 
time Higher Turning
Turning time
The turning time was defined as the time 
between the last contact of the second foot 
before the first turn foot and the first contact of 
the second foot with a normal angle coming out 
of the turn. In which the first turn foot is defined 
as the first foot deviating from the normal angle 




The standard deviation in the stride width in 
centimetres Higher Base of support
Stride width
The distance from heel centre of one footprint 
to the line of progression formed by two 
footprints of the opposite foot in centimetres
Lower Base of support
* A sidestep was defined as a step next to the line on the walkway, which was followed by a step with the 
same foot or a step with the other foot. 
SD = standard deviation, %GC = as a percentage of the stride time. 
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Supplementary Table 2 Overview of number of participants per cognitive and motor test.




Analysis of motor 
function
(N=8297)
Word Fluency Test 9458 (99.4)
Letter-Digit Substitution Test 9419 (99.0)
Stroop Test: Reading 9311 (97.9)
Stroop Test: Naming 9300 (97.8)
Stroop Test: Interference 9281 (97.6)
Word Learning Test: Immediate recall 7875 (82.8)
Word Learning Test: Delayed recall 7875 (82.8)
Word Learning Test: Recognition 7882 (82.8)
Design Organisation Test 5561 (58.5)
Purdue Pegboard Test 8225 (99.1)
Archimedes Spiral Test 5424 (65.4)
Gait assessments 4154 (50.1)
Numbers are presented as number of participants per cognitive or motor test (% of total number of 
participants for cognitive or motor tests).
N = number of participants.
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Aged ≥90 years 
at time of first 
assessment 
(N=33)
Age‡, years, mean (SD) 73.0 (13.7) 72.6 (9.3) 88.2 (4.7)
Women, No. (%) 2509 (64.8) 844 (56.5) 19 (57.6)
Educational level, No. (%)
 Primary 1087 (28.1) 466 (31.2) 11 (33.3)
 Lower 1327 (34.3) 575 (38.5) 10 (30.3)
 Intermediate 802 (20.7) 334 (22.4) 6 (18.2)
 Higher 341 (8.8) 90 (6.0) 3 (9.1)
Body mass index, kg/m2, mean (SD) 26.6 (4.0) 26.4 (4.1) 25.6 (2.9)
Smoking, No. (%)
 Never 1367 (35.3) 486 (32.5) 18 (54.5)
 Former 1403 (36.2) 567 (38.0) 11 (33.3)
 Current 805 (20.8) 399 (26.7) 1 (3.0)
Alcohol use, No. (%) 1663 (42.9) 781 (52.3) 17 (51.5)
Systolic blood pressure, mm Hg, mean (SD) 143 (22.9) 144 (23.6) 145 (18.9)
Diabetes mellitus, No. (%) 527 (13.6) 211 (14.1) 5 (15.2)
APOE ε4 carrier, No. (%) 714 (18.4) 364 (24.4) 6 (18.2)
Characteristics are measured at study entry.
Missing values for all characteristics are not imputed and therefore numbers do not always sum up to 
100%.
* In total, 5405 out of 14 926 participants were excluded. Characteristics of participants without consent for 
follow-up (n=5) are not shown. † Also comprises participants with insufficient data to determine a history 
of one of these diseases. ‡ Age at study entry, not age at first assessment. 
APOE = apolipoprotein E, N = number of participants, SD = standard deviation.
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Trajectories of cognitive function prior to cancer diagnosis
van der Willik KD, Hauptmann M, Jóźwiak K, Vinke EJ, Ruiter R, 




Background An emerging body of research suggests that non-central nervous system (CNS) 
cancer may negatively impact the brain apart from effects of cancer treatment. However, 
studies assessing cognitive function in newly diagnosed cancer patients cannot exclude 
selection bias and psychological effects of cancer diagnosis. To overcome these limitations, 
we investigated trajectories of cognitive function in patients before cancer diagnosis.
Methods Between 1989 and 2013, 2059 participants from the population-based Rotterdam 
Study were diagnosed with non-CNS cancer. Cognitive assessments were performed every 
three to six years using a neuropsychological battery. The general cognitive factor was 
composed of individual cognitive tests to assess global cognition. Using linear mixed models 
we compared change in cognitive function in cancer cases before diagnosis with cognitive 
change in age-matched cancer-free controls (1:2). In addition, we performed sensitivity 
analyses by discarding assessments of controls five years before the end of follow-up to 
exclude effects from potential undiagnosed cancer. All statistical tests were two-sided.
Results The Word Learning Test: Immediate recall declined faster among cases than among 
controls (-0.05 [95% confidence interval = -0.09 to -0.01] versus 0.01 [95% confidence 
interval = -0.01 to 0.03], P for difference = .003). However, this difference was not statistically 
significant in sensitivity analyses. Furthermore, no statistically significant differences were 
observed in change in other individual cognitive tests and in the general cognitive factor.
Conclusions In this study we evaluated cognitive function in a large group of cancer patients 
prior to diagnosis, thereby excluding the psychological impact of cancer diagnosis and biased 
patient selection. In contrast to previous studies shortly after cancer diagnosis, we found no 
difference in change in cognitive function between cancer patients and controls.
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INTRODUCTION
About 20 to 30% of the patients with non-central nervous system (CNS) cancer report cognitive 
problems following cancer diagnosis and cancer treatment that can persist into the survivorship 
period.1-3 Whereas most studies have focused on the effects of chemotherapy on the brain, 
more recent evidence has shown that newly diagnosed cancer patients may already perform 
lower than expected on cognitive tests prior to cancer treatment, including surgery.4-9 Although 
these patients have just been confronted with a cancer diagnosis, cognitive impairment 
persisted after statistical correction for psychological distress and fatigue. This suggests that 
shared risk factors for both cancer and cognitive impairment, such as genetic susceptibility, 
ageing, and lifestyle could contribute to the development of cognitive impairment in cancer 
patients.10 Also, tumour growth itself may cause cognitive impairment, for instance through 
inflammatory or vascular processes.5,11 
 If the previously reported cognitive impairment in newly diagnosed cancer patients is 
related to shared risk factors for both cancer and cognitive impairment or to a growing, yet 
undiagnosed, cancer, it is conceivable that future cancer patients would already demonstrate 
altered cognitive function compared to cancer-free controls some time before cancer diagnosis. 
Based on this reasoning, it is expected that cancer patients’ cognitive function declines faster 
prior to cancer diagnosis than cognitive function in controls.
 Understanding the origin of cognitive impairment in cancer patients is essential for 
prevention and treatment. We aimed to contribute to this understanding by evaluating cognitive 
function in cancer patients longitudinally prior to the clinical manifestation of the disease. We 
evaluated the longitudinal change in cognitive function to learn about the effect of shared risk 
factors and cancer itself as determinants of cognition. This approach is superior to a cross-
sectional comparison of absolute cognition levels prior to diagnosis because it includes all 
available assessments. Using the unique context of a population-based cohort, we compared 
cognitive trajectories between individuals prior to cancer diagnosis and individuals who 





We used data from the Rotterdam Study, a Dutch population-based prospective cohort. The 
initial cohort (RS-I) started in 1989 with 7983 participants aged 55 years and older who reside 
in the district Ommoord in Rotterdam, the Netherlands. The cohort was expanded with 3011 
participants in 2000 (RS-II), followed by an additional inclusion of 3392 participants aged 45 
years and older in 2006 (RS-III). 
 Participants were interviewed at home by a trained research assistant, followed by two 
visits to the research facility for laboratory assessments, imaging, and physical examinations. 
Follow-up examinations are aimed to take place every three to six years. The design of the 
Rotterdam Study has been previously described in detail.12 
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands. Written 
informed consent was obtained from all participants.
Study population
Of the 14 926 participants of the Rotterdam Study, we excluded those with a history of 
cancer at study entry (n=566), prevalent dementia at study entry (n=521), those who were 
insufficiently screened for prevalent dementia (n=601), a history of stroke (n=341), and those 
without informed consent to access medical records for follow-up (n=165), leaving 12 732 
eligible participants (Figure 1).
Cases
Of the 2308 participants who were diagnosed with cancer during follow-up (between 1989 and 
2013), we excluded those with primary CNS cancer (n=15), dementia before cancer diagnosis 
(n=62), stroke before cancer diagnosis (n=99), and participants without cognitive test results 
prior to cancer diagnosis (n=73), resulting in 2059 cases.
Controls
From participants who remained cancer-free during follow-up (n=10 424), we excluded 
cognitive test results after dementia or stroke diagnosis. Although this exclusion resulted in 
a lower number of assessments, it did not change the number of cancer-free participants, 
because participants with a history of dementia or stroke at study entry were already excluded 
(Supplementary Table 1). Subsequently we excluded participants without cognitive test 
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Figure 1 Flowchart of study population, separately for cancer cases and cancer-free 
controls per cognitive test. 
* The number of assessments discarded after dementia or stroke diagnosis and after matching are 
presented in Supplementary Table 1. 
CNS = central nervous system, LDST = Letter-Digit Substitution Test, MMSE = Mini-Mental State 






• History of cancer (n=566)
• History of dementia (n=521)
• Not sufficiently screened for             
history of dementia (n=601)
• History of stroke (n=341)
• No informed consent (n=165)
Participants with incident cancer
(n=2308)
Excluded
• CNS cancer (n=15)
• Dementia before cancer (n=62)
• Stroke before cancer (n=99)
• No cognitive test results before 
cancer diagnosis (n=73)
Incident cancer cases (n=2059)




• Stroop Test: Reading (n=1237)
• Stroop Test: Naming (n=1234)
• Stroop Test: Interference (n=1231)
• PPT (n=904)
• WLT: Immediate recall (n=782)
• WLT: Delayed recall (n=782)
• WLT: Recognition (n=784) 
• General cognitive factor (n=701)
Excluded
• No cognitive test results before 
censoring (n=224)
Cancer-free controls (n=10 200)
Eligible controls per cognitive test
• MMSE (n=10 182)
• LDST (n=8074)
• WFT (n=8114)
• Stroop Test: Reading (n=7994)
• Stroop Test: Naming (n=7985)
• Stroop Test: Interference (n=7968)
• PPT (n=7145)
• WLT: Immediate recall (n=6892)
• WLT: Delayed recall (n=6892)
• WLT: Recognition (n=6899)
• General cognitive factor (n=6425)
Participants without incident cancer 
(n=10 424)
Matching of cases and controls




• Stroop Test: Reading (n=1237)
• Stroop Test: Naming (n=1234)
• Stroop Test: Interference (n=1231)
• PPT (n=904)
• WLT: Immediate recall (n=782)
• WLT: Delayed recall (n=782)
• WLT: Recognition (n=784) 
• General cognitive factor (n=701)




• Stroop Test: Reading (n=2474)
• Stroop Test: Naming (n=2468)
• Stroop Test: Interference (n=2462)
• PPT (n=1808)
• WLT: Immediate recall (n=1564)
• WLT: Delayed recall (n=1564)
• WLT: Recognition (n=1568)
• General cognitive factor (n=1402)
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results before end of follow-up (n=224), leaving 10 200 participants as eligible controls.
Matching procedure
Each case was individually matched to two randomly selected cancer-free controls at the 
age of diagnosis of the case (index age). A participant was eligible as control if he or she had 
at least one cognitive assessment before index age and no dementia or stroke diagnosis 
prior to index age. To avoid overmatching, we only matched on index age.13 Assessments of 
controls after the index age were discarded (Supplementary Table 1). Matching started with 
the oldest case and was performed without replacement for each cognitive test separately. 
Ascertainment of cancer
Cancer incidence up to January 1st, 2014 was based on medical records of general practitioners 
(including hospital discharge letters) and through linkage with Dutch Hospital Data, Netherlands 
Cancer Registry, and histology and cytopathology registries in the region. Incident cancer was 
defined as any primary malignant tumour, excluding non-melanoma skin cancer. Diagnoses 
were coded independently by two physicians according to the International Classification of 
Diseases, tenth revision (ICD-10).14 In case of discrepancy, consensus was sought through 
consultation with a physician specialised in internal medicine. Date of diagnosis was based 
on date of biopsy (solid tumours) and laboratory assessment (haematological tumours), or – if 
unavailable – date of hospital admission or discharge letter. Level of uncertainty of diagnosis 
was defined as follows: certain (pathology-confirmed), probable (clinic-based on imaging 
or elevated tumour markers), and possible (clinic-based, suspicion based on symptoms 
or physical examination). Only pathology-confirmed cancers were included in the primary 
analysis. In sensitivity analyses, we included cases with probable or possible cancer and 
excluded controls who had probable or possible cancer.
Cognitive function assessment
Cognitive function was assessed by a neuropsychological test battery during research centre 
visits. Up to 2013, the following tests were administrated: Mini-Mental State Examination, 
Letter-Digit Substitution Test, Word Fluency Test, Stroop Test (Reading, Naming, and 
Interference), Purdue Pegboard Test (right, left, and both hands), and 15-Word Learning Test 
(Immediate recall, Delayed recall, and Recognition).15-20 
 A measure of global cognitive function was established by the general cognitive factor 
based on the Letter-Digit Substitution Test, Word Fluency Test, Stroop Test: Interference 
subtask, sum-score of individual Purdue Pegboard Test subtasks, and Word Learning Test: 
Delayed recall and was identified as the first unrotated component of a principal component 
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analysis which explained at least 46.1% of the total variance in individual cognitive tests.21 The 
general cognitive factor was only computed if all five individual tests were completed. 
 The total number of individuals differed per cognitive test because of different moments 
of implementation of cognitive tests in the examination program or because of missing data 
(Figure 1). All available cognitive test results prior to index age were included for analysis. An 
overview of the cognitive tests is provided in Supplementary Table 2. 
Measurement of covariates
During the home interview, we assessed educational level (primary: primary education; 
lower: lower or intermediate general education, or lower vocational education; intermediate: 
intermediate vocational education or higher general education; or higher: higher vocational 
education or university), smoking status (never, current, or former), and alcohol use (yes 
or no). Symptoms of depression were evaluated with the Centre for Epidemiologic Studies 
Depression scale (CES-D), which was converted to a sum-score.22 Body mass index (BMI, kg/
m2) was computed from measurements of height and weight. 
Statistical analysis
Each cognitive test was modelled with a two-level linear mixed model with the test result as 
the outcome and each observation representing one individual cognitive test result. Cognitive 
test results were transformed, if necessary, to reach an approximate normal distribution. When 
a transformation did not change the statistical significance, results were reported based on 
untransformed values for interpretation purposes. 
 Covariates were case-control status (cancer = 1 for cases, cancer = 0 for controls) and 
time of cognitive assessments expressed as time to index age (e.g. time = 0 for time at index 
age, time = -5 for 5 years prior to index age). An interaction term between these two variables 
reflects whether the change in cognitive function over time differs between cases and controls. 
Other covariates related to both change in cognitive function23-28 and cancer29-31 were age at 
first test (continuous), sex (women or men), educational level (primary, lower, intermediate, 
or higher), smoking status (never, current, or former), alcohol use (yes or no), CES-D sum-
score (continuous), and BMI (continuous). In case of time-varying covariates – that is smoking 
status, alcohol use, CES-D sum-score, and BMI – values of covariates measured closest to 
the date of cognitive assessment were used.
 Missing data on covariates were generally between 0% and 2%, except for the CES-D 
sum-score which was missing in 16% of the total study population. Missing values were 
replaced with mean (continuous) or mode (categorical) values of the observed data (cases 




Cognitive test resultij = (β00 + u0i) + (β1 + u1i)Timeij + β2Canceri + β3{Timeij*Canceri) + β4Agei + 
β5Sexi + β6Educationi + β7Smokingi + β8Alcoholi + β9CESDi + β10BMIi + εij 
 The β parameters are fixed effects, while the u parameters are random effects, allowing 
variation of the intercept and slope of time between subjects. A random intercept β00 + u0i was 
used to allow for differences in cognitive test results at time of index age (Timeij = 0). A random 
slope of time β1 + u1i allowed the change in cognitive function over time to vary between 
participants if the model fit improved based on the Bayesian Information Criterion (BIC). This 
criterion penalises -2 log likelihood by the number of parameters multiplied by the logarithm 
of the sample size. The model with the lowest BIC represents the best fitting model.32 The 
residual term ε was modelled with the autocorrelation structure of the variance-covariance 
matrix,33 and the general positive-definite matrix was used for the random part. The average 
change in cognitive test result per year for controls before index age was equal to β1, whereas 
the change for cases was equal to β1 + β3, i.e., β3 indicates whether the change differs between 
cases and controls. Sensitivity analyses comparing models with a random intercept only and 
with a random intercept and slope showed that the choice of models has no effect on β3 (data 
not shown). Furthermore, we evaluated non-linearity in time by determining whether including 
time squared improved the model fit. The normality assumption of the residuals was checked 
by visual inspection of the QQ-plots.
 We performed separate analyses for the most frequent cancer sites (breast, prostate, 
colorectal, and lung) for which the matching procedure was repeated, with breast cancer 
cases matched to female controls, and prostate cancer cases to male controls only. In 
addition, we investigated whether change in cognitive function was different in cases who had 
metastatic cancer at diagnosis compared to controls, excluding cases with unknown tumour 
stage (n=718 out of 2059).
 To investigate the robustness of our findings, we conducted two sensitivity analyses: (i) 
including cases and excluding controls with probable or possible cancer (i.e., cancer not 
confirmed by pathology); and (ii) discarding assessments of controls less than five years 
before the end of follow-up to minimise effects of potential undiagnosed cancer. 
 All statistical tests were two-sided and a P-value of less than .05 was considered 
statistically significant. Multiple testing for individual cognitive tests was accounted for by 
using the Bonferroni method so that a P-value of less than .005 was considered statistically 
significant. 
 Statistical analyses were performed using SPSS34 and the ‘nlme’ package from R software 
Version 3.3.2.35




At the first cognitive assessment, cases were older than controls and were more often men 
and current smokers (Table 1). Furthermore, controls had more often a higher education 
than cases. Mean (standard deviation [SD]) age at cancer diagnosis was 73.8 years (8.3). 
Most frequently diagnosed cancer sites were prostate (31.7% among men), breast (29.2% 
among women), colorectal (16.0%), and lung (12.1%). Of the cases with a known tumour 
stage (n=1341), 280 had metastatic cancer at diagnosis (20.9%). More details are presented 
in Supplementary Table 3. 
Change in cognitive function prior to cancer diagnosis
The Word Learning Test: Immediate recall declined among cases by 0.05 units per year 
prior to index age (95% CI = -0.09 to -0.01), whereas it increased by 0.01 units per year 
among controls (95% CI = -0.01 to 0.03; P for difference = .003, Table 2). The difference was 
statistically significant after correction for multiple testing and corresponds to 2.4 years of 
age, given a decline in the Word Learning Test: Immediate recall of 0.25 units per ten years.21 
Although the change over time was different, there was no statistically significant difference 
between cases and controls at index age. Furthermore, no statistically significant difference in 
change between cases and controls was observed for the other nine individual cognitive test 
scores. Also on the general cognitive factor no statistically significant difference was found 
between cases and controls (P=.613, Figure 2): cases decreased by 0.02 units per year (95% 
CI = -0.05 to 0.00) versus 0.03 units per year among controls (95% CI = -0.04 to -0.02). 
 Separate analyses by cancer site revealed relatively homogeneous cognitive trajectories 
of both individual cognitive tests and the general cognitive factor (Table 3). Also no statistically 
significant differences in cognitive change were observed between cancer cases with 
metastatic disease at cancer diagnosis and cancer-free controls.
Sensitivity analyses
After inclusion of cases (n=143) and exclusion of eligible controls with probable or possible 
cancer, cases still declined faster on the Word Learning Test: Immediate recall than controls 
(0.04 versus 0.00 units per year, P=.009). No statistically significant differences were observed 
for other cognitive test scores (Supplementary Table 4). 
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Age, years, median (IQR) 64.7 (60.2 to 71.5) 62.5 (58.3 to 70.6) <.001
Women, No. (%) 980 (47.6) 4446 (60.1) <.001
Educational level, No. (%) <.001
 Primary 349 (16.9) 1067 (14.4)
 Lower 847 (41.1) 3155 (42.6)
 Intermediate 607 (29.5) 2040 (27.6)
 Higher 256 (12.4) 1141 (15.4)
Smoking status, No. (%) <.001
 Never 452 (22.0) 2149 (29.0)
 Former 1107 (53.8) 3796 (51.3)
 Current 500 (24.3) 1458 (19.7)
Alcohol use, No. (%) 1685 (81.8) 6059 (81.8) .99
CES-D sum-score, median (IQR) 3 (0 to 7) 4 (1 to 8) <.001
BMI, kg/m2, median (IQR) 26.7 (24.5 to 29.2) 27.0 (24.6 to 29.7) <.001
Age at time of cancer diagnosis, years, mean (SD) 73.8 (8.3)
* Controls were matched to cases per individual cognitive test. Some controls were matched to cases for 
different cognitive tests, whereas other controls were only matched to cases for one cognitive test. The 
controls in this Table represent all individual controls used for the different cognitive test analyses.
† Two-sided P-values were calculated using the independent samples t test (for continuous variables with 
a normal distribution), the Wilcoxon signed-rank test (for continuous variables with a skewed distribution), 
and the chi-square test (for categorical variables) to investigate differences in characteristics between 
cases and controls. A P-value of less than .05 was considered as statistically significant.
BMI = body mass index, CES-D = Centre for Epidemiologic Studies Depression Scale, IQR = interquartile 
range, SD = standard deviation.
 After discarding assessments of controls less than five years before the end of follow-
up to exclude effects of potentially undiagnosed cancer, there was no statistically significant 
difference in change on the Word Learning Test: Immediate recall between cases and 
controls (P=.872, Supplementary Table 5). The score of the Word Learning Test: Delayed 
recall declined by 0.04 units per year (95% CI = -0.12 to 0.04) among cases compared with 
an increase by 0.03 units per year among controls (95% CI = -0.02 to 0.08). However, this 
difference was not statistically significant after correction for multiple testing (P=.042).
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Figure 2 Trajectories of the general cognitive factor scores reflecting global cognitive 




This study investigated the change in cognitive function among non-CNS cancer patients 
prior to cancer diagnosis using the unique setting of a large population-based study. There is 
a key need to understand the causes of cognitive impairment after non-CNS cancer. Cases 
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However, this difference disappeared in sensitivity analyses when excluding the effects of 
potentially undiagnosed cancer. We therefore found no evidence in the current study that 
cognitive function changes differently over time between individuals who will be diagnosed 
with cancer and individuals who will remain free of cancer. 
 The hypothesis that cancer outside the CNS does impact the brain resulting in alterations 
of cognitive function has been posed by several studies that have investigated cognitive 
function in cancer patients after diagnosis36 and prior to any type of treatment including 
surgery. Five out of six studies have observed cognitive impairment in patients compared to 
either study-specific controls or normative data.4-9 These observations, differentially explained 
by inflammation processes triggering neurotoxic cytokine responses, vascular changes, or 
oxidative stress,1,5,37 have been supported by preclinical studies showing that tumour-bearing, 
treatment-naive rodents can have impaired declarative memory.38-40 However, at this moment, 
we do not exactly know if and in what way processes may affect cognitive function and if 
specific cognitive domains may be particularly vulnerable.
 How can we explain the disconnect between the current results and these previous 
findings? First, although most studies carried out after diagnosis and prior to subsequent 
treatment have tried to adjust for the psychological impact of being recently confronted with 
a cancer diagnosis, residual confounding can still be a concern.41-43 This confounder is non-
existent in the current study. Second, recruiting patients who have been diagnosed recently 
with cancer can be challenging, resulting in small sample sizes and susceptibility for selection 
bias, whereas our study consisted of a large unselected group of both cases and controls.44,45 
Third, our results may not be directly comparable to previous studies because of differences 
in study design. In the current study, we looked at cognitive changes over time in the years 
preceding a cancer diagnosis, whereas the other studies have measured cognitive function 
only once shortly after diagnosis. Also in preclinical studies, cognitive function has been 
assessed within a short time frame after the tumour had reached a certain size.38 Fourth, 
cancer patients in our study were somewhat older (mean age at diagnosis was 73.8 years) 
than patients in previous studies (mean age generally ranged between 48.6 and 60.5 years,4-8 
only in one study was the mean age 79.8 years9). It is questionable, however, whether this 
difference in age contributes to the discrepant results, because it would require the mechanism 
of cognitive impairment in cancer patients to be dependent on age.
 Since we did not observe statistically significant differences in trajectories of cognitive 
function between cancer patients and controls prior to cancer diagnosis, a strong role of 
shared risk factors for both cancer and cognitive impairment prevalent in our study population 
is less plausible. However, cancer itself could still be considered as a potential underlying 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cognitive function repeatedly within a short timeframe, for example in the weeks directly 
preceding cancer diagnosis. 
 This latter point is one of several limitations that we faced. Because of the design of the 
Rotterdam Study in which cognition is intended to be assessed every three to six years, 
we could not investigate cognitive function within smaller timeframes directly preceding 
cancer diagnosis. In addition, by using linear mixed models we assumed a linear change 
in cognitive function, which may have led to model misspecification if cognitive change is 
not linear. However, including time squared in the model did not improve the model fit and 
resulted in less power to detect differences in cognitive change. Therefore, we have chosen 
not to include non-linear parameters in the model. Also, we investigated the average cognitive 
trajectories by which we may not have been able to identify subgroups of patients who do 
have steeper cognitive declines prior to cancer diagnosis. Lastly, we did not have information 
about the location of metastases at time of cancer diagnosis and could therefore not exclude 
participants with brain metastases. However, we did not observe that cognitive function 
changed differently among cases with metastatic disease than among controls.
 In addition, our study has multiple and unique strengths. It is a population-based cohort 
with standardised ascertainment of cognitive function and cancer incidence, providing the 
opportunity to investigate change in cognitive function prior to cancer diagnosis. We studied 
an unselected sample of cases and controls, thereby minimising the effects of selection bias. 
By using linear mixed models, we were able to investigate the change in cognitive function 
per year. Also, our study has by far the largest number of participants in this research area. 
Most previous studies have included 56 up to 174 patients,4-8 and even the largest study with 
341 patients9 is much smaller than the current study. This enabled us to investigate cognitive 
trajectories for different cancer sites. Lastly, we investigated the trajectory of the general 
cognitive factor in addition to the trajectories of the individual cognitive tests, because we did 
not have an indication for a specific cognitive domain to be affected.
 In conclusion, we found no evidence that cognitive function declines differently over time 
among individuals who will be diagnosed with cancer prior to disease manifestation than 
among individuals who will remain cancer-free. Our results suggest that the role of shared 
risk factors for both cancer and cognitive impairment on cognitive function in cancer patients 
is limited. Future research needs to confirm our findings and to evaluate cognitive function 
within a short period before cancer diagnosis to estimate the effects of undiagnosed cancer 
on cognitive function more accurately. 
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Brain structure prior to non-central nervous system cancer diagnosis
van der Willik KD, Yılmaz P, Compter A, Hauptmann M, Jóźwiak K, 
Ruiter R, Stricker BHCh, Vernooij MW, Ikram MA, de Ruiter MB**, 
Schagen SB**




Background Many studies have shown that patients with non-central nervous system (CNS) 
cancer can have brain abnormalities, such as reduced grey matter volume and cerebral 
microbleeds. These abnormalities can sometimes be present even before start of treatment, 
suggesting a potential detrimental effect of non-CNS cancer itself on the brain. In these 
previous studies, psychological factors associated with a cancer diagnosis and selection bias 
may have influenced results. To overcome these limitations, we investigated brain structure 
with magnetic resonance imaging (MRI) prior to cancer diagnosis.
Methods Between 2005 and 2014, 4622 participants from the prospective population-based 
Rotterdam Study who were free of cancer, dementia, and stroke, underwent brain MRI and 
were subsequently followed for incident cancer until January 1st, 2015. We investigated the 
association between brain MRI measurements, including cerebral small vessel disease, 
volumes of global brain tissue, lobes, and subcortical structures, and global white matter 
microstructure, and the risk of non-CNS cancer using Cox proportional hazards models. Age 
was used as time scale. Models were corrected for e.g. sex, intracranial volume, educational 
level, body mass index, hypertension, diabetes mellitus, smoking status, alcohol use, and 
depression sum-score. 
Results During a median (interquartile range) follow-up of 7.0 years (4.9 to 8.1), 353 
participants were diagnosed with non-CNS cancer. Results indicated that persons who 
develop cancer do not have more brain abnormalities before clinical manifestation of the 
disease than persons who remain free of cancer. The largest effect estimates were found for 
the relation between presence of lacunar infarcts and the risk of cancer (hazard ratio [HR] 
95% confidence interval [CI] = 1.39 [0.97 to 1.98]) and for total brain volume (HR [95% CI] per 
standard deviation increase in total brain volume = 0.76 [0.55 to 1.04]).
Conclusions We did not observe associations between small vessel disease, brain tissue 
volumes, and global white matter microstructure, and subsequent cancer risk in an unselected 
population. These findings deviate from previous studies indicating brain abnormalities among 
patients shortly after cancer diagnosis.
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INTRODUCTION
Patients with non-central nervous system (CNS) cancer frequently report cognitive problems 
during and after cancer treatment.1-3 Whereas most research has focused on the effects of 
cancer treatment (e.g. chemotherapy) on brain health and cognitive function, several studies 
have shown that cancer patients can have impaired cognitive function even before start of 
cancer treatment.4-12 This pretreatment cognitive impairment can sometimes persist after 
adjustment for psychological factors, suggesting that non-CNS cancer may impact the brain 
apart from cancer treatment, for instance through inflammatory or vascular processes.1,8,13-15 
This hypothesis has further been supported by preclinical studies showing that tumour-
bearing, treatment-naive rodents can have impaired memory function.16-18
 Understanding the underlying causes of cognitive impairment in non-CNS cancer patients 
is pivotal to develop prevention and intervention strategies. Several neuroimaging studies have 
performed brain magnetic resonance imaging (MRI) to investigate the neural underpinnings 
of cognitive impairment in cancer patients from pre- to posttreatment.19-21 These studies have 
shown subtle changes in grey and white matter volumes and frontal lobe hyperactivation before 
start of treatment, and various brain abnormalities after treatment, including reductions in grey 
matter volume, cerebral microbleeds, and decreased white matter microstructure.5-7,12,20,22-28 
 However, these studies are challenged by the effects of psychological factors 
accompanying a cancer diagnosis, including stress, depression, and anxiety, which may 
influence brain structure.29,30 Also, the feasibility of a baseline assessment after diagnosis 
but before subsequent treatment is limited, resulting in high rates of non-participation and 
selection bias.31 These limitations can be overcome by studying brain structure and function 
of cancer patients before cancer diagnosis, with the underlying assumption that cancer is 
already present, yet not diagnosed.
 Within the unique setting of the prospective population-based Rotterdam Study, we have 
previously shown that the trajectory of cognitive function prior to cancer diagnosis did not 
differ between participants who developed cancer and those who remained cancer-free 
during follow-up.32 Since in general, changes in brain structure correlate only moderately 
with cognitive function,33 absence of accelerated change in cognitive function before cancer 
diagnosis does not preclude presence of abnormalities in brain structure. 
 Here, we studied the association between brain MRI measurements of cerebral small 
vessel disease, brain tissue volumes, and white matter microstructure prior to the clinical 
manifestation of cancer, and the subsequent risk of different types of non-CNS cancer. Such 
associations may reflect whether there are differences in brain structure between participants 
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who are diagnosed with cancer during follow-up and those who remain cancer-free. This 
study population is defined by the availability of brain MRI scans. Therefore, the study is 
conducted in a slightly different sample than the sample in which we found no indication of 
impaired cognitive function before cancer diagnosis.32 For this reason, we also explored the 




This study was embedded in the Rotterdam Study, an ongoing population-based prospective 
cohort study that investigates determinants and occurrence of chronic diseases in the middle-
aged and elderly population. The design of the Rotterdam Study has been described in 
detail previously.34 Briefly, the initial cohort started in 1989 with 7983 participants aged 55 
years  and over residing in the district Ommoord in Rotterdam, the Netherlands. The cohort 
was expanded with 3011 participants in 2000, followed by an additional inclusion of 3392 
participants aged at least 45 years in 2006. From 2005 onwards, brain MRI was implemented 
into the study protocol of the Rotterdam Study.35 
 Participants were interviewed at home by a trained research assistant, followed by two 
visits to the research facility for different examinations including laboratory assessments and 
imaging. Follow-up examinations take place every three to five years. 
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands. Written 
informed consent was obtained from all participants. 
Study population
Out of the 14 926 participants of the Rotterdam Study, 5766 had at least one brain MRI 
scan acquired between 2005 and 2014. Of the 5766 participants, we excluded those without 
informed consent to access medical files during follow-up (n=30), with a history of dementia 
(n=57) or who were not sufficiently screened for history of dementia (n=43), with a history of 
stroke (n=198), with a history of cancer (n=464), and those without any cognitive test result 
(n=9), resulting in 4965 eligible participants. Subsequently, we excluded participants who had 
MRI scans with artefacts and unreliable tissue segmentation (n=121), without FreeSurfer 
segmentation (n=37), with poor FreeSurfer segmentation quality (n=94), and with MRI-defined 
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cortical infarcts (n=91), ending up with 4622 participants. For diffusion tensor imaging (DTI) 
analyses we additionally excluded participants who had MRI scans, but no available DTI data 
(n=268), resulting in 4354 participants for DTI analyses (Figure 1). If a participant had multiple 
MRI scans, we included only the first obtained scan for analyses to avoid bias because of the 
prospective cohort design.
MRI acquisition and processing
Brain MRI was performed on a 1.5-tesla MRI scanner with a dedicated 8-channel head coil 
(General Electric Healthcare, Milwaukee, USA). The scan protocol and sequence details have 
been described in detail previously and are summarised in Supplementary Table 1.35 Scans 
for brain volumetry included T1-weighted (voxel size 0.49 x 0.49 x 1.6 mm3), proton density-
weighted (voxel size 0.6 x 0.98 x 1.6 mm3), and fluid-attenuated inversion recovery (FLAIR, 
voxel size 0.78 x 1.12 x 2.5 mm3) sequences which were used for automated segmentation of 
supratentorial grey matter volume, white matter volume, cerebrospinal fluid, and white matter 
hyperintensities.36,37 Pre-processing included co-registration, correction of non-uniformity, 
and variance scaling. Before segmentations, the brain is extracted from the scan using a 
manually segmented brain mask that is non-rigidly registered to the T1-weighted image using 
Elastix.38 We used the k-nearest neighbour segmentation to classify scans into brain tissue 
volumes and cerebrospinal fluid.39 All segmentations were inspected and manually corrected 
if necessary using a dedicated tool that has been developed in MevisLab that can visualize 
the original scan with the image processing results.35 Editing tools were available to adjust 
segmentations if necessary. Manual editing of errors was needed in less than ten percent.
 Markers of cerebral small vessel disease included white matter hyperintensity volume 
(mL), presence of cerebral microbleeds, and presence of infarcts. Cerebral microbleeds were 
rated on a 3-dimensional, T2*-weighted gradient-recalled echo MRI scan (voxel size 0.78 x 
1.12 x 1.6 mm3) as focal areas of very low signal intensity. Infarcts were categorised as cortical 
infarcts (infarcts with involvement of cortical grey matter which were excluded for analyses for 
reliability of tissue segmentations) and lacunar infarcts (focal lesions between 3 and 15 mm in 
non-cortical tissue with signal intensity similar to that of cerebrospinal fluid on all sequences, 
and, when located supratentorially, with a hyperintense rim on the FLAIR sequence).40,41
 Total brain volume (mL) was defined as the sum of grey matter volume (mL) and white 
matter volume (mL, sum of normal appearing white matter and white matter hyperintensity 
volume). Intracranial volume (mL) was the sum of total brain volume and cerebrospinal 
fluid. Although these volumes were restricted to the supratentorial region, we refer to these 
volumes as total brain volume and intracranial volume. Lobar volumes were segmented by 
using an atlas in which the lobes were manually outlined.42 This atlas was subsequently 
Chapter 6
150
Figure 1 Flowchart of study population.
DTI = diffusion tensor imaging, MRI = magnetic resonance imaging.
Number of participants with




- No informed consent (n=30)
- History of dementia (n=57)
- Not sufficiently screened for history
of dementia (n=43)
- History of stroke (n=198)
- History of cancer (n=464)
- No cognitive test result (n=9)
Eligible participants 
(n=4965)
Brain tissue volumes and small 




- Scans with artefacts hampering
automated processing and unreliable
tissue segmentation (n=121)
- Failed FreeSurfer segmentation
(n=37)
- Poor quality FreeSurfer
segmentation (n=94)




- No DTI data 
available (n=268)
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non-rigidly transformed to each brain to obtain the volume of each lobe.35 Lobar volumes 
included both grey matter and white matter. T1-weighted MR images were processed using 
FreeSurfer (version 6.0) to calculate cortical thickness (mm), cortical surface area (mm2), and 
subcortical volumes (mL) of the hippocampus, amygdala, caudate, putamen, thalamus, and 
pallidum (FreeSurfer is freely available for download online at http://surfer.nmr.mgh.harvard.
edu/). For quality assessment, we have randomly selected a subset of scans that we visually 
inspected. Next, we identified a cut-off on our automated quality assessment metric which 
allowed us to exclude unusable FreeSurfer data.43 This cut-off has subsequently been applied 
to the remaining data and all scans below this cut-off were excluded. We have confirmed that 
several metrics (e.g., cortical thickness) have no significant correlation with the automated 
quality assessment metric after the exclusions have been performed.44 
 Measurements of white matter microstructure were obtained from DTI (supratentorially, 
voxel size 3.3 x 2.2 x 3.5 mm3), which was embedded in the protocol of the Rotterdam Study 
from March 2006 onwards.37,45 Echo-planar imaging (EPI) was used as readout module. 
Normal appearing white matter was distinguished from white matter hyperintensities using 
an automatic post-processing step based on the FLAIR image and the tissue segmentation.36 
Next, the segmentation of white matter hyperintensities was mapped into DTI image space 
using boundary-based registration performed on the white matter segmentation and the T1-
weighted image.46 Co-registrations of the DTI to the T1-weighted image were visually inspected 
to ensure a good fit and that DTI measures did not include grey matter or cerebrospinal fluid 
partial volumes. This co-registration partly corrected potential non-linear changes induced 
by the EPI readout module. DTI data were pre-processed using a standardised pipeline 
that included correction for subject motion and Eddy currents, estimation of the diffusion 
tensor, and registration to tissue segmentation matter.45 Diffusion tensors were estimated 
using a non-linear Levenberg-Marquardt estimator (available in Explore DTI),47 from which 
global mean fractional anisotropy (FA) and mean diffusivity (MD, 10-3 mm2/s) in the normal 
appearing white matter were obtained. FA reflects the degree of diffusion directionality of 
water molecules.48 MD represents the average diffusion of water molecules. Lower FA and 
higher MD are indications of lower white matter microstructure. DTI images were manually 
inspected for registration and segmentation and corrected where possible. Between February 
2007 and May 2008, 1169 participants were scanned with the phase and frequency encoding 
directions swapped for the diffusion acquisition due to a technical issue. We have therefore 
included phase encoding direction as covariate in the analyses (see statistical analysis).49 
Cognitive function assessment
Cognitive function was assessed by a neuropsychological test battery administered at the 
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research centre. Assessments took place between 2002 and 2014. The cognitive assessment 
corresponding to the same visit round as the visit round of the MRI scan was used, with a 
median (interquartile range [IQR]) time between cognitive function assessment and MRI scan 
of -0.13 years (-0.31 to -0.08). Up to 2015, the following cognitive tests were administered: 
Mini-Mental State Examination (MMSE), Word Fluency Test (WFT), Letter-Digit Substitution 
Test (LDST), Stroop Test (Reading, Naming, Interference), Purdue Pegboard Test (PPT, 
right, left, both hands), and 15-Word Learning Test (WLT, Immediate recall, Delayed recall, 
Recognition).50-55 
 Global cognitive function was assessed by the general cognitive factor based on WFT, 
LDST, Stroop Test: Interference, sum-score of individual PPTs, and WLT: Delayed recall and 
was identified as the first unrotated component of a principal component analysis, which 
explained at least 48.0% of the total variance in individual cognitive tests.56 The general 
cognitive factor was only computed if all five individual tests were completed. 
 Self-reported memory complaints were measured with three yes/no questions: (i) ‘Do you 
have more problems remembering things than before?’; (ii) ‘Has there been an increase in the 
times that you forgot what you were up to?’; and (iii) ‘Do you have more word-finding problems 
than before?’.
Ascertainment of cancer
Diagnoses of cancer were based on medical records of general practitioners (including 
hospital discharge letters) and through linkage with Dutch Hospital Data, Netherlands Cancer 
Registry, and histology and cytopathology registries in the region.34 Incident cancer was 
defined as any primary malignant tumour, excluding non-melanoma skin cancer. Diagnoses 
were coded independently by two physicians according to the International Classification of 
Diseases, tenth revision (ICD-10). In case of discrepancy, consensus was sought through 
consultation with a physician specialised in internal medicine. Date of diagnosis was based 
on date of biopsy (solid tumours) and laboratory assessment (haematological tumours), or 
– if unavailable – date of hospital admission or discharge letter. Only pathology-confirmed 
cancers were included in the analysis. Follow-up of cancer registration was completed up to 
January 1st, 2015. 
Measurement of covariates
During home interviews, participants provided information on educational level, smoking 
status, and alcohol use. Educational level was classified into primary, lower (lower or 
intermediate general education, or lower vocational education), intermediate (intermediate 
vocational education or higher general education), or higher (higher vocational education 
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or university). Smoking was categorised as never, current, or former. Alcohol use was 
classified into any use or no use of alcohol. At the research centre, height and weight were 
measured from which the body mass index (BMI, kg/m2) was computed. Furthermore, systolic 
and diastolic blood pressures were measured twice on the right arm with a random-zero 
sphygmomanometer of which the mean was used for analyses. Hypertension was defined 
as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 mm Hg, or 
use of antihypertensive medication.57 Diabetes mellitus was defined as fasting serum glucose 
level ≥7.1 mmol/L, a random serum glucose level ≥11.1 mmol/L, or use of glucose-lowering 
medication.58 Symptoms of depression were evaluated with the Centre for Epidemiologic 
Studies Depression scale (CES-D), which was converted to a sum-score.59
Statistical analysis
We investigated the association between brain MRI measurements including cerebral small 
vessel disease, brain tissue volumes, and white matter microstructure, and the risk of cancer 
using Cox proportional hazards models.60 Cox proportional hazards models are semiparametric 
regression models for survival data and can be used to obtain hazard ratios (HRs) and 95% 
confidence intervals (95% CIs). The hazard is the instantaneous risk of an event at time t, 
given that the event has not occurred until time t. In the current study, we are interested in 
cancer as the event. For interpretation purposes and to facilitate comparisons across different 
MRI measurements, we standardised continuous brain MRI measurements (i.e., white matter 
hyperintensity volume, brain tissue volumes, and white matter microstructure) by creating 
Z-scores (individual value minus population mean, divided by population standard deviation 
[SD]). Therefore, the HR for continuous variables indicates the change in the risk of cancer if 
the brain MRI measurement of interest rises by one SD.61 A HR above one indicates that the 
risk of cancer increases for every SD increase in the brain MRI measurement. For categorical 
variables (i.e., cerebral microbleeds and lacunar infarcts) the hazard ratio can be interpreted 
as the ratio of the hazard for cancer at time t for participants with microbleeds or infarcts to the 
hazard for cancer at t for those without microbleeds or infarcts. A HR above one indicates that 
participants with microbleeds or infarcts have a higher risk of cancer than participants without 
microbleeds or infarcts. 
 White matter hyperintensity volume was transformed using the natural logarithm to reach 
a normal distribution. For volumes of the lobes and subcortical structures we used the average 
of the left and right hemisphere. We explored non-linear associations by categorising global 
brain volumes into quantiles. For each MRI measurement, we constructed two nested models. 
Covariates were selected based on previous literature62 on the relation between cancer, brain 
abnormalities, and cognitive function. In Model I, the effect of each MRI measurement was 
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adjusted for sex and intracranial volume. In a middle-aged to elderly population, correcting 
for intracranial volume is preferred over correcting for total brain volume to better estimate 
the extent of global atrophy or atrophy between different regions.63,64 In addition to these 
adjustments for all MRI measurements, the effect of grey matter volume was adjusted for 
total white matter volume (i.e., normal appearing white matter volume plus white matter 
hyperintensity volume), and analyses for measurements of white matter microstructure were 
adjusted for normal appearing white matter volume, white matter hyperintensity volume, and 
phase encoding direction. Model II was Model I plus additional adjustment for educational 
level (primary, lower, intermediate, or higher), BMI (continuous), hypertension (yes or no), 
diabetes mellitus (yes or no), smoking status (never, current, or former), alcohol use (yes or 
no), and CES-D sum-score (continuous). An overview of the distributions of the continuous 
determinants and covariates used in the models is provided in Supplementary Figure 1.65 
Ethnicity was not used as a covariate since nearly all participants (97.0%) were of European 
descent. Age was used as the underlying time scale in all Cox models to control for the 
confounding effects of age and to allow a non-parametric age effect.66,67 Follow-up time 
was measured from the date of first MRI scan until the date of cancer diagnosis, death, 
loss to follow-up, or January 1st, 2015, whichever came first. Participants with CNS cancer 
were censored at date of diagnosis (i.e., follow-up was terminated at date of CNS cancer 
diagnosis), because mechanisms underlying brain abnormalities differ between non-CNS and 
CNS cancers, given that CNS cancer can cause direct damage to the brain.68 Multicollinearity 
was checked by calculating the Variance Inflation Factor (VIF). None of the covariates had a 
VIF above ten.69 The proportional hazards assumption was checked by visual inspection of 
the Schoenfeld residuals.70 
 Given that cortical grey matter volume is approximated by the product of cortical thickness 
and cortical surface area, we explored whether any association between grey matter volume 
and risk of cancer may be driven by one of these features. Cortical surface area is the main 
determinant of variation in cortical grey matter volumes between individuals.71 Cortical 
thickness and surface area decrease both during aging, but it has been shown that reduced 
cortical thickness is probably the main driver of decreasing cortical grey matter volume. 
 Next, to investigate the robustness of our findings, we conducted sensitivity analyses in 
which we limited the analyses to a shorter follow-up time by censoring all participants two 
years after MRI scan. Cancer might indirectly affect the brain through inflammatory or vascular 
processes.72 Tumour progression has been associated with inflammation and vascular 
changes.73 We therefore hypothesised that if growing, yet undiagnosed cancer affects the 
brain, brain abnormalities will become more apparent closer to the date of cancer diagnosis. 
 Next, we analysed effects separately for the most frequent cancer types (breast, prostate, 
Brain imaging prior to cancer diagnosis
155
colorectal, or lung) and cancer stage (local versus metastatic). In addition, we studied effect 
modification for sex by stratifying. We adjusted these models for the same covariates that 
were used in Model II. Participants were censored at time of cancer diagnosis if they were 
diagnosed with another type of cancer than the cancer type of interest.
 We subsequently investigated the relation between tested cognitive function and self-
reported memory function, and the risk of cancer. A Cox model with a particular cognitive 
test result included also information on sex, educational level, BMI, hypertension, diabetes 
mellitus, smoking status, alcohol use, and CES-D sum score. The cognitive test results were 
standardised by creating Z-scores to facilitate comparisons across the different measures.
 Lastly, we repeated analyses using the MRI scan closest to cancer diagnosis in a matched 
cohort design by matching each participant with cancer to three cancer-free participants 
based on age, sex, and follow-up time. These analyses provided similar findings to those 
obtained from the original cohort design using the first available MRI scan and are therefore 
not reported separately.
 Multiple imputation was used for missing covariates (maximum of 0.9%) based on 
determinants, outcome, and covariates. The missing values were imputed five times, resulting 
in five datasets. Rubin’s method was used to estimate pooled HRs and 95% CIs from these 
five datasets.74 A two-sided P-value of <.05 was considered statistically significant. We did not 
correct for multiple testing, because the brain MRI measurements were not independent from 
each other and the analyses were exploratory. Correction for multiple testing may therefore 
be too conservative.75 In total, 36 Cox proportional hazards models were run for the main 
analyses, six to explore non-linear associations by categorising global brain tissue volumes, 
18 for analyses stratified by sex, 90 for analyses stratified by cancer type, 18 for sensitivity 
analyses, and 14 for analyses on cognitive function. All analyses were performed using the 
‘survival’ package from R software Version 3.4.1.76
RESULTS
Characteristics of participants at time of MRI scan are presented in Table 1. During a median 
(IQR) follow-up of 7.0 years (4.9 to 8.1), 353 out of 4622 participants (7.6%) were diagnosed 
with cancer. The most frequently diagnosed cancer types were prostate (16.1%), female 
breast (13.0%), colorectal (17.8%), and lung (10.5%). The median time (IQR) between MRI 




Table 1 Baseline characteristics of total study population.
Characteristic All participants(N=4622)
Age, years, median (IQR) 61.6 (55.5 to 71.7)
Women, No. (%) 2574 (55.7)
Educational level, No. (%)
 Primary 390 (8.4)
 Lower 1743 (37.7)
 Intermediate 1368 (29.6)
 Higher 1080 (23.4)
Body mass index, kg/m2, mean (SD) 27.4 (4.1)
Hypertension, No. (%) 2823 (61.1)
Diabetes mellitus, No. (%) 315 (6.8)
Smoking, No. (%)
 Never 1426 (30.9)
 Former 2436 (52.7)
 Current 734 (15.9)
Alcohol use, No. (%) 4072 (88.1)
CES-D sum score, median (IQR) 4.0 (3.0 to 8.0)
Cerebral small vessel disease
 White matter hyperintensity volume, mL, median (IQR) 2.8 (1.6 to 5.7)
 Microbleeds, No. (%) 840 (18.2)
 Lacunar infarcts, No. (%) 283 (6.1)
Global brain tissue volume, mL, mean (SD)
 Intracranial volume 1138.9 (116.1)
 Total brain volume 939.9 (100.6)
 Grey matter 530.6 (55.4)
 Normal appearing white matter 403.8 (60.9)
Lobar brain tissue volume, mL, mean (SD)
 Frontal 79.5 (8.2)
 Parietal 52.0 (5.6)
 Temporal 49.1 (5.3)
 Occipital 22.8 (2.8)
Values are shown without imputation and therefore not always add up to 100%.
CES-D = Centre for Epidemiological Studies Depression Scale, IQR = interquartile range, N = number of 
participants, SD = standard deviation.
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Table 1 Baseline characteristics of total study population (continued).
Characteristic All participants(N=4622)
Subcortical structure volume, mL, mean (SD)
 Hippocampus 3.9 (0.4)
 Amygdala 1.4 (0.2)
 Caudate 3.3 (0.5)
 Putamen 4.2 (0.5)
 Thalamus 6.6 (0.7)
 Pallidum 1.6 (0.2)
White matter microstructure*, mean (SD)
 Global fractional anisotropy 0.34 (0.02)
 Global mean diffusivity, mm2/s 0.74 * 10-3 (0.03)
Cognitive function†
 Mini-Mental State Examination, median (IQR) 28.0 (27.0 to 29.0)
 Word Fluency Test, mean (SD) 23.0 (5.9)
 Letter-Digit Substitution Test, mean (SD) 30.6 (6.9)
 Stroop Test: Naming, median (IQR) 16.4 (14.7 to 18.5)
 Stroop Test: Reading, median (IQR) 22.4 (20.0 to 25.4)
 Stroop Test: Interference, median (IQR) 44.3 (37.2 to 54.3)
 Purdue Pegboard Test, mean (SD) 36.2 (5.2)
 Word Learning Test: Immediate recall, mean (SD) 7.8 (2.1)
 Word Learning Test: Delayed recall, mean (SD) 7.8 (2.9)
 Word Learning Test: Recognition, median (IQR) 14.0 (13.0 to 15.0)
 General cognitive factor, mean (SD) 0.0 (1.0)
Self-reported memory complaints‡, No. (%)
 More problems remembering 2082 (46.4)
 Forgetting (daily) pursuits 1318 (29.4)
 Word-finding problems 1182 (26.3)
Values are shown without imputation and therefore not always add up to 100%.
* FA and MD were measured in 4354 participants due to missing diffusion tensor imaging data. † Number 
of participants differed per cognitive test. ‡ Self-reported memory complaints were measured in 4486 
participants.
IQR = interquartile range, N = number of participants, SD = standard deviation.
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Cerebral small vessel disease
No associations were found between white matter hyperintensity volume or presence of 
microbleeds and the risk of cancer (HR [95% CI] per SD increase in white matter hyperintensity 
volume = 0.98 [0.87 to 1.09], P=.67 and for presence of microbleeds = 1.00 [0.77 to 1.29], 
P=.98, Table 2). The largest HR for cerebral small vessel disease was observed for presence 
of lacunar infarcts and the risk of all cancers combined (HR [95% CI] = 1.39 [0.97 to 1.98], 
P=.07, Table 2). This effect estimate was more pronounced in sensitivity analyses when 
censoring the follow-up time after the first two years after the MRI scan (HR [95% CI] = 1.65 
[0.95 to 2.86], P=.07, Supplementary Table 2). 
 We found no differences in associations for different cancer types (Supplementary Table 
4), nor between men and women (Supplementary Table 6).
Table 2 Association between markers of cerebral small vessel disease and risk of cancer.
MRI measurement Cancer (n/N = 353/4622)
Model I
HR (95% CI) P
Model II
HR (95% CI) P
White matter hyperintensity volume, mL*,† 0.99 (0.88 to 1.10) .81 0.98 (0.87 to 1.09) .67
Microbleeds 1.01 (0.78 to 1.31) .96 1.00 (0.77 to 1.29) .98
Lacunar infarcts 1.46 (1.02 to 2.07) .04 1.39 (0.97 to 1.98) .07
Model I: adjusted for sex and total intracranial volume. Model II: Model I plus adjusted for education, body 
mass index, hypertension, diabetes mellitus, smoking status, alcohol use, and CES-D sum score.
* Expressed per standard deviation increase. † Transformed with a natural logarithm.
CES-D = Centre for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 
ratio, MRI = magnetic resonance imaging, n = number of participants with incident cancer, N = number 
of participants. 
Brain tissue volumes
Overall, we found no associations between global and lobar brain tissue volumes and the risk 
of cancer. The majority of the effect estimates for brain tissue volumes were below one, with 
the most pronounced HR for total brain volume and the risk of cancer (HR [95% CI] per SD 
increase in total brain volume = 0.76 [0.55 to 1.04], P=.09, Table 3). We did not observe a non-
linear pattern when categorising the volumes into quantiles (data not shown). No associations 
were found between cortical thickness and risk of cancer (HR [95% CI] per SD increase in 
cortical thickness = 0.94 [0.84 to 1.06], P=.33), and cortical surface area and risk of cancer 
(HR [95% CI] per SD increase in cortical surface area = 0.93 [0.72 to 1.20], P=.58). Regarding 
subcortical structures, the most pronounced effect estimate was found for hippocampal 
volume and the risk of cancer (HR [95% CI] = 0.87 [0.75 to 1.01], P=.07, Table 3). 
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Table 3 Association between brain tissue volumes and microstructural brain measurements and 
risk of cancer.
MRI measurement* Cancer (n/N = 353/4622)
Model I
HR (95% CI) P
Model II
HR (95% CI) P
Global brain tissue volume, mL
 Total brain volume 0.74 (0.54 to 1.01) .06 0.76 (0.55 to 1.04) .09
 Grey matter 0.89 (0.71 to 1.11) .31 0.91 (0.73 to 1.14) .41
 Normal appearing white matter 0.86 (0.73 to 1.02) .09 0.87 (0.73 to 1.03) .11
Lobar brain tissue volume, mL
 Frontal 0.87 (0.70 to 1.08) .06 0.90 (0.73 to 1.12) .34
 Parietal 0.86 (0.71 to 1.05) .31 0.87 (0.72 to 1.07) .19
 Temporal 0.90 (0.74 to 1.10) .09 0.92 (0.75 to 1.13) .43
 Occipital 0.99 (0.85 to 1.14) .06 0.99 (0.85 to 1.14) .85
Subcortical structure volume, mL
 Hippocampus 0.86 (0.74 to 1.00) .05 0.87 (0.75 to 1.01) .07
 Amygdala 0.99 (0.86 to 1.15) .94 1.00 (0.86 to 1.15) .95
 Caudate 1.04 (0.92 to 1.17) .55 1.03 (0.92 to 1.16) .61
 Putamen 0.91 (0.79 to 1.03) .15 0.90 (0.79 to 1.03) .13
 Thalamus 0.94 (0.80 to 1.12) .51 0.95 (0.80 to 1.12) .52
 Pallidum 0.97 (0.85 to 1.10) .63 0.97 (0.85 to 1.11) .68
White matter microstructure†
 Global fractional anisotropy 0.98 (0.86 to 1.12) .79 0.98 (0.86 to 1.12) .75
 Global mean diffusivity, 10-3 mm2/s 1.02 (0.87 to 1.19) .85 1.01 (0.86 to 1.19) .89
Model I: adjusted for sex and total intracranial volume. For grey matter volume additionally adjustment 
for total white matter volume. For white matter microstructure additional adjustment for normal appearing 
white matter volume, white matter hyperintensity volume, and phase encoding direction. Model II: Model 
I plus adjusted for education, body mass index, hypertension, diabetes mellitus, smoking status, alcohol 
use, and CES-D sum score.
* Expressed per standard deviation increase. † Fractional anisotropy and mean diffusivity were measured 
in 4354 participants due to missing diffusion tensor imaging data.
CES-D = Centre for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 
ratio, MRI = magnetic resonance imaging, n = number of participants with incident cancer, N = number 
of participants. 
 When limiting the follow-up to two years after the MRI scan, effect estimates were more 
pronounced for the association between volumes of total brain and hippocampus with the 
risk of cancer (Supplementary Table 3, HR [95% CI] per SD increase in total brain volume = 




 Regarding cancer type, we found that higher volumes of total brain, grey matter, and 
hippocampus were associated with a statistically significantly lower risk of lung cancer 
(Figure 2). In contrast, higher volumes of total brain and grey matter were associated with 
a higher risk of colorectal cancer. No differences were observed for the other cancer types 
and for metastatic cancer, but small numbers led to wide confidence intervals. Results for 
the remaining brain tissue volumes and risk of cancer stratified by cancer type are shown in 
Supplementary Table 5.
 Lastly, we found no evidence for effect modification by sex (Supplementary Table 7). 
White matter microstructure
Global measurements of white matter microstructure were not associated with the risk of 
cancer (HR [95% CI] per SD increase in global FA = 0.98 [0.86 to 1.12], P=.75 and in global 
MD = 1.01 [0.86 to 1.19], P=.89, Table 3 and Supplementary Table 3).
 Also no associations were found when stratifying by cancer type (Supplementary Table 
5) and by sex (Supplementary Table 7).
Cognitive function
All effect estimates for the relation between individual cognitive tests and the risk of cancer 
were around 1.0, indicating that there are no associations between different cognitive test 
scores and the risk of cancer (Supplementary Table 8). Per SD increase in the general 
cognitive factor as measurement of global cognitive function the HR (95% CI) for cancer was 
1.03 (0.89 to 1.20), P=.66. Also no associations were found between self-reported memory 
function and the risk of cancer.
DISCUSSION
In this population-based study, we aimed to obtain more insight into the impact of cancer 
on brain structure by investigating the presence of brain abnormalities in non-CNS cancer 
patients prior to the clinical manifestation of cancer. We found no meaningful associations 
between cerebral small vessel disease, brain tissue volumes, and white matter microstructure, 
and the risk of cancer. These findings suggest that persons who develop cancer do not have 
more brain abnormalities before cancer diagnosis than persons who remain free of cancer.
 Our current findings obtained prior to cancer diagnosis deviate from previously observed 


























































































































































































































































































































































































































































































































































































































































































brain changes after diagnosis but before treatment such as lower grey matter volume and 
white matter microstructure (i.e., lower FA and higher axial diffusivity).4,12,77 Although we did 
not find any statistically significant associations, we observed that almost all effect estimates 
for brain tissues volumes were below one, suggesting that we cannot completely rule out a 
subtle effect of cancer on the brain. In addition, effect estimates for the association between 
presence of lacunar infarcts, total brain volume, hippocampal volume, and the risk of cancer 
were more pronounced when the study follow-up was limited to two years after MRI scan. 
This may indicate that brain changes (i.e., more lacunar infarcts and smaller brain volumes) 
become more apparent closer to the date of cancer diagnosis. Given that we did not observe 
this pattern for any of the cognitive tests, this might suggest that brain changes might arise 
before they become clinically apparent, as seen in dementia.78 This may also apply to 
cancer patients, with cognitive function first being preserved by compensation, followed by 
loss of compensatory activation, which results eventually in cognitive impairment.1 Different 
underlying mechanisms by which non-CNS cancer may affect the brain have been proposed, 
including peripheral inflammation triggering neurotoxic cytokine response, oxidative stress, or 
vascular changes.1,8,13-15,79 In addition, the associations were most pronounced for lung cancer, 
which is strongly associated with inflammation and oxidative stress.80,81 Accordingly, we can 
conclude that if subclinical non-CNS cancer affects the brain, the effects are limited and may 
only result in subtle changes that are not evidently detected by measures of supratentorial 
brain tissue volumes, subcortical brain structure volumes, white matter pathology, and white 
matter microstructure, or effects are restricted to certain types of non-CNS cancer, such as 
lung cancer.
 Our study has some limitations. First, measurement error in brain MRI volumes might have 
attenuated the association. For instance, it might have been possible that usage of a higher 
magnetic field strength or alternative imaging processing pipelines would have resulted in a 
more pronounced association between certain MRI measurements and the risk of cancer.28,82 
Second, although the statistical power in our main analysis was sufficient to detect a potential 
association (we were powered to detect a HR of 0.84 for the relation between total brain 
volume and risk of cancer [α= 0.05, β= 0.80]), the power might have been too limited to find 
statistically significant associations when limiting the follow-up time to two years and when 
focusing on different cancer types. Therefore, replication of this study in a larger sample with 
MRI scans performed more closely to the clinical manifestation of cancer is desirable.5 In 
addition, it would be interesting to investigate the change in MRI measurements from before 
to after cancer diagnosis. Third, we had no information on fatigue and frailty, which may be 
confounding factors that would have further attenuated the effect estimates. Fourth, with 
the current analyses we were not able to study interrelationships between different brain 
Brain imaging prior to cancer diagnosis
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MRI measurements and therefore we might have missed more complex patterns of brain 
abnormalities related to the risk of cancer.
 Strengths of this study include the unique design by which we could assess brain MRI 
before clinical manifestation of cancer. Hereby, we excluded the effects of psychological 
factors associated with a cancer diagnosis on the brain and the potential effects of selection 
bias.29,30 Also, we have a larger sample size than that of other studies assessing brain MRI in 
cancer patients prior to treatment (number of patients ranging between 10 and 74, compared 
to 353 patients in our study), and we included different cancer types as outcome whereas 
previous studies primarily focused on breast cancer. 
 In conclusion, we found that persons who develop non-CNS cancer did not have more 
brain abnormalities before cancer diagnosis than persons who remained free of cancer. Our 
findings do not support that non-CNS cancer affects global brain structure measurements 
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Word Learning Test: Delayed recall score
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Word Learning Test: Recognition score
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































−5.0 −2.5 0.0 2.5
General cognitive factor score
EE General cognitive factor Supplementary Figure 1 Raincloud plots for continuous determinants and covariates that 
were used in the different models. 
The cloud represents the distribution of the data 
and the rain (grey dots) shows the jittered raw 
data. The boxplot shows the median and the 
interquartile ranges. 
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Supplementary Table 2 Association between markers of cerebral small vessel disease and risk of 
cancer when limiting the follow-up time to two years after brain MRI.
MRI measurement Cancer(n/N = 107/4622)
HR (95% CI) P
White matter hyperintensity volume, mL*,† 0.94 (0.78 to 1.13) .50
Microbleeds 0.85 (0.53 to 1.37) .51
Lacunar infarcts 1.65 (0.95 to 2.86) .07
Hazard ratios are adjusted for sex and total intracranial volume, education, body mass index, hypertension, 
diabetes mellitus, smoking status, alcohol use, and CES-D sum score.
* Expressed per standard deviation increase. † Transformed with a natural logarithm.
CES-D = Centre for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 




Supplementary Table 3 Association between brain tissue volumes and microstructural brain 
measurements and risk of cancer when limiting the follow-up time to two years after brain MRI.
MRI measurement* Cancer(n/N = 107/4622)
HR (95% CI) P
Global brain tissue volume, mL
 Total brain volume 0.63 (0.35 to 1.12) .12
 Grey matter 0.76 (0.51 to 1.14) .18
 Normal appearing white matter 0.91 (0.66 to 1.24) .54
Lobar brain tissue volume, mL
 Frontal 0.79 (0.53 to 1.17) .23
 Parietal 0.96 (0.66 to 1.38) .81
 Temporal 0.94 (0.65 to 1.35) .73
 Occipital 0.97 (0.74 to 1.26) .82
Subcortical structure volume, mL
 Hippocampus 0.75 (0.58 to 0.98) .04
 Amygdala 0.90 (0.69 to 1.18) .46
 Caudate 0.95 (0.78 to 1.17) .64
 Putamen 0.90 (0.72 to 1.14) .40
 Thalamus 0.78 (0.57 to 1.07) .13
 Pallidum 0.84 (0.66 to 1.07) .15
White matter microstructure†
 Global fractional anisotropy 1.06 (0.85 to 1.33) .59
 Global mean diffusivity, 10-3 mm2/s 0.97 (0.74 to 1.27) .80
Hazard ratios are adjusted for sex and total intracranial volume, education, body mass index, hypertension, 
diabetes mellitus, smoking status, alcohol use, and CES-D sum score. For grey matter volume additionally 
adjustment for total white matter volume. For white matter microstructure additional adjustment for normal 
appearing white matter volume, white matter hyperintensity volume, and phase encoding direction.
* Expressed per standard deviation increase. † Fractional anisotropy and mean diffusivity were measured 
in 4354 participants due to missing diffusion tensor imaging data.
CES-D = Centre for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 
ratio, MRI = magnetic resonance imaging, n = number of participants with incident cancer, N = number 
of participants.
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Supplementary Table 6 Association between markers of cerebral small vessel disease and risk of
cancer stratified by sex.
MRI measurement Women(n/N = 157/2574)
Men
(n/N = 196/2048)
HR (95% CI) P HR (95% CI) P
White matter hyperintensity volume, mLa,b 1.01 (0.85 to 1.21) .87 0.96 (0.83 to 1.12) .62
Microbleeds 1.12 (0.76 to 1.66) .56 0.88 (0.62 to 1.25) .49
Lacunar infarcts 1.60 (0.88 to 2.92) .12 1.20 (0.77 to 1.87) .42
Models are adjusted for total intracranial volume, education, body mass index, hypertension, diabetes 
mellitus, smoking status, alcohol use, and CES-D sum score.
a Expressed per standard deviation increase. b Transformed with a natural logarithm.
CES-D = Center for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 




Supplementary Table 7 Association between brain tissue volumes and microstructural brain 
measurements and risk of cancer stratified by sex.
MRI measurementa Women(n/N = 157/2574)
Men
(n/N = 196/2048)
HR (95% CI) P HR (95% CI) P
Global brain tissue volume, mL
Total brain volume 0.73 (0.44 to 1.22) .23 0.87 (0.57 to 1.33) .52
Gray matter 0.83 (0.58 to 1.18) .30 1.04 (0.77 to 1.38) .81
Normal appearing white matter 0.91 (0.68 to 1.22) .53 0.86 (0.69 to 1.08) .19
Lobar brain tissue volume, mL
Frontal 0.81 (0.58 to 1.13) .22 1.04 (0.78 to 1.38) .80
Parietal 1.00 (0.73 to 1.37) .99 0.81 (0.62 to 1.05) .11
Temporal 0.99 (0.72 to 1.38) .97 0.91 (0.71 to 1.18) .49
Occipital 0.97 (0.77 to 1.23) .81 1.00 (0.84 to 1.20) .97
Subcortical structure volume, mL
Hippocampus 0.91 (0.72 to 1.16) .45 0.91 (0.72 to 1.16) .11
Amygdala 1.07 (0.84 to 1.36) .58 1.07 (0.84 to 1.36) .64
Caudate 0.94 (0.78 to 1.14) .54 0.94 (0.78 to 1.14) .15
Putamen 0.83 (0.67 to 1.02) .08 0.83 (0.67 to 1.02) .82
Thalamus 0.77 (0.58 to 1.01) .06 0.77 (0.58 to 1.01) .37
Pallidum 0.88 (0.71 to 1.10) .26 0.88 (0.71 to 1.10) .67
White matter microstructureb
Global fractional anisotropy 0.88 (0.72 to 1.07) .20 1.06 (0.89 to 1.27) .53
Global mean diffusivity, 10-3 mm2/s 1.15 (0.90 to 1.46) .26 0.91 (0.73 to 1.14) .42
Models are adjusted for total intracranial volume, education, body mass index, hypertension, diabetes 
mellitus, smoking status, alcohol use, and CES-D sum score. For gray matter volume additionally 
adjustment for total white matter volume. For white matter microstructure additional adjustment for normal 
appearing white matter volume, white matter hyperintensity volume, and phase encoding direction.
a Expressed per standard deviation increase. b Fractional anisotropy and mean diffusivity were measured 
in less participants due to missing diffusion tensor imaging data. In these analyses, 129 out of 2,426 
women were diagnosed with cancer and 152 out of 1,928 men were diagnosed with cancer.
CES-D = Center for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 
ratio, MRI = magnetic resonance imaging, n = number of participants with incident cancer, N = number 
of participants.
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179
Supplementary Table 8 Association between cognitive function and risk of cancer. 
Cognitive test Cancer
n/N HR (95% CI) P
Mini-Mental State Examination 353/4614 1.00 (0.94 to 1.07) .95
Word Fluency Test 347/4486 1.01 (0.99 to 1.03) .47
Letter-Digit Substitution Test 347/4496 1.01 (0.99 to 1.03) .34
Stroop Test*
 Naming 334/4343 1.02 (0.99 to 1.05) .28
 Reading 333/4342 1.00 (0.97 to 1.02) .84
 Interference 333/4336 1.00 (1.00 to 1.01) .58
Purdue Pegboard Test 326/4326 0.99 (0.97 to 1.02) .56
Word Learning Test
 Immediate recall 327/4278 1.01 (0.96 to 1.07) .64
 Delayed recall 327/4277 1.00 (0.96 to 1.04) .85
 Recognition 331/4318 0.97 (0.92 to 1.02) .25
General cognitive factor 298/3927 1.03 (0.89 to 1.20) .66
Self-reported memory complaints
 More problems remembering 342/4486 1.18 (0.95 to 1.47) .14
 Forgetting (daily) pursuits 342/4486 0.99 (0.77 to 1.26) .91
 Word-finding problems 342/4486 1.17 (0.92 to 1.48) .21
Hazard ratios are adjusted for sex, education, body mass index, hypertension, diabetes mellitus, smoking 
status, alcohol use, and CES-D sum score.
* Better performance corresponds to lower scores.
CES-D = Centre for Epidemiological Studies Depression Scale, CI = confidence interval, HR = hazard 
ratio, n = number of participants with incident cancer, N = number of participants. 

Chapter 7
Change in cognitive function before and after non-central nervous 
system cancer diagnosis
van der Willik KD, Jóźwiak K, Hauptmann M, van de Velde EED, 




Background Studies showing that non-central nervous system cancer patients can develop 
cognitive impairment, have primarily focused on patients with specific cancer types and 
intensive treatments. These results may have been unduly influenced by patient selection. 
Such selection may be limited by studying cancer patients in a population-based setting. 
To better understand the course of cognitive function in the general population of cancer 
patients, we assessed cognitive trajectories of patients before and after cancer diagnosis in 
such population-based setting and compared these with cognitive trajectories of cancer-free 
controls.
Methods We evaluated 718 of the 2211 participants from the population-based Rotterdam 
Study who had been diagnosed with cancer between 1989 and 2014 and who had undergone 
at least one cognitive assessment before and after diagnosis. Cognition was measured 
every three to six years using a neuropsychological battery. Linear mixed models were used 
to compare cognitive trajectories of patients before and after diagnosis with those of age-
matched cancer-free controls (sampled in a ratio of 1:3).
Results The median age at cancer diagnosis was 70.3 years and 47.1% were women. Most 
patients (68.1%) had received local treatment only. Cognitive trajectories of patients before 
and after cancer diagnosis were largely similar to those of controls. After diagnosis, the largest 
difference was found on a memory test (patients declined with 0.14 units per year on the Word 
Learning Test: Delayed recall [95% confidence interval = -0.35 to 0.07] and controls with 0.09 
units [95% confidence interval = -0.18 to -0.00], P for difference = .59). 
Conclusions At a population-level, cognitive function in cancer patients declines similarly 
to that in cancer-free controls. This finding provides some reassurance to patients who have 
received local treatment. Larger numbers are needed to evaluate cognitive change in patients 
with specific cancer types and treatments.
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INTRODUCTION
During and following cancer treatment, non-central nervous system (CNS) cancer patients 
frequently report cognitive problems that adversely affect their quality of life and daily 
functioning.1-4 Multiple clinical studies have shown that cancer treatment, and in particular 
chemotherapy, can negatively affect cognitive function.5-9 In addition, it has been found that in 
some patients cognitive impairment occurs before start of cancer treatment, suggesting that 
cancer itself may also impact cognitive function.10-16 
 Although these studies have contributed greatly to our current understanding of cognitive 
impairment in cancer patients, they have generally focused on patients with specific types 
of cancer – in particular breast cancer – or patients treated with intensive, systemic cancer 
treatments. The clinical setting of most of these studies might also have attracted more 
participants with cognitive problems. This potential selection of patients may have unduly 
influenced the prevalence and severity of cognitive problems in cancer patients.1 As yet, 
there is therefore insufficient understanding of the course of cognitive function in the general, 
unselected population of cancer patients with different cancer types and treatments. 
 We have previously investigated the course of cognitive function before cancer diagnosis in 
such an unselected population of cancer patients by studying participants from the population-
based Rotterdam Study.17 In this cohort study participants undergo cognitive testing every 
three to six years, and some of these participants are subsequently diagnosed with cancer. In 
this population-based setting, we found no evidence that cognitive function declines differently 
in individuals who will be diagnosed with cancer than in those who will remain cancer-free, 
indicating that the impact of cancer itself on the brain is limited before clinical manifestation of 
the disease. 
 The current study expands our previous investigation and studies the cognitive trajectories 
of cancer patients before and after cancer diagnosis in the Rotterdam Study, allowing us to 
include cancer patients with different cancer types and cancer treatments. Our primary aim 
was to assess if the rate of change in cognitive function among cancer patients before and 
after cancer diagnosis is different from the rate of change in cognitive function in cancer-free 





This study is embedded within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of age-related diseases in the general 
population. The design has been described in detail previously.18 Briefly, in 1989 all inhabitants 
aged 55 years and over of the district Ommoord in Rotterdam, the Netherlands, were invited 
to participate. This initial cohort comprised 7983 participants (response of 78%) and was 
extended with a second subcohort in 2000 with 3011 participants (response of 67%) who 
had become 55 years of age or moved into the study district. In 2006, the cohort was further 
extended with 3932 participants (response of 65%) aged 45 years and over. 
 Participants were interviewed at home by a trained research assistant, followed by two 
visits to the research centre for different examinations including laboratory assessments, 
imaging, and physical examinations. Follow-up examinations took place every three to six 
years. 
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands. Written 
informed consent was obtained from all participants. 
Study population
Of the total of 14 926 participants, we excluded those with a history of cancer (n=567), history 
of dementia (n=521) or who were insufficiently screened for history of dementia (n=601), 
history of stroke (n=341), or history of Parkinson’s disease (n=77). Next, we excluded those 
without informed consent to access medical records for follow-up (n=165), leaving 12 654 
eligible participants (Figure 1).
Cases
Out of the 12 654 eligible participants, 2403 were diagnosed with cancer during a median 
(interquartile range [IQR]) follow-up of 10.0 years (7.0 to 5.2, up to January 1st, 2015). Of 
these participants, we excluded those with primary CNS cancer (n=15) and those diagnosed 
with dementia (n=66), stroke (n=102), or Parkinson’s disease (n=9) after study entry but 
before cancer diagnosis. Participants who were diagnosed with dementia, stroke, Parkinson’s 
disease, or secondary CNS cancer after non-CNS cancer diagnosis were censored at date 
of diagnosis to exclude cognitive test results obtained after such diagnoses. Lastly, we 
excluded participants without any cognitive assessment (n=45), those without at least one 
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Figure 1 Flowchart of the study population.
* History of diseases at study entry. † CNS cancer, dementia, stroke, or Parkinson’s disease diagnosis 
after study entry but before non-CNS cancer diagnosis. ‡ Dementia, stroke, or Parkinson’s disease 
after study entry but before first cognitive assessment. § Number of matched controls depended on the 
cognitive test.
CNS = central nervous system, LDST = Letter-Digit Substitution Test, MMSE = Mini-Mental State 






• History of cancer (n=567)
• History of dementia (n=521)
• Not sufficiently screened for             
history of dementia (n=601)
• History of stroke (n=341)
• History of Parkinson’s
disease (n=77)
• No informed consent (n=165)
Participants with incident cancer
(n=2403)
Excluded†
• CNS cancer (n=15)
• Dementia before cancer (n=66)
• Stroke before cancer (n=102)
• Parkinson’s disease before 
cancer (n=9)
• No cognitive assessment 
during follow-up (n=45)
• No cognitive assessment 
before cancer (n=27)
• No cognitive assessment after 
cancer (n=1421)
Incident cancer cases (n=718)
Excluded‡
• Dementia before first cognitive 
assessment (n=100)
• Stroke before first cognitive 
assessment (n=97)
• Parkinson’s disease before first 
cognitive assessment (n=11)
• Less than two cognitive 
assessments during follow-up 
(n=1884)
Cancer-free controls (n=8159)
Participants without incident cancer 
(n=10 251)
Matching of cases and controls




• Stroop Test: Reading (n=401)
• Stroop Test: Naming (n=402)
• Stroop Test: Interference (n=402)
• PPT (n=269)
• WLT: Immediate recall (n=210)
• WLT: Delayed recall (n=210)
• WLT: Recognition (n=215)




• Stroop Test: Reading (n=1203)
• Stroop Test: Naming (n=1206)
• Stroop Test: Interference (n=1206)
• PPT (n=807)
• WLT: Immediate recall (n=630)
• WLT: Delayed recall (n=630)
• WLT: Recognition (n=645)
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cognitive assessment before cancer diagnosis (n=27), or those without at least one cognitive 
assessment after diagnosis (n=1421), resulting in 718 cases for analysis who had at least two 
cognitive assessments.
Cancer-free controls
Out of the 12 654 eligible participants, 10 251 remained free of cancer during follow-up. 
We censored these participants at date of diagnosis of dementia, stroke, or Parkinson’s 
disease. Participants were excluded if their diagnosis of dementia (n=100), stroke (n=97), 
or Parkinson’s disease (n=11) was before their first cognitive assessment. We subsequently 
excluded participants without at least two cognitive test results during follow-up (n=1884), 
leaving 8159 participants as eligible controls.
Matching procedure
Each case was individually matched to three randomly selected cancer-free controls for the 
age at cancer diagnosis of the case (index age). To avoid overmatching, we only matched for 
age.19 An eligible control had undergone at least one cognitive assessment before and one 
assessment after the index age. Matching started with the oldest case and was done without 
replacement. We separately performed matching for each individual cognitive test. 
Ascertainment of cancer
Diagnoses of cancer were based on medical records of general practitioners (including 
hospital discharge letters) and through linkage with Dutch Hospital Data, Netherlands Cancer 
Registry, and histology and cytopathology registries in the region. Incident cancer was 
defined as any primary malignant tumour, excluding non-melanoma skin cancer. Diagnoses 
were coded independently by two physicians according to the International Classification of 
Diseases, tenth revision (ICD-10). In case of discrepancy, consensus was sought through 
consultation with a physician specialised in internal medicine. Date of diagnosis was based 
on date of biopsy (solid tumours) and laboratory assessment (haematological tumours), or 
– if unavailable – date of hospital admission or discharge letter. Only pathology-confirmed 
cancers were included in the analysis. We collected information about cancer treatment, 
which was categorised into no or local treatment (yes or no), hormonal therapy (yes or no), or 
chemotherapy (yes or no). Follow-up was completed up to January 1st, 2015.
Cognitive function assessment
Between 1989 and 2014, participants underwent cognitive screening using the Mini-Mental 
State Examination (MMSE)20 during home interviews by trained interviewers. From 1997 
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onwards, participants underwent in addition cognitive assessments at the research centre 
using a neuropsychological battery that included the Letter-Digit Substitution Test (LDST),21,22 
Word Fluency Test (WFT),23 and Stroop Test (Reading, Naming, and Inference subtask).24,25 
In 1999, the Purdue Pegboard Test (PPT) was added to the test battery.26 The test battery 
was further expanded in 2002 with the 15-Word Learning Test (WLT, Immediate recall, 
Delayed recall, and Recognition).27,28 Because tests were implemented into the study protocol 
at different moments, the number of participants differs per cognitive test (Supplementary 
Table 1).
Measurement of covariates
During the home interview, participants provided information on educational level, smoking 
habits, and alcohol use. Educational level was classified into primary education, lower (lower 
or intermediate general education, or lower vocational education), intermediate (intermediate 
vocational education or higher general education), or higher (higher vocational education or 
university). Smoking was categorised as never, current, or former. Alcohol use was based on 
total consumption in grams per day and was categorised as 0, ≤10, 10-≤20, or >20 grams.29 
Symptoms of depression were evaluated with the Centre for Epidemiologic Studies Depression 
scale (CES-D), which was converted to a sum-score.30 Height and weight were measured at 
the research centre and the body mass index (BMI, kg/m2) was computed. 
Statistical analysis
Differences in characteristics between cases and cancer-free controls were investigated using 
the independent samples t test (normally distributed continuous variables), the Wilcoxon 
signed-rank test (non-normally distributed continuous variables), and the chi-square test 
(for categorical variables). Next, we used the same statistical tests to explore differences in 
characteristics between included cases and cancer patients who were excluded because they 
had no cognitive assessment after diagnosis. 
 We determined and visualised cognitive trajectories of cases before and after cancer 
diagnosis and cognitive trajectories of controls over a similar time period using a two-level 
linear mixed model with a random intercept and slope for each cognitive test. If models did 
not converge with both random intercepts and time slopes, only a random intercept was 
used. Skewed cognitive test results (i.e., MMSE, Stroop tests, and WLT: Recognition) were 
transformed with the natural logarithm to reach an approximate normal distribution and were 
back-transformed for visualisation. Time to cancer diagnosis was used as underlying time 
scale (i.e., Time = 0 at cancer diagnosis, i.e., index age for controls, Time = -5 for five years 
before cancer diagnosis, and Time = 5 for five years after cancer diagnosis). To capture 
Chapter 7
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possible non-linearity, time was represented as a natural cubic B-spline with one interior knot 
at time of index age (Time = 0) via the ns(Time, 2, knots = 0) function using the ‘splines’ 
package from R software Version 3.3.2. An interaction term between time and case-control 
status (Cancer = 1 for cases and Cancer = 0 for controls) allowed a difference in change 
over time between cases and controls. These models were only adjusted for the age at first 
cognitive test (continuous). Visualisations of the trajectories were shown for the median age 
at first cognitive test of cases and controls combined.
 Next, we determined the change in cognitive test score per year using two-level linear 
mixed models, because usage of splines limits the interpretation of the corresponding 
coefficients. In these models, we evaluated different slopes of the trajectory before and 
after index age, because we hypothesised that cognitive function might decline faster after 
cancer diagnosis than before diagnosis. In order to do so, we included a second time variable 
(Time2), which is obtained by subtracting the time at which the slope is allowed to change 
(i.e., Time = 0) from the original time variable. Time2 is set at 0 if it has a negative value, i.e., 
before cancer diagnosis. This linear fit is the best linear approximation to the true functional 
relationship. Skewed cognitive test results were also transformed with the natural logarithm 
for these analyses, but when transformation did not change the statistical significance, we 
reported the results based on untransformed values for interpretation purposes. We modelled 
the jth cognitive test result of participant i as:
Cognitive test resultij = (β00 + u0i) + (β1 + u1i)Timeij + (β2 + u2i)Time2ij + β3Canceri + 
β4{Timeij*Canceri) + β5{Time2ij*Canceri) + β6Agei + β7Sexi + β8Educationi + β9Smokingi + 
β10Alcoholi + β11CESDi + β12BMIi + εij 
  In this formula, cognitive test resultij is the score of the cognitive assessment. Timeij 
represents the time to cancer diagnosis. The β parameters are fixed effects, while the u 
parameters are random errors, allowing variation of the intercept and slope of time between 
subjects. The residual term ε was modelled with the autocorrelation structure of the variance-
covariance matrix, and the general positive-definite matrix was used for the random part. 
 The average change in cognitive test result per year for controls before index age was 
equal to β1, whereas the change for cases before cancer diagnosis was equal to (β1 + β4), i.e., 
β4 indicates whether the change differs between cases and controls. After the index age, the 
average change in cognitive test result per year was (β1 + β2) for controls and (β1 + β2 + β4 + 
β5) for cases, with (β4 + β5) indicating the difference in change between cases and controls.
 Models were adjusted for age at first test and in addition for sex (women or men), 
educational level (primary, lower, intermediate, or higher), smoking status (never, current, or 
former), alcohol use (0, ≤10, 10-≤20, or >20 grams/day), CES-D sum-score (continuous), and 
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BMI (continuous). Values of covariates measured closest to the index age were used. 
 Because the slope of the estimated trajectories might have been influenced by test results 
of participants who had been assessed multiple years before or after the index age, we 
subsequently examined the difference in cognitive test scores between cases and controls 
using one-level linear regression models. This analysis was limited to the last cognitive 
assessment before the index age and the first cognitive assessment after the index age. We 
modelled the difference in cognitive test result of participant i as:
Cognitive test result after index agei - Cognitive test result before index agei = β0 + β1Canceri 
+ β2Cognitive test result before index agei + β3Timei + β4Agei + β5Sexi + β6Educationi + 
β7Smokingi + β8Alcoholi + β9CESDi + β10BMIi
 The outcome was defined as the cognitive test score after index age minus the cognitive 
test score before index age. Analyses were additionally adjusted for the cognitive test score 
before index age (continuous) and follow-up time between the assessment before and after 
index age (continuous). 
 Lastly, we performed analyses by cancer type (prostate, breast, colorectal, and other 
cancers) and cancer treatment (no or local treatment, hormonal therapy, and chemotherapy) 
in cases only to examine the effects of cancer-related variables on cognitive decline after 
cancer diagnosis. These analyses were adjusted for index age (continuous) instead of age at 
first cognitive assessment.
 Missing values of covariates (maximum of 2.1%) were replaced with mean (continuous, 
except CES-D sum-score), median (CES-D sum-score) or mode (categorical) values of the 
observed data (cases and controls combined). 
 Statistical analyses were performed using the ‘nlme’ and ‘splines’ packages from R 
software Version 3.3.2.31
RESULTS
Characteristics of included cases and controls are presented in Table 1A. Cases were slightly 
older at the first cognitive assessment than controls. Also, they were more often men and 
former smokers. The median (IQR) age at cancer diagnosis was 70.3 years (65.1 to 76.2). 
Most frequently diagnosed cancer types were prostate (27.6%), female breast (20.6%), and 




Table 1A Characteristics of cases and matched cancer-free controls.






Age at first cognitive 
assessment, years, 
median (IQR)
62.8 (59.3 to 69.0) 62.1 (58.5 to 68.0) .002 65.3 (60.5 to 72.3) <.001
Women, No. (%) 338 (47.1) 2917 (60.0) <.001 687 (48.3) .46
Educational level, No. 
(%) .07 <.001
 Primary 92 (12.8) 567 (11.7) 265 (18.6)
 Lower 281 (39.1) 2049 (42.2) 591 (41.6)
 Intermediate 239 (33.3) 1423 (29.3) 385 (27.1)
 Higher 106 (14.8) 820 (16.9) 163 (11.5)
Body mass index, kg/
m2, mean (SD) 26.7 (4.9) 26.9 (5.2) .12 27.1 (4.1) .69
Smoking status, No. 
(%) .007 <.001
 Never 164 (22.8) 1389 (28.6) 295 (20.8)
 Former 427 (59.5) 2640 (54.3) 746 (52.5)
 Current 127 (17.7) 830 (17.1) 374 (26.3)
Daily grams of alcohol 
consumption, No. (%) .008 <.001
 0 121 (16.9) 647 (13.3) 339 (23.9)
 ≤10 338 (47.1) 2887 (59.4) 557 (39.2)
 10-≤20 108 (15.0) 757 (15.6) 182 (12.8)
 >20 101 (14.1) 568 (11.7) 169 (11.9)
CES-D sum-score, 
median (IQR) 3 (0 to 8) 3 (1 to 7) .24 3 (0 to 8) .99
* Cases were excluded because they had no cognitive measurement after cancer diagnosis. Missing data 
for these cases were not imputed and therefore numbers do not always add up to 100%. † P-value for 
difference in characteristics between included cases and cancer-free controls. ‡ P-value for difference 
in characteristics between included and excluded cases. § Controls were matched to cancer patients 
per individual cognitive test. Therefore, some controls were used for different cognitive tests, whereas 
other controls were only matched to cancer patients for one cognitive test, and some were not used at 
all (n=3300). The controls in this table represent all unique controls used for the different cognitive test 
analyses. Of the 4859 controls, 41% were matched for one test, 24% for two tests, 16% for three tests, 
and 19% for four or more tests. 
CES-D = Centre for Epidemiologic Studies Depression Scale, IQR = interquartile range, SD = standard 
deviation.
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Table 1B Cancer-related characteristics of included and excluded cases.




Age at cancer diagnosis, years, median (IQR) 70.3 (65.1 to 76.2) 75.7 (69.5 to 81.4) <.001
Cancer type, No. (%) <.001
 Head and neck 31 (4.3) 46 (3.2)
 Oesophagus and gastric 16 (2.2) 107 (7.5)
 Colorectal 111 (15.5) 233 (16.4)
 Hepato-pancreato-biliary 2 (0.3) 90 (6.3)
 Lung and mesothelioma 26 (3.6) 261 (18.4)
 Female breast 148 (20.6) 151 (10.6)
 Female genital organs 36 (5.0) 59 (4.2)
 Male genital organs 199 (27.7)‡ 152 (10.7)§
 Urinary tract 50 (7.0) 103 (7.2)
 Haematological 50 (7.0) 127 (8.9)
 Other 48 (6.7) 41 (2.9)
 Unknown primary origin 1 (0.1) 51 (3.6)
Cancer treatment||, No. (%) <.001
 No treatment 61 (8.5) 60 (4.2)
 Local treatment 489 (68.1) 982 (69.1)
 Hormonal therapy 87 (12.1) 108 (7.6)
 Chemotherapy 81 (11.3) 271 (19.1)
* Cases were excluded because they had no cognitive measurement after cancer diagnosis. † P-value 
for difference in characteristics between included and excluded cases. ‡ 198 out of 199 were prostate 
cancers. § 151 out of 152 were prostate cancers. || Any line of cancer treatment for included cases, 
first line cancer treatment for excluded cases. If cases received more than one treatment, cases were 
categorised as receiving either chemotherapy or hormonal therapy.
IQR = interquartile range.
 Cancer patients who were excluded because they had only cognitive assessments before, 
but not after diagnosis, were older at the first cognitive assessment and at cancer diagnosis 
than included cases (Table 1B). In addition, they had more often a primary educational level, 
were more frequently current smokers, and less frequently alcohol users. Most frequent cancer 
types among excluded cancer patients were lung and mesothelioma (18.4%), colorectal 
(16.4%), female breast (10.6%), and prostate (10.6%). Reasons for missing cognitive 
assessments after diagnosis are presented in Table 2. The majority of the excluded cancer 
patients (46.9%) had died within five years after their last visit.
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Table 2 Reasons for absent cognitive assessment after cancer diagnosis.
Reason for absent cognitive assessment
Cancer patients without cognitive assessment 
after cancer diagnosis 
(n=1421)
Dementia <5 years after last visit 15 (1.1)
 Age at dementia diagnosis, years 81.0 (75.2 to 85.6)
Stroke <5 years after last visit 41 (2.9)
 Age at stroke diagnosis, years 77.4 (72.4 to 85.6)
Parkinson’s disease <5 years after last visit 4 (0.3)
 Age at Parkinson’s disease diagnosis, years 75.5 (71.1 to 77.1)
End of follow-up (2015) <5 years after last visit 120 (8.4)
Deceased <5 years after last visit 666 (46.9)
 Age at death, years 76.3 (69.8 to 81.8)
Other reasons 575 (40.5)
 Refused 305 (53.0)
 Physical or mental problems 143 (24.9)
 Deceased >5 years after last visit 32 (5.6)
 Other 22 (3.8)
 Unknown 73 (12.7)
Categorical data are presented as count (percent), continuous data are presented as median (interquartile 
range).
 Figure 2 shows the cognitive trajectories of cases and controls. Cases declined with a 
similar rate as controls on all cognitive tests before cancer diagnosis (Figure 2 and Table 
3). Also after diagnosis, trajectories were largely similar between cases and controls after 
diagnosis. The largest difference was found on the WLT: Delayed recall (cases declined with 
0.14 units per year [95% confidence interval [CI] = -0.35 to 0.07] whereas controls declined 
with 0.09 units [95% CI = -0.18 to -0.00], P for difference = .59, Table 3). The total number of 
cognitive assessments and the time between assessments are presented in Supplementary 
Table 1.
 When including only one cognitive assessment before and one assessment after index 
age to minimise possible effects of leverage points, we found that the difference in WLT: 
Immediate and Delayed recall scores was larger in cases than in controls (cases declined 
with an additional 0.27 units [95% CI = -0.53 to -0.01] on the WLT: Immediate recall and with 
an additional 0.34 units [95% CI = -0.68 to 0.00] on the WLT: Delayed recall, Supplementary 
Table 2). 
 


























































































































































































Word Learning Test: Immediate recall
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Word Learning Test: Delayed recall
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Figure 2 Trajectories of cognitive decline for cases (yellow) before and after cancer diagnosis and 
for cancer-free controls (blue) over a similar time period.
* Higher score indicates worse performance.
CI = confidence interval. 
 Subgroup analyses by cancer type showed that cognitive function in patients with breast, 
prostate, and colorectal cancer declined with a similar rate after cancer diagnosis as cognitive 
function in patients with other cancer types (Supplementary Table 3). We found that cases 
who received chemotherapy declined slightly faster on Stroop Test reading subtask and PPT 
than patients who had received no or local cancer treatment, but effect sizes were small 
(Supplementary Table 4).
DISCUSSION
In this population-based study we found that the mean rate of cognitive decline seen in cancer 
patients from before to after cancer diagnosis is no faster than that observed in cancer-free 
controls over a similar time period. When focusing on only one cognitive assessment before 
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appeared to decline faster, but this difference was only marginally significant. Our analyses 
within cancer patients showed that patients treated with chemotherapy declined faster on two 
out of ten cognitive tests, but numbers were small and additional data is needed for definite 
statements about systemic treatment. 
 Previous clinical studies that have investigated cognitive effects of specific cancer types 
or systemic cancer treatments have shown that cancer patients have more often impaired 
cognitive function than cancer-free controls, also before start of cancer treatment.1-16 These 
studies were often limited to specific cancer types, leaving doubts about generalisability to 
other cancer types. Animal studies have confirmed findings from clinical studies, showing that 
for example both treatment-naive rodents with cancer and rodents treated with chemotherapy 
can have cognitive impairment.32-36 Based on these clinical and preclinical findings, different 
causes and mechanisms underlying cancer-related cognitive impairment have been proposed, 
including psychological factors that accompany a cancer diagnosis, cancer itself, and cancer 
treatment.3,37 
 Our current findings at a population-level show similar trajectories of cognitive function 
between cancer patients and cancer-free controls. When limiting the number of cognitive 
assessments – and thus the study period – we found only a slight tendency for a steeper 
decline on the memory tests WLT: Immediate and Delayed recall in cancer patients after 
diagnosis. These findings indicate that in general, cognitive function in cancer patients does 
not decline faster than in cancer-free controls.
 An important explanation for the discrepancy between our findings and those of previous 
clinical studies lies in the difference between study populations. Firstly, we have included 
a heterogeneous population of cancer patients with different cancer types and treatments. 
Most cancer patients (68.1%) did receive local treatment only. Secondly, we had to exclude 
almost two thirds of cancer patients in the Rotterdam Study, because they had no cognitive 
assessment after cancer diagnosis. Compared to these excluded patients, included cancer 
patients were younger, had more favourable cancer types, and underwent less aggressive 
treatments. Also, because cognitive assessments in this population-based study take place 
every three to six years, and patients had to visit the research centre to undergo the variety of 
neuropsychological tests, we may have selected the most ‘healthy’ cancer patients. In clinical 
studies, patients are assessed shortly after diagnosis. Therefore, patients who die within a few 
years after diagnosis may still have been included in a clinical study. Despite this selection of 
healthier cancer patients, we nevertheless feel that our study provides key insights into the 
course of cognitive decline for a large group of cancer patients. Such insights into cognitive 




 A few limitations of our study need to be addressed. Although we included a large number 
of cancer patients, they represent a very heterogeneous group in terms of cancer types and 
treatments. Therefore, the statistical power to detect small to moderate differences in cognitive 
function over time within different subgroups of cancer patients was likely low (for instance, 
only 19 out of 148 breast cancer patients were treated with chemotherapy). Another limitation 
is that we were unable to identify any risk factors that might be associated with accelerated 
cognitive decline in cancer patients as risk factors for cognitive decline such as smoking and 
alcohol can also affect the risk of cancer. To be able to determine the effect of smoking on 
cognitive decline in cancer patients, it is necessary to take into account the mediating effect 
of smoking through cancer. As yet, the application of mediation analysis in longitudinal data 
is limited. Another possibility is to apply the well-established prediction models for cognitive 
decline, since we assume that these risk factors will not affect cognitive function in cancer 
patients differently than that in cancer-free controls. However, application of such models 
requires a larger population of cancer patients.
 Despite these limitations, our study design and setting also have many strengths. Firstly, 
the baseline assessment in the current study was a cognitive assessment before cancer 
diagnosis, which is necessary to control the effects of psychological factors that accompany 
a new cancer diagnosis. Secondly, instead of assessing cognitive function at a single time 
point after cancer diagnosis or treatment, we assessed cognitive function over time. Thirdly, 
we included a large number of cancer patients with different types of cancer and different 
treatments, enabling us to generalise our findings to a larger population of cancer patients. 
 In conclusion, we found that at a population-level, cognitive function in cancer patients 
from before to after diagnosis declines similarly to that in cancer-free controls. This finding 
provides some reassurance to cancer patients with favourable cancer types and those who 
have received local treatment. Even larger numbers of patients with cognitive assessments 
would be needed to evaluate cognitive changes in patients with specific cancer types and 
following certain treatments and to identify subgroups of cancer patients who are at high risk 
for developing cognitive impairment.
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Supplementary Table 2 Difference between cases and cancer-free controls in the change in 
cognitive test scores between before and after cancer diagnosis based on one cognitive test 
before cancer diagnosis and one cognitive test after cancer diagnosis using linear regression 
models.
Cognitive test N Cases N Controls β Cancer* (95% CI)
Mini-Mental State Examination 718 2154 0.07 (-0.08 to 0.23)
Letter-Digit Substitution Test 416 1248 -0.32 (-0.77 to 0.12)
Word Fluency Test 420 1258 -0.10 (-0.53 to 0.34)
Stroop Test: Reading† 401 1203 0.33 (-0.02 to 0.68)
Stroop Test: Naming† 402 1206 -0.40 (-0.98 to 0.18)
Stroop Test: Interference† 402 1206 -0.37 (-3.19 to 2.45)
Purdue Pegboard Test 269 807 -0.28 (-0.74 to 0.18)
Word Learning Test: Immediate recall 210 630 -0.27 (-0.53 to -0.01)
Word Learning Test: Delayed recall 210 630 -0.34 (-0.68 to 0.00)
Word Learning Test: Recognition 215 645 -0.24 (-0.51 to 0.04)
Results based on the model Cognitive test result after index agei - Cognitive test result before index agei 
= β0 + β1Canceri + β2Cognitive test result before index agei + β3Timei + β4Agei + β5Sexi + β6Educationi + 
β7Smokingi + β8Alcoholi + β9CESDi + β10BMIi for participant i.
* β1, † Positive values indicate worse test scores. 
BMI = body mass index, CES-D = Centre for Epidemiologic Studies Depression Scale, CI = confidence 
interval, N = number. 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Alzheimer’s disease as a multistage process
Licher S, van der Willik KD, Vinke EJ, Yılmaz P, Fani L, Schagen SB, 




Background In cancer research, multistage models are used to assess the multistep process 
that leads to the onset of cancer. In view of biological and clinical similarities between cancer 
and dementia, we used these models to study Alzheimer’s disease (AD).
Methods From the population-based Rotterdam Study, we included 9362 participants free 
from any type of dementia, of whom 1124 developed AD during up to 26.1 years of follow-
up. Under a multistage model, we regressed the logarithm of AD incidence rate against the 
logarithm of five-year age categories. The slope in this model reflects the number of steps 
(n–1) required for disease onset before the final step leading to disease manifestation.
Results A linear relationship between log incidence rate and log age was observed, with a 
slope of 12.8 (95% CI 9.0 to 16.6), equivalent to 14 steps. We observed fewer steps for those 
at high genetically determined risk: 12 steps for APOE-ε4 carriers, and ten steps for those at 
highest genetic risk based on APOE and a genetic risk score. 
Conclusions The pathogenesis of AD complies with a multistage disease-model, requiring 14 
steps before disease manifestation. Genetically predisposed individuals require fewer steps 
indicating that they already inherited multiple of these steps. Unravelling these steps in AD 
pathogenesis could benefit the development of intervention strategies.
Alzheimer’s disease as a multistage process
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INTRODUCTION
Over the past decades, major advances have been made in the understanding of the role of 
amyloid and cerebrovascular pathology in the onset and progression of Alzheimer’s disease 
(AD).1 However, the underlying number of pathological changes and the subsequent final 
trigger leading to clinical disease manifestation, remain largely unclear. AD has a strong 
genetic component with a heritability of 60 to 80%, with additional AD-susceptibility genes 
that are still being identified.2,3 These findings suggest that an individual’s genetic architecture 
is key in determining if and when disease emerges.2-4 Notwithstanding the importance of 
environmental and lifestyle factors, it remains difficult to quantify to what extent this genetic 
predisposition is deterministic for AD onset.
 Originated in cancer research, multistage models have been used to gain more insight 
in the number of steps before disease manifestation. These models are able to estimate 
the number of steps (‘mutations’) required for a healthy cell to become malignant.5 After 
undergoing several of these rate-limiting steps, the last mutation will ultimately lead to clinical 
manifestation of the disease. These models have yielded consistent findings across a variety 
of cancers, supporting the notion that the occurrence of cancer is the end result of seven, 
successful mutations.5 
 Cancer and neurodegenerative disease, including AD as its most common form, may 
be seen as two opposite ends in cell proliferation. Yet they share biological and clinical 
characteristics, including dysregulations in key DNA repair and inflammation processes, an 
increasing incidence with advancing age, and rapid disease progression after diagnosis.6,7 
Moreover, they share a complex inheritance pattern with genetic pleiotropy.8 For instance, a 
recent genome-wide association study (GWAS) found a positive genetic correlation between 
AD and cancer genes, further supporting the genetic overlap between these two diseases.8 
 Given the commonalities between neurodegenerative diseases and cancer, the multistage 
model has recently been successfully applied to model the incidence rate of amyotrophic lateral 
sclerosis, a rare neurodegenerative disease, as a six-step process.9 So far, this multistage 
modelling has not been used for AD. We therefore applied a multistage model within a large, 
population-based study to test the hypothesis that AD is a multistage process. We determined 
the number of steps required for disease onset and hypothesised that if AD complies with a 
multistage process, the number of steps will be smaller in genetically predisposed individuals 





This study was conducted within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of age-related diseases in the general 
population. Details regarding the objectives and design have been reported previously.10 
Briefly, in 1989 inhabitants aged 55 years and older from a well-defined suburb in the city 
of Rotterdam, the Netherlands were invited to participate. The initial cohort comprised 7983 
individuals. In 2000, 3011 individuals who had become 55 years of age or moved into the 
study district since the start of the study if aged at least 55 years, were added to the cohort. In 
2006, a further extension of the cohort was initiated in which 3932 individuals were included 
who were aged at least 45 years. In total, the Rotterdam Study comprises 14 926 individuals 
aged 45 years and older. The overall response rate for all three recruitment waves was 72%.
 To model AD as a multistage process, we excluded participants with a history of any type 
of dementia at baseline (N=531) and those who were insufficiently screened for dementia 
(N=637). We further excluded participants who did not provide informed consent to access 
medical records or hospital discharge letters (N=159). Lastly, participants without information 
on their APOE genotype (N=964) or AD-associated genetic variants to calculate the genetic 
risk score (N=1565) were excluded, leaving 11 070 participants for analyses (Figure 1). 
APOE genotyping and calculation of a weighted genetic risk score
DNA was extracted from blood samples drawn by venepuncture at baseline. APOE genotype 
was determined using polymerase chain reaction on coded DNA samples in the initial cohort 
and with a bi-allelic TaqMan assay (rs7412 and rs429358) in the two extensions (RS-II and RS-
III). The majority of samples (81.1%) were further genotyped with the Illumina 610K and 660K 
chips and imputed to the Haplotype Reference Consortium reference panel (version 1.0) with 
Minimac 3. We included 23 genetic variants that showed genome wide significant evidence of 
association with AD to calculate a weighted genetic risk score (Supplementary Table 1 for an 
overview of the included variants).9,11-25 This score was calculated as the sum of the products 
of single nucleotide polymorphism dosages of the 23 genetic variants (excluding APOE) and 
their respective reported effect estimates. All 23 variants selected for the calculation of the 
genetic risk score were well imputed (imputation score R2 >0.3, median 0.99).
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Included participants for analysis 
(n=9362)
Excluded (n=1327)
• Prevalent dementia (n=531)
• Not sufficiently screened for dementia (n=637)
• No informed consent (n=159)
Participants Rotterdam Study 
(n=14 926)
Participants for AD follow-up 
(n=13 599)
Excluded (n=2529)
• No information about APOE genotype (n=964)
• No information about AD-associated genetic 
variants (n=1565)
Eligible participants for analysis 
(n=11 070)
Excluded (n=1708)
• Contributed only to age categories with <500 
person-years or an incidence rate <1 per 1000 
person-years (n=1708)
Figure 1 Flowchart of study population.




Ascertainment methods of dementia
Baseline and follow-up ascertainment methods for dementia have previously been described 
in detail.26 Participants were screened for dementia at baseline and subsequent centre visits 
with the Mini-Mental State Examination and the Geriatric Mental Schedule organic level. 
Those with a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 
underwent further investigation and informant interview, including the Cambridge Examination 
for Mental Disorders of the Elderly. All participants also underwent routine cognitive 
assessment. In addition, the entire cohort was continuously under surveillance for dementia 
through electronic linkage of the study database with medical records from general practitioners 
and the regional institute for outpatient mental health care. Available information on cognitive 
testing and clinical neuroimaging was used when required for diagnosis of dementia subtype. 
A consensus panel led by a consultant neurologist established the final diagnosis according 
to standard criteria for AD (NINCDS–ADRDA). Participants were censored at date of any type 
of dementia diagnosis, death, loss to follow-up, or January 1st, 2016, whichever came first. 
Follow-up was virtually complete (96.3% of potential person-years).27 
The multistage model
Multistage models originate from cancer epidemiology, where they were first employed to 
study the age distribution of several cancer types.5,28-30 Within this framework it is assumed 
that cancer manifests clinically after a certain threshold number has been reached composed 
of n mutations within one cell. This threshold for disease occurrence in that cell has a certain 
probability distribution over time (t), e.g., for an individual the nth mutation occurs at age 50 
years, whereas for another individual this nth mutation may occur at age 80 years. Of the 
required mutations, (n−1) mutations have independently taken place at a certain point during 
the lifespan. For each of these mutations, a certain probability per time unit (e.g., year) exists 
that a mutation will occur (λ). When a cell is primed, such that it has undergone all of these 
necessary preceding mutations, the final mutation (nth mutation) leads to clinical manifestation 
of disease. Subsequently, this final nth mutation has to occur after all of these steps and can 
for example not occur in between preceding steps. So, the probability density function of time-
point t, when the nth change takes place is:
  f(t) ~ λ1λ2...λn-1λntn-1
 It was noted in cancer epidemiology that the age-specific incidence rate of cancer (‘i’) 
roughly coincided with the probability that at least one cell of all independent cells acquired 
the necessary number of seven mutations by that specific age. This means that for most 
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types of cancer six preceding rate-limiting steps (n−1) are necessary during the lifespan, 
with a seventh and final mutation (nth mutation), leading to disease manifestation.31 It can 
subsequently be shown that if the disease under study fits a multistep process, the number of 
these steps (n) can be estimated with the following formula:
  log(i) = (n-1)log(t) + c
in which c is a constant number containing log(λ1λ2...λn-1λn). The common ground of these 
rate-limiting definitions is that the speed of a reaction step will have a significant effect on 
the speed of the overall chain of events to which the step belongs.32 A reaction step is thus 
subsequently considered a rate-limiting step, when the rate of that particular step is identical 
to the overall rate of the entire reaction. 
Statistical analysis
We applied a multistage model to determine the slope and the number of steps for the 
development and clinical onset of AD. In line with previous studies, the incidence rate of AD 
was calculated per five years age categories.5,9 Each participant contributed person-years to 
specific age categories, until the age at AD diagnosis or censoring. To minimise the effects 
of outliers on the slope of the model, we excluded age categories with less than 500 person-
years or with an incidence rate below 1 per 1000 person-years given that estimated incidence 
rates often become instable in the extremes of the age distribution.30 This additional criterion 
resulted in an exclusion 213 530.6 person-years, which corresponded to the exclusion of 1708 
of the 11 070 participants with age at AD or censoring below the first included age category. 
This left 9362 participants available for the final analyses (Figure 1). The incidence rate of AD 
and the five-years age categories (log age) were natural log-transformed. Linearity was tested 
based on the adjusted R-squared obtained from a linear regression model with log age and 
incidence rate of AD as outcome. Linear models were unadjusted. 
 Additionally, we stratified according to APOE ε4 carrier status and on tertiles of a weighted 
genetic risk score in mutually exclusive categories of genetic risk and by combining both in 
order to be able to stratify those individuals with the lowest and those with the highest AD 
genetic risk. 
 Data were handled and analysed with SPSS Statistics version 24.0.0.1 (IBM Corp., 




During a follow-up of up to 26.1 years, 1124 out of 9362 participants were diagnosed with AD 
during a median (interquartile range) follow-up 10.3 years (5.1 to 15.3). Table 1 shows the 
baseline characteristics of the study population. In this sample, 58.2% of the participants were 
women. Of the included participants, 2624 were APOE ε4 carriers (28.0%).
Table 1 Baseline characteristics of total study population.
Characteristic Study population(N=9362)
Age, years, median (IQR) 65.0 (60.1 to 72.7)
Women, No. (%) 5453 (58.2)
APOE ε4 carrier status, No. (%)
 Carrier 2624 (28.0)
 Non-carrier 6738 (72.0)
Weighted genetic risk score, No. (%)
 First tertile 3146 (33.6)
 Second tertile 3120 (33.3)
 Third tertile 3096 (33.1)
Educational level, No. (%)
  Primary 1689 (18.0)
 Lower 3941 (42.1)
 Intermediate 2512 (26.8)
 Higher 1101 (11.8)
Body mass index, mean (SD), kg/m2 26.8 (3.9)
Systolic blood pressure, mm Hg, mean (SD) 140 (22)
Diastolic blood pressure, mm Hg, mean (SD) 76 (12)
Total cholesterol, mmol/L, mean (SD) 6.3 (1.2)
Diabetes mellitus, No. (%) 1026 (11.0)
Smoking status, No. (%)
 Never 3021 (32.2)
 Former 4276 (45.7)
 Current 1938 (20.7)
Alcohol use, No. (%) 6763 (72.2)
Values are shown without imputation and therefore not always add up to 100%.
APOE = apolipoprotein E, IQR = interquartile range, SD = standard deviation.
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Multistep model
The adjusted R-squared for the relation between log AD incidence rate and log age was 0.93, 
indicating a linear correlation, which is in line with the multistage model. The estimate of the 
slope (number of steps minus 1) for AD was 12.8 (95% confidence interval [CI] 9.0 to 16.6), 
indicating that 14 steps are needed for the development of AD (Figure 2, Table 2). 
Considering genetic risk
When considering only the APOE-related risk of developing AD, we found that APOE ε4 
genotype non-carriers needed more steps to develop AD than APOE ε4 carriers (16 steps 
for non-carriers, 12 for carriers). In an exploratory analysis, we also examined the number 
of steps among participants homo- or heterozygous for APOE ε4 separately. Participants 
homozygous for the APOE ε4 allele required ten steps, while participants heterozygous for 
APOE with ε3 and ε4 or ε2 and ε4 required 16 steps to develop AD. Similarly, we found for 
participants in the low-risk tertile of the genetic risk score that more steps were required to 
develop AD than for those in the high-risk tertile (16 steps versus 13 steps). When stratifying 
on both APOE ε4 carriership and the genetic risk score, we found that for every increase in 
tertile of the genetic risk score, APOE ε4 carriers needed less steps to develop AD than APOE 
ε4 non-carriers. This translated into ten steps for APOE ε4 carriers in the high-risk tertile, 
compared to 16 steps for non-carriers for APOE in the low-risk tertile (Table 2).
 




























measured log incidence rate
fitted log incidence rate curve
Figure 2 Plotted log incidence rate of Alzheimer’s disease (y-axis) against log age (x-axis). 
The dashed line shows the most optimal linear correlation.
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Table 2 Overview of estimates for slopes across groups with different genetic 
risks.
Study population n/N n-1 (95% CI) R-squared* 
Total study population 1124/9362 12.8 (9.01 to 16.6) 0.925
APOE ε4
 Carrier 481/2624 10.6 (6.0 to 15.2) 0.849
 Homozygote 70/213 8.9 (5.7 to 12.1) 0.923
 Heterozygote 411/2411 14.9 (8.1 to 21.7) 0.878
 Non-carrier 643/6738 15.0 (11.3 to 18.8) 0.946
Weighted genetic risk score - tertiles
 First 296/3146 15.0 (9.4 to 20.7) 0.885
 Second 376/3120 12.8 (9.9 to 15.7) 0.956
 Third 452/3096 11.7 (7.4 to 16.1) 0.886
Weighted genetic risk score - first tertile
 APOE ε4 carrier 124/843 8.5 (1.9 to 15.0) 0.886
 APOE ε4 non-carrier 172/2303 15.3 (11.8 to 18.8) 0.954
Weighted genetic risk score - second tertile
 APOE ε4 carrier 161/930 10.3 (6.8 to 13.8) 0.905
 APOE ε4 non-carrier 215/2190 15.5 (12.0 to 19.0) 0.955
Weighted genetic risk score - third tertile
 APOE ε4 carrier 196/851 8.9 (3.5 to 14.4) 0.738
 APOE ε4 non-carrier 256/2245 14.4 (9.8 to 19.0) 0.915
* Obtained from linear regression model log(Alzheimer’s disease incidencei) = β0 + β1*log(agei) 
APOE = apolipoprotein E, n = number of incident Alzheimer’s disease events, N = total number of 
participants, n-1 = estimate for slope (i.e., number of steps minus 1).
DISCUSSION
In this population-based study using long-term follow-up of AD, we found evidence that the 
development of AD follows a multistage process with 14 steps. This indicates that 14 steps 
are required for the clinical occurrence of AD in the general population. The number of steps 
was modified by the level of genetic predisposition, translating into six less steps for those 
individuals at highest genetic risk for AD than the number of steps for those at the lowest 
genetic risk.
 The multistage models have been extensively used in cancer research to provide more 
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insight in their underlying pathogenesis.28,33-36 Several studies have shown that seven steps were 
required to develop cancer, which may reflect somatic mutations, genomic rearrangements, or 
changes in tissue interactions and environment. Neurodegenerative diseases show several 
similarities with cancer such as dysregulation of DNA repair mechanisms. Yet, the multistage 
model has only been applied to amyotrophic lateral sclerosis which appears to follow a 
multistage process with six rate-limiting steps. In this study, we show that AD can also be 
modelled as a multistage condition consisting of 14 steps, stressing the genetic complexity 
and the variety of potential biological pathways involved in the development of this disease. 
 We found that the number of steps for AD differed between individuals with different 
degrees of genetic predisposition. APOE ε4 carriers require a smaller number of steps to 
develop AD than APOE ε4 non-carriers. In addition, these effects became even more 
pronounced when additionally considering 23 AD-associated genetic variants. Compared to 
those at highest genetic risk (i.e., APOE ε4 carrier and within the third tertile of the weighted 
genetic score), individuals at lowest genetic risk (i.e., APOE ε4 non-carrier and within the first 
tertile of weighted genetic score) needed six more rate-limiting steps to develop AD. These 
findings are in line with previous observations in cancer research showing different thresholds 
before the disease becomes clinically apparent for inherited and sporadic cancer events. 
For instance, individuals with familial adenomatous polyposis are at increased risk of colon 
cancer due to one mutated copy of the APC gene. It has been shown that these individuals 
need one step less in the overall pathological process to develop clinical colon cancer than 
individuals without this mutated gene.33 Also, children with inherited retinoblastoma required 
only one hit to develop this disease, whilst sporadic retinoblastoma cases became clinically 
apparent after two hits.37 Our findings may suggest that individuals with genetic predisposition 
begin several stages further down the chain of the required pathological threshold before AD 
becomes clinically apparent.
 Although our findings suggest that 14 steps are needed for AD to emerge clinically, 
the underlying biological pathways and changes reflected by these steps still need to be 
identified. To date, eight different biological pathways involved in the pathogenesis of AD 
have been identified using genetic variants in AD.38 The APOE ε4 allele is the most significant 
genetic risk factor due to its high prevalence and strong relation to AD. It is involved in four 
of these pathways, including cholesterol transport, haematopoietic cell lineage, clathrin/AP2 
adaptor complex, and protein folding pathways. Our finding that APOE ε4 non-carriers need 
four more steps before AD clinically manifests compared to APOE ε4 carriers taps into this 
observation, and could indicate that changes in the abovementioned four pathways are indeed 
necessary to acquire before AD manifests clinically. This could mean that these pathways are 
already changed or dysregulated at birth in APOE ε4 carriers, indicating that these individuals 
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subsequently have a lower resilience to the development of dementia. This could in turn lead 
to a lower required number of subsequent steps before disease manifestation. Indeed, up to 
18% of the APOE ε4 carriers in this study developed AD during follow-up, yet the lifetime risk 
of AD among these individuals is even higher with almost half of all them developing AD in 
their remaining lifetime. For carriers homozygous for APOE ε4 in the high-risk tertile, this risk 
is even higher, and the disease moreover manifests earlier, with a 29-year difference in age 
at onset for AD, compared to homozygous APOE carriers at the low-risk tertile of the genetic 
risk score.2
  The search of finding successful AD therapies is among the most challenging and 
expensive healthcare issue to date. So far, many disease-modifying agents reduce the 
production of amyloid-beta (Aβ), or target only one other specific part of the disease process.39 
Our present study shows that as many as 14 steps are required before AD becomes clinically 
apparent. This high number of required steps may signal the need to develop multi-domain 
approaches to target various underlying disease-processes simultaneously in order to halt or 
deter neurodegeneration.
 Several limitations of this study need to be discussed. Firstly, although the use of multistage 
models produces a number as simple, and concrete result, its exact biological meaning is 
complex and remains hard to interpret. For instance, multistage models reflect the notion and 
the trajectory of a single cell or cell lineage to become malignant in several rate limiting steps 
in cancer research. However, the biological unit and meaning of these independent steps is 
more variable in the case of AD, as indeed it is for other neurodegenerative diseases such as 
amyotrophic lateral sclerosis. This could for instance reflect an essential pathophysiological 
change in a single neurovascular unit, but could also relate to a key genetic mutation in a 
single cell or cell lineage. Secondly, the underlying multistage model assumes that disease 
development is predominantly genetically determined. This means that a certain number of 
steps, all with a similar exposure time, have to occur before the specific disease manifests 
clinically. In most instances, this means that the exposure under study must be present at birth 
or during an individual’s early life, such as their genes, ethnicity, sex, or environmental factors 
present from birth onwards. This leaves little room for the incorporation of environmental 
factors that start later in life, such as smoking. While AD has a strong genetic component,2 
the importance of lifestyle and environmental factors is also substantial.26,40 These factors 
remain however in part unaddressed in the current multistage models. Some studies in 
cancer epidemiology have tried to model these effects in more complex multistage models, 
but the results of these models turned out to be difficult to interpret and are currently poorly 
validated.33 Since this is the first application of the multistage modelling in AD, we relied on 
a simpler, yet widely used multistage model. Future research is encouraged to incorporate 
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(time-varying) extensions with environmental and lifestyle factors. Thirdly, results derived 
from exploratory analyses amongst participants either homo- or heterozygous for APOE ε4 
should be interpreted with caution as these analyses are based on relatively small sample 
sizes. Fourthly, due to various reasons including for instance selection bias, the presented 
frequencies of homo- and heterozygous carriers for the APOE ε4 allele in this population-
based cohort study (2.8% homozygous, 25.8% heterozygous), may differ from those in the 
unselected general population.41 Nevertheless, the frequencies in this study fell within the 
reported ranges from several other, large population-based cohort studies (Supplementary 
Table 2). Finally, estimates of multistage models are vulnerable for several artificial influences 
on the observed incidence patterns, such as community-wide disease screening programs or 
misclassification of diagnoses at high ages due to restrained diagnostic work-ups.42 For some 
diseases, this subsequently could influence the estimation of the slope and thus the number 
of steps needed for disease onset. We nevertheless minimised these effects by using a cohort 
study with standardised and consistent AD ascertainment over time with virtually complete 
follow-up (>95% of potential person-years). 
 In conclusion, we found that AD complies with a multistage model characterised by 14 
steps that include essential facets of biological change which are required before AD becomes 
clinically apparent. Moreover, we observed that individuals with a higher genetic susceptibility 
require less of these additional steps before disease manifests clinically. Future research is 
warranted to validate the number of steps, to study the effects of environmental and lifestyle 
factors, and to further investigate the processes underlying these rate-limiting steps. These 
findings could further increase the understanding of the pathogenesis of AD, which in turn 
could benefit the development of prevention and treatment strategies.
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Supplementary Table 2 Frequency of APOE alleles in study population.
APOE genotype Study population (N=9362) 
ε2/ε2 63 (0.7) 
ε2/ε3 1208 (12.9) 
ε2/ε4 250 (2.7) 
ε3/ε3 5467 (58.4) 
ε3/ε4 2161 (23.1) 
ε4/ε4 213 (2.8) 
Data are presented as number (percentage) of participants.




Mild cognitive impairment and dementia show contrasting 
associations with cancer
van der Willik KD, Ruiter R, Wolters FJ, Ikram MK, Stricker BHCh, 




Background To investigate and to compare the relation between dementia and cancer with 
the association between mild cognitive impairment (MCI) and cancer.
Methods A total of 13 207 persons from the Rotterdam Study were followed between 1989 and 
2013 for the onset of dementia and cancer (sample 1). Between 2002 and 2005, a subset of 
5181 persons underwent extensive cognitive testing for MCI and were subsequently followed 
up for cancer until 2013 (sample 2). We used Cox proportional hazards models to determine 
the association between dementia and cancer, and MCI and cancer. 
Results In sample 1, 1404 patients were diagnosed with dementia, and 2316 developed 
cancer (63 among dementia cases). Dementia was associated with a decreased risk of 
cancer (hazard ratio [HR] 0.53, 95% confidence interval [CI] = 0.41 to 0.68). In sample 2, 513 
persons were diagnosed with MCI and 670 persons developed cancer (81 among MCI cases). 
In contrast to individuals with dementia, those with MCI tended to have an increased risk of 
cancer (HR 1.25, 95% CI = 0.99 to 1.58). 
Conclusions We found that persons with MCI tended to have an increased risk of cancer, 
whereas patients with dementia had a decreased risk of cancer. These findings call into 
question a biological explanation for the inverse link between dementia and cancer, thereby 
suggesting the presence of methodological bias. 
Mild cognitive impairment, dementia, and risk of cancer
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INTRODUCTION
Dementia, including Alzheimer’s disease (AD), and cancer are global health priorities. 
Interestingly, several studies have consistently shown an inverse link between the two 
diseases. Patients with dementia have a decreased risk of cancer,1-7 while persons with a 
history of cancer are affected less often from subsequent dementia.1,2,4,5,8 
 Different biological mechanisms underlying this inverse association have been proposed, 
including pathways of cell proliferation and cell survival.9,10 In addition, epigenetic processes 
including DNA methylation have been considered contributing to this inverse association. Yet, 
patients with dementia are less likely to be screened for other diseases and have a limited 
life expectancy, both potentially contributing to a decreased subsequent incidence of cancer. 
Therefore, methodological bias, such as surveillance and survival bias, possibly explaining 
the inverse link between dementia and cancer has so far not been satisfactory ruled out. 
 If indeed a biological mechanism underlies the association between dementia and cancer, 
this would likely extend across the different preclinical stages of cognitive impairment. Mild 
cognitive impairment (MCI) is often considered the transitional stage between normal cognition 
and dementia, although not all cases of MCI ultimately lead to dementia.11,12 As such, it is 
considered an early clinical manifestation of the same pathological processes that underlie 
dementia and AD. Accordingly, we hypothesised that if the inverse link between dementia and 
cancer is truly biologically determined, this should be also reflected in the association between 
MCI and cancer. 
 We therefore investigated and compared the association between dementia and cancer 
with the association between MCI and cancer. 
METHODS
Setting 
This study is embedded in the Rotterdam Study, a population-based prospective cohort that 
started in 1989 in the Netherlands. The initial cohort (RS-I) consisted of 7983 participants (78% 
of invitees) aged 55 years or older residing in the district Ommoord in Rotterdam. The second 
cohort (RS-II) started in 2000 and was composed of 3011 participants (67% of invitees) in the 
same district who had turned 55 years or moved into this area. The third cohort (RS-III) was 
started in 2006, in which 3392 participants (65% of invitees) were included. The design of the 
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Rotterdam study has been described in detail previously.13 
 The Rotterdam Study was approved by the Medical Ethics Committee of Erasmus Medical 
Centre and by the board of The Netherlands Ministry of Health, Welfare, and Sports. A written 
informed consent was obtained from all participants. 
Study population
For the current study, two partly overlapping samples from the Rotterdam Study were defined. 
First, in sample 1, we investigated the association between dementia and risk of cancer, using 
dementia as a time-varying exposure. This analysis used the complete sample and follow-up 
of the Rotterdam Study. Of 14 926 study participants, we excluded patients with prevalent 
dementia (n=527), participants who were not sufficiently screened for dementia (n=743), and 
participants with prevalent cancer (n=449), leaving a total of 13 207 persons (Figure 1A). 
 Second, in sample 2, we investigated the association between MCI and risk of cancer, 
using MCI at a single assessment, since assessment of incident MCI is more difficult than 
incident dementia in a population-based setting due to limited information about the date of 
onset. This sample originated from the fourth follow-up round of RS-I, the second round of 
RS-II, and the first round of RS-III. In total 9065 participants were assessed for MCI, of whom 
we excluded patients with prevalent dementia (n=124), persons not sufficiently screened 
for dementia (n=283), not sufficiently screened for MCI (n=326), or aged below sixty years 
(n=2599). In addition, participants with prevalent cancer (n=214) or incident cancer before 
MCI assessment (n=338) were excluded, resulting in 5181 participants for the MCI analysis 
(Figure 1B). To enhance comparability between the analyses for dementia and MCI, we 
additionally performed a comparative analysis between dementia and cancer in sample 2 by 
using a single assessment of prevalent dementia (n=124). Persons with MCI (n=513) were 
excluded for this analysis (Figure 1B). 
Ascertainment of incident dementia
Participants were screened for dementia at baseline and subsequent centre visits with the Mini-
Mental State Examination (MMSE) and the Geriatric Mental Schedule (GMS) organic level.14 
Those with a MMSE score <26 or GMS score >0 underwent further investigation and informant 
interview, including the Cambridge Examination for Mental Disorders of the Elderly. During each 
centre visit, all participants also underwent routine cognitive assessment, including a verbal 
fluency test (Word Fluency Test [WFT], animal categories), Letter-Digit Substitution Task (LDST), 
Stroop Test, Purdue Pegboard Test, and 15-Word Learning Test (15-WLT). In addition, the entire 
cohort was continuously under surveillance for dementia through electronic linkage of the study 
database with medical records from general practitioners and the regional institute for outpatient 
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Participants for analysis cancer 
risk in dementia (n=13 207)
Excluded (n=1719)
• Prevalent dementia (n=527)
• Not sufficiently screened for 
dementia (n=743)
• Prevalent cancer (n=449)
Participants with information about MCI and 
prevalent dementia, without cancer (n=5305)
Excluded (n=124)




Participants for analysis 
cancer risk in MCI 
(n=5181)
Participants for analysis 
cancer risk in prevalent 
dementia (n=4792) 
Excluded (n=3760)
• Not sufficiently screened for 
dementia (n=283) or MCI 
(n=326)
• Aged <60 years (n=2599)
• Prevalent cancer (n=214)
• Incident cancer before MCI 
(n=338)
A Sample 1 B Sample 2
Rotterdam Study participants at 
study entry (n=14 926)
Rotterdam Study participants at 
time of MCI assessment (n=9065)
Figure 1 Flowchart of participants in sample 1 and 2.
The association between incident dementia and cancer was studied in sample 1. For sample 1, all 
participants of the Rotterdam Study were included at study entry, that is, the first rounds of the first (RS-
I), second (RS-II), and third cohort (RS-III). In total, sample 1 consisted of 13 207 participants. Sample 2 
originated from the fourth follow-up round of RS-I, the second round of RS-II, and the first round of RS-III. 
In this sample, the association between MCI and cancer was investigated after excluding participants with 
prevalent dementia, since absence of dementia is part of the definition of MCI. In addition, a comparative 
analysis was performed in sample 2 investigating the risk of cancer in patients with prevalent dementia. 
For this comparative analysis, persons with MCI were excluded. 
MCI = mild cognitive impairment.
mental health care. Available information on clinical neuroimaging was used when required for 
diagnosis of dementia subtype. A consensus panel led by a consultant neurologist established 
the final diagnosis according to standard criteria for dementia (DSM-III-R, Diagnostic and 
Statistical Manual of Mental Disorders, Third Edition, Revised), AD (NINCDS-ADRDA, National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease 
and Related Disorders Association), and vascular dementia (NINDS-AIREN, National Institute 
of Neurological Disorders and Stroke and the Association Internationale pour la Recherché et 
l’Enseignement en Neurosciences). Follow-up until January 1st, 2013 was virtually complete 
(92.4% of potential person-years). 
Assessment of MCI
Extensive cognitive testing for MCI assessment was implemented in the Rotterdam Study 
between 2002 and 2005, which encompasses the fourth examination round of RS-I, the 
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second examination round of RS-II, and the first examination round of RS-III. MCI was 
defined as the presence of self-perceived cognitive complaints (defined as at least one of 
six questions on memory and daily functioning) and cognitive impairment as assessed with 
neuropsychological tests in the absence of dementia, in persons aged at least 60 years.15 
The neuropsychological tests measured memory function (15-WLT: Immediate and Delayed 
recall), information-processing speed (LDST, Stroop: Reading and Naming subtask), and 
executive functioning (LDST, Stroop: Interference subtask, and WFT). 
 MCI was classified as amnestic (impaired scores on memory function irrespective of other 
domains) and non-amnestic MCI (normal memory function but impaired score on information-
processing speed or executive function). 
Assessment of incident cancer
The primary outcome of interest was incidence of cancer. Two research physicians 
independently assessed the diagnosis of cancer based on medical records obtained through 
general practitioners and hospital discharge letters. Additional information was collected 
through linkage with the Dutch Hospital Data, Netherlands Cancer Registry, and Dutch 
pathology database (PALGA). Only cases confirmed by pathology were used. Cancer was 
classified according to the International Classification of Diseases tenth edition. In case 
of discrepancy, consensus was sought through consultation with a cancer epidemiologist. 
Follow-up of cancer registration was completed up to January 1st, 2013. Non-melanoma skin 
cancers (NMSC) were not included in the definition of cancer for the analysis.
Other assessments
Baseline was study entry for sample 1 and time of MCI assessment for sample 2. Educational 
level (primary: primary education, lower: lower general education, intermediate general 
education, or lower vocational education, intermediate: intermediate vocational education or 
higher general education, or higher: higher vocational education or university), smoking status 
(current, former, or never), alcohol use (yes or no), and psycholeptic drug use (yes or no) 
were assessed at baseline by interview. Body mass index (BMI, kg/m2) was computed from 
measurements of height and weight. 
Statistical analysis 
Cox proportional hazards models were used to study the association between incident 
dementia and cancer in sample 1. Dementia was used as time-varying variable. In sample 
2, we used Cox proportional hazards models investigating the relation between MCI and 
cancer. All analyses were adjusted for age (continuous), sex, BMI (continuous), educational 
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level, smoking status, alcohol use, and psycholeptic drug use. Ethnicity was not used as a 
confounder since nearly all participants (98%) were of European descent. Follow-up time 
started from inclusion in the Rotterdam Study until the date of incident cancer, death, loss to 
follow-up, or January 1st, 2013, whichever came first. Censoring non-exposed participants 
at date of death allowed us to compute cause-specific hazard ratios (HRs). To minimise the 
potential impact of pre-existing subclinical malignancy on cognition (i.e., reverse causation), we 
repeated analyses after excluding the first two and five years of follow-up. This was performed 
in sample 1 by excluding the first two and five years following study entry for persons free of 
dementia, and the first two and five years after dementia diagnosis for dementia patients.16,17 
In sample 2, the first two and five years after baseline were excluded for both persons with 
and without MCI. Additionally, we explored effect modification by stratifying for age, sex, and 
smoking status. In sensitivity analyses, we repeated the analyses using age instead of follow-
up time as time scale. The proportional hazards assumption was checked by visual inspection 
of the Schoenfeld residuals.
 To enhance comparability between the dementia and MCI analyses, we performed a Cox 
proportional hazard analysis in sample 2 to study the risk of cancer in patients with prevalent 
dementia. In this sample, we additionally censored follow-up time at date of NMSC, stroke, 
or dementia diagnosis, limiting the effect of possible over- or underdiagnoses of cancer after 
these conditions. 
 Finally, direct comparison of the risk of cancer between dementia and MCI was performed 
by testing whether the HRs of cancer for dementia in sample 1 and 2 differed from the HR of 
cancer for MCI in sample 2 using a t test. 
 Missing covariates were imputed using the mean of five imputations based on the 
investigated covariates and outcome. All analyses were performed using IBM SPSS Statistics 
Version 21.0 and the ‘survival’ package in RStudio Version 3.3.2.
RESULTS
Table 1 shows the characteristics of the study population. Persons who developed dementia 
during follow-up were at baseline older, were more often women, had a lower BMI, had more 
often a primary or lower educational level, and less often an intermediate or higher educational 
level than participants who were not diagnosed with dementia during follow-up. Additionally, 
persons who developed dementia were less frequently smokers and alcohol users, and used 
less often psycholeptic drugs. Participants with MCI were older, were more often men, had a 
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Table 1 Characteristics of study population for dementia and MCI.
Sample 1 Sample 2








median (IQR) 61.8 (57.6 to 70.2) 73.2 (67.2 to 79.0) 69.5 (64.1 to 75.8) 72.0 (65.9 to 78.6)
Women, No. (%) 6676 (56.6) 996 (70.9) 2732 (58.5) 265 (51.7)
Body mass index, 
kg/m2, mean (SD) 26.9 (4.0) 26.5 (3.6) 27.7 (4.1) 27.8 (4.0)
Educational level, 
No. (%)
 Primary 1869 (15.8) 430 (30.6) 488 (10.5) 97 (18.9)
 Lower 4743 (40.2) 603 (42.9) 2087 (44.7) 214 (41.7)
 Intermediate 3318 (28.1) 289 (20.6) 1392 (29.8) 143 (27.9)
 Higher 1873 (15.9) 82 (5.8) 701 (15.0) 59 (11.5)
Smoking status, 
No. (%)
 Never 3689 (31.3) 615 (44.8) 1415 (30.3) 143 (27.9)
 Former 5395 (45.7) 556 (39.6) 2644 (56.6) 293 (57.1)
 Current 2719 (23.0) 233 (16.6) 609 (13.0) 77 (15.0)
No alcohol use, 
No. (%) 1823 (15.4) 304 (21.7) 628 (13.5) 98 (19.1)
No psycholeptic 
drug use, No. (%) 10 410 (88.2) 1142 (81.3) 4065 (87.1) 416 (81.1)
IQR = interquartile range, MCI = mild cognitive impairment, N = number of persons, SD = standard 
deviation.
lower educational level, were less often alcohol users, and used less frequently psycholeptic 
drugs than participants without MCI.
Dementia and the risk of cancer
In sample 1, 1404 (10.6%) participants were diagnosed with dementia and 2316 (17.5%) 
participants developed cancer, of whom 63 (4.5%) after a diagnosis of dementia. Those who 
developed dementia had a median follow-up time of 13.2 years (interquartile range [IQR] 8.8 
to 19.0 years), whereas the median follow-up time for participants who were not diagnosed 
with dementia was 8.4 years (IQR 5.3 to 13.0 years). The most frequently observed cancer 
sites were colorectal (15.7%), prostate (15.5%), breast (13.9%), and lung (11.9%). 
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 Dementia was associated with a decreased risk of cancer (HR 0.53 [95% confidence 
interval [CI] = 0.41 to 0.68], Figure 2). The risk estimates were similar for AD and vascular 
dementia. The risk was still reduced after excluding the first two and five years of follow-up 
time (the respective HRs were 0.44 [95% CI = 0.30 to 0.65] and 0.48 [95% CI = 0.26 to 0.90]). 
Dementia-related cancer risks did not significantly differ by age, sex, and smoking.
 Reduced risks were observed when using age as time scale in the Cox model; for 
instance, the HR for cancer among dementia patients was 0.61 (95% CI = 0.47 to 0.78). 
MCI and the risk of cancer
In sample 2, 513 (9.9%) participants had MCI. Six hundred and seventy (12.9%) participants 
developed cancer, of whom 81 (12.0%) had MCI. The median follow-up time for persons 
with MCI was 7.6 years (IQR 4.6 to 8.9 years), and 7.9 years (IQR 5.5 to 9.1 years) for those 
without MCI. A similar distribution of cancer sites was observed as in sample 1. 
 Participants with MCI had a borderline statistically significantly increased risk of cancer 
(HR 1.25 [95% CI = 0.99 to 1.58], Figure 3). This increased risk was particularly pronounced 
for amnestic MCI (HR 1.42 [95% CI = 1.02 to 1.98]). This risk increase was consistent when 
excluding the first two and five years of follow-up time (the respective HRs were 1.25 [95% 
CI = 0.95 to 1.66] and 1.73 [95% CI = 1.19 to 2.51]). Risk estimates for younger participants 
tended to be stronger than for older individuals, but a formal interaction term did not reach 
statistical significance (P=.09). Results were comparable when using age as time scale. 
 The risk of cancer in patients with prevalent dementia in sample 2 was comparable to 
the cancer risk after incident dementia in sample 1 (HR 0.47 [95% CI = 0.21 to 1.06], Table 
2). Risk estimates did not change materially after censoring for NMSC, stroke, or dementia 
(Table 2).
 The abovementioned HR of cancer for MCI (1.25) was significantly different from the HR of 
cancer for dementia in sample 1 (0.53, P=.001) and sample 2 (0.47, P=.02), that is, persons 
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Figure 2 Forest plot dementia and risk of cancer.
Hazard ratios with 95% confidence intervals for the risk of cancer among patients with dementia. Hazard 
ratios are adjusted for age, sex, body mass index, educational level, smoking status, alcohol use, and 
psycholeptic drug use. Characteristics are measured at time of study entry. 
CI = confidence interval. 
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Figure 3 Forest plot MCI and risk of cancer.
Hazard ratios with 95% confidence intervals for the risk of cancer among persons with MCI. Hazard 
ratios are adjusted for age, sex, body mass index, educational level, smoking status, alcohol use, and 
psycholeptic drug use. Characteristics are measured at the time of MCI assessment. 
CI = confidence interval, MCI = mild cognitive impairment. 
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Table 2 Risk of cancer in persons with MCI or prevalent dementia at time of MCI 
assessment.













MCI and risk of cancer
 No MCI 4668 589 1.00 540 1.00
 MCI 513 81 1.25 (0.99 to 1.58) 76 1.29 (1.02 to 1.65)
 Censored for NMSC 483 74 1.28 (1.00 to 1.63) 69 1.30 (1.01 to 1.68)
 Censored for stroke 454 73 1.36 (1.07 to 1.74) 69 1.42 (1.10 to 1.83)
 Censored for dementia 513 73 1.22 (0.95 to 1.56) 68 1.24 (0.96 to 1.60)
 Censored for stroke  
 and dementia 454 65 1.32 (1.01 to 1.71) 61 1.36 (1.04 to 1.77)
Prevalent dementia and 
risk of cancer
 No prevalent dementia 4668 589 1.00 540 1.00
 Prevalent dementia 124 6 0.47 (0.21 to 1.06) 5 0.43 (0.18 to 1.05)
 Censored for NMSC 121 6 0.49 (0.22 to 1.09) 5 0.45 (0.18 to 1.09)
 Censored for stroke 104 6 0.60 (0.27 to 1.35) 5 0.56 (0.23 to 1.35)
Hazard ratios are adjusted for age, sex, body mass index, educational level, smoking status, alcohol use, 
and psycholeptic drug use. 
CI = confidence interval, HR = hazard ratio, MCI = mild cognitive impairment, NMSC = non-melanoma 
skin cancer.
DISCUSSION
In this population-based cohort study, we found opposite effects of MCI and dementia with 
respect to subsequent risk of cancer. While we confirmed that persons with dementia had a 
decreased risk of cancer, those with MCI did not have a decreased risk and even tended to 
have an increased risk of cancer. 
 Strengths of our study are its prospective, population-based design, the number of cancer 
diagnoses, and the standardised ascertainment of the determinants and outcome. Also, by 
focusing on MCI we were able to reduce the effect of a possible surveillance bias and the 
decreased life expectancy in dementia patients. In addition, we excluded the first two and five 
years of follow-up time in order to limit reverse causality.
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 Our study has some limitations. First, the cognitive tests for assessing MCI were 
implemented between 2002 and 2005, precluding MCI assessment at baseline for RS-I and 
RS-II. To increase the comparability between the samples used for analyses of dementia 
and MCI, we investigated the risk of cancer in patients with prevalent dementia in the same 
sample as the MCI-analysis and we found similar results to the overall population. Second, we 
did not have baseline information about potential confounders such as depressive and anxiety 
disorders, which could have resulted in an overestimation of the observed associations 
between dementia and cancer, and MCI and cancer. Third, the Rotterdam Study includes 
mostly white, middle class persons, possibly limiting the generalisability of our findings to 
other ethnic and socioeconomic groups. Finally, patients with AD represented the largest 
group of people with dementia. Therefore, we were not able to reliably study the association 
with cancer for other dementia types.
 We found that dementia is associated with a decreased risk of cancer, which is in line 
with findings from previous studies for various cancer types including breast, prostate, 
colon, and NMSC.1-8,18 Various biological mechanisms have been proposed, and the most 
frequently postulated mechanisms are to do with a genetic predisposition for either promoting 
or suppressing metabolic survival or apoptotic cellular pathways.10 For instance, the tumour 
suppressor protein p53 induces apoptosis in the face of DNA damage, which protects against 
cancer, while in dementia, it could induce neuronal death.19 Methodological explanations – like 
surveillance and survival bias – could also have accounted for the observed inverse relation, 
but these have not been sufficiently ruled out. As MCI is often considered an early manifestation 
of the same pathological processes as dementia and AD, we investigated the risk of cancer 
among persons with MCI. We argued that if the inverse link between dementia and cancer 
is rooted in biology, this decreased risk would be reflected in persons with MCI as well. One 
previous study has looked into history of cancer among persons with and without MCI and has 
shown that 31% of the persons with MCI were previously diagnosed with cancer.8 However, 
no longitudinal analysis was performed in this group of persons and the risk of cancer after 
MCI or dementia diagnosis was not investigated. 
 In contrast to the decreased risk of cancer observed in our patients with dementia, we found 
that MCI was associated with an increased risk of cancer, which was borderline significant. 
Importantly, the difference between the risk of cancer after dementia and MCI was statistically 
significant. Before interpreting our results further, a word of caution is warranted. A basic 
premise of our study is that MCI and dementia share the same pathological underpinnings.11 
We do emphasise though that only half of MCI patients convert to dementia over a five year 
period with the other half remaining stable or even reverting back to normal, suggesting that the 
underlying pathology between MCI and dementia does not entirely overlap.11,12 Nevertheless, 
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two observations in our study support our basic premise in interpreting our findings. First, 
we found stronger effects for amnestic MCI than non-amnestic MCI. Indeed, amnestic MCI 
is more closely linked to AD pathology than non-amnestic MCI.15 Second, censoring for 
dementia did not materially change the risk of cancer after MCI – if anything, the risk slightly 
attenuated. This suggests that those persons with MCI that went on to develop dementia (i.e., 
those that were censored) actually had an even higher risk of cancer than those with MCI that 
did not develop dementia. 
 The inverse link between dementia and cancer is often linked to genes involved in pathways 
with opposite effects in dementia and cancer. Our findings, however, point towards biological 
mechanisms with similar effects in both diseases. Several processes including angiogenesis, 
inflammation, and oxidative stress have proven to be important for tumorigenesis and there is 
increasing evidence that these processes also have a prominent role in the pathophysiology 
of AD.20,21 For instance, different inflammatory biomarkers are elevated in both MCI and 
dementia, suggesting a chronic inflammatory state.22 Inflammatory cells can promote tumour 
cell growth, facilitate genomic instability, and influence tumour cell migration, and many chronic 
inflammatory conditions are associated with cancer.23 Further, tumour cells can produce 
various cytokines and chemokines, such as tumour necrosis factor-alpha, interleukins, and 
interferons, to attract leukocytes and enhance inflammation. This shows that dementia and 
cancer could be parallel processes as a result of inflammation. In addition, several proteins are 
involved in the pathogenesis of both dementia and cancer. For instance, AD is characterised 
by the accumulation of plaques containing amyloid-beta (Aβ) peptide within the brain. It has 
been shown that plasma levels of Aβ40 and Aβ42 are increased in cancer patients.24 Also, Aβ 
precursor protein can promote cell proliferation and is increased in different types of cancer, 
suggesting a potential role for Aβ in cancer.25 Finally, there has been increasing evidence that 
patients with cancer have lower cognitive function and differences in brain structure prior to 
cancer treatment compared to persons without cancer, indicating continuity with dementia 
rather than an inverse association.26,27 Investigation of the risk of MCI in cancer patients would 
therefore be very interesting, although appropriate methods should be used to deal with same 
potential biases as in the current study.
 In conclusion, this is the first study to show that persons with MCI do not have a decreased 
risk of cancer as observed in patients with dementia, and even tended to have an increased 
risk. This suggests that the previously reported inverse link between dementia and cancer 
is based on methodological limitations. Future studies should further verify our observations 
and seek to elucidate the underlying shared – instead of opposite – mechanisms between 
dementia and cancer. Clinically, our findings imply that for persons presenting with dementia, 
treating physicians should be aware of their increased risk of cancer.
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Chapter 10
Higher plasma amyloid-β levels are associated with a higher risk of 
cancer
van der Willik KD, Ghanbari M, Fani L, Compter A, Ruiter R, 




Background Various studies have shown an inverse relation between Alzheimer’s disease 
(AD) and cancer, but findings are likely to be biased by surveillance and survival bias. Plasma 
amyloid-β (Aβ) is defined as a preclinical feature of AD, with lower levels of Aβ42 being 
associated with a higher risk of AD. To get more insight into the biological link between AD 
and cancer, we investigated plasma Aβ levels in relation to the risk of cancer.
Methods Between 2002 and 2005, we measured plasma Aβ40 and Aβ42 levels in 3949 
participants from the population-based Rotterdam Study. These participants were followed 
for the onset of cancer, all-cause dementia, death, loss to follow-up, or January 1st, 2014, 
whichever came first. We used Cox proportional hazards models to investigate the association 
between plasma Aβ40 and Aβ42 levels, and the risk of cancer. Analyses were stratified by 
cancer site. 
Results During a median (interquartile range) follow-up of 9.0 years (6.9 to 10.1), 560 
participants were diagnosed with cancer. Higher levels of log2 plasma Aβ40 and Aβ42 were 
associated with a higher risk of cancer (hazard ratio [95% confidence interval] per standard 
deviation increase for Aβ40 = 1.12 [1.02 to 1.23] and Aβ42 = 1.12 [1.03 to 1.23]). These 
effect estimates were most pronounced for haematological cancers, urinary tract cancers, and 
cancers of unknown primary origin.
Conclusions We found that higher levels of both plasma Aβ40 and Aβ42 were associated 
with a higher risk of cancer. This suggests a potential biological link between AD and cancer. 
The pathophysiological role of Aβ in cancer and its causality warrant further investigation. 
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INTRODUCTION
Alzheimer’s disease (AD) and cancer are common diseases in the elderly population that 
pose a high burden of morbidity and mortality on societies.1,2 Various observational studies 
have suggested that patients with AD have a lower risk of non-central nervous system 
(CNS) cancer and vice versa,3-7 which was not driven by a specific cancer type. However, 
methodological issues including surveillance and survival bias may drive the association 
towards an inverse direction.8 In fact, recent evidence points towards the possibility of a 
positive link,9,10 which is supported by overlapping risk factors for AD and cancer, such as age 
and smoking, and by overlapping pathways, including genome instability and inflammation.11 
Against this background, we recently showed that persons with mild cognitive impairment 
(MCI), a preclinical stage of AD, tended to have a higher risk of cancer (hazard ratio [HR] 
= 1.25 [95% confidence interval [CI] = 0.99 to 1.58]). This risk was statistically significantly 
higher than the decreased risk of cancer of patients with AD (HR = 0.52 [95% CI = 0.39 to 
0.69]).10
 Investigating the preclinical stage of AD and linking it to cancer could further unravel the 
association between these diseases. Accumulation of plaques containing amyloid-β (Aβ) 
in the brain is a defining feature of AD pathology.12 Aβ is currently the earliest detectable 
pathological change in the preclinical stage of AD13 and can be measured non-invasively 
in plasma. Although endothelial cells of blood vessels and platelets are the main source 
of circulating Aβ,14 Aβ is also produced by neuronal cells and is subsequently transported 
across the blood-brain barrier.15 During the earliest stages of AD, neuronal Aβ production is 
first increased, resulting in higher plasma Aβ levels. Plasma Aβ40 and Aβ42 levels decrease 
during the incipient clinical phase of the disease as a result of Aβ deposition in the brain.16,17 
A substantial amount of Aβ accumulates before the manifestation of clinical symptoms – thus 
also before MCI – but the exact onset of deposition is as yet unknown.13 In turn, lower plasma 
Aβ42 levels are associated with a higher risk of dementia,18-21 although not all persons with Aβ 
accumulation will eventually have clinically manifested dementia.22 Previous work on Aβ in the 
oncology field has shown that cancer patients, in particular those with hepatic cancer, have 
higher plasma Aβ40 and Aβ42 levels than controls.23 Yet, to understand the role of Aβ in the 
context of the relation between AD and cancer, it is pivotal to study plasma Aβ before cancer 
diagnosis.
 We hypothesised that if there is a biological link between AD and cancer, this should 
probably extend through all preclinical stages of AD. The life expectancy of persons in the 
preclinical stage of AD is longer than that of patients with clinically manifested AD, thereby 
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limiting the effects of survival bias. We have previously shown in the prospective population-
based Rotterdam Study that higher levels of plasma Aβ42 are associated with a lower risk 
of AD.21 Given that early-stage AD is characterised by higher plasma Aβ levels, whereas Aβ 
levels decrease during disease progression, any association between plasma Aβ and cancer 
may support a biological association between AD and cancer. A positive association might 
suggest that the very early stage of AD is related to cancer, whereas a negative association 
might reflect a link between a later preclinical stage of AD and cancer. We therefore determined 




This study is embedded within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of diseases in the elderly population. The 
details of this cohort have been described in detail previously.24 Briefly, in 1990, after the pilot 
phase in 1989, all inhabitants aged 55 years and over from the Ommoord area, a suburb of 
in Rotterdam, the Netherlands, were invited to participate. This initial cohort (RS-I) consisted 
of 7983 participants and was subsequently extended with a second subcohort (RS-II) in 2000 
with 3011 participants who had reached the age of 55 years or moved into the study area. 
In 2006, the cohort was further expanded (RS-III) with 3932 participants aged 45 years and 
over. In total, the Rotterdam Study comprises 14 926 participants (overall response rate 72%).
 The Rotterdam Study complies with the Declaration of Helsinki and has been approved 
by the Medical Ethics Committee of Erasmus Medical Centre and by the board of The 
Netherlands Ministry of Health, Welfare, and Sports. A written informed consent was obtained 
from all participants. 
 The population for the current study was defined by availability of -80⁰C stored plasma 
samples obtained from participants during the fourth visit of RS-I between January 2002 and 
July 2004, and the second visit of RS-II between July 2002 and December 2005. From this 
selection of 5094 participants with plasma samples available, we excluded participants who did 
not provide informed consent to access medical records and hospital discharge letters during 
follow-up (n=6), those with a history of cancer at blood sample draw (n=408), participants with 
a history of all-cause dementia (n=25) or insufficient data to determine their cognitive status 
(n=1), and participants with missing (n=471) or invalid test results for plasma Aβ40 and Aβ42 
Plasma amyloid-β and risk of cancer
249
levels (n=234). Missing and invalid test results were missing at random. As a result, the final 
sample included 3949 participants for analyses. 
Assessment of plasma Aβ40 and Aβ42
Blood samples of participants were collected during the research centre visit. Blood was 
sampled in EDTA-coated tubes and centrifuged, of which subsequently plasma was aliquoted 
and frozen at -80⁰C according to standard procedures. Measurements of plasma Aβ levels 
were performed at Quanterix (Lexington, MA, USA) on a Simoa HD-1 analyser platform using 
the Simoa Human Neurology 3-Plex A assay.25 Measurements were done in two separate 
batches and samples were tested in duplicate. Two quality control samples were run on 
each plate for each analyte. When duplicate measurements were missing (e.g. blood sample 
was not good) or inconsistent, or if the concentration coefficient of variation exceeded 20%, 
participant’s samples were not valid and were therefore not included.
Assessment of cancer
Registration of prevalent and incident cancer diagnoses was based on medical records 
of general practitioners (including hospital discharge letters) and through linkage with the 
Netherlands Cancer Registry, Dutch Hospital Data, and histology and cytopathology registries 
in the region (PALGA). Each diagnosis of cancer was coded independently by two physicians 
and classified according to the International Classification of Diseases, 10th revision. In case 
of discrepancy between the two physicians, consensus was sought through consultation with 
a physician specialised in internal medicine. Cancer diagnosis was defined as any primary 
malignant tumour that was confirmed by pathology, excluding non-melanoma skin cancer. 
Date of diagnosis was based on date of biopsy for solid tumours, laboratory assessment for 
haematological tumours, or – if information on these dates was unavailable – date of hospital 
admission or hospital discharge letter. Follow-up of cancer registration was completed up to 
January 1st, 2014. Only non-CNS cancers were included in the analysis.
Other assessments
Participants provided information on educational level, smoking habits, and alcohol use 
during the home interview. Educational level was classified into primary, lower (lower or 
intermediate general education or lower vocational education), intermediate (intermediate 
vocational education or higher general education), or higher (higher vocational education or 
university). Smoking habits were classified into never, current, or former smoker. Alcohol use 
was categorised as any use or no use. 
 Height and weight were measured at the research centre from which the body mass 
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index (kg/m2) was computed. Hypertension was defined as a systolic blood pressure ≥140 
mm Hg, a diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medication.26 
Hypercholesterolaemia was defined as a serum total cholesterol >6.5 mmol/L or use of lipid-
lowering medication. Diabetes mellitus was defined as a fasting serum glucose level ≥7.1 
mmol/L, a random serum glucose level ≥11.1 mmol/L, or use of antidiabetic medication.27 
Symptoms of depression were assessed using the Centre for Epidemiologic Studies 
Depression scale (CES-D) and were converted into a sum-score. Apolipoprotein E (APOE) 
genotype was determined using polymerase chain reaction on coded DNA samples in the 
subcohort RS-I and with a bi-allelic TaqMan assay in the subcohort RS-II.28,29 APOE ε4 carrier 
status was defined as carrier of at least one APOE ε4 allele. Granulocyte, lymphocyte, and 
platelet counts were quantified using the COULTER® Ac·T diff2™ Haematology Analyser 
(Beckman Coulter, San Diego, California, USA). Granulocyte-to-lymphocyte ratio (GLR) was 
calculated as the ratio of granulocyte to lymphocyte count and platelet-to-lymphocyte ratio 
(PLR) as the ratio of platelet to lymphocyte count. Systemic immune-inflammation index 
(SII) was calculated as platelet count times GLR. Serum creatinine was measured with 
an enzymatic assay method and was subsequently standardised to isotope–dilution mass 
spectrometry–traceable measurements.30 
 Incidence of all-cause dementia was evaluated by screening of participants at the research 
centre visit using the Mini-Mental State Examination and the Geriatric Mental Schedule organic 
level. Participants with a Mini-Mental State Examination score below 26 or Geriatric Mental 
Schedule score of at least one underwent further investigation, including the Cambridge 
Examination for Mental Disorders of the Elderly. In addition, the cohort was electronically 
linked with medical records from general practitioners and the regional institute for outpatient 
mental health care to ensure continuous surveillance for all-cause dementia.31
Statistical analysis
We used Cox proportional hazards models to obtain HRs and 95% CIs to investigate the 
association between plasma Aβ40 and Aβ42 levels with risk of non-CNS cancer. Aβ levels 
were log2 transformed to reach a normal distribution and were subsequently standardised. 
The standard deviation (SD) increase in Aβ level on the log2 scale can then be multiplied with 
two to obtain the corresponding SD increase in Aβ level on the original scale. As yet, neither 
reference values for plasma Aβ nor thresholds for preclinical AD are available. We therefore 
investigated the association with continuous Aβ and Aβ levels divided into quartiles, using 
two nested models: Model I was adjusted for age at blood sample draw, sex, and assay batch 
number; Model II was Model I plus additional adjustment for covariates related to both AD and 
cancer, including education, body mass index, hypertension, hypercholesterolaemia, diabetes 
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mellitus, smoking status, alcohol use, depression (as measured with CES-D sum-score), and 
inflammation (using the SII). Because of collinearity, we only adjusted for SII and not for GLR 
and PLR. Follow-up time was used as time scale. Follow-up time started at date of blood 
sample draw (i.e., at the fourth visit of participants of RS-I and at the second visit of participants 
of RS-II) until date of incident cancer, all-cause dementia, death, loss to follow-up, or January 
1st, 2014, whichever came first. Participants were censored at date of CNS cancer diagnosis, 
because we hypothesised that the potential mechanisms underlying any association between 
Aβ and cancer would differ between non-CNS and CNS cancers, given that CNS cancer can 
cause direct damage to the brain.32 We repeated analyses using age as time scale instead of 
follow-up to verify that the choice of the time scale did not affect the results. We checked the 
proportional hazards assumption by visual inspection of the Schoenfeld residuals. 
 To further evaluate the robustness of our findings, we performed two sensitivity analyses: 
(i) adjusting for creatinine to minimise the effect of impaired kidney function, because plasma 
Aβ is partly cleared by the kidney; and (ii) excluding the first two and five years of follow-up time 
to examine reverse causation (i.e., the possible effect of subclinical cancer on plasma Aβ). In 
this latter analysis, only those participants with a follow-up time of more than, respectively, two 
and five years were included.
 We studied effect modification for median age, sex, education, smoking status, APOE ε4 
carrier status, and inflammatory ratios by stratification and by adding multiplicative interaction 
terms to the model. Lastly, we stratified analyses by primary cancer site.
 We used multiple imputation for missing covariates (maximum of 3.2%), with five imputed 
datasets based on the covariates and outcome. We used Rubin’s method for pooled HRs 
and 95% CIs.33 Statistical analyses were performed using the R package ‘survival’ in RStudio 
Version 3.3.2.34
RESULTS
Characteristics of the study population are presented in Table 1. The median (interquartile 
range [IQR]) age at blood sample draw was 70.4 years (65.8 to 76.4) and 57.7% were women. 
During a median (IQR) follow-up of 9.0 years (6.9 to 10.1), 560 out of 3949 participants were 
diagnosed with cancer. In the same follow-up period, 303 participants developed all-cause 
dementia (of whom 247 with AD) and 712 participants died. Most frequently diagnosed cancer 
sites were breast (30.4% among women), male genital organs (29.1% among men), colorectal 
(16.3%), and lung (14.5%).
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Age, years, median (IQR) 70.4 (65.8 to 6.4) 75.6 (69.7 to 80.9)
Women, No. (%) 2277 (57.7) 442 (62.7)
Educational level, No. (%)
 Primary 421 (10.7) 118 (16.7)
 Lower 1711 (43.3) 318 (45.1)
 Intermediate 1200 (30.4) 194 (27.5)
 Higher 557 (14.1) 69 (9.8)
Body mass index, kg/m2, mean (SD) 27.6 (4.1) 27.6 (4.4)
Hypertension, No. (%) 3091 (78.3) 595 (84.4)
Hypercholesterolaemia, No. (%) 1580 (40.0) 263 (37.3)
Diabetes mellitus, No. (%) 421 (10.7) 100 (14.2)
Smoking, No. (%)
 Never 1159 (29.3) 221 (31.3)
 Former 2222 (56.3) 394 (55.9)
 Current 491 (12.4) 70 (9.9)
Alcohol use, No. (%) 3319 (84.0) 565 (80.1)
CES-D sum-score, median (IQR) 3 (1 to 8) 5 (1 to 10)
APOE ε4 carrier, No. (%) 1044 (26.4) 186 (26.4)
Inflammatory ratios, median (IQR)
 Granulocyte-to-lymphocyte ratio 1.8 (1.4 to 2.4) 2.0 (1.5 to 2.5)
 Platelet-to-lymphocyte ratio 120 (96 to 153) 128 (100 to 161)
 Systemic immune-inflammation index 455 (338 to 621) 497 (355 to 682)
Plasma amyloid-β40, pg/mL, median (IQR) 258 (229 to 291)
Plasma amyloid-β42, pg/mL, median (IQR) 10.3 pg/mL (8.9 to 11.9)
Characteristics were measured during the visit of the blood sample draw (i.e., at the fourth visit of 
participants of RS-I and at the second visit of participants of RS-II). Missing values are not imputed and 
therefore numbers do not always sum up to 100%. 
* Excluded participants in this table only include those participants who were excluded due to missing test 
results (n=471) or invalid test results (n=234).
APOE = apolipoprotein E, CES-D = Centre for Epidemiologic Studies Depression scale, IQR = interquartile 
range, SD = standard deviation.
 Higher levels of log2 plasma Aβ40 and Aβ42 were associated with a higher risk of cancer 
(HR [95% CI] per SD increase in Aβ40 = 1.12 [1.02 to 1.23] and Aβ42 = 1.12 [1.03 to 1.23], 
Table 2). Given that the unadjusted HR for the risk of cancer per one year increase in age is 
1.01 (95% CI = 1.00 to 1.02), the HR per SD increase in Aβ corresponds with a risk increase 
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Table 2 The association between standardised log2 transformed plasma amyloid-β40 and 
amyloid-β42 levels with risk of cancer. 
Plasma assessment (pg/mL)* Cancer




Per SD increase 560/3949 1.13 (1.03 to 1.24) 1.12 (1.02 to 1.23)
Quartiles (range)
 1st quartile (-8.05 to -0.61) 126/988 1.00 1.00
 2nd quartile (-0.61 to -0.01) 138/987 1.10 (0.86 to 1.40) 1.11 (0.87 to 1.42)
 3rd quartile (-0.01 to 0.59) 136/987 1.12 (0.87 to 1.43) 1.13 (0.88 to 1.44)
 4th quartile (0.59 to 4.24) 160/987 1.47 (1.14 to 1.88) 1.43 (1.11 to 1.83)
P for trend .004 .005
Amyloid-β42
Per SD increase 560/3949 1.12 (1.03 to 1.23) 1.12 (1.03 to 1.23)
Quartiles (range)
 1st quartile (-11.4 to -0.53) 124/988 1.00 1.00
 2nd quartile (-0.53 to 0.03) 136/987 1.11 (0.87 to 1.42) 1.13 (0.88 to 1.44)
 3rd quartile (0.03 to 0.59) 140/987 1.14 (0.89 to 1.45) 1.16 (0.91 to 1.47)
 4th quartile (0.59 to 8.46) 160/987 1.38 (1.09 to 1.75) 1.38 (1.09 to 1.76)
P for trend .009 .009
Hazard ratios in Model I are adjusted for age at blood draw, sex, and assay batch number. Hazard 
ratios in Model II are adjusted for covariates in model I plus adjustment for education, body mass index, 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, alcohol use, CES-D sum-score, and 
systemic immune-inflammation index. 
* Plasma assessments are log2 transformed and standardised.
CES-D = Centre for Epidemiologic Studies Depression scale, CI = confidence interval, HR = hazard ratio, 
n = number of participants with incident cancer, N = total number for participants, SD = standard deviation.
in cancer of at least 10.2 years of age (the unrounded HR for age is 1.0117 and for Aβ40 
is 1.1193, thus .1193/.0117 = 10.2). Participants with plasma Aβ40 and Aβ42 levels in the 
highest quartile had a higher risk of cancer than those with levels in the lowest quartile (HR 
[95% CI] for Aβ40 = 1.43 [1.11 to 1.83] and Aβ42 = 1.38 [1.09 to 1.76]). Additional adjustment 
for creatinine did not meaningfully change the estimated HRs (Table 3). Also, exclusion of the 
first two and five years of follow-up time did not affect the risk estimates (Table 3). 
 Stratified analyses showed that the association between plasma Aβ and cancer was 
more profound in older participants, men, former smokers, participants with an intermediate 
educational level, and APOE ε4 carriers (Figure 1). Regarding inflammatory status, 
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Table 3 Sensitivity analyses for the association between plasma amyloid-β40 and amyloid-β42 
levels with risk of cancer. 
Plasma assessment (pg/mL)* Cancer
n/N HR (95% CI)
Additional adjustment for creatinine level (μmol/L)†
 Amyloid-β40 229/1514 1.13 (0.96 to 1.33)
 Amyloid-β42 229/1514 1.10 (0.94 to 1.28)
Excluding first two years of follow-up
 Amyloid-β40 438/3672 1.08 (0.97 to 1.20)
 Amyloid-β42 438/3672 1.07 (0.97 to 1.18)
Excluding first five years of follow-up
 Amyloid-β40 242/3271 1.12 (0.96 to 1.29)
 Amyloid-β42 242/3271 1.15 (1.01 to 1.32)
Hazard ratios are adjusted for age at blood draw, sex, assay batch number, education, body mass index, 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, alcohol use, CES-D sum-score, and 
systemic immune-inflammation index.
* Plasma assessments are log2 transformed and standardised. † Creatinine levels were measured in a 
random sample of 1514 out of 3949 participants. 
CES-D = Centre for Epidemiologic Studies Depression scale, CI = confidence interval, HR = hazard ratio, 
n = number of participants with incident cancer, N = total number for participants. 
participants with higher GLR had a higher risk of cancer than those with a lower GLR, which 
was not observed for PLR and SII (Supplementary Figure 1). All interactions were tested on 
the multiplicative scale and did not reach statistical significance. 
 Analyses per cancer site showed that the association was most pronounced between 
plasma Aβ40 and Aβ42 and haematological cancer (HR [95% CI] per SD increase in log2 
Aβ40 = 1.56 [1.12 to 2.17] and Aβ42 = 1.30 [0.94 to 1.79], Figure 2). The association was also 
stronger for cancer of unknown primary origin and cancer in the urinary tract, oesophagus and 
stomach (only for Aβ40), and head and neck (only for Aβ42), albeit not statistically significantly. 
In a post-hoc analysis we found a strong association with pancreatic cancer, although the 
power was limited by the number of participants with pancreatic cancer (n=13, HR [95% CI] 
per SD increase in log2 Aβ40 = 1.52 [0.83 to 2.79] and Aβ42 = 1.51 [0.98 to 2.31]).
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Figure 1 Forest plot of association between log2 transformed and standardised plasma amyloid-β40 
and amyloid-β42 levels with risk of cancer, stratified by median age at blood draw, sex, education, 
smoking status, and APOE ε4 carrier status. 
Hazard ratios are adjusted for age at blood draw, sex, assay batch number, education, body mass index, 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, alcohol use, CES-D sum-score, and 
systemic immune-inflammation index. APOE ε4 carrier status was missing for 118 participants. Missing 
values of education and smoking were imputed and therefore the total number of participants per smoking 
category is higher than the number of participants presented in Table 1.
APOE = apolipoprotein E, CES-D = Centre for Epidemiologic Studies Depression scale, CI = confidence 
interval, HR = hazard ratio, n = number of participants with incident cancer, N = total number for participants.
DISCUSSION
In this population-based cohort study, we found that higher plasma levels of both Aβ40 and 
Aβ42 were associated with a higher risk of cancer. This indicates that Aβ could be involved in 
the pathophysiology of cancer and may further support a potential biological link between AD 
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Figure 2 Association between log2 transformed and standardised plasma amyloid-β40 and 
amyloid-β42 levels with different cancer types. 
Hazard ratios are adjusted for age at blood draw, sex, assay batch number, education, body mass index, 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, alcohol use, CES-D sum-score, and 
systemic immune-inflammation index.
* Thirteen out of 22 participants were diagnosed with pancreatic cancer. Higher levels of amyloid-β40 and 
amyloid-β42 were associated with a higher risk of cancer (HR for amyloid-β40 = 1.52 [95% CI = 0.83 to 
2.79] and amyloid-β42 = 1.51 [95% CI = 0.98 to 2.31]).
CES-D = Centre for Epidemiologic Studies Depression scale, CI = confidence interval, HR = hazard ratio, 
n = number of participants with incident cancer, N = total number for participants.
cancer warrant further investigation.
 Our finding is in line with a previously conducted cross-sectional study showing that 
individuals who have been diagnosed with cancer have higher plasma Aβ levels.23 To further 
understand this association and its interpretation regarding the link between AD and cancer, 
it is necessary to first elaborate on the Aβ pathway. Aβ is the product of cleavage of amyloid 
precursor protein (APP), which is expressed in neuronal and non-neuronal tissues including 
the kidney, lung, and pancreas. Aβ is formed as product of APP cleavage by α-secretase, 
followed by β-secretase. APP cleavage can result in different isoforms of Aβ, depending on 
the number of amino acids (i.e., 38, 40, and 42), with longer isoforms being more prone to 
aggregation.35 Although many tissues contain APP, Aβ can only be produced in cells that also 
express β-secretase, e.g. neuronal cells, muscle cells, platelets, and vascular wall endothelial 
cells. Plasma Aβ can therefore have different sources. 
 Against this background, there are different explanations for the association between Aβ 
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and the risk of cancer. First, the plasma Aβ can be of neuronal origin. Aβ might be reflective 
of an underlying early-stage AD process and our findings might be pointing towards a shared 
causal predisposition between cancer and AD. Although effect estimates hardly changed 
when excluding the first two and five years of follow-up, we cannot fully exclude reverse 
causation. An alternative explanation therefore is that the blood-brain barrier permeability 
can increase due to subclinical cancer.36 Different animal and in vitro studies have shown 
that systemic inflammation can disrupt the integrity of the blood-brain barrier.37,38 Because 
higher inflammatory markers are associated with a higher risk of cancer,39 the integrity of the 
blood-brain barrier might be altered by subclinical cancer due to systemic inflammation. This 
could result in leakage of neuronal Aβ to the peripheral circulation. Such reverse causality is 
compatible with higher Aβ levels reflective of a higher risk of getting diagnosed with clinical 
cancer. Second, the plasma Aβ can be of non-neuronal origin. It is conceivable that platelets 
and vascular wall endothelial cells – the main sources of circulating Aβ14 – are activated as 
response to subclinical cancer,40 resulting in more Aβ production before the cancer is diagnosed. 
For instance, platelets were indeed more activated in multiple myeloma patients than in 
healthy controls.41 In addition, platelets promoted proliferation of multiple myeloma cells and 
that of acute myeloid leukaemia blasts in vitro.42 This may partly explain the strong association 
with haematological cancers, but it should be noted that the group of haematological cancers 
is composed of different types of leukaemia and lymphoma. In the same context of an extra-
neuronal origin of Aβ, Aβ might be produced by organs that express APP, but not β-secretase, 
for instance pancreas, kidney, and lung.43 Cancer cells in these organs might be mutated such 
that β-secretase expression gets enhanced, resulting in Aβ production. We indeed found that 
the relation between plasma Aβ and cancer risk was stronger for those cancer sites with cells 
that express APP. Interestingly, APP is upregulated in pancreatic cancer cells.44 In light of 
this, we examined the association between Aβ and pancreatic cancer in a post-hoc analysis. 
Although limited by power, we found that higher plasma Aβ levels were associated with a 
higher risk of pancreatic cancer. Third, shared mechanisms such as inflammation can cause 
both higher levels of plasma Aβ and cancer.23 Higher inflammatory ratios are associated with 
a higher risk of cancer, indicating a pro-inflammatory state before cancer diagnosis, and 
interestingly have also been linked with AD.39,45 This might also explain why the association 
between plasma Aβ and cancer was more pronounced – albeit not statistically significantly – 
in APOE ε4 carriers than in non-carriers. Human cell studies and animal studies have shown 
that APOE4 may predispose cells to inflammation and may promote a greater inflammatory 
response following immune activation than other APOE isoforms, resulting in the secretion of 
inflammatory factors.46 Figure 3 summarises the potential biological mechanisms underlying 
the association between plasma Aβ and cancer. Lastly, we cannot completely rule out that 
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the association is partly driven by methodological bias. We have previously shown that lower 
plasma Aβ levels are associated with a higher risk of AD.21 Given this association, we might 
expect that – if cancer and AD are positively associated – lower plasma Aβ levels would be 
associated with a higher risk of cancer. The finding that higher plasma Aβ levels are related to 
a higher risk of cancer might be explained because those persons with low plasma Aβ levels 
are more likely to develop dementia before they might have been diagnosed with cancer. 
Consequently, higher plasma Aβ levels are associated with a higher risk of cancer.
 Some limitations of this study need to be addressed. First, we had no measurements of 
Aβ within the brain, for instance, measured in cerebrospinal fluid (CSF) or by amyloid positron 
emission tomography (PET) neuroimaging. However, previous studies have shown correlation 
between plasma Aβ and CSF or amyloid PET.16,47 Second, we cannot determine the origin of 
the measured plasma Aβ levels. Third, although we tried to take the effect of reverse causation 
into account by excluding the first two and five years of follow-up, we cannot determine the 
causal effect of Aβ on cancer. The length of the latency period between cancer initiation and 
manifestation differs per cancer site and can range from five to forty years for solid tumours.48 
Fourth, it should be noted that although the missing and invalid plasma Aβ levels were missing 
at random, the characteristics of participants with known plasma Aβ levels differed from those 
of participants with unknown or invalid plasma Aβ levels. This, as well as that most of the 
included participants were middle class persons of European descent (98.5%), could possibly 
limit the generalisability of our findings to other populations. Strengths include using Aβ as 
proxy for preclinical AD to circumvent surveillance and survival bias, the large sample size, 
and the inclusion of participants with different cancer sites. Although this enabled us to explore 
the association between plasma Aβ and different cancer sites, the groups of different cancer 
sites were heterogeneous and analyses were limited by the low number of cases per cancer 
site.
 In conclusion, we found that higher plasma Aβ40 and Aβ42 levels are associated with 
a higher risk of cancer. This finding may support a potential biological link between AD and 
cancer. Also, this association may indicate a potential pathophysiological role of Aβ in cancer, 
outside the context of AD. The causality of this association warrants further investigation, for 
instance by investigating the trajectory of plasma Aβ levels before cancer diagnosis. 
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Figure 3 Overview of potential mechanisms underlying the association between plasma 
amyloid-β and the risk of cancer. 
There are different sources of plasma amyloid-β: neuronal cells (A) and non-neuronal cells (B and C). 
Neuronal amyloid-β production might reflect an underlying AD process (A, this image was modified from 
Servier Medical Art, licensed under a Creative Common Attribution 3.0 Generic License. http://smart.
servier.com/). Extra-neuronal amyloid-β production can be caused by activation of platelets and vascular 
wall cells (C). This activation might be due to subclinical cancer. In addition, subclinical cancer cells might 
produce amyloid-β if they also express β-secretase due to mutations (C). Inflammation can stimulate the 
pathogenesis of both AD and cancer (B), and could therefore indirectly lead to higher plasma amyloid-β 
levels (D). In turn, higher plasma amyloid-β levels are associated with a higher risk of cancer (E). However, 
the causality of this association warrants further investigation.
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Supplementary Figure 1 Forest plot of association between log2 transformed and standardised 
plasma amyloid-β40 and amyloid-β42 levels with risk of cancer, stratified by median granulocyte-
to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune-inflammation index. 
Hazard ratios are adjusted for age at blood draw, sex, assay batch number, education, body mass index, 
hypertension, hypercholesterolaemia, diabetes mellitus, smoking, alcohol use, and CES-D sum-score.
CES-D = Centre for Epidemiologic Studies Depression scale, CI = confidence interval, GLR = granulocyte-
to-lymphocyte ratio, HR = hazard ratio, n = number of participants with incident cancer, N = total number 




Association between the tumour marker carcinoembryonic antigen 
and the risk of dementia




Background There is an ongoing debate about how cancer and dementia relate to each 
other, and whether their relation is biologically determined or caused by surveillance and 
survival bias. 
Methods We aimed to circumvent these biases by determining the relation between the 
tumour marker carcinoembryonic antigen (CEA) and the risk of dementia in 6692 participants 
from the population-based Rotterdam Study. 
Results We found that higher levels of CEA were associated with a higher risk of dementia 
(hazard ratio per standard deviation increase in CEA = 1.11 [95% confidence interval = 1.04 
to 1.18]). 
Conclusions This finding may indicate that cancer and dementia are positively associated, 
but the mechanisms underlying the relation between CEA and dementia warrant further 
investigation.
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INTRODUCTION
Cancer and dementia are leading causes of morbidity and mortality worldwide.1,2 Although both 
diseases are common in the elderly population, their relation is poorly understood.3 Various 
observational studies have shown that patients with cancer have a lower risk of developing 
dementia, and vice versa.4-8 Different biological explanations underlying this inverse association 
have been proposed, including genetic predisposition for either promoting or suppressing 
cell proliferation and cell survival pathways.9 Yet, patients with cancer or dementia are less 
likely to be screened for other diseases and have often a limited life expectancy. Therefore, 
methodological issues including surveillance and survival bias might drive the association 
towards an inverse direction.
 Several studies have tried to tackle these methodological issues, for instance by studying 
the risk of dementia in patients with different stages of cancer. Patients with advanced stage 
cancer had the lowest risk of dementia, probably because their mortality risk is higher than 
that of patients with early stage cancer.10 In addition, it has been shown that with appropriate 
model specification, patients with cancer do not have a lower risk of dementia.11 Lastly, we 
have shown that persons with mild cognitive impairment (MCI), the transitional stage between 
normal cognition and dementia, even tended to have a higher risk of cancer than persons with 
normal cognition.12 Although MCI and dementia share the same biological underpinnings, 
the life expectancy of persons with MCI is longer than that of patients with dementia, thereby 
limiting the effects of the competing risk of mortality. The higher risk of cancer in persons with 
MCI therefore suggests that the association between cancer and dementia might even be 
positive rather than inverse. 
 Studying the preclinical stage of one disease and linking it to the other disease could limit 
the effects of surveillance and survival bias, because the life expectancy of persons in the 
preclinical stage of a disease is longer than that of patients with clinically-manifested disease. 
Censoring for death as competing risk could result in biased effect estimates, if censoring 
happens to be informative.13,14 Also, studying the preclinical stage can reduce the effects of 
selective survival, i.e., those patients who survive cancer are likely to have some protective 
characteristics that help them to survive.15 This can further improve our understanding of the 
biological association between cancer and dementia. Carcinoembryonic antigen (CEA) is an 
often-used tumour marker, usually in clinical settings to monitor cancer recurrence in curated 
cancer patients rather than for screening purposes. In this study, we used CEA as marker 
for preclinical, undiagnosed cancer in community-dwelling individuals free from clinically-
diagnosed cancer and related this to the risk of dementia. Using this design, we aimed to 
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circumvent the effects of the competing risk of mortality on the relation between cancer and 








Figure 1 Schematic relation between carcinoembryonic antigen, cancer and dementia. 
The time between the first cancer cell and clinical manifestation of the disease can last up to many years. 
Before clinical manifestation of cancer, cancer cells might already produce different factors including 
carcinoembryonic antigen. Therefore, carcinoembryonic antigen levels could be elevated before the 
diagnosis of cancer (scenario A, upper arrow). It is also possible that a person develops both dementia 
and cancer. Before this person is diagnosed with dementia, this person can already have a preclinical 
stage of cancer (scenario B, lower arrow). During this preclinical stage of cancer, carcinoembryonic 
antigen levels might already be elevated. These carcinoembryonic antigen levels could therefore be used 
to link the preclinical stage of cancer to dementia. 
METHODS
Study population
This study is embedded within the Rotterdam Study, a prospective population-based cohort 
designed to study the occurrence and determinants of diseases in the elderly population. The 
cohort has been described in detail previously.16 Briefly, in 1989 all inhabitants aged 55 years 
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or over from the district Ommoord in Rotterdam, the Netherlands, were invited to participate. 
This initial cohort (RS-I) comprised 7983 participants and was extended (RS-II) in 2000 with 
3011 participants who had become 55 years of age or moved into the study district. In 2006, 
the cohort was further extended (RS-III) with 3932 participants aged 45 years or over. In total, 
the Rotterdam Study comprises 14 926 participants (overall response rate 72%).
 The Rotterdam Study has been approved by the Medical Ethics Committee of Erasmus 
Medical Centre and by the board of The Netherlands Ministry of Health, Welfare, and Sports. 
A written informed consent was obtained from all participants. 
 CEA levels were determined in plasma samples of 7305 participants that had been 
obtained during the third visit of RS-I (1997 to 1999) and the first visits of RS-II (2000 to 2001) 
and RS-III (2006 to 2008). From these 7305 participants, we excluded those with a history 
of dementia (n=75) or insufficient data to determine cognitive status (n=65). In addition, we 
excluded participants with a history of cancer (n=425) to study the association between CEA 
and dementia in a population free from clinically-manifested cancer. It is, however, possible 
that participants had an undiagnosed, preclinical stage of cancer at the date of blood sample 
draw. Lastly, we excluded participants without informed consent to access medical records 
during follow-up (n=48). This resulted in 6692 participants for analyses. 
CEA assessment
Blood was sampled in EDTA coated tubes and centrifuged, of which subsequently plasma was 
aliquoted and frozen at -80⁰C according to standard procedures. CEA (µg/L) was measured 
using the Roche Modular P800 Analyser (Roche Diagnostics, Indianapolis, IN, USA). The 
coefficient of variation for intermediate precision was 17.3%, and for repeatability was 13.9%.
Dementia assessment
Participants were screened for dementia at baseline and subsequent centre visits with the 
Mini-Mental State Examination and the Geriatric Mental Schedule organic level.17 Those with 
a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 underwent 
further investigation and informant interview, including the Cambridge Examination for Mental 
Disorders of the Elderly. In addition, the entire cohort was continuously under surveillance 
for dementia through electronic linkage of the study database with medical records from 
general practitioners and the regional institute for outpatient mental health care. Available 
information on clinical neuroimaging was used when required for diagnosis of dementia 
subtype. A consensus panel led by a consultant neurologist established the final diagnosis 
according to standard criteria for dementia based on information collected during centre visits 
and obtained from medical records (Diagnostic and Statistical Manual of Mental Disorders III-
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revised). Follow-up until January 1st, 2016 was virtually complete (93.8% of potential person-
years observed).
Other assessments
During home interviews, participants provided information on educational level, smoking 
status, and alcohol use. Educational level was categorised as primary education, lower (lower 
general education, intermediate general education, or lower vocational education), intermediate 
(intermediate vocational education or higher general education), or higher (higher vocational 
education or university). Smoking status was classified into never, current, or former. Alcohol 
use was categorised as no use or any use. At the research centre, height and weight were 
measured from which the body mass index (kg/m2) was computed. Diagnosis of cancer was 
obtained from general practitioners’ medical records (including hospital discharge letters), 
and through linkage with Dutch Hospital Data, regional histopathology and cytopathology 
registries, and the Netherlands Cancer Registry.18 Follow-up of cancer registration was 
completed up to January 1st, 2015.
Statistical analysis
Characteristics of the study population were stratified by normal (CEA <5.0 µg/L) and high 
(CEA ≥5.0 µg/L) CEA levels. This cut-off value between normal and high CEA levels has been 
proposed by the Colorectal Working Group of the American Joint Committee on Cancer.19 
 We used Cox proportional hazards models to obtain hazard ratios (HRs) and 95% 
confidence intervals (95% CIs) to investigate the association between CEA (continuous 
and in quartiles) and the risk of dementia. In addition, we compared the risk of dementia in 
participants with normal CEA levels (CEA <5.0 µg/L) and high CEA (CEA ≥5.0 µg/L) levels. 
CEA levels were standardised to obtain the effect per one standard deviation (SD) in CEA. 
 Follow-up time was used as time scale and started at the date of the blood sample draw 
until the date of dementia diagnosis, death, loss to follow-up, or January 1st, 2016, whichever 
came first. We verified that the choice of the time scale (follow-up versus age) did not affect 
the results. HRs were adjusted for age at blood sample draw, sex, education, body mass 
index, smoking status, and alcohol use. The proportional hazards assumption was checked 
by visual inspection of the Schoenfeld residuals. 
 In sensitivity analyses we censored participants after two and five years of follow-up to 
examine the strength of the association between CEA and dementia when CEA was measured 
more closely to the date of dementia diagnosis.
 Lastly, to support the use of CEA levels as proxy for the preclinical stage cancer, we 
determined the relation between CEA levels and the risk of cancer using the same models 
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as those used in the analysis for the relation between CEA levels and the risk of dementia. In 
this analysis we included the participants with a history of dementia or with insufficient data to 
determine their cognitive status. Follow-up time started again at the date of the blood sample 
draw, but ended at the date of cancer diagnosis, death, loss to follow-up, or January 1st, 2015, 
whichever came first.
 Multiple imputation was used for missing covariates (maximum of 0.9%) with five imputed 
datasets based on other covariates and outcome. Rubin’s method was used for pooled HRs 
and 95% CIs. Statistical analyses were performed using the package ‘survival’ in RStudio 
Version 3.3.2.20 
RESULTS
Table 1 shows the characteristics of participants with normal (n=6238) and high (n=454) CEA 
levels. The median (interquartile range) age of participants with normal CEA values was 60.3 
years (56.3 to 67.9), and that of participants with high CEA values was 60.2 years (56.3 to 
67.9). Participants with high CEA levels were more often current smokers than those with 
normal CEA levels. During a median (interquartile range) follow-up of 8.8 years (7.2 to 14.5), 
471 out of 6692 participants were diagnosed with dementia, of whom 25 (5.3%) had high CEA 
levels.
 Higher levels of CEA were associated with a higher risk of dementia (HR per SD increase 
in CEA level = 1.11 [95% CI = 1.04 to 1.18], Table 2). Participants with high CEA levels had 
a higher risk of dementia than those with normal CEA levels, albeit not statistically significant 
(HR = 1.14 [95% CI = 0.76 to 1.72]). Compared to participants with CEA levels in the lowest 
quartile, those with levels in the highest quartile had a higher risk of dementia (HR = 1.28 [95% 
CI = 0.99 to 1.65]).
 Sensitivity analyses yielded slightly higher effect estimates when censoring participants 
after two years (HR per SD increase in CEA level = 1.16 [95% CI = 1.09 to 1.23]) and five year 
of follow-up (HR per SD increase in CEA level = 1.13 [95% CI = 1.07 to 1.20], Table 2).
 Supplementary Table 1 shows the results regarding the relation between CEA levels and 
the risk of cancer. Higher levels of CEA were associated with a higher risk of cancer (HR per 
SD increase in CEA level = 1.18 [95% CI = 1.15 to 1.21]). This relation was most pronounced 
in participants with high CEA levels (HR 2.51 [95% CI 2.00 to 3.13]). The effect estimates 
hardly changed when censoring participants after two and five years of follow-up. 
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Age, years, median (IQR) 60.3 (56.3 to 67.9) 60.2 (56.3 to 67.9)
Women, No. (%) 3544 (56.8) 267 (58.8)
Educational level, No. (%)
 Primary 681 (10.9) 66 (14.5)
 Lower 2488 (39.9) 201 (44.3)
 Intermediate 1766 (28.3) 113 (24.9)
 Higher 1250 (20.0) 70 (15.4)
Body mass index, kg/m2, mean (SD) 27.5 (4.2) 26.6 (4.5)
Smoking status, No. (%)
 Never 1594 (25.6) 33 (7.3)
 Former 3213 (51.5) 163 (35.9)
 Current 1414 (22.7) 256 (56.4)
Alcohol use, No. (%) 5396 (86.5) 380 (83.7)
Carcinoembryonic antigen, µg/L, median (IQR) 1.7 (1.2 to 2.5) 6.5 (5.6 to 7.9)
Characteristics were measured during the visit of the blood sample draw. Missing values are not imputed 
and therefore numbers do not sum up to 100%. 
IQR = interquartile range, SD = standard deviation.
DISCUSSION
CEA is a tumour marker widely used in oncology for surveillance and to assess treatment 
response. The observed association between higher levels of CEA and a higher risk of 
dementia may imply that patients with dementia are more likely to have preclinical cancer prior 
to their dementia diagnosis. These findings are further supported by a previous study showing 
that patients with dementia have higher CEA levels than healthy persons.21 
 The current findings indicate the possibility of a positive association between cancer 
and dementia. Given that higher CEA levels are associated with more advanced stages 
of cancer,22 the slightly higher risk of dementia when censoring participants after two and 
five years of follow-up might suggest that cancer is already more advanced shortly before 
dementia diagnosis. It has indeed been shown that dementia patients who were subsequently 
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Table 2 The association between carcinoembryonic antigen and the risk of dementia. 
Carcinoembryonic antigen (µg/L)* Dementia
n/N HR (95% CI)
Continuous† 471/6692 1.11 (1.04 to 1.18)
Cut-off value 5 µg/L
 <5 µg/L 446/6238 1.00
 ≥5 µg/L 25/454 1.14 (0.76 to 1.72)
Quartiles (range)
 1st quartile (-0.88 to -0.46) 112/1673 1.00
 2nd quartile (-0.46 to -0.21) 104/1673 0.92 (0.70 to 1.20)
 3rd quartile (-0.21 to 0.17) 124/1673 0.98 (0.76 to 1.28)
 4th quartile (0.17 to 38.0) 131/1673 1.28 (0.99 to 1.65)
P for trend .05
Censored after two years of follow-up
 Continuous† 32/6692 1.16 (1.09 to 1.23)
Censored after five years of follow-up
 Continuous† 124/6692 1.13 (1.07 to 1.20)
Hazard ratios are adjusted for age at blood sample draw, sex, education, body mass index, smoking 
status, and alcohol use. 
* Carcinoembryonic antigen levels were standardised. † Expressed per standard deviation increase.
CI = confidence interval, HR = hazard ratio, n = number of participants with incident dementia, N = total 
number of participants. 
diagnosed with cancer, had more advanced stages of cancer.23 Nevertheless, given that
observational studies repeatedly find a lower risk of dementia in cancer patients,4 it is likely 
that cancer remains undiagnosed in the majority of the patients after dementia diagnosis. 
Cancer-related symptoms may be obscured by dementia-related frailty (i.e., surveillance 
bias), or remain subclinical due to early death (i.e., survival bias).3 
 The potential positive link between cancer and dementia may be explained by three 
proposed underlying mechanisms. Firstly, cancer and dementia share multiple risk factors 
such as higher age, obesity, lack of activity, smoking, and alcohol use. Secondly, several 
pathways are involved in the pathogenesis of both diseases, including inflammation, genome 
instability, and angiogenesis.24 Thirdly, different proteins that are related to neurodegeneration, 
including amyloid-β and tau,25,26 can be elevated in cancer patients, suggesting that these 
proteins might also be involved in the pathogenesis of cancer.27-29 In addition, overexpression 
of the amyloid precursor protein in cancer cells is associated with cell proliferation, migration, 
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and invasion.29 Also, the tumour suppression protein BRCA1 has been linked to dementia.30 
Higher amyloid-β burden was associated with BRCA1 dysfunction, resulting in more DNA 
damage and in deterioration of genomic integrity. Future research on potential underlying 
mechanisms should further elaborate on the relation between different types of cancer and 
cancer treatments, and dementia.
 However, a word of caution is warranted. Although the tumour marker CEA is often 
elevated in patients with different types of cancer, including colorectal, pancreatic, and breast 
cancer,31 it is primarily used for monitoring recurrence in curatively treated patients with 
colorectal cancer.22 Although we found that higher CEA levels were associated with a higher 
risk of cancer, CEA is not used for screening of cancer in the general, unselected population, 
because the sensitivity and specificity are limited.32 CEA can be elevated due to other reasons 
apart from cancer, such as smoking, inflammation, and hepatic insufficiency.33,34 Despite the 
fact that these conditions are partly related to cancer, they offer an alternative explanation for 
our finding as drivers of the observed association between CEA and dementia.
 In conclusion, the relation between CEA and dementia is intriguing and points toward a 
positive association between cancer and dementia and not to the often postulated inverse 
association. The mechanisms underlying the association between CEA and dementia and its 
causality warrant further examination.
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SUPPLEMENTARY MATERIAL
Supplementary Table 1 The association between carcinoembryonic antigen and the risk of cancer.
Carcinoembryonic antigen (µg/L)* Cancer
n/N† HR (95% CI)
Continuous‡ 889/6820 1.18 (1.15 to 1.21)
Cut-off value 5 µg/L
 <5 µg/L 797/6357 1.00
 ≥5 µg/L 92/463 2.51 (2.00 to 3.13)
Quartiles (range)
 1st quartile (-0.89 to -0.46) 189/1705 1.00
 2nd quartile (-0.46 to -0.21) 221/1705 1.25 (1.03 to 1.52)
 3rd quartile (-0.21 to 0.18) 220/1705 1.31 (1.08 to 1.60)
 4th quartile (0.18 to 38.2) 259/1705 1.87 (1.54 to 2.27)
P for trend <.001
Censored after two years of follow-up
 Continuous‡ 47/6820 1.14 (1.09 to 1.19)
Censored after five years of follow-up
 Continuous‡ 122/6820 1.16 (1.12 to 1.19)
Hazard ratios are adjusted for age at blood sample draw, sex, education, body mass index, smoking 
status, and alcohol use. 
* Carcinoembryonic antigen levels were standardised. † Carcinoembryonic antigen levels were measured 
in 7305 participants. Participants with a history of dementia or insufficient data were included in this 
analysis. We excluded participants with a history of cancer (n=433) and those without informed consent 
to access medical records during follow-up (n=52). ‡ Expressed per standard deviation increase.




Does selection bias explain the inverse relation between cancer and 
dementia?
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Background Observational studies have repeatedly shown that cancer patients have a lower 
risk of dementia than persons without a history of cancer. To illustrate the potential effects of 
selection bias on this inverse association between cancer and dementia, we replicated and 
compared previously used study designs. In addition, we presented alternative approaches to 
account for selection bias. 
Methods Within the setting of the prospective population-based Rotterdam Study, we followed 
8899 participants who were dementia-free at baseline over a period of 15 years. We replicated 
the following four study designs: (i) cohort study with cancer as time-dependent variable; (ii) 
cohort study with cancer as time-independent variable; (iii) nested case-control study with 
cancer as time-independent variable; and (iv) cross-sectional case-control study. For (i-iii) we 
estimated hazard ratios (HRs) with Cox proportional hazards models and for (iv) odds ratios 
(ORs) based on logistic regression models. Next, we presented the following three different 
methods to account for immortal time bias: (i) time-dependent cancer; (ii) inverse probability 
weighting (IPW); and (iii) cloning and censoring. To deal with the competing risk of death, we 
compared the risk of dementia among participants with and without cancer, as if (i) we could 
eliminate death; and (ii) regardless of death. We calculated the risk of dementia at each time 
point using pooled logistic regression.
Results Out of 8899 participants, 1813 (20.4%) were diagnosed with cancer, of whom 68 
(3.8%) were subsequently diagnosed with dementia, 183 (10.1%) were lost to follow-up, and 
890 (49.1%) died. The risk of dementia in patients with cancer depended on the study design. 
For instance, when cancer was treated as time-dependent variable the HR for dementia was 
0.91 (95% confidence interval [CI] = 0.71 to 1.16]), as time-independent the HR was 0.44 
(95% CI 0.35 to 0.56), and in the case-control study the OR for dementia was 0.28 (95% 
CI = 0.02 to 1.31). When using the alternative methods to deal with immortal time and the 
competing risk of death, the risk of dementia in participants with cancer was similar to that in 
participants without cancer.
Conclusions This study indicates that selection bias may drive the inverse association 
between cancer and dementia. Immortal time bias and competing events should be taken into 
account by using appropriate analytical methods, because these diseases are strongly related 
to death. In addition, future studies should further disentangle the processes underlying a 
cancer diagnosis to estimate the causal effect of cancer on dementia.
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INTRODUCTION
Ageing populations worldwide have resulted in an increased prevalence of non-communicable 
diseases.1,2 There is a particular interest in the link between the non-communicable diseases 
cancer and dementia, because these diseases share multiple common risk factors including 
higher age and smoking. In addition, cancer and dementia have several overlapping pathways 
such as DNA damage and inflammation, suggesting that these diseases frequently co-
occur.3,4 Many clinical studies have indeed found that patients with cancer often have impaired 
cognitive function.5-7 Observational studies, however, have repeatedly shown that patients 
with cancer have a lower risk of dementia than persons without a history of cancer.8-21 Several 
pathophysiological mechanisms underpinning this potential inverse link have been proposed 
and primarily involve differential expression of cell proliferation and survival pathways.22 
 In addition to these biological mechanisms, selection bias due to shortcomings in previous 
study designs and analytical decisions may underlie the inverse association between cancer 
and dementia.4,23 Selection bias can manifest itself in different ways of which we will highlight 
three examples, i.e., survival bias, immortal time bias, and bias due to the competing risk 
of death. Firstly, in cross-sectional studies, participants have to be alive at the moment of 
assessment to be included in the study. Such conditioning on participants who have survived 
up to the moment of study assessment can lead to survival bias. Secondly, in longitudinal 
studies, participants are followed until the date of dementia diagnosis or death. The starting 
point of follow-up can differ between participants who remain free of cancer during follow-up 
and those who are diagnosed with cancer during follow-up. Exclusion or misclassification of 
the time between study entry and cancer diagnosis, i.e., immortal time, may cause differences 
in baseline characteristics between participants with and without cancer and can induce 
immortal time bias.24 Thirdly, most longitudinal studies assume that death occurs at random, 
whereas in fact, risk factors that are related to death are usually the same that are related to 
cancer and dementia. This results in that the participant with the worst risk factor profile will 
die first.25,26
 In the current study, we illustrate how decisions on study design and statistical analyses 
may induce selection bias when studying the association between cancer and dementia. In 
order to do so, we use data from the prospective population-based Rotterdam Study. Firstly, 
we provide a visual explanation of the potential problem of selection bias due to study design. 
Secondly, we replicate previous study designs and analytical decisions and show how results 
vary accordingly. Thirdly, we present three different methods to account for immortal time bias 





This study is embedded in the Rotterdam Study, a prospective population-based cohort study 
that was designed to determine causes of diseases in the middle-aged and elderly population.27 
After the pilot phase in 1989, all inhabitants aged 55 years and over of the Ommoord area 
in Rotterdam, the Netherlands, were invited to participate between 1990 and 1993. This first 
subcohort comprised 7983 participants (response of 78%) and was extended with the second 
subcohort between 2000 and 2001 consisting of 3011 participants (response of 67%) who had 
reached the age of 55 years or who had moved into the study area.  
 Participants were interviewed at home by a trained research assistant, followed by two 
visits at the research centre for different examinations including physical examinations, 
laboratory assessments, and imaging. Follow-up examinations of the first subcohort took 
place from 1993 to 1995, from 1997 to 1999, from 2002 to 2004, from 2009 to 2011, and from 
2014 to 2015. For the second subcohort, follow-up examinations took place between 2004 
and 2005, and between 2011 and 2012.
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
Medical Centre and by the Ministry of Health, Welfare and Sport of the Netherlands. Written 
informed consent was obtained from all participants. 
 Of the total of 10 994 participants, we excluded those with a history of dementia (n=515) 
or who were insufficiently screened for history of dementia (n=349), those without informed 
consent to access medical records during follow-up (n=135), and participants with incomplete 
data on baseline characteristics including education, smoking, body mass index (BMI), systolic 
blood pressure, and hypertension (n=1096), resulting in 8899 participants for analyses. 
Participants who had incomplete baseline characteristics were older at baseline (median age 
[interquartile range [IQR]] 73.4 years [63.8 to 82.4] versus 65.7 years [60.4 to 73.2]) and were 
more often women than included participants (68.2% versus 57.4%).
Ascertainment of cancer
Cancer was diagnosed based on medical records of general practitioners (including hospital 
discharge letters) and through linkage with the Netherlands Cancer Registry, Dutch Hospital 
Data, and histology and cytopathology registries in the region. Cancer was defined as 
any primary malignant tumour, excluding non-melanoma skin cancer, that was confirmed 
by pathology. Diagnoses were coded independently by two physicians according to the 
International Classification of Diseases, tenth revision (ICD-10). In case of discrepancy, 
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consensus was sought through consultation with a physician specialised in internal medicine. 
Date of diagnosis was based on date of biopsy (solid tumours) and laboratory assessment 
(haematological tumours), or – if unavailable – date of hospital admission or discharge letter. 
Follow-up was completed up to January 1st, 2015.
Ascertainment of dementia
Participants were screened for dementia at baseline and subsequent centre visits with the 
Mini-Mental State Examination and the Geriatric Mental Schedule organic level.28 Those with 
a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 underwent 
further investigation and informant interview, including the Cambridge Examination for Mental 
Disorders of the Elderly. In addition, the entire cohort was continuously under surveillance for 
dementia through electronic linkage of the study database with medical records from general 
practitioners and the regional institute for outpatient mental health care. A consensus panel 
led by a consultant neurologist established the final diagnosis according to standard criteria 
for dementia (Diagnostic and Statistical Manual of Mental Disorders III-revised). Follow-up 
was completed up to January 1st, 2016.
Ascertainment of covariates
During home interviews, participants provided information on educational level and smoking 
habits. Educational level was categorised into lower (primary education or lower vocational 
education), intermediate (lower secondary education, intermediate vocational education, or 
general secondary education), or higher (higher vocational education or university). Smoking 
habits were classified as never, former, or current smoking. At the research centre, height 
and weight were measured to calculate the BMI (kg/m2). Systolic and diastolic blood pressure 
were measured twice on the right arm using a random-zero sphygmomanometer of which 
the mean was used. Hypertension was defined as a systolic blood pressure of ≥140 mm Hg, 
a diastolic blood pressure of ≥90 mm Hg, or use of antihypertensive medication.29 Diabetes 
mellitus was defined fasting serum glucose level ≥7.1 mmol/L, a random serum glucose level 
≥11.1 mmol/L, or use of glucose-lowering medication.30 History of coronary heart disease 
(myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting) 
and stroke was assessed by interview and verified by reviewing medical records.31,32
Statistical analyses
We first visualised the number of years spent in different transition states using raw data to 




Replication of previous studies
Next, we replicated the following study designs and statistical analyses that have previously 
been used to study the association between cancer and dementia. To understand the 
difference between these studies, we define the time zero as the moment at which we start 
observing participants based on their exposure level.24 Given that a cancer diagnosis can 
occur at any moment in time, previous studies have considered cancer as a time-dependent 
variable (history of cancer at study entry and incident cancer after cancer diagnosis versus 
no cancer at study entry and during follow-up) or as a time-independent variable (history 
of cancer at study entry versus no history of cancer at study entry, or ever versus never 
cancer). Following these definitions, we replicated (i) cohort study using Cox proportional 
hazards models and using cancer as time-dependent variable and performing a sensitivity 
analysis by restricting the study population to participants who survived up to age eighty 
years during follow-up;10,13,16 (ii) cohort study using Cox proportional hazards models and 
using cancer as time-independent variable;11,15-17,19 (iii) nested case-control study using Cox 
proportional hazards models and using cancer as time-independent variable (note that this 
design was previously used to investigate the risk of cancer in patients with dementia);17 and 
(iv) cross-sectional case-control study using logistic regression models.9,12 As previous studies 
corrected for baseline characteristics, we adjusted models for age, sex, educational level, 
smoking, BMI, systolic blood pressure, hypertension, diabetes mellitus, history of coronary 
heart disease, and history of stroke. Follow-up time was used as underlying time scale and 
was rounded to years. Participants were censored at date of loss to follow-up, death, or after 
15 years since start of follow-up. For the nested case-control study, we matched participants 
who were diagnosed with cancer to two participants who were free from cancer during study 
follow-up based on the age of cancer diagnosis and sex. For the cross-sectional study, we 
identified participants who visited at the fourth follow-up round of the first subcohort and the 
second follow-up round of the second subcohort. In addition, we selected participants who 
were diagnosed within six months after these follow-up rounds, because dementia is often 
diagnosed as result of examinations performed during the follow-up round. We subsequently 
used logistic regression models with history of incident cancer as determinant. 
Alternative methods to account for selection bias
In the abovementioned study designs, depending on how time zero was handled, immortal 
time bias could be inflicted. Immortal time bias can arise when we fail to align the start of 
follow-up in participants who develop cancer versus those who remain free of cancer during 
follow-up.24 Participants who survive longer have a higher probability to be diagnosed with 
cancer than those who have a shorter survival time. When cancer is treated as a time-
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independent variable, such as when the time zero for individuals with cancer is the time of 
cancer diagnosis, persons who died before cancer diagnosis are by definition excluded from 
this group. In contrast, when the time at study entry is considered as the time zero in both 
groups and time of cancer diagnosis is a time-dependent variable, immortal time bias can be 
reduced. To prevent immortal time bias, we must however consider alternative methods that 
we will discuss later in this section.24,33
 For all replications of previous study designs and statistical analyses, death was considered 
as an uninformative censoring event. A censoring event is an event that prevents observing 
the true outcome, including the outcome of dementia. For instance, being lost to follow-up is 
considered as a censoring event, which could be prevented in the study design. We consider a 
censoring event being uninformative if we assume that persons who are censored are similar 
to those who remained alive during the study period, given the available covariates. However, 
by definition, everyone who dies before the outcome, will not develop dementia. This cannot 
be prevented by the study design, and therefore we can consider death as a competing event. 
 In the current study, we used the following three alternative approaches to deal with 
immortal time bias: (i) a naïve approach in which cancer is treated as time-dependent variable; 
(ii) inverse probability weights (IPW) for the time until cancer diagnosis; and (iii) cloning and 
censoring.33 These different approaches are implemented to answer two different questions 
based on how we include death. The first question is ‘what is the risk of dementia among 
participants who develop cancer versus among those who remain free of cancer during 
follow-up, considering that we could eliminate death?’. This question reflects the hypothetical 
scenario were we could prevent death and therefore treat death as a censoring event. We 
refer to this question as the direct controlled effect.25 Given that this question relies on the 
strong assumption of uninformative censoring, we consider time-dependent covariates to 
simulate a scenario in which censoring for death is uninformative. The second question we 
propose is ‘what is the risk of dementia among participants who develop cancer versus among 
those who remain free of cancer during follow-up, regardless of death?’. This question does 
not require any strong assumption on the competing event of death, but the risk of dementia 
will be affected by the relation between cancer and death.34 We refer to this question as 
the total effect.25 In the following paragraphs, we will describe the technical details of these 
different approaches.
IPW for the time until cancer diagnosis
We computed weights for the time until cancer diagnosis by fitting a pooled logistic model. 
The product of the estimated conditional probabilities at each time was subsequently used to 
estimate the time-dependent weight for each participant at each time point, reflecting the time-
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dependent weight inversely proportional to the probability of not being diagnosed with cancer. 
Weights were fitted considering time until cancer diagnosis in years, cancer, the interaction 
between time and cancer, sex, age at study entry, cohort, education, and hypertension, and 
time-updated covariates including smoking, systolic blood pressure, BMI, history of stroke, 
history of diabetes, and history of coronary heart disease. Time, systolic blood pressure, and 
BMI were modelled non-linearly using B-spines with three degrees of freedom.
Cloning and censoring 
Details of this method have been described previously.33 In brief, first, we made two copies 
of each participant. One of the copies was allocated to a ‘cancer’ arm and the other copy 
to a ‘cancer-free’ arm. Participants who were diagnosed with cancer during follow-up were 
censored at date of end of follow-up in the ‘cancer’ arm and at date of cancer diagnosis in the 
‘cancer-free’ arm. Those who remained free from cancer during follow-up were censored after 
a pre-specified period of 15 years in the ‘cancer’ arm, or if their follow-up time was shorter at 
date of end of follow-up. In the ‘cancer-free’ arm, these participants were censored at date 
of end of follow-up. Censoring is informative and therefore we accounted for this type of 
censoring using IPW as described above. 
Risk of dementia with elimination of death
To “eliminate death”, i.e., to account for potential non-differential death between participants 
who were diagnosed with cancer and those who remained free of cancer, we computed IPW 
for death by fitting a pooled logistic model that included time-depended covariates. This 
resulted in a time-depended weight inversely proportional to the probability of not dying for 
each participant, considering the time-depended covariates that relate to death and dementia, 
including sex, age at study entry, cohort, education, smoking status, systolic blood pressure, 
hypertension, BMI, history of stroke, history of diabetes, and history of coronary heart disease. 
Follow-up time, systolic blood pressure, and BMI were modelled non-linear using B-spines 
with three degrees of freedom. In addition, we used these time-depended covariates to 
calculate IPW for loss to follow-up.
Risk of dementia regardless of death
To estimate the risk of dementia regardless of death, we do not rely in the strong assumption 
of uninformative censoring. We estimated the risk of dementia by the joint probability of 
incurring either dementia or death at each time point. We calculated the cumulative sum of 
the probability of surviving both events multiplied by the instantaneous cause-specific hazard 
of dementia.25,35 In this approach, we only considered censoring and IPW for loss to follow-up. 
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Combining the approaches for immortal time bias and the competing risk of death, we 
performed six different analyses. We created standardised cumulative incidence curves using 
pooled logistic regression. The 95% confidence intervals (CIs) were obtained by bootstrapping. 
Statistical analyses were performed using R software Version 3.6.1. The code to run the 
analyses will be made available on GitHub.
RESULTS
During a median (IQR) follow-up of 13.0 years (7.0 to 15.0), 1813 (20.4%) out of 8899 
participants were diagnosed with cancer. Of the participants who were diagnosed with cancer, 
68 (3.8%) were subsequently diagnosed with dementia, 183 (10.1%) were lost to follow-
up, and 890 (49.1%) died during follow-up. Of the 7086 participants who remained free of 
cancer, 781 (11.0%) were diagnosed with dementia, 1330 (18.8%) were lost to follow-up, and 
1341 (18.9%) died (Figure 1). Table 1 shows the baseline characteristics of the total study 
population. An overview of the different transition stages among participants who developed 
either cancer or dementia and died during follow-up is presented in Figure 2. The median 
(IQR) age at cancer diagnosis of these participants was 75.0 years (69.1 to 80.4), whereas the 
median (IQR) age at dementia diagnosis of these participants was 82.5 years (77.5 to 86.9). 
Replication of previous studies
When using cancer as time-dependent variable, the risk of dementia in participants with 
cancer was similar to that in participants without cancer (hazard ratio [HR] = 0.91 [95% CI = 
0.71 to 1.16], Table 2). This risk was comparable when restricting the analysis to participants 
who survived up to at least eighty years (HR = 0.91 [95% CI = 0.67 to 1.26]). Participants 
with cancer had a lower risk of dementia than those without cancer when using cancer as 
time-independent variable (HR = 0.44 [95% CI = 0.35 to 0.56]) and in the nested case-control 
setting (HR = 0.53 [95% CI = 0.41 to 0.69]).
 The number of participants that was included in the cross-sectional study design was 
5278. Out of these participants, 50 had a dementia diagnosis during the research centre visit. 
This design is illustrated by Figure 3. Participants with a history of cancer had an odds ratio 
(OR) of 0.28 (95% CI = 0.02 to 1.31) for dementia. When including also participants who were 
diagnosed with dementia within six months after the research centre visit, the OR was 0.61 




















Figure 1 Flowchart of outcomes stratified by incident cancer diagnosis.
Alternative methods to account for selection bias
Figure 4 shows that the risk of death among participants with cancer is higher than among 
those without cancer. Standardised cumulative incidence curves for the six different analyses 
are presented in Figure 5. When using cancer as time-dependent variable and eliminating 
death, participants with cancer had a higher risk of dementia than those without cancer, but 
CIs were overlapping (Figure 5A). The risk of dementia regardless of the risk of death was 
higher in participants with cancer than in those without cancer up to 12 years of follow-up. 
After 12 years, the difference in the risk of dementia narrows, but CIs largely overlap over 
the entire follow-up (Figure 5B). The risk of dementia was higher when estimating the risk 
of dementia with elimination of death rather than regardless of death. When we computed 
IPW for the time until cancer diagnosis, cumulative incidence curves crossed after 12 years 
of follow-up in both approaches that we used to deal with the competing risk of death (Figure 
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Table 1 Baseline characteristics of study population
Characteristic Participants(N=8899)
Age, years, median (IQR) 65.7 (60.4 to 73.2)
Women, No. (%) 5112 (57.4)
Educational level, No. (%)
 Lower 4220 (47.4)
 Intermediate 3695 (41.5)
 Higher 984 (11.1)
Smoking, No. (%)
 Never 2914 (32.7)
 Former 3931 (44.2)
 Current 2054 (23.1)
Body mass index, kg/m2, mean (SD) 26.6 (3.8)
Systolic blood pressure, mm Hg, mean (SD) 140.5 (22.2)
Hypertension, No. (%) 5514 (62.0)
Diabetes mellitus, No. (%) 852 (9.6)
History of coronary heart disease, No. (%) 694 (7.8)
History of stroke, No. (%) 254 (2.9)
IQR = interquartile range, N = number of participants, SD = standard deviation.
5C and 5D). Lastly, when using the cloning and censoring method, we found that cumulative 
incidence curves for participants with and without cancer were completely overlapping, with a 
slight deviation after 15 years of follow-up when estimating the risk of dementia regardless of 

















Figure 2 Graphic overview of transition states for participants who were free of cancer and 
dementia at study entry and who developed cancer or dementia during follow-up and died. 
This graph consists of raw data (i.e., participants were not censored after dementia diagnosis and follow-
up was not censored after 15 years) of 1556 participants. Out of these participants, 935 (60.1%) were 
diagnosed with cancer, 546 (36.2%) with dementia, and 75 (4.8%) with both cancer and dementia. The 
median (interquartile range) age at cancer diagnosis of these participants was 75.0 years (69.1 to 80.4), 
whereas the median (interquartile range) age at dementia diagnosis of these participants was 82.5 years 
(77.5 to 86.9). The dotted line indicates the median age at death for participants with cancer (77.5 years 
[interquartile range = 71.7 to 82.9]). 
Free from cancer
and dementia
Cancer Dementia DeathCancer and
dementia
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total HR (95% CI)
Cancer as time-dependent variable 1813 875 8899 0.91 (0.71 to 1.16)
Survived up to at least 80 years 619 523 3423 0.91 (0.67 to 1.26)
Cancer as time independent variable 1813 875 8899 0.44 (0.35 to 0.56)
Nested case-control setting 1805* 409 5414 0.53 (0.41 to 0.69)
OR (95% CI)
Dementia at ERGO4 359 50 5278 0.28 (0.02 to 1.31)
Dementia <6 months after ERGO4 405 142 5278 0.61 (0.26 to 1.24)
Model is adjusted for baseline measurements of age, sex, education, smoking status, body mass index, 
systolic blood pressure, hypertension, diabetes mellitus, history of coronary heart disease, and history 
of stroke.
* Eight out of 1813 participants with cancer could not be matched to a control. One participant with cancer 
was matched to only one control.
ERGO4 = fourth visit of the first subcohort and the second visit of the second subcohort, HR = hazard 
ratio, N = number of participants, OR = odds ratio.
Dementia Free of dementia

















Figure 3 Graphic overview of cross-sectional study design when the assessment took place in 
2002 to 2003. 
This graph consists of raw data (i.e., participants were not censored after dementia diagnosis and follow-
up was not censored after 15 years) of a random sample of participants from the first subcohort of the 
Rotterdam Study. When assessing participants during the fourth visit round in 2002 and 2003, only 
those who have survived up to 2002 and 2003 will be included in the study population. Therefore, cross-
sectional study designs may result in selection bias. 































95% CI cancer 95% CI cancer−free
Risk of death
Figure 4 Risk of death for participants who are diagnosed with cancer and those who remain free 
of cancer during follow-up.
CI = confidence interval.
DISCUSSION
This study shows that the direction and magnitude of the risk of dementia in cancer patients 
is affected by the characteristics of the study design and statistical analyses. When using 
appropriate methods to account for immortal time bias and the competing event of death, 
patients with cancer are not at decreased risk of developing dementia. This suggests that 
the frequently observed inverse relation between cancer and dementia may be based on 
selection bias. These findings underline the importance of using appropriate study designs 
and statistical analyses when studying an exposure and outcome that are strongly related to 
death. 
 When we replicated study designs and statistical analyses performed in previous literature, 
hazard ratios for the risk of dementia in cancer patients varied between 0.44 and 0.91. 
These effect estimates are comparable to those obtained from previous studies on cancer 
and dementia.8-21 The lowest effect estimates were found for cross-sectional study designs. 
In cross-sectional studies, participants had to survive up to a certain moment in time to be 
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Figure 5 Standardised survival curves for dementia.
Curves for participants with cancer are presented in yellow and for participants without cancer in blue. 
Panels on the left (A, C, and E) represent the risk of dementia when we eliminated death, i.e., the 
controlled direct effect. Panels on the right (B, D, and F) represent the risk of dementia regardless of 
death, i.e., the total effect. Panel A and B show the curves when immortal time is handled by treating 
cancer as time-depended variable. Panel C and D are the curves obtained after we computed IPW for the 
time until cancer diagnosis. Panel E and F show the curves after cloning and censoring.
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included in the study. Participants who have survived longer are more likely to be included in 
a cross-sectional study than those who have a shorter survival time (Figure 3). This can result 
in a selected group of participants who may be healthier and have a longer survival than the 
general population. 
 Regarding longitudinal studies, we found a lower risk of dementia in participants with 
cancer when using cancer as time-independent variable (HR = 0.44 in the cohort setting 
and HR = 0.53 in the nested case-control setting) than when studying cancer as time-
dependent variable (HR = 0.91), which was also observed by Hanson et al.23 The difference 
between these outcomes may be explained by selection bias due to immortal time.34 We have 
accounted for immortal time using three different methods: (i) using cancer as time-dependent 
variable; (ii) using IPW for the time until cancer diagnosis; and (iii) cloning and censoring. 
These three different methods provided similar results. The time-dependent Cox proportional 
hazards model also reduces immortal time bias, but cannot completely prevent such bias and 
has two additional shortcomings, i.e., (i) hazard ratios represent a weighted average of the 
time-dependent hazard ratios of the total follow-up period and may therefore lose information 
that is preserved by presenting cumulative incidence curves36; and (ii) the model assumes that 
censoring of death is uninformative. 
 This latter assumption of the Cox proportional hazards model is often not examined. Given 
that persons need to survive long enough to develop dementia (median age [IQR] of dementia 
diagnosis in our study was 82.5 years [77.5 to 86.9]), and that dementia shares risks factors 
related to cardiovascular disease and cancer, they are at increased risk of death. Censoring 
for death is therefore informative and may result in biased effect estimates.25 Hanson et al. 
compared the following two competing risk models to illustrate the effect of the competing 
risk of death on the relation between cancer and dementia: Fine and Gray and Kalbfleisch 
and Prentice.23,37,38 The Fine and Gray model calculates the absolute risk of dementia and 
allows participants to be at risk for dementia after they have experienced the competing risk of 
death. The subdistribution hazard for dementia was lower than the cause specific hazard for 
dementia, indicating that mortality was higher in patients with cancer than in persons without 
cancer. The Kalbfleisch and Prentice method uses internal time-dependent covariates that are 
strongly related to the competing risk of death. The significant, positive association between 
these covariates and dementia indicated non-independence between dementia and death. 
Other studies have tried to account for the effects of the competing risk of death by studying 
negative control diseases39 such as stroke and automobile injuries,19,40,41 focusing on different 
cancer types,8,18,19,41,42 and stratifying follow-up time.21 In addition, we have previously used the 
tumour marker carcinoembryonic antigen as a proxy of preclinical cancer and studied the risk 
with dementia, given that persons with a preclinical stage of the disease have on average a 
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longer life expectancy than patients with clinically manifested disease.43 Interestingly, higher 
levels of the tumour marker carcinoembryonic antigen were associated with a higher risk of 
dementia suggesting that, from a biological perspective, cancer and dementia might even 
be positively associated rather than inversely. In the current study, we accounted for the 
competing risk of death by multiplying the instantaneous hazard of dementia by the probability 
of being free of any event (i.e., total effect of cancer on dementia) and by computing IPW for 
death (i.e., direct effect of cancer on dementia, not mediated by death). 
 It must be noted however, that we, like previous studies, defined cancer as a pathology-
confirmed cancer diagnosis. A cancer diagnosis can represent multiple causal pathways as 
will be explained below. We therefore did not examine the causal effect of cancer when using 
the alternative methods to account for immortal time bias and the competing risk of death, and 
as such, we did not consider confounders for the association between cancer, dementia, and 
death. If future studies aim to understand the causal relation between cancer and dementia, 
the research question should be redefined, because cancer diagnosis itself does not cause 
dementia. An ill-defined research question may result in wrong interpretation of the causal 
effects.25 Cancer diagnosis may be considered as a proxy for other underlying processes that 
may cause cognitive impairment and subsequently dementia, see the corresponding directed 
acyclic graph (DAG) in Figure 6. This DAG represents four proposed mechanisms underlying 
cognitive problems in cancer patients.44-46 Given that cognitive impairment precedes dementia, 
we hypothesised that these mechanisms may also underlie a causal association between 
cancer and dementia. Firstly, shared risk factors for cancer and dementia such as higher 
age, genetics, and smoking may increase the risk of both cancer and dementia. Secondly, 
the tumour itself can induce different biological processes including inflammation, vascular 
changes, oxidative stress, and production of extracellular vesicles that can affect cognitive 
function.44 These processes may differ between different types of cancer and disease stages. 
Thirdly, cancer treatment can accelerate the ageing process by inducing DNA damage, 
telomere shortening, oxidative stress, inflammation, and changes in hormonal levels.45,47 In 
addition, chemotherapy can have direct neurotoxic effects.46,48 Fourthly, psychological distress 
including depression, anxiety, stress, and fatigue may be caused by cancer diagnosis and 
cancer treatment. Such factors can also affect cognitive function and the risk of dementia.49
 Each of these causal pathways may require adjustment for different confounding 
structures. For this reason, we recommend future studies to specify the specific pathway of 
interest. Importantly, measurement error for the proxy of cancer diagnosis may be different for 
each of these pathways. In addition, even if the causal pathway has been correctly specified, 
one must assume to have all required information to control for the collider-bias that is induced 
by condition on surviving (Figure 6). 
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 In conclusion, our findings indicate that the type of study design can influence results when 
studying diseases that are strongly related to death. When taking immortal time bias and the 
competing risk of death into account, we found that patients with cancer did not have a lower 
risk of dementia than those without a history of cancer, nor did they have a higher risk. Given 
the ill-defined definition of cancer diagnosis, we cannot answer the causal effect of cancer on 
the risk of dementia. Future studies should further disentangle the processes underlying a 
cancer diagnosis to estimate the causal effect.
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Inflammation markers and cognitive performance in breast cancer 
survivors 20 years after completion of chemotherapy
van der Willik KD, Koppelmans V, Hauptmann M, Compter A, 




Background Inflammation is an important candidate mechanism underlying cancer and 
cancer treatment-related cognitive impairment. We investigated levels of blood-cell based 
inflammatory ratios in breast cancer survivors on average twenty years after chemotherapy 
and explored the relation between these ratios and global cognitive function.
Methods One hundred sixty-six breast cancer survivors who received post-surgical 
radiotherapy and six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil 
(CMF) chemotherapy on average twenty years before enrolment were compared with 1344 
cancer-free women from a population-based sample (aged between 50 and 80 years). Breast 
cancer survivors were excluded if they used adjuvant hormonal therapy, or if they developed 
relapse, metastasis, or second primary malignancies. Systemic inflammation status was 
assessed by the granulocyte-to-lymphocyte ratio (GLR), platelet-to-lymphocyte ratio (PLR), 
and systemic immune-inflammation index (SII). Cognitive function was assessed using an 
extensive neuropsychological test battery from which the general cognitive factor was derived 
to evaluate global cognitive function. We examined the association between cancer, the 
general cognitive factor, and inflammatory ratios using linear regression models.
Results Breast cancer survivors had a lower general cognitive factor than non-exposed 
participants from the comparator group (mean difference = -0.21 [95% confidence interval [CI] 
= -0.35 to -0.06]). Inflammatory ratios were higher in cancer survivors than in non-exposed 
participants (mean difference for log[GLR] = 0.31 [95% CI = 0.24 to 0.37], log[PLR] = 0.14 
[95% CI = 0.09 to 0.19], log[SII] = 0.31 [95% CI = 0.24 to 0.39]). The association between 
higher levels of inflammatory ratios and lower general cognitive factor was statistically 
significant in cancer survivors but not among non-exposed participants. We found a group-
by-inflammatory ratio interaction: cancer survivors showed additional lower general cognitive 
factor per standard deviation increase in inflammatory ratios (P for interaction for GLR = .038, 
PLR = .003, and SII = .033).
Conclusions This is the first study to show that (i) cancer survivors have higher levels of 
inflammation on average twenty years after treatment; and (ii) these inflammatory levels are 
associated with lower cognitive function. Although this association needs verification by a 
prospective study to determine causality, our findings can stimulate research on the role of 
inflammation in long-term cognitive problems and possibilities to diminish such problems. 
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INTRODUCTION
Patients with cancer frequently report cognitive problems that can affect their quality of life 
and daily functioning substantially. Studies have shown that patients with non-central nervous 
system (non-CNS) cancer can experience cognitive problems during and after completion of 
treatment including chemotherapy, and a subgroup of patients had cognitive problems up to 
twenty years after treatment.1,2
 The cancer survivor population is ageing and growing because of increased life expectancy 
and more specifically because of advances in cancer treatment and improved screening. 
In turn, this has resulted in an increasing number of cancer survivors coping with cognitive 
problems. The driving forces underlying these cognitive problems have not been sufficiently 
clarified, impeding the approach and process of developing effective interventions. Cognitive 
problems in cancer patients could be induced by cancer itself, cancer-related treatment, or 
shared risk factors for the development of both cancer and cognitive problems.3,4 Disentangling 
the effects and mechanisms of these causes of disruption of normal cognitive function is 
challenging. Different mechanisms, including genetic susceptibility, telomere shortening, 
changes in hormone levels, and inflammation, have been proposed and revealed.3 
 In recent years, inflammation in particular has been suggested as an important and 
potentially intervenable mechanism in the pathogenesis of cognitive problems in patients with 
cancer. Higher levels of inflammatory factors such as cytokines are observed in patients with 
cancer prior to start of any treatment,5 during chemotherapy,6-10 and after chemotherapy11,12 up 
to five years after treatment initiation.13 Several studies have found an association between 
cytokines and cognitive impairment in patients with cancer across different cognitive domains, 
such as psychomotor speed,8 executive functioning,14 and memory.5,10,11,13 However, these 
studies did not agree on the involved cytokines or on the affected cognitive domain. Also, 
because the longest follow-up in these studies was five years, it remains unknown whether 
inflammation also has a role in long-term or late cognitive problems. Filling this knowledge 
gap is important as insight into underlying causes of (long-term) cognitive impairment helps to 
identify those cancer patients at increased risk of developing cognitive problems and opens 
venues for preventive and therapeutic interventions. 
 Most studies examined the inflammation status by investigating cytokines using different 
cytokine panels.5,6,8-19 In contemporary studies, systemic inflammatory response ratios 
measured in blood, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte 
ratio (PLR), and systemic immune-inflammation index (SII), are increasingly used. These 
ratios have reliable prognostic and predictive value in patients with cancer and can easily 
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be calculated from readily available standard full blood examination, making them more 
convenient to use in a clinical setting.20-24 If related to cognitive problems, these ratios could 
potentially be used as biomarkers for cancer-related cognitive impairment.
 In this study, we investigated global cognitive function, levels of blood cell-based 
inflammatory ratios, and their relation in breast cancer survivors who had received post-surgical 
radiotherapy and six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil 
(CMF) chemotherapy on average more than twenty years previously. We furthermore 
examined whether inflammation and cognitive function were differentially associated between 
breast cancer survivors and cancer-free women from a population-based sample.
METHODS
Study population
In this study, we selected women who had survived breast cancer and had received adjuvant 
CMF chemotherapy. We compared them with women from the general population, who were 
cancer-free and had never received chemotherapy.
Breast cancer survivors
Women with a history of unilateral, invasive breast cancer were identified on the basis of 
registries of the Netherlands Cancer Institute in Amsterdam and the Daniel den Hoed Cancer 
Clinic of the Erasmus Medical Centre in Rotterdam as described previously.2 Briefly, women 
were selected if they had received post-surgical radiotherapy and six cycles of adjuvant CMF 
chemotherapy between 1976 and 1995. 
 Breast cancer survivors were eligible if they were 50 to 80 years old at time of inclusion in 
2008, if invasive breast cancer was their first and only malignancy, if they had not developed 
relapse or distant metastasis, if they had sufficient command of the Dutch language, and if 
they did not have any contraindications for magnetic resonance imaging (MRI). In addition, 
ever use of hormonal therapy was applied as an exclusion criterion. Since adjuvant hormonal 
therapy was not part of the standard treatment for breast cancer patients in the Netherlands 
until the mid-1990s, only a few women received this treatment. To enhance homogeneity 
within the group of breast cancer survivors, we included hormone treatment-naive cancer 
survivors only.
 Three hundred fifty-nine breast cancer survivors were assessed for eligibility and 292 
were selected. Of these 292 women, 196 agreed to participate and provided informed 
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consent. We previously reported on cognitive function in these survivors in comparison 
with cancer-free women identified within the Rotterdam Study.2 For the current study, the 
following additional inclusion criteria were defined: availability of blood measurements and 
completeness of neuropsychological test data to calculate the general cognitive factor. Thirty 
of the 196 (15.3%) breast cancer survivors were excluded because of missing data on blood 
measurements (n=5) and incomplete data of neuropsychological tests (n=25, Figure 1A). 
Because breast cancer survivors did not receive an extensive dementia screening, history of 
dementia was not applied as an exclusion criterion. However, based on the interviews with 
a trained psychologist, subjective memory complaints, cognitive tests, and brain MRI, it is 
unlikely that the included breast cancer survivors had dementia at the time of examinations.
Population-based non-exposed participants
Cancer-free women were selected from the Rotterdam Study, an ongoing population-based 
prospective cohort that started in 1989 in Rotterdam, the Netherlands. The main objective 
of the Rotterdam Study is to investigate risk factors of diseases in the elderly. By the end of 
2008, the Rotterdam Study consisted of three subcohorts, comprising 14 926 individuals. The 




• Current address unavailable (n=20)
• Contra-indication for MRI (n=45)
• Insufficient Dutch language (n=2)
Excluded (n=2358)
• Male sex (n=1680)
• Aged <50 or >80 years (n=503)
• Prevalent cancer (n=130)
• No information about prevalent 
dementia (n=32)
• No informed consent (n=13)
A B
Assessed for eligibility 
(n=359)
Assessed for eligibility 
(n=3932)
Excluded (n=126)
• Not agreed to participate (n=96)
• No blood measurements available 
(n=5)









• No blood measurements available 
(n=39)
• No general cognitive factor 
available (n=191)
Figure 1 (A) Flowchart for breast cancer survivors, (B) Flowchart for non-exposed participants.
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 The third subcohort (RS-III) started in 2006 and was the first cohort in which an extensive 
set of neuropsychological tests was implemented at baseline. For this reason, RS-III was 
chosen as the reference subcohort, which was composed of 3392 participants (65% out of 
invitees). From these participants, women between 50 and 80 years old without a history 
of cancer or dementia were eligible as non-exposed participants (n=1574). This sample 
comprised the non-exposed participants used in our previous cognitive study.2 Two hundred 
thirty persons were additionally excluded because of lack of blood measurements (n=39) 
and incomplete data of neuropsychological tests (n=191), resulting in 1344 non-exposed 
participants (Figure 1B). 
Assessment of inflammatory ratios
All participants had fasting blood samples taken during the research centre visit. Full blood 
count measurements were performed by using a COULTER® Ac·T diff2™ Haematology 
Analyser (Beckman Coulter, San Diego, California, USA) directly after the blood sample 
was drawn. Haematological measurements included absolute granulocyte, lymphocyte, and 
platelet counts in 109 per litre. 
 We used the granulocyte count as proxy for the neutrophil count because we did not have 
this measurement available in our sample. Because most of the granulocytes are represented 
by neutrophils, we believe this did not affect our results.26,27 For accuracy purposes, we will 
refer to the granulocyte-to-lymphocyte ratio (GLR) instead of using the term NLR.
 The GLR and PLR were calculated as the ratio of granulocyte count to lymphocyte count, 
and as the ratio of platelet count to lymphocyte count, respectively.28 The SII was defined 
as platelet count times the GLR.22 Because they are either ratios or indices, the derived 
inflammatory ratios did not have a unit. 
Assessment of cognitive function
Cognitive function was evaluated between November 2009 and June 2010 for breast cancer 
survivors and between February 2006 and December 2008 for non-exposed participants 
on the same day as the blood sample was drawn. Cognitive function was assessed by a 
neuropsychological test battery in the research centre of the Rotterdam Study. Six tests were 
administrated: the Mini Mental State Examination, Letter-Digit Substitution Test (LDST), Word 
Fluency Test (WFT), Stroop Test (Reading, Naming, and Interference), Purdue Pegboard 
Test (PPT, right, left, and both hands) and 15-Word Learning Test (15-WLT, Immediate recall, 
Delayed recall, and Recognition). Global cognitive function was assessed via the general 
cognitive factor, which was generated by using principal component analysis of the following 
tests: LDST (total completion time), WFT (number of words), Stroop interference (time in 
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seconds, adjusted for errors), PPT (total number of pins across three subtasks), and 15-WLT 
(number of words during delayed recall).29 
Other assessments
We assessed educational level (primary: primary education, lower: lower general education, 
intermediate general education, or lower vocational education, intermediate: intermediate 
vocational education or higher general education, higher: higher vocational education or 
university) and smoking status (current, former, and never) by interview. Body mass index 
(BMI, kg/m2) was computed from measurements of height and weight. Diabetes mellitus was 
defined as use of antidiabetic medication, a fasting serum glucose level of at least 7.1 mmol/L, 
or a random serum glucose level of at least 11.1 mmol/L.30 History of stroke and myocardial 
infarction were assessed by interview.31,32 Symptoms of depression were evaluated with the 
Centre for Epidemiologic Studies Depression scale (CES-D), which was converted to a sum-
score.33 We had no information about anxiety and fatigue and could therefore not control for 
these symptoms.
Statistical analyses
Linear regression models were used to investigate mean differences in the general cognitive 
factor and inflammatory ratios between breast cancer survivors and non-exposed participants. 
Inflammatory ratios were logarithmic transformed because of their skewed distribution. We 
constructed two nested models: Model I was adjusted for age (continuous) and education (four 
categories) and Model II was additionally adjusted for smoking status (three categories), BMI 
(continuous), diabetes mellitus (yes or no), history of stroke (yes or no), history of myocardial 
infarction (yes or no), and CES-D sum-score (continuous). To investigate whether levels of 
the general cognitive factor were explained by different inflammatory ratios, we adjusted 
additionally for each inflammatory ratio separately.
 The association between the general cognitive factor and inflammatory ratios was 
investigated for breast cancer survivors and non-exposed participants using linear regression 
models. To study whether this association was stronger in breast cancer survivors than in 
non-exposed participants, we computed interaction terms between history of cancer/cancer 
treatment and each inflammatory ratio. We explored effect modification by stratifying for mean 
BMI.
 Since mean age was higher in the breast cancer survivors than in the non-exposed 
participants (Table 1), we repeated all analyses using age-matched non-exposed participants 
to minimise residual confounding. These analyses provided comparable estimates to using all 
non-exposed participants and therefore are not reported separately.
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 Multiple imputation was used for missing data on covariates (generally between 0.1% 
and 0.3% with a maximum of 1.8% for the CES-D sum-score) with five imputed datasets, 
based on history of cancer/cancer treatment, inflammatory ratios, general cognitive factor, 
and other covariates (i.e., age, sex, education, BMI, smoking status, presence of diabetes 
mellitus, history of stroke, history of myocardial infarction, and CES-D sum-score). Rubin’s 
method was used for pooled regression coefficients (β) and 95% confidence intervals (CIs).34 
All analyses were performed by using IBM SPSS Statistics Version 24.0 and RStudio Version 
3.3.2. All statistical tests were two-sided, and a P-value of less than .05 was considered as 
statistically significant.
RESULTS
Characteristics of breast cancer survivors and non-exposed participants are presented in 
Table 1. Breast cancer survivors were older than non-exposed participants. Additionally, they 
generally had completed higher levels of education and had more often had diabetes mellitus 
and a history of myocardial infarction. Lastly, although the numbers of never smokers were 
similar between the two groups, breast cancer survivors were more frequently former smokers 
and less often current smokers.
Inflammatory ratios
Breast cancer survivors had higher median levels of GLR, PLR, and SII than non-exposed 
participants. History of breast cancer/cancer treatment was associated with higher 
inflammatory ratios, also after adjustment for age, education, smoking, BMI, diabetes mellitus, 
history of stroke, history of myocardial infarction, and CES-D sum-score (mean difference for 
log[GLR] = 0.31, 95% CI = 0.24 to 0.37, log[PLR] = 0.14, 95% CI = 0.09 to 0.19, log[SII] = 
0.31, 95% CI = 0.24 to 0.39, Table 2). Inflammatory ratios were positively associated with age 
in both groups.35
Cognitive function
Breast cancer survivors had a lower general cognitive factor than non-exposed participants 
(mean difference = -0.21, 95% CI = -0.35 to -0.06, corresponding with an effect of 3.6 years 
of age given a decline in general cognitive factor of 0.59 points per 10 years, Table 2).29 
Further adjustment for inflammatory factors changed the estimates slightly, indicating that 
inflammatory ratios explained only a small part of the difference in general cognitive factor
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Age, years, mean (SD) 64.0 (6.7) 57.9 (5.2) <.001
Educational level, No. (%) <.001
 Primary 14 (8.4) 158 (11.8)
 Lower 59 (35.5) 616 (45.8)
 Intermediate 33 (19.9) 287 (21.4)
 Higher 60 (36.1) 283 (21.1)
Body mass index, kg/m2, mean (SD) 26.9 (4.6) 27.4 (4.8) .18
Smoking status, No. (%) <.001
 Never 57 (34.3) 475 (35.3)
 Former 93 (56.0) 574 (42.7)
 Current 16 (9.6) 295 (21.9)
Diabetes mellitus, No. (%) 14 (8.4) 54 (4.0) .01
History of stroke, No. (%) 1 (0.6) 19 (1.4) .72
History of myocardial infarction, No. (%) 6 (3.6) 11 (0.8) .001
CES-D sum-score, median (IQR) 6 (4 to 9) 6 (4 to 10) .08
General cognitive factor, mean (SD) -0.39 (1.14) 0.05 (0.97) <.001
Inflammatory ratios, median (IQR)
 GLR 2.06 (1.67 to 2.66) 1.52 (1.20 to 1.92) <.001
 PLR 145 (119 to 176) 124 (102 to 151) <.001
 SII 618 (469 to 796) 443 (328 to 595) <.001
Age at cancer diagnosis, years, mean (SD) 42.9 (5.6)
Time since cancer diagnosis, years, mean (SD) 21.0 (4.5)
CES-D = Centre for Epidemiologic Studies Depression Scale, IQR = interquartile range, GLR = 
granulocyte-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio, SD = standard deviation, SII = 
systemic immune-inflammation index.
in addition to the effect of history of cancer/cancer treatment (mean difference for history of 
cancer/cancer treatment after adjustment for log[GLR] = -0.18, 95% CI = -0.33 to 0.02, log 
[PLR] = -0.21, 95% CI = -0.36 to 0.06, log[SII] = -0.19, 95% CI = -0.34 to 0.03).
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Table 2 Association between the general cognitive factor and history of cancer, and inflammatory 
ratios and history of cancer.
Model I Model II




 Granulocyte-to-lymphocyte ratio 0.30 (0.24 to 0.36) 0.31 (0.24 to 0.37)
 Platelet-to-lymphocyte ratio 0.16 (0.10 to 0.21) 0.14 (0.09 to 0.19)
 Systemic immune-inflammation index 0.30 (0.23 to 0.38) 0.31 (0.24 to 0.39)
Cognition‡
 General cognitive factor -0.18 (-0.34 to -0.03) -0.21 (-0.35 to -0.06)
Model I is a linear regression of the general cognitive factor or logarithmic transformed inflammatory 
ratios on cancer status adjusted for age and education. Model II is as Model I plus adjustment for smoking 
status, body mass index, diabetes mellitus, history of stroke, history of myocardial infarction, and CES-D 
sum-score.
* All types inflammatory ratios were natural logarithmic transformed. † Mean difference in general cognitive 
factor between breast cancer survivors and non-exposed participants. ‡ Mean difference in inflammatory 
ratios between breast cancer survivors and non-exposed participants.
CI = confidence interval. 
Association between cognitive function and inflammatory ratios by cancer status
A lower general cognitive factor was associated with higher inflammatory ratios in breast 
cancer survivors (Table 3). In non-exposed participants, higher inflammatory ratios tended to 
be associated with a lower general cognitive factor, albeit not statistically significant. 
 The interaction term between inflammatory ratios and history of cancer/cancer treatment 
was significant for each inflammatory ratio, indicating that the association between higher 
inflammation levels and lower general cognitive factor was more pronounced in breast cancer 
survivors than in non-exposed participants (P for interaction between cancer and standardised 
logarithmic transformed GLR = .038, PLR = .003, and SII = .033, Figure 2). 
 The association between higher inflammatory ratios and lower general cognitive factor 
differed more between breast cancer survivors and non-exposed participants with a higher 
BMI than in those with a lower BMI. However, stratified analyses for BMI showed that the 
effect of one standard deviation increase in inflammatory ratio on general cognitive factor was 
higher among breast cancer survivors with a BMI below 27.3 kg/m2 than among those with a 
higher BMI (Table 4).
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P for interaction = .038



























P for interaction = .003



























P for interaction = .033
Figure 2 (A) Interaction of log(GLR) and cancer status with the general cognitive factor as outcome. 
(B) Same as A, for log (PLR). (C) Same as A and B, for log(SII). 
Model used for figure is only adjusted for age.
GLR = granulocyte-to-lymphocyte ratio, PLR = platelet-to-lymphocyte ratio, SII = systemic immune-
inflammation index.
Table 3 Association between the general cognitive factor and inflammatory ratios in breast cancer 













 Granulocyte-to-lymphocyte ratio -0.24 (-0.40 to -0.08) -0.04 (-0.09 to 0.00) .06
 Platelet-to-lymphocyte ratio -0.13 (-0.29 to 0.03) 0.05 (0.01 to 0.10) .003
 Systemic immune-inflammation index -0.22 (-0.38 to -0.07) -0.03 (-0.08 to 0.01) .05
Model II
 Granulocyte-to-lymphocyte ratio -0.23 (-0.39 to -0.08) -0.02 (-0.07 to 0.02) .04
 Platelet-to-lymphocyte ratio -0.18 (-0.33 to -0.02) 0.03 (-0.01 to 0.08) .003
 Systemic immune-inflammation index -0.23 (-0.38 to -0.07) -0.01 (-0.06 to 0.03) .03
Model I is a linear regression of the general cognitive factor on each logarithmic transformed inflammatory 
ratio adjusted for age and education. Model II is as Model I plus adjustment for smoking status, body mass 
index, diabetes mellitus, history of stroke, history of myocardial infarction, and CES-D sum-score.
* All types inflammatory ratios were natural logarithmic transformed. † Mean difference in general cognitive 
factor per standard deviation increase in inflammatory ratio. ‡ P-value for interaction term between history 
of cancer/cancer treatment and inflammatory ratio.
CI = confidence interval.
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Table 4 Association between the general cognitive factor and inflammatory ratios in 












Body mass index <27.3 kg/m2 n=104 n=749
 Granulocyte-to-lymphocyte ratio -0.29 (-0.49 to -0.10) -0.04 (-0.10 to 0.02) .48
 Platelet-to-lymphocyte ratio -0.22 (-0.42 to -0.02) 0.01 (-0.05 to 0.08) .31
 Systemic immune-inflammation index -0.28 (-0.48 to -0.09) -0.04 (-0.10 to 0.02) .56
Body mass index <27.3 kg/m2 n=62 n=595
 Granulocyte-to-lymphocyte ratio -0.16 (-0.41 to 0.09) 0.01 (-0.06 to 0.08 .01
 Platelet-to-lymphocyte ratio -0.16 (-0.42 to 0.10) 0.05 (-0.02 to 0.12 <.001
 Systemic immune-inflammation index -0.12 (-0.38 to 0.14) 0.02 (-0.05 to 0.09 .005
Model I is a linear regression of the general cognitive factor on each log transformed inflammatory ratio 
adjusted for age and education. Model II is as Model I plus adjustment for smoking status, diabetes 
mellitus, history of stroke, history of myocardial infarction, and CES-D sum-score. 
* All types inflammatory ratios were natural logarithmic transformed. † Mean difference in general cognitive 
factor per standard deviation increase in inflammatory ratio. ‡ P-value for interaction term between history 
of cancer/cancer treatment and inflammatory ratio.
CI = confidence interval, SD = standard deviation.
DISCUSSION
This study is the first report investigating the association between blood-cell-based 
inflammatory ratios and cognitive function in breast cancer survivors with an average time 
since cessation of chemotherapy of more than twenty years. Breast cancer survivors had 
lower global cognitive function and higher inflammatory ratios compared with women without 
a history of cancer. The tendency for lower global cognitive function with higher inflammatory 
ratios was more pronounced in breast cancer survivors, suggesting a potential role for 
inflammation in the pathophysiology of cognitive problems in cancer survivors. This effect was 
not modified by BMI. More insight in mechanisms underlying cognitive problems could help 
identifying those women who are at an increased risk of cognitive problems and developing 
prevention strategies. 
 We previously reported on differences in cognitive function between breast cancer survivors 
and non-exposed participants.2 In this previous study, we tested between-group performance 
differences of individual cognitive outcome measures that were currently used to construct the 
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general cognitive factor and observed that breast cancer survivors performed worse compared 
to non-exposed participants within several cognitive domains. This suggested that cognitive 
problems in cancer survivors can be long-lasting. In the present study, we evaluated global 
cognitive function using the general cognitive factor because we did not expect a specific 
cognitive domain to be affected by inflammation. We chose to use a robust cognitive summary 
measure, thereby reducing the number of comparisons. 
 Interestingly, levels of inflammatory ratios were higher in breast cancer survivors than 
in non-exposed participants, on average twenty years after cancer treatment. Inflammation 
plays a critical role in tumorigenesis, tumour progression, and cancer metastasis.36,37 
Research has shown that chronic inflammation is associated with an increased cancer risk.37 
Moreover, different markers of inflammation, such as cytokines, C-reactive protein, and NLR, 
are often elevated in cancer patients and are associated with poor survival.9,15-17,24,38 One study 
investigating inflammation levels after cancer treatment found that C-reactive protein and 
cytokine levels were elevated up to five years after treatment.19 Our observation that systemic 
inflammation ratios are higher in breast cancer survivors than in non-exposed participants on 
average twenty years after cancer treatment suggests deregulation of the immune system. 
Whether this is a consequence of cancer or cancer treatment (or both), or a pre-existing 
deregulation before cancer development cannot be determined with the current study. 
 The found association of blood-cell based inflammatory ratios and cognitive function in 
breast cancer survivors is in line with previous observations before, during, and shortly after 
cancer therapy.6,17,18 Two studies investigated the link between inflammation and cognitive 
function prior to start of cancer treatment. The first study showed that elevated levels 
of interleukin-6 (IL-6) in patients with acute myelogenous leukaemia or myelodysplastic 
syndrome were associated with poorer executive functioning before cancer treatment.14 
The second study showed that high levels of soluble tumour necrosis factor receptor type 
II (sTNF-RII) were related to reduced verbal memory function in newly diagnosed breast 
cancer patients.5 More studies in breast cancer patients have tried to elucidate the role of 
inflammation in impaired cognitive function during chemotherapy and two of these studies 
identified specific cytokines to be involved. Williams et al. focused on sTNR-RII and found that 
higher levels of this receptor were associated with visual memory function.10 Cheung et al. 
observed an association between increased levels of IL-6 and IL-1β, and poorer psychomotor 
speed function during chemotherapy.8 Shortly after cancer treatment, higher levels of sTNF-
RII were associated with increased memory complaints,11 and on average five years after 
cancer treatment, elevated IL-6 and TNFα levels were associated with worse verbal memory.13 
Importantly, the association between inflammation and cognitive function is supported by 
animal studies. Acute peripheral immune challenges using lipopolysaccharide resulted 
Chapter 13
318
in cognitive impairments in a spatial working memory task in mice. Cognitive impairments 
were observed 1.5-2 hours after injection in tumour-bearing mice but not in tumour-free 
mice. These cognitive effects could be prevented when using a technique to enhance innate 
immune reactivity.39 Together, these results support the hypothesis that inflammation has a 
role in the complex pathogenesis of both short-term and longer-term cognitive problems in 
cancer patients. 
 Owing to our study design, we cannot determine whether the association between 
inflammation and impaired cognitive function is causal. However, also a causal association 
could not illuminate the exact underlying mechanisms by which inflammation leads to brain 
changes and subsequent cognitive problems. Peripheral pro-inflammatory cytokines are able to 
cross the blood-brain barrier, which may initiate the release of local cytokines.40 Local cytokine 
production could result in neurotransmitter deregulation, increased oxidative stress, and 
decreased neurogenesis and neuroplasticity, which in turn can lead to cognitive dysfunction.41 
It is also possible that inflammation induces epigenetic changes and chromosomal instability, 
which can be persistent and therefore could be associated with long-term cognitive problems.42
 Our study has several strengths. First, we have a large sample size of breast cancer 
survivors who have been treated on average more than twenty years ago, enabling us to 
investigate long-term effects. Moreover, we used non-exposed participants from a population-
based cohort study, who underwent the same examinations as the breast cancer survivors. 
This design provided standardised ascertainment of outcome and covariates. All participants 
received a neuropsychological test battery, enabling us to investigate global cognitive function 
by the general cognitive factor. Lastly, we were able to investigate inflammation status using 
blood cell-based inflammatory ratios, which are low-cost and easy to use in the clinic. 
 Study limitations include the design by which we cannot disentangle the effects of cancer 
and cancer treatment on cognition and levels of inflammatory ratios. Some studies show 
that patients treated with chemotherapy have higher inflammatory ratios during and after 
treatment than chemotherapy-naïve patients.12 However, because inflammatory ratios and 
cognitive problems can already occur in newly diagnosed cancer patients, it is unlikely that 
inflammation is only important in chemotherapy-treated patients.5 Owing to the cross-sectional 
design, we do not have information about cognitive function and levels of inflammatory ratios 
before cancer diagnosis and treatment. Moreover, breast cancer patients nowadays receive 
chemotherapy regimens other than CMF, either with or without adjuvant endocrine therapy, 
limiting the generalisability to current breast cancer patients. However, cyclophosphamide 
and 5-fluoroacil are still frequently used in other regimens for adjuvant chemotherapy. 
Furthermore, we were not able to exclude individuals whose systemic inflammatory ratios 
may have been elevated due to acute infections and to control for acute-phase reactants such 
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as C-reactive protein, but we expect that this effect is similar for cancer survivors and non-
exposed participants. Lastly, we need to emphasise that by measuring the GLR, PLR, and SII, 
we cannot identify the exact phenotype of the underlying immune cell populations. Although 
these ratios are proven to be related to chronic systemic inflammation, it is unknown whether 
they also reflect higher levels of pro-inflammatory cytokines. In other words, we cannot confirm 
that observed shifts in the granulocytes, lymphocytes, and platelets cause higher cytokine 
levels and thereby are functional. To elucidate the exact immune cell populations involved in 
increases of the GLR, PLR, and SII, determination of different cytokines is needed.
 In conclusion, we found that breast cancer survivors who had been treated with 
chemotherapy on average more than twenty years ago have higher blood cell-based 
inflammatory ratios than women without a history of cancer. Higher levels of inflammatory 
ratios tended to be associated with poorer cognitive function in both cancer survivors and 
cancer-free women, and expression was stronger in breast cancer survivors. This finding 
suggests that inflammation could have a role in the pathogenesis of long-term cognitive 
impairment in cancer survivors. Further prospective studies are important to determine the 
causality of the association and to investigate the effects of lowering inflammation on the 
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Background Immunity has been suggested to be important in the pathogenesis of dementia. 
However, the contribution of innate versus adaptive immunity in the development of dementia 
is not clear. In this study, we aimed to investigate (i) the association between components of 
innate immunity (granulocytes and platelets) and adaptive immunity (lymphocytes) with risk 
of dementia; and (ii) the association between their derived ratios (granulocyte-to-lymphocyte 
ratio [GLR], platelet-to-lymphocyte ratio [PLR], and systemic immune-inflammation index 
[SII]), reflecting the balance between innate and adaptive immunity, with risk of dementia.
Methods Blood cell counts were measured repeatedly between 2002 and 2015 in dementia-
free participants of the prospective population-based Rotterdam Study. Participants were 
followed-up for dementia until January 1st, 2016. Joint models were used to determine the 
association between granulocyte, platelets, and lymphocyte counts, and their derived ratios 
with risk of dementia.
Results Of the 8313 participants (mean [standard deviation] age 61.1 [7.4] years, 56.9% 
women), 664 (8.0%) developed dementia during a median follow-up of 8.6 years. Doubling of 
granulocyte and platelet counts tended to be associated with an increased risk of dementia 
(hazard ratio [HR] for granulocytes = 1.22, [95% confidence interval [CI] = 0.89 to 1.67] and for 
platelets = 1.45 [1.07 to 1.95], respectively). Doubling of the derived ratios GLR, PLR, and SII 
was associated with an increased dementia risk (HR [95% CI] for GLR = 1.26 [1.03 to 1.53], 
for PLR = 1.27 [1.05 to 1.53], and for SII = 1.15 [0.98 to 1.34]).
Conclusions GLR, PLR, and SII are associated with an increased risk of dementia in the 
general population. This supports the role of an imbalance in the immune system towards 
innate immunity in the pathogenesis of dementia.
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INTRODUCTION
Dementia poses a huge burden on societies in terms of financial costs as well as on individual 
patients and their caregivers regarding suffering and grief.1 Dementia is a multifactorial 
disease, in which various pathologies interact during the long preclinical phase, ultimately 
resulting in its clinical manifestations of cognitive decline and loss of independence. While 
amyloid depositions, neuronal loss, and vascular damage have long been established as key 
pathologies underlying dementia,2 recent findings point towards a key role for the immune 
system.3-5 The immune system is a highly complex system involving multiple synergistic 
and antagonistic substrates, yet broadly can be classified into two components, i.e., innate 
immunity and adaptive immunity.6 Innate immunity refers to immune responses present at 
birth, forming a first line of defence, whereas adaptive immunity is acquired during life by 
exposure to specific antigens.7 High activity of innate immunity can lead to disrupted neuronal 
integrity and ultimately to cell death.8 Although these components of the immune system work 
closely together, adaptive immunity is considered to be more neuroprotective than innate 
immunity, presumably by stimulating phagocytosis of amyloid fibrils.9,10
 Exact quantification of these opposing components of the immune system is challenging 
and focus of ongoing research, but recent work from the field of cancer research has 
suggested that easily obtainable laboratory measurements may in fact capture their relative 
activity levels to a reliable degree.11 Measuring granulocytes, including the most abundant 
subtype neutrophils, and platelets provides important markers of the innate immunity, whereas 
measuring lymphocytes yields information on the adaptive immunity.12,13 Furthermore, 
combining these measurements into ratios, i.e., the neutrophil-to-lymphocyte ratio (NLR), 
platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), is thought 
to even better reflect the relative balance between innate and adaptive immunity.11,14-16 Previous 
work on the link between innate versus adaptive immunity and dementia has shown higher 
NLR and PLR in dementia patients than in healthy individuals.17-19 Yet, to really understand the 
role of the immune system in the risk of developing dementia, it is pivotal to study how these 
markers change during the preclinical phase of the disease. 
 We thus investigated the longitudinal association of markers of the innate versus adaptive 
immune system with the risk of dementia. The underlying hypothesis was that higher activity 
of the innate versus adaptive immune system would be associated with an increased risk of 
dementia. A further methodological novelty of our study was the use of joint modelling that 
enabled us to study the longitudinal evolution of the various markers during the preclinical 





The present study is embedded in the Rotterdam Study, a prospective population-based 
cohort study in Rotterdam, the Netherlands. The Rotterdam Study started in 1989 with 7983 
persons (response of 78%) aged 55 years and over and residing in the district Ommoord, a 
suburb of Rotterdam. This first subcohort (RS-I) was extended with a second subcohort (RS-
II) in 2000, consisting of 3011 persons (response of 67%) and with a third subcohort (RS-III) 
in 2006, composed of 3932 persons aged 45 years and over (response of 65%). The design 
of the Rotterdam Study has been described in detail previously.20 In brief, participants were 
examined in detail at study entry and at follow-up visits every three to six years. They were 
interviewed at home by a trained research nurse, followed by two visits at the research facility 
for additional interviewing, laboratory assessments, imaging, and physical examinations.
 The Rotterdam Study was approved by the Medical Ethics Committee of Erasmus Medical 
Centre and by the board of The Netherlands Ministry of Health, Welfare, and Sports. A written 
informed consent was obtained from all participants. 
 Laboratory tests for granulocytes, platelets, and lymphocytes were introduced from 
2002 onwards, corresponding with the following assessment rounds in the Rotterdam Study 
(baseline in this study): i.e., fourth round of RS-I, second round of RS-II, and first round of RS-
III, comprising 9994 participants. From these 9994 eligible participants, we excluded those 
without complete baseline blood measurements (n=1288). Of the remaining participants, 
we excluded those with a history of dementia (n=52), participants who were insufficiently 
screened for dementia (n=62), and those without informed consent to assess medical records 
during follow-up (n=39). Lastly, we excluded participants with missing apolipoprotein E (APOE) 
genotype (n=240), resulting in 8313 participants for analysis (flowchart of study population is 
presented in Figure 1).
Assessment of blood cell counts and their derived ratios 
Fasting blood samples were taken during each visit at the research centre with a maximum 
of three visits during follow-up. Full blood count measurements were performed using the 
COULTER® Ac·T diff2™ Haematology Analyser (Beckman Coulter, San Diego, California, 
USA) directly after blood sample drawn. Laboratory measurements included absolute 
granulocyte, platelet, and lymphocyte counts in 109 per litre. Since neutrophil counts were 
not available, we used granulocyte count as a reliable proxy given that these are the most 
abundant subtype of neutrophils.21,22
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Included participants for analysis
(n=8313)
Excluded (n=1681)
• No laboratory assessment at study baseline (n=1288)
• Prevalent dementia (n=52)
• Not sufficiently screened for dementia (n=62)
• No informed consent (n=39)
• Unknown APOE genotype (n=240)
Participants study baseline
(n=9994)
Figure 1 Flowchart participants for analysis association between blood cell counts and their 
derived ratios, and dementia.
APOE = apolipoprotein E.
 The granulocyte-to-lymphocyte ratio (GLR) and PLR were calculated as the ratio of 
granulocyte count to lymphocyte count, and as the ratio of platelet count to lymphocyte count, 
respectively. The SII was defined as platelet count times the GLR.
Assessment of dementia
Participants were screened for dementia at baseline and subsequent centre visits with the 
Mini-Mental State Examination and the Geriatric Mental Schedule organic level.23 Those with 
a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 underwent 
further investigation and informant interview, including the Cambridge Examination for Mental 
Disorders of the Elderly. The entire cohort was continuously under surveillance for dementia 
through electronic linkage of the study database with medical records from general practition-
ers and the regional institute for outpatient mental health care. Available information on clinical 
neuroimaging was used when required for diagnosis of dementia subtype. A consensus panel 
led by a consultant neurologist established the final diagnosis according to standard criteria 
for dementia (Diagnostic and Statistical Manual of Mental Disorders III-revised), Alzheimer’s 
disease (AD, National Institute of Neurological and Communicative Disorders and Stroke and 
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the Alzheimer’s Disease and Related Disorders Association), and vascular dementia (Nation-
al Institute of Neurological Disorders and Stroke and Association Internationale pour la Re-
cherché et l’Enseignement en Neurosciences). Follow-up until January 1st, 2016 was virtually 
complete (93.8% of potential person-years observed). 
Other measurements
We assessed education and smoking by interview. Educational level was classified into primary 
education, lower (lower general education, intermediate general education, or lower vocational 
education), intermediate (intermediate vocational education or higher general education), or 
higher (higher vocational education or university). Smoking status was categorised as never, 
former, or current smoker. Body mass index (BMI) was computed from measurements of 
height and weight (kg/m2). Diabetes mellitus was defined as use of antidiabetic medication, 
fasting serum glucose level ≥7.1 mmol/L, or random serum glucose level ≥11.1 mmol/L.24 
History of stroke was assessed by interview and verified by reviewing medical records.25 
APOE genotype was determined using polymerase chain reaction on coded DNA samples in 
RS-I and with a bi-allelic TaqMan assay in the two extensions (RS-II and RS-III).26,27 APOE ε4 
carrier status was defined as carrier of one or two APOE ε4 alleles.
Statistical analysis
We associated the different blood cell counts and their derived ratios with the risk of all-cause 
dementia using the framework of joint models for longitudinal and survival data. In this way, 
we are able to account for the endogenous nature (i.e., blood cell counts can be measured 
with error during follow-up and their values at any time point can be affected by an event 
occurring at an earlier time point) 28 and the correlations in the repeated measurements of 
granulocyte, platelet, and lymphocyte counts.29
 In order to normalise the skewed distribution of granulocyte, platelet, and lymphocyte 
counts, and their derived ratios, we used a natural logarithmic transformation. Hazard ratios 
(HRs) with 95% confidence intervals (CIs) were obtained from the joint models, using the 
piecewise-constant baseline hazard, and multiplied with log(2), providing a HR for doubling 
of the blood cell counts and their ratios. We computed two nested models: Model I was 
adjusted for baseline age (continuous, centred as age minus mean age) and sex; Model II 
was additionally adjusted for education, smoking status, BMI (continuous), diabetes mellitus, 
history of stroke, and APOE ε4 carrier status. For assessment of the association between 
the individual components of the ratios and dementia, we repeated analyses with adjustment 
for the baseline blood cell counts of the remaining two blood cell types (for instance, the 
association of granulocyte count with dementia was adjusted for platelet and lymphocyte 
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counts). Follow-up time was used as time scale and started at the first laboratory assessment 
until date of all-cause dementia diagnosis, death, loss to follow-up, or January 1st, 2016, 
whichever came first. Censoring participants at date of death allowed us to compute cause-
specific HRs.
 In sensitivity analyses, we repeated all analyses using age as time scale instead of follow-
up time to account for potential residual confounding by age and to minimise potential effects 
of left truncation. We additionally censored for stroke events during follow-up to preclude 
that the observed effect may be driven by incident strokes that occurred before dementia 
diagnosis. Moreover, we investigated the association between the ratios and AD or vascular 
dementia separately. Lastly, we explored effect modification by stratifying by median age, sex, 
smoking status, diabetes mellitus, and APOE ε4 carrier status. 
 Multiple imputation was used for missing covariates (maximum of 0.99%), with five imputed 
datasets based on other covariates and the outcome. Rubin’s method was used for pooled 
HRs and 95% CIs.30 Two-sided P<.05 was considered statistically significant. Statistical 
analyses were performed using the R packages ‘survival’, ‘nlme’, ‘JM’, and ‘JMbayes’ in 
RStudio Version 3.3.2.28,29,31,32
RESULTS
Characteristics of included and excluded study participants are presented in Table 1. An 
overview of the median blood cell counts and blood cell-based ratios per assessment round 
is shown in Supplementary Table 1. Mean age of included study participants was 61.1 years 
and 56.9% were women. During a median follow-up of 8.6 years (70 273 person-years), 664 
participants developed all-cause dementia (543 AD, 31 vascular dementia) with an incidence 
rate (95% CI) of 9.4 (8.7 to 10.2) per 1000 person-years. 
 Higher levels of granulocytes reflecting higher innate immunity were associated with an 
increased risk of dementia, but only after correcting for the platelet and lymphocyte counts 
(HR for doubling granulocyte count [95% CI] = 1.33 [0.99 to 1.79], Table 2). Doubling of 
platelets was associated with an increased risk of dementia (HR [95% CI] = 1.48 [1.11 to 
1.96]). Regarding adaptive immunity, higher levels of lymphocytes were associated with a 
decreased risk of dementia (HR for doubling lymphocyte count [95% CI] = 0.80 [0.64 to 0.99]).
 Higher levels of GLR, PLR, and SII were associated with an increased dementia risk (HR 
[95% CI] for doubling GLR = 1.34 [1.10 to 1.63], for PLR = 1.29 [1.08 to 1.55], and for SII = 
1.18 [1.02 to 1.39], respectively [Table 2]). Risk estimates were comparable when using the 
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Age, years, mean (SD) 61.1 (7.4) 72.6 (11.8) 61.7 (8.2)
Women, No. (%) 4729 (56.9) 845 (65.6) 160 (66.7)
Educational level, No. (%)
 Primary 908 (10.9) 233 (18.1) 25 (10.4)
 Lower 3329 (40.0) 537 (41.7) 95 (39.6)
 Intermediate 2429 (29.2) 336 (26.1) 57 (23.8)
 Higher 1588 (19.1) 161 (12.5) 37 (15.4)
Body mass index, kg/m2, mean (SD) 27.6 (4.3) 27.6 (4.5) 28.2 (4.8)
Smoking status, No. (%)
 Never 2479 (29.8) 403 (31.3) 70 (29.2)
 Former 4191 (50.4) 550 (42.7) 106 (44.2)
 Current 1595 (19.2) 308 (23.9) 57 (23.8)
Diabetes mellitus, No. (%) 501 (6.0) 136 (10.6) 15 (6.3)
History of stroke, No. (%) 305 (3.7) 54 (4.2) 11 (4.6)
APOE ε4 carrier, No. (%) 2328 (28.0) 244 (18.9)
Blood cell types, 109/L, median (IQR)
 Granulocytes 3.8 (3.1 to 4.7) 4.0 (3.2 to 4.9)
 Platelets 263 (223 to 307) 277 (232 to 319)
 Lymphocytes 2.2 (1.8 to 2.6) 2.3 (1.9 to 2.8)
Blood cell-based ratios, median (IQR)
 Granulocyte-to-lymphocyte ratio 1.7 (1.4 to 2.3) 1.7 (1.4 to 2.2)
 Platelet-to-lymphocyte ratio 120 (96 to 151) 119 (96 to 150)
 Systemic immune-inflammation index 455 (339 to 619) 473 (339 to 651)
Values are shown before multiple imputation and therefore not always add up to 100%.
* Excluded participants in this table only include those participants who were excluded due no complete 
blood measurements or unknown APOE ε4 carrier status.
APOE = apolipoprotein E, IQR = interquartile ratio, n = number of participants, SD = standard deviation.
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Table 2 Association between blood cell counts and derived ratios, and risk of all-cause 
dementia.






 Granulocytes 1.14 (0.87 to 1.50) 1.07 (0.80 to 1.43)
 Corrected for platelets and lymphocytes 1.33 (0.99 to 1.79) 1.22 (0.89 to 1.67)
 Platelets 1.48 (1.11 to 1.96) 1.43 (1.08 to 1.90)
 Corrected for granulocytes and lymphocytes 1.48 (1.10 to 2.00) 1.45 (1.07 to 1.95)
 Lymphocytes 0.80 (0.64 to 0.99) 0.81 (0.64 to 1.03)
 Corrected for granulocytes and platelets 0.76 (0.61 to 0.96) 0.78 (0.62 to 1.00)
Inflammatory ratios
 Granulocyte-to-lymphocyte ratio 1.34 (1.10 to 1.63) 1.26 (1.03 to 1.53)
 Platelet-to-lymphocyte ratio 1.29 (1.08 to 1.55) 1.27 (1.05 to 1.53)
 Systemic immune-inflammation index 1.18 (1.02 to 1.39) 1.15 (0.98 to 1.34)
Model I is adjusted for age and sex. Model II is adjusted for age, sex, education, smoking status, body 
mass index, diabetes mellitus, history of stroke, and APOE4 ε4 carrier status.
* All types of blood cells and their derived ratios were natural logarithmic transformed.
APOE = apolipoprotein E, CI = confidence interval, HR = hazard ratio, n = number of incident dementia 
events, N = number of participants for analysis.
  
adjusted model and when using age as time scale instead of follow-up time. 
 Censoring for stroke did not meaningfully change the risk estimates (Table 3). Higher 
levels of platelets showed a slightly stronger association with AD than with all-cause dementia, 
whilst the association with granulocytes was less pronounced for AD. Risk estimates for all-
cause dementia and AD were comparable for the ratios. For vascular dementia, risk estimates 
regarding the individual blood cell components and their derived ratios were more pronounced 
than for all-cause dementia, but small numbers led to wider confidence intervals (n=31).
 Stratified analyses showed that the association between the ratios and dementia was 
particularly pronounced in participants aged below the median age of 65.4 years, women, 
and non-smokers (Figure 2). However, formal interaction terms did not reach statistical 
significance. Also, no significant effect modification was observed across different strata of 
these variables for the association between granulocyte, platelet, and lymphocyte counts, and 
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Figure 2 Forest plots of the association of the granulocyte-to-lymphocyte ratio, platelet-to-
lymphocyte ratio, and systemic immune-inflammation index, and risk of dementia. 
Hazard ratios are shown in logarithmic scale with stratification by median age, sex, smoking status, 
diabetes mellitus, and APOE ε4 carrier status. 
APOE = apolipoprotein E, n = number of incident dementia events, N = number of participants for analysis.
DISCUSSION 
In this population-based study, we found that higher levels of granulocyte and platelet counts 
are related to an increased risk of dementia, whereas a higher lymphocyte count is associated 
with a decreased dementia risk. Furthermore, higher levels of their derived ratios, i.e., GLR, 
PLR, and SII are associated with an increased risk of all-cause dementia, including its subtype 
AD and even more with vascular dementia.
 Activation of the immune systems can result in inflammation by production of different 
cytokines.33 These cytokines can act as a link between the innate and the adaptive immune 
system, having pro- or anti-inflammatory effects depending on the type of cytokine.34 A recent 
meta-analysis of 175 studies has suggested that AD is accompanied by an inflammatory 
response and that this can be reflected by a variety of systemic cytokines, for instance 
interferon-γ, interleukin-2 (IL-2), and in particular IL-6, of which dysregulation has been 
associated with multiple chronic inflammatory diseases.35,36 It is now recognised that systemic 
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Figure 3 Forest plots of the association of granulocytes, platelets, and lymphocytes, and the risk 
of dementia. 
Hazard ratios are shown in logarithmic scale with stratification by median age, sex, smoking status, 
diabetes mellitus, and APOE ε4 carrier status. 
APOE = apolipoprotein E, n = number of incident dementia events, N = number of participants for analysis.
inflammation can trigger or exacerbate the inflammatory environment of the brain, thereby 
contributing to chronic neuro-inflammation and neurodegeneration.37 A plausible explanation 
for the occurrence of this chronic neuro-inflammation in (pre)demented individuals involves a 
disruption of a process called resolution.38 Resolution is an active process that halts the acute 
phase of inflammation and restores tissue homeostasis. The acute inflammatory phase is 
usually initiated in response to infection, neoplasia, tissue injury, or other major homeostatic 
stressors. This phase is accompanied by the increased release of pro-inflammatory mediators 
such as prostaglandins, leading to leukocyte recruitment. Normally, resolution would clear the 
recruited granulocytes.39 However, it has been shown that failure of resolution, induced by any 
chronic inflammatory state, is associated with an overactive innate immune system, resulting 
in the development of chronic inflammation, which could subsequently lead to AD.38,40,41 
Our finding that an increase in the granulocyte count, resulting in a higher GLR and SII, is 
associated with an increased risk of dementia could therefore support the role of insufficient 
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 HR (95% CI) HR (95% CI) HR (95% CI)
Blood cells
 Granulocytes 1.13 (0.83 to 1.56) 1.03 (0.75 to 1.42) 1.99 (0.52 to 7.55)
 Corrected for platelets and  
 lymphocytes 1.36 (0.96 to 1.93) 1.12 (0.79 to 1.58) 1.92 (0.44 to 8.41)
 Platelets 1.45 (1.07 to 1.96) 1.59 (1.17 to 2.17) 3.86 (1.02 to 14.6)
 Corrected for granulocytes and  
 lymphocytes 1.47 (1.07 to 2.02) 1.63 (1.18 to 2.27) 3.39 (0.84 to 13.7)
 Lymphocytes 0.80 (0.62 to 1.02) 0.85 (0.66 to 1.10) 0.76 (0.25 to 2.30)
 Corrected for granulocytes and  
 platelets 0.76 (0.58 to 0.98) 0.81 (0.62 to 1.06) 0.64 (0.20 to 2.03)
Inflammatory ratios
 Granulocyte-to-lymphocyte ratio 1.33 (1.07 to 1.65) 1.17 (0.95 to 1.46) 1.85 (0.74 to 4.62)
 Platelet-to-lymphocyte ratio 1.31 (1.07 to 1.60) 1.30 (1.06 to 1.60) 1.99 (0.82 to 4.81)
 Systemic immune-inflammation  
 index 1.19 (1.01 to 1.41) 1.15 (0.97 to 1.37) 1.77 (0.87 to 3.63)
Models are adjusted for age, sex, education, smoking status, body mass index, diabetes mellitus, history 
of stroke, and APOE4 ε4 carrier status.
* All types of blood cells and their derived ratios were natural logarithmic transformed. † Number of 
participants for analysis is 8313 minus participants with a history of stroke (n=305). 
APOE = apolipoprotein E, CI = confidence interval, HR = hazard ratio, n = number of incident dementia 
events, N = number of participants for analysis.
 Only few studies have examined the interplay between the innate and adaptive immunity 
by studying levels of these blood cell-based ratios in dementia patients. Two cross-sectional 
studies have shown that NLR and PLR were elevated in AD patients compared to dementia-
free controls.17,18 In contrast, a longitudinal study assessing the trajectory of NLR has found no 
difference in its longitudinal evolution between AD patients and dementia-free participants.19 
Although they have examined differences between AD patients and dementia-free controls, 
they did not investigate the risk of developing dementia in dementia-free participants in relation 
to their levels of NLR. In the present study, we did take the time until dementia into account by 
a joint modelling approach and were therefore able to assess the risk of dementia in relation 
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to the change in blood cell counts and their derived ratios.
 Interestingly, recent evidence has shown that the NLR and PLR are partly genetically 
determined with 36% estimated heritability for NLR and 64% for PLR in a healthy population.42 
Moreover, different single nucleotide polymorphisms (SNPs) identified through genome-wide 
association study (GWAS) were significantly related to the PLR phenotype, but not to NLR.43 
Importantly, some but not all of these SNPs were also related to platelets, indicating that these 
SNPs capture the interplay between platelets and lymphocytes. Thus far, no GWAS for SII has 
been performed. Exploring the dementia risk by genetically predicted blood cell-based ratios 
may provide more insight in the causal role of immunity in dementia. 
  Strengths of our study include the population-based setting and the thorough follow-up for 
dementia. Another strength is the prospective design of this study, with the blood cell counts 
being measured at multiple time points. Using an innovative statistical method, we combined 
these repeated measurements with dementia as survival outcome. Moreover, we used blood 
cell counts and their derived ratios, which are low-cost and easy to implement in the clinic 
and other research settings. Although these ratios are proven to be associated with chronic 
systemic inflammation, we need to emphasise that it is unknown whether higher levels of 
GLR, PLR, and SII are functional and cause higher levels of pro-inflammatory cytokines. To 
identify the actual involved immune cell populations determination of different cytokines is 
still needed. In addition, the innate and adaptive immune systems are overlapping, making it 
difficult to completely distinguish their separate effects. Also, we used the granulocyte count 
as proxy for the neutrophil count. Although the relative proportion of neutrophils compared 
to eosinophils and basophils may be lower in persons with several specific diseases such 
as parasitic infections, asthma, or immune diseases, neutrophils are generally the most 
important subtype of granulocytes. If anything, misclassification of the granulocytes would be 
non-differential and would therefore lead to underestimation of the estimates.11 In addition, we 
cannot rule out reversed causality, i.e., that dementia is subclinical at time of the laboratory 
assessments and causes higher levels of GLR, PLR, and SII. Lastly, we did not have the 
power to study other neurodegenerative diseases beyond dementia, such as Parkinson’s 
disease or amyotrophic lateral sclerosis. It would be interesting for future studies to also 
investigate the relation between inflammation and these diseases.
 In conclusion, higher levels of the ratios GLR, PLR, and SII are associated with an 
increased risk of developing dementia in the general population. Higher activation of the 
innate immune system reflected by higher levels of granulocytes and platelets is associated 
with an increased dementia risk, while the adaptive immune system is suggested to be more 
neuroprotective. These findings support the role of dysregulation of the immune systems in 
the pathogenesis of dementia. Further studies are warranted to assess during which phase of 
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the pathogenesis of dementia immunity is involved and to assess causality in order to develop 
prevention and therapeutic strategies.
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SUPPLEMENTARY MATERIAL
Supplementary Table 1 Overview of median blood cell counts and blood cell-based ratios 











Blood cell types, 109/L, median 
(IQR)
 Granulocytes 3.8 (1.6) 4.0 (1.6) 3.6 (1.5)
 Platelets 263 (84) 262 (83) 224 (75)
 Lymphocytes 2.2 (0.8) 2.2 (0.8) 1.9 (0.9)
Blood cell-based ratios, median 
(IQR)
 Granulocyte-to-lymphocyte 
 ratio 1.7 (0.9) 1.8 (0.9) 1.9 (1.1)
 Platelet-to-lymphocyte ratio 120 (55) 116 (53) 117 (59.1)
 Systemic immune- 
 inflammation index 455 (280) 461 (283) 421 (290)
* The first measurement corresponds with the fourth round of RS-I, second round of RS-II, and first round 
of RS-III. † The second measurement corresponds with the fifth round of RS-I, third round of RS-II, and 
second round of RS-III. ‡ The third measurement corresponds with the sixth round of RS-I and the fourth 
round of RS-II.
IQR = interquartile ratio, N = number of participants, RS = Rotterdam Study.
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Background Atherosclerosis and cancer share multiple disease pathways. Yet, it is unclear 
if atherosclerosis is associated with a subsequent higher cancer risk. We determined 
the association of atherosclerotic calcification in the aortic arch, as proxy for systemic 
atherosclerosis, with the risk of cancer.
Methods Between 2003 and 2006, 2404 participants (mean age: 69.5 years, 52.5% women) 
from the prospective population-based Rotterdam Study underwent computed tomography 
to quantify calcification in the aortic arch. Participants were followed for the onset of cancer, 
death, loss to follow-up, or January 1st, 2015, whichever came first. We computed sex-specific 
tertiles of aortic arch calcification volumes. Next, we examined the association between the 
volume and severity (i.e., tertiles) of aortic arch calcification and the risk of cancer using Cox 
proportional hazards models. 
Results During a median (interquartile range) follow-up of 9.6 years (8.9 to 10.5), 348 participants 
were diagnosed with cancer. Participants with the greatest severity of aortic arch calcification 
had a higher risk of cancer (hazard ratio [95% confidence interval] for the third tertile compared 
to the first tertile of aortic arch calcification volume in the total population is 1.39 [1.04 to 1.86]). 
Conclusions Individuals with the most severe aortic arch calcification had a higher risk of 
cancer. While this could reflect the impact of long-term exposure to shared risk factors, it might 
also point towards the co-occurrence of both conditions.
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INTRODUCTION
Cardiovascular diseases and cancer remain the leading causes of morbidity and mortality 
worldwide.1,2 Several studies have shown that patients with cancer are at higher risk of 
developing cardiovascular disease.3,4 This may be due to a cancer-induced hypercoagulable 
state,5 or as a consequence of the detrimental effects of cancer treatment on the 
vascular system.4,6,7 Additionally, it has also been proposed that atherosclerosis, the most 
important underlying condition of cardiovascular events, and cancer may share a common 
pathophysiology.8 
 Common risk factors such as age, smoking, obesity, and genetic susceptibility are known to 
contribute to the risk of both atherosclerosis and cancer. Specific molecular pathways leading 
to atherosclerosis, including inflammation, oxidative stress, and uncontrolled cell proliferation, 
are also involved in the pathogenesis of cancer.9,10 As such, both diseases are likely to co-
occur. Although many studies have focused on the presence of atherosclerosis after cancer 
diagnosis, less is known about the presence and extent of atherosclerosis before cancer 
manifestation. This is of particular interest, since the first atherosclerotic lesions may already 
develop during infancy.11 Understanding the sequence and timing between these potentially 
interconnected diseases is pivotal as it may help to identify high-risk patients and to develop 
preventive strategies for both diseases. 
 Due to the central anatomical location in the arterial system, the presence and amount 
of atherosclerosis in the aortic arch may provide an easy measurable proxy of the systemic 
burden of atherosclerosis within an individual. As such, aortic arch atherosclerosis has 
repeatedly been linked to mortality, in particular also of non-cardiovascular origin, of which 
cancer represents a substantial part.12,13 Hence, to further investigate the link between 
atherosclerosis and cancer, we determined the association between aortic arch calcification 
– as proxy for systemic atherosclerosis – with the subsequent risk of cancer within the setting 





This study is embedded within the Rotterdam Study, a prospective population-based cohort 
study that investigates determinants and occurrence of chronic diseases in the middle-aged 
and elderly population. The design of the Rotterdam Study has been described in detail 
previously.14 At study entry, all participants were interviewed at home by a trained research 
assistant, followed by two visits to the research facility to undergo different examinations 
including laboratory assessments and imaging. Follow-up examinations take place every 
three to six years. 
Study population
For the present study, we used the follow-up visit between 2003 and 2006 as baseline, because 
during this period, participants who visited the research centre were invited to undergo non-
contrast multi-detector computed tomography (MDCT) scanning of the aortic arch as part of 
a project of visualising arterial calcification.15 We scanned 2524 participants (response rate, 
78%). Out of 2524 scans, six scans were ungradable for aortic arch calcification because of the 
presence of image artefacts, leaving a total of 2518 complete examinations with information 
on calcification. We excluded participants with a history of cancer (n=114), resulting in 2404 
participants for analysis. The follow-up for cancer took place continuously and was completed 
for this study until January 1st, 2015.
 The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus 
MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and 
Sport (Population Screening Act WBO, license number 1071272-159521-PG). The Rotterdam 
Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.
nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/
network/primary/en/) under shared catalogue number NTR6831. All participants provided 
written informed consent to participate in the study and to have their information obtained 
from treating physicians.
Assessment of aortic arch calcification
We used a 16-slice or 64-slice MDCT scanner (Somatom Sensation 16 or 64; Siemens, 
Forchheim, Germany) to perform non-contrast CT scanning. We scanned the aortic arch using 
an extra-cardiac scan that reached from the aortic arch to the intracranial vasculature (1 cm 
above the sella turcica). Detailed information on both scans is provided elsewhere.16,17 As proxy 
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of aortic arch atherosclerosis, we quantified aortic arch calcification on the extra-cardiac scan 
by including all calcification from the origin of the aortic arch (defined as the image in which the 
ascending and descending aorta merge into the inner curvature of the aortic arch) to the first 1 cm 
of the branches originating from the arch.18 Calcification volumes were calculated using dedicated 
software (Syngo Calcium Scoring; Siemens, Forchheim, Germany) and were expressed in mm3. 
 
Assessment of cancer
Diagnoses of cancer were based on medical records of general practitioners (including 
hospital discharge letters) and through linkage with Dutch Hospital Data, the Netherlands 
Cancer Registry, and histology and cytopathology registries in the region. Incident cancer 
was defined as any primary malignant tumour, excluding non-melanoma skin cancer. Only 
pathology-confirmed cancers were included in analysis to exclude the possibility of false-
positive cancer diagnoses. Diagnoses were coded independently by two physicians according 
to the International Classification of Diseases, tenth revision (ICD-10). In case of discrepancy, 
consensus was sought through consultation with a physician specialised in internal medicine. 
Date of diagnosis was based on date of biopsy (solid tumours) and laboratory assessment 
(haematological tumours), or – if unavailable – date of hospital admission or discharge letter. 
Follow-up of cancer registration was complete until January 1st, 2015. 
 
Measurement of covariates
Information on educational level, smoking behaviour, and use of antidiabetic-, antihypertensive-, 
lipid-lowering-, and antithrombotic medication was obtained by trained interviewers. 
Educational level was classified into primary education, lower education (lower or intermediate 
general education, or lower vocational education), intermediate (intermediate vocational 
education or higher general education), or higher (higher vocational education or university). 
Smoking status was categorised as never, current, or former. At the research centre, height 
and weight were measured from which the body mass index (BMI, kg/m2) was computed. In 
addition, systolic and diastolic blood pressures were measured twice on the right arm with a 
random-zero sphygmomanometer of which the mean was used for analyses. Hypertension 
was defined as a systolic blood pressure of ≥140 mm Hg, a diastolic blood pressure of ≥90 
mm Hg, or use of antihypertensive medication.19 Hypercholesterolaemia was defined as 
use of lipid-lowering medication or serum total cholesterol >6.5 mmol/L. Diabetes mellitus 
was defined as use of antidiabetic medication, fasting serum glucose level ≥7.1 mmol/L, or 
random serum glucose level ≥11.1 mmol/L.20 We defined history of cardiovascular disease 
as history of myocardial infarction, stroke, percutaneous transluminal coronary angioplasty, 
or coronary artery bypass graft.21-23 Granulocyte count was measured using the COULTER® 
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Ac·T diff2™ Haematology Analyser (Beckman Coulter, San Diego, California, USA). 
 
Statistical analysis
Considering the skewed distribution of aortic arch calcification volumes, we performed a 
natural log-transformation and added 1 mm3 to each non-transformed volume to deal with 
calcium scores of 0 (Ln[calcification volume+1.00mm3]). First, we used Cox proportional 
hazards models to determine the association between aortic arch calcification (per 1-standard 
deviation [SD] increase) and the subsequent risk of cancer. Model I was adjusted for age at 
MDCT scan and sex. To investigate to which extent any association would be driven by shared 
risk factors, Model II was additionally adjusted for shared risk factors including educational 
level, smoking status, BMI, hypertension,24 hypercholesterolaemia,25 diabetes mellitus, history 
of cardiovascular disease, and granulocyte count. We chose to use granulocyte count as 
markers of inflammation, since these blood cells in particular are related to larger volumes of 
arterial calcification.26 
 Second, we computed tertiles of calcification severity and investigated associations with 
the risk of cancer, using the same two Cox proportional hazards models as described above 
and using the first tertile as reference category. As calcification volumes were larger in men 
than in women, the tertiles were computed sex-specifically. Also, considering differences in 
risk factors for atherosclerosis and cancer between men and women,27 we performed analyses 
stratified by sex. 
 For all Cox proportional hazards models, follow-up time was used as time scale and 
started at date of MDCT scan until date of incident cancer, death, loss to follow-up, or January 
1st, 2015, whichever came first. Censoring unexposed participants at date of death allowed 
us to compute cause-specific hazard ratios (HRs). The proportional hazards assumption was 
met for all analyses (Schoenfeld residuals test, all P-values >.05).
 To explore the robustness of our findings, we performed several sensitivity analyses 
to assess potential bias associated with mortality given the strong association between 
atherosclerosis and mortality.13 First, we restricted the analyses to shorter follow-up periods 
to limit the number of mortality events. To this end, participants with longer follow-up duration 
were censored at respectively two, three, four, and five years after the MDCT-scan. Second, 
we repeated the continuous analyses for the most common cancer types, i.e., breast 
cancer (among women), prostate cancer (among men), colorectal cancer, and lung cancer. 
Third, we stratified analyses by use of lipid-lowering and antithrombotic medication, and by 
median granulocyte count. In addition, we formally tested interaction by adding multiplicative 
interaction terms to the model. 
 To account for missing data of covariates (maximum amount of missing data: 5.9%) we 
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used multiple imputation (n=five imputations) by chained equations along with age, sex, 
calcification volumes, cardiovascular risk factors, and cancer incidence. Statistical analyses 
were performed using STATA v.15 (StataCorp).
RESULTS
Characteristics of participants at time of MDCT scan are presented in Table 1. In addition, 
population characteristics stratified by tertiles of aortic arch calcification volumes are shown in 
Supplementary Table 1. The mean (SD) age was 69.5 years (6.8) and 52.5% were women. 
Among participants in the highest tertile of aortic arch calcification, a higher prevalence of 
cardiovascular risk factors was observed than in participants in the lowest tertile. During a 
median (interquartile range) follow-up of 9.6 years (8.9 to 10.5), 348 out of 2404 participants 
were diagnosed with cancer, and 463 participants died. The most frequently diagnosed cancer 
types were prostate (39.2% among men), breast (34.4% among women), colorectal (16.1% 
overall), and lung (11.5% overall). 
 We found no statistically significant association between continuous volumes of aortic 
arch calcification and the risk of cancer (Table 2). When investigating tertiles of calcification, 
we found that severe calcification was associated with a higher risk of cancer in the total 
population and in men (adjusted HR [95% confidence interval [CI]] for the third tertile compared 
to the first tertile of aortic arch calcification in total population = 1.39 [1.04 to 1.86] and in men 
= 1.44 [1.00 to 2.09]). This association was also observed in women, albeit not statistically 
significant (HR = 1.33 [95%CI = 0.83 to 2.13]). Effect estimates were slightly attenuated when 
we corrected for different cardiovascular risk factors. 
 When censoring participants with a follow-up duration longer than two years, we found 
that effect estimates were higher for both continuous aortic arch calcification volume as well 
as for severe calcification, albeit not statistically significant (adjusted HR [95%CI] per 1-SD 
increase in aortic calcification = 1.24 [0.90 to 1.71], and adjusted HR [95%CI] for the third 
tertile compared to the first tertile of aortic arch calcification = 1.53 [0.75 to 2.13]). The effect 
estimates decreased with inclusion of longer follow-up duration (Table 3). 
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Age, years, mean (SD) 69.5 (6.8) 69.6 (6.6) 69.5 (6.9)
Educational level, No. (%)
 Primary 198 (8.2) 70 (6.1) 128 (10.2)
 Lower 1023 (42.6) 298 (26.1) 725 (57.5)
 Intermediate 737 (30.7) 444 (38.8) 293 (23.2)
 Higher 446 (18.6) 331 (29.0) 115 (9.1)
Body mass index, kg/m2, mean 
(SD) 27.7 (4.1) 27.4(3.5) 27.9 (4.5)
Smoking, No. (%)
 Never 687 (28.6) 157 (13.7) 530 (42.0)
 Former 1339 (55.7) 777 (68.0) 562 (44.6)
 Current 378 (15.7) 209 (18.3) 169 (13.4)
Hypertension, No. (%) 1800 (74.9) 860 (75.2) 940 (74.5)
Hypercholesterolaemia, No. 
(%) 1017 (42.3) 422 (36.9) 595 (47.2)
Lipid-lowering medication use, 
No. (%) 598 (24.9) 292 (25.5) 306 (24.3)
Antithrombotic medication use, 
No. (%) 591 (24.6) 349 (30.5) 242 (19.2)
Diabetes mellitus, No. (%) 328 (13.6) 170 (14.9) 158 (12.5)
History of cardiovascular 
disease, No. (%) 296 (12.3) 204 (17.8) 92 (7.3)
Granulocyte count, median 
(IQR) 3.8 (3.0 to 4.6) 4.0 (3.2 to 4.8) 3.6 (2.9 to 4.4)
Aortic arch calcification mm3, 
median (IQR) 263.8 (46.5 to 883.2) 296.9 (52.9 to 1009.5) 228.5 (41.8 to 825.0)
Characteristics were measured at time of MDCT-scan. Numbers are shown after multiple imputation. 
IQR = interquartile range, SD = standard deviation.
 Regarding specific cancer types, we found that among women, aortic arch calcification 
was associated with a lower risk of breast cancer (HR [95%CI] per 1-SD increase in aortic arch 
calcification = 0.71 [0.52 to 0.98]) and with a higher risk of lung cancer in the total population 
(HR [95% CI] = 2.35 [1.39 to 3.96], Table 4).
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Table 2 The association between aortic arch calcification and the risk of cancer.
Aortic arch calcification Risk of cancer
n/N Model IHR (95% CI)
Model II
HR (95% CI)
Total population Per 1-SD increase* 348/2404 1.12 (0.99 to 1.27) 1.09 (0.96 to 1.24)
Tertiles
T1 107/802 1.00 1.00
T2 98/801 0.91 (0.69 to 1.20) 0.89 (0.67 to 1.18)
T3 143/801 1.48 (1.12 to 1.95) 1.39 (1.04 to 1.86)
Women Per 1-SD increase* 131/1261 1.10 (0.90 to 1.33) 1.05 (0.88 to 1.28)
Tertiles
T1 41/421 1.00 1.00
T2 35/420 0.85 (0.54 to 1.34) 0.82 (0.52 to 1.30)
T3 55/420 1.45 (0.93 to 2.27) 1.33 (0.83 to 2.13)
Men Per 1-SD increase* 217/1143 1.14 (0.97 to 1.33) 1.12 (0.96 to 1.32)
Tertiles
T1 66/381 1.00 1.00
T2 63/381 0.95 (0.67 to 1.35) 0.94 (0.66 to 1.34)
T3 88/381 1.49 (1.04 to 2.12) 1.44 (1.00 to 2.09)
Hazard ratios in Model I are adjusted for age (and sex in the total population). Hazard ratios in Model 
II are adjusted for covariates in Model I plus adjustment for education, smoking status, body mass 
index, hypertension, hypercholesterolaemia, diabetes mellitus, history of cardiovascular disease, and 
granulocyte count. 
*Ln(calcification volume+1 mm3)−transformed volumes.
CI = confidence interval, HR = hazard ratio, n = number of participants with incident cancer, N = total 
number for participants, SD = standard deviation, T = tertile.
 No effect modification was observed by lipid-lowering and antithrombotic medication use 
and by median granulocyte count. All interactions were tested on the multiplicative scale and 
did not reach statistical significance (P>0.05).
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Table 3 The association between aortic arch calcification and the risk of cancer while censoring 
at different time-points. 
Aortic arch calcification Risk of cancer
n/N Model IHR (95% CI)
Model II
HR (95% CI)
Restricted to two 
years of follow-up
Per 1-SD increase* 62/2404 1.25 (0.92 to 1.70) 1.24 (0.90 to 1.71)
Tertiles
T1 1.00 1.00
T2 1.15 (0.59 to 2.27) 1.13 (0.57 to 2.24)
T3 1.59 (0.80 to 3.15) 1.53 (0.75 to 2.13)
Restricted to three 
years of follow-up
Per 1-SD increase* 103/2404 1.13 (0.90 to 1.43) 1.12 (0.88 to 1.42)
Tertiles
T1 1.00 1.00
T2 1.02 (0.60 to 1.72) 1.01 (0.60 to 1.72)
T3 1.45 (0.86 to 2.46) 1.43 (0.83 to 2.47)
Restricted to four 
years of follow-up
Per 1-SD increase* 137/2404 1.04 (0.86 to 1.27) 1.04 (0.85 to 1.27)
Tertiles
T1 1.00 1.00
T2 0.83 (0.53 to 1.29) 0.82 (0.53 to 1.28)
T3 1.08 (0.69 to 1.69) 1.06 (0.67 to 1.69)
Restricted to five 
years of follow-up 
Per 1-SD increase* 183/2404 1.02 (0.87 to 1.20) 1.02 (0.87 to 1.21)
Tertiles
T1 1.00 1.00
T2 0.80 (0.55 to 1.17) 0.81 (0.55 to 1.18)
T3 1.11 (0.75 to 1.62) 1.11 (0.74 to 1.65)
Hazard ratios in Model I are adjusted for age (and sex in the total population). Hazard ratios in Model 
II are adjusted for covariates in Model I plus adjustment for education, smoking status, body mass 
index, hypertension, hypercholesterolaemia, diabetes mellitus, history of cardiovascular disease, and 
granulocyte count. 
*Ln(calcification volume+1 mm3)−transformed volumes.
CI = confidence interval, HR = hazard ratio, n = number of participants with incident cancer, N = total 
number for participants, SD = standard deviation, T = tertile. 
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Table 4 The association between aortic arch calcification and the risk of different 
cancer types.
Risk of cancer
n/N Model IHR (95% CI)*
Model II
HR (95% CI)*
Breast cancer 45/1261 0.75 (0.55 to 1.00) 0.71 (0.52 to 0.98)
Prostate cancer 72/1143 1.08 (0.82 to 1.39) 1.07 (0.81 to 1.40)
Colorectal cancer 56/2404 1.18 (0.86 to 1.63) 1.04 (0.76 to 1.43)
Lung cancer 40/2404 2.87 (1.72 to 4.78) 2.35 (1.39 to 3.96)
Hazard ratios in Model I are adjusted for age. Hazard ratios in Model II are adjusted for covariates in Model 
I plus adjustment for education, smoking status, body mass index, hypertension, hypercholesterolaemia, 
diabetes mellitus, history of cardiovascular disease, and granulocyte count. 
* HR is expressed per 1SD increase in aortic arch calcification volume. Volumes were transformed as 
Ln(calcification volume+1 mm3).
CI = confidence interval, HR = hazard ratio, n = number of participants with incident cancer, N = total 
number for participants, SD = standard deviation. 
DISCUSSION
In this population-based study, we found that only individuals with the most severe aortic arch 
calcification had a higher risk of cancer, in particular in the short term. 
 It has previously been shown that atherosclerosis and cardiovascular events occur after 
cancer diagnosis potentially as a result of cancer itself – by inducing a hypercoagulable state – 
and cancer treatment. Based on the shared risk factors and pathophysiology, we hypothesised 
that atherosclerosis is also associated with a subsequent higher risk of cancer and that the 
strength of this association would diminish after adjustment for shared risk factors. When 
investigating the association between the amount of aortic arch calcification and the risk of 
cancer, we found only a slightly higher risk, which was not statistically significant. However, 
when targeting the group of individuals in the highest tertile of calcification, we found 39% 
increase of the risk of cancer compared to those with the lowest tertile. Further investigation 
of this association demonstrated that the effect of atherosclerosis on cancer seems to be 
largest in the short term (during the first two years of follow-up). Although this indicates that 
severe atherosclerosis may be present before cancer diagnosis, it might also reflect reverse 
causation. It is possible that subclinical cancer development already influences the course of 
atherosclerosis. Since both atherosclerosis and cancer are conditions with a long preclinical 
phase, we cannot prove causality, nor can we rule out reverse causation.
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 Overall, we found no prominent differences in the association between atherosclerosis 
and cancer before and after adjustment for cardiovascular risk factors. This suggests that 
overall, traditional cardiovascular risk factors do not fully explain potential co-occurrence of 
atherosclerosis and cancer. This could point towards other factors, such as genetic variation 
or exogenous factors that may explain the differential susceptibility to either atherosclerosis 
or cancer. However, exposure to shared risk factors might explain the higher risk of cancer in 
those individuals with the most severe aortic arch calcification and the strong association with 
lung cancer. It is likely that individuals who have been exposed to shared risk factors for a long 
period, and in high amounts, have both the largest volumes of aortic arch calcification and the 
highest risk of cancer. This suggests that the co-occurring deterioration of atherosclerosis and 
development of cancer is due to long and severe exposure to risk factors. However, also in 
these individuals, the size of the effects estimates only slightly diminished after correction for 
shared risk factors.
 Sex differences – reflected by differences in hormonal levels – may also influence the apparent 
different impact of shared risk factors on the development of atherosclerosis and cancer. Aortic 
arch calcification was associated with a lower risk of breast cancer in women. It has previously 
been proposed that an inverse association between aortic atherosclerosis and cancer holds in 
particular for cancers that are hormone-dependent or highly affected by genetics rather than 
for those caused by exogenous factors.28 Also, aortic arch calcification in particular is strongly 
associated with mortality, indicating that the inverse relation between aortic arch calcification and 
cancer may partly be due to residual survival bias.13 More in-depth inquiry on this topic is required. 
 Several strengths of our study are worth mentioning. Our study is a large prospective 
population-based study and therefore less vulnerable to selection and information bias than 
retrospective ones. In addition, we have prospective and unbiased collection of many risk 
factors which are not available in healthcare databases. All cancers were pathology proven, 
which excludes the chance of misclassification. Also, we had an image-based assessment of 
calcification volumes and standardised ascertainment of cancer incidence. 
 Yet, some potential limitations need to be addressed. First, despite sufficient power to 
detect a large effect size of 1.5 for all-cancers (α= 0.05, β= 0.80), we acknowledge the lack 
of statistical power to elaborate on specific cancer types. Second, strong associations of 
atherosclerosis with the risk of cardiovascular events and mortality may have weakened any 
potential association of atherosclerosis with cancer. Nevertheless, our finding that the most 
severe aortic calcification is associated with a higher risk of cancer – while these persons 
have the highest risk of mortality – might indicate that the effect of survival is limited. Third, the 
burden of atherosclerosis may influence the prognosis and course of cancer rather than the 
development itself. Ideally, measures of atherosclerosis at multiple time points are needed to 
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also assess changes in atherosclerotic burden before cancer diagnosis. Future studies are 
needed to unravel differences in the aetiology between atherosclerosis and cancer explained 
by other factors such as genetic and exogenous factors. Lastly, calcification is only a part 
of the atherosclerotic plaque. Non-calcified parts of the plaques cannot be visualised with 
non-enhanced CT. Nevertheless, it has been shown that calcification volume is an adequate 
measure for the total underlying plaque burden.29 
 We found that only individuals with the most severe aortic arch calcification had a higher 
risk of cancer, potentially through long-term parallel exposure to shared risk factors. Other 
factors, such as genetic variation or exogenous factors, may further explain susceptibility to 
either atherosclerosis or cancer.
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Table 1 Characteristics of the study population stratified by tertiles of aortic arch calcification 
volumes.
Characteristic Tertile 1 Tertile 2 Tertile 3
Age, years, mean (SD) 66.1 (4.8) 69.1 (6.0) 73.4 (7.2)
Educational level, No. (%)
 Primary 32 ( 4.0) 56 (7.0) 110 (13.7)
 Lower 348 (43.4) 329 (41.1) 346 (43.2)
 Intermediate 237 (29.6) 270 (33.7) 230 (28.7)
 Higher 185 (23.1) 146 (18.2) 115 (14.4)
Body mass index, kg/m2, 
mean (SD) 27.6 (3.9) 27.8 (4.0) 27.7 (4.3)
Smoking, No. (%)
 Never 279 (34.8) 239 (29.8) 169 (21.1)
 Former 425 (53.0) 445 (55.6) 469 (58.6)
 Current 98 (12.2) 117 (14.6) 163 (20.3)
Hypertension, No. (%) 520 (64.8) 599 (74.8) 681 (85.0)
Hypercholesterolaemia, No. 
(%) 284 (35.4) 348 (43.4) 385 (48.1)
Lipid-lowering medication 
use, No. (%) 140 (17.5) 202 (25.2) 256 (32.0)
Antithrombotic medication 
use, No. (%) 113 (14.1) 183 (22.8) 295 (36.8)
Diabetes mellitus, No. (%) 84 (10.5) 105 (13.1) 139 (17.4)
History of cardiovascular 
disease, No. (%) 45 ( 5.6) 82 (10.2) 169 (21.1)
Granulocyte count, median 
(IQR) 3.6 (2.9 to 4.4) 3.7 (3.0 to 4.6) 4.0 (3.2 to 4.9)
Aortic arch calcification, mm3, 
median (IQR) 15.9 (0.6 to 46.6) 263.9 (161.0 to 389.4) 1356.2 (884.4 to 2491.9)
Characteristics are measured at time of MDCT-scan. Numbers are shown after multiple imputation. 




Long-term effects of adjuvant treatment for breast cancer on carotid 
plaques and brain perfusion 
Koppelmans V, van der Willik KD, Aleman BMP, van Leeuwen FE, 




Background Breast cancer treatment has been associated with vascular pathology. It is 
unclear if such treatment is also associated with long-term cerebrovascular changes. We 
studied the association between radiotherapy and chemotherapy with carotid pathology and 
brain perfusion in breast cancer survivors. 
Methods We included 173 breast cancer survivors exposed to radiotherapy and chemotherapy, 
assessed on average 21.2 years after cancer diagnosis, and 346 age-matched cancer-free 
women (1:2) selected from the population-based Rotterdam Study. Outcome measures were 
carotid plaque score, intima-media thickness (IMT), total cerebral blood flow (tCBF), and brain 
perfusion. Additionally, we investigated the association between inclusion of the carotid artery 
in the radiation field (no, small, or large part), tumour location, and these outcome measures 
within cancer survivors. 
Results No statistically significant differences were observed between cancer survivors and 
cancer-free women regarding plaque score or IMT. Cancer survivors had lower tCBF (-19.6 
mL/min, 95% confidence interval [CI] = -37.3 to -1.9) and brain perfusion (-2.5 mL/min per 100 
mL, 95% CI = -4.3 to -0.7) than cancer-free women. Among cancer survivors, a large versus 
a small part of the carotid artery in the radiation field was associated with a higher IMT (0.05, 
95% CI = 0.01 to 0.09). Also, survivors with a right-sided tumour had lower left carotid plaque 
score (-0.31, 95% CI = -0.60 to -0.02) and higher brain perfusion (3.5 mL/min per 100 mL, 
95% CI = 0.7 to 6.2) than those with a left-sided tumour.
Conclusions On average two decades post-diagnosis, breast cancer survivors had lower 
tCBF and brain perfusion than cancer-free women. Also, survivors with a larger area of the 
carotid artery within the radiation field had a larger IMT. Future studies should confirm if these 
cerebrovascular changes underlie the frequently observed cognitive problems in cancer 
survivors.
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INTRODUCTION
Breast cancer patients are at an increased risk of developing cardiovascular diseases due 
to effects of cancer treatment on the vascular system.1-3 Adjuvant chemotherapy has been 
associated with vascular damage,4 specifically with narrowing of the vascular lumen as a 
result of thickening of the vessel wall through endothelial damage.5 In addition, it has been 
related to cardiotoxicity through injury of cardiac myocytes and antimetabolites, which is 
associated with myocardial ischemia.6 Adjuvant radiotherapy for breast cancer has also been 
linked to vascular pathology,7 including carotid stenosis,8,9 and carotid stiffness,10 as well 
as to an increased risk of stroke.11 In addition, breast cancer patients may have a higher 
risk of congestive heart failure and myocardial infarction that can persist up to twenty years 
after treatment.3,12-14 However, the synergistic effects of chemotherapy and radiotherapy on 
vascular pathology in breast cancer patients that may arise due to accumulation of vascular 
damage remain largely unknown.
 Cardiovascular diseases including carotid pathology can result in changes in total cerebral 
blood flow (tCBF).15 In turn, a preclinical study has shown that disrupted tCBF in mice can 
lead to cognitive deficits16 and lower tCBF has been associated with accelerated cognitive 
decline and dementia in humans.17 As yet, it is unknown if the potential cardiovascular side 
effects of breast cancer itself and breast cancer treatment are associated with disruptions in 
tCBF and therefore with brain perfusion. Such knowledge is of particular interest, because it 
could contribute to the understanding of the well-documented brain structural alterations and 
cognitive deficits that are prevalent in about 20% to 30% of cancer survivors.18 
 We have previously shown that such structural brain alterations including reductions in total 
brain volume and grey matter volume, and cognitive deficits can occur up to twenty years after 
cessation of cancer treatment in breast cancer survivors who were treated with radiotherapy 
and subsequent CMF (Cyclophosphamide-Methotrexate-Fluorouracil) chemotherapy.19,20 In 
the current study that uses the same study population, we characterised the combined effects 
of cancer itself, radiotherapy, and chemotherapy, on atherosclerotic carotid disease and tCBF 
by comparing these breast cancer survivors to a 1:2 age-matched population-based, cancer-
free reference group. To gain further insight into the contribution of regional radiotherapy on 
carotid pathology, we assessed the association between carotid atherosclerosis and radiation 
fields. The prevalence of cardiovascular diseases may differ between patients with left and 
right-sided breast tumours.3 Also, due to left-right differences in anatomy, a larger part of the 
left carotid artery may lie in the radiation field than of the right artery. We therefore determined 






We identified women with a history of unilateral, invasive breast cancer from the registries 
of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and the Daniel den 
Hoed Cancer Clinic of the Erasmus Medical Centre. Women were selected for the current 
study if they had been treated with both post-surgical radiotherapy and six cycles of adjuvant 
CMF chemotherapy (Cyclophosphamide 100 mg/m2 on days 1-14; Methotrexate 40 mg/m2 
on days 1 and 8; 5-Fluorouracil 600 mg/m2 on days 1 and 8) between 1976 and 1995. The 
radiotherapy regimen depended on type of surgery and disease stage and was classified 
into one or more of the following fields: axillary, breast, chest wall, internal mammary chain, 
McWhirter, or supraclavicular radiation.
 Breast cancer survivors were eligible if they were between 50 and 80 years of age at time 
of selection, if invasive breast cancer was their first and only malignancy, if they had remained 
cancer-free since treatment for breast cancer, and if they had sufficient command of the Dutch 
language. Exclusion criteria were use of adjuvant endocrine therapy and magnetic resonance 
imaging (MRI) contraindications.
  A detailed overview of the participant inclusion has been described previously.21 In short, 
195 (67.0%) of the 291 eligible breast cancer survivors agreed to participate and were assessed 
between October 2008 and October 2009. Of the 195 women who participated, in four of 
them no tCBF data was available because they had not completed the MRI examination due 
to claustrophobia. In another four participants the ultrasound images of the carotid arteries 
of either one or two vessel beds were unusable. Hence, total plaque score could not be 
calculated for these participants. Lastly, intima-media thickness (IMT) was not measured for 
five participants. Finally, 182 participants were available for analyses. 
Population-based reference women
Women without a history of cancer were selected from the prospective population-based 
Rotterdam Study.22,23 As of 2008, the study includes 14 926 participants. By the end of the 
inclusion period of chemotherapy-exposed breast cancer survivors (October 2009), 1337 
female participants of the Rotterdam Study had undergone complete carotid artery ultrasound 
assessment and a brain MRI.23 Each breast cancer survivor was randomly matched to two 
out of these 1337 cancer-free women based on age at time of carotid artery ultrasound (age 
range +/- 4 years). Nine out of 182 breast cancer survivors could not be matched. We chose 
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to match two cancer-free women per breast cancer survivor to limit the number of unmatched 
participants, which might induce selection bias.
Methods
All examinations for both the breast cancer survivors and the reference women took place at 
the research centre of the Rotterdam Study and were conducted by the same technicians. 
Breast cancer survivors were assessed between October 2008 and October 2009, and 
reference women were examined between April 2006 and August 2009.
Carotid artery ultrasound
Ultrasonography of both carotid arteries was performed with a 7.5-MHz linear-array 
transducer and a duplex scanner (EnVisor; Philips Medical Systems Nederland B.V., 
Eindhoven, Netherlands). Plaques, defined as focal widenings of the vessel wall relative to 
adjacent segments with protrusion into the lumen composed of either only calcified deposits 
or a combination of calcified and non-calcified material, were examined at six sites for both 
the left and right side including: the anterior (near) and posterior (far) walls of the (i) internal 
carotid artery; (ii) carotid bifurcation; and (iii) common carotid artery.24 A weighted plaque 
score ranging from 0 to 6 was computed by adding the number of sites at which a plaque 
was detected, divided by the total number of sites for which an ultrasonographic image 
was available and multiplied by 6 (the maximum number of sites). IMT was measured on 
a longitudinal, two-dimensional (2D) ultrasound image of the distal common carotid artery, 
on which the near and far walls were displayed as two bright white lines separated by a 
hypoechogenic space.25 IMT was defined as the distance between the leading edge of the far 
wall – displayed as the first bright line – and the leading edge of the near wall, i.e., the second 
bright line. The mean IMT was calculated as the average of three measurements of both the 
left and right carotid arteries.
MRI acquisition and processing
MRI was performed on a 1.5-Tesla MRI scanner (General Electric Healthcare, Milwaukee, 
Wisconsin). During the study period, no software or hardware upgrades were performed. 
Breast cancer survivors and reference women were scanned using the same MRI scanner.
 Our full scan protocol has been described in detail previously.23 In short, for tCBF 
measurement, 2D phase-contrast imaging was performed. First, a sagittal 2D phase-contrast 
MRI angiographic scout image was performed. On this scout image, a transverse imaging 
plane perpendicular both to the precavernous portion of the internal carotid arteries and to the 
middle part of the basilar artery was chosen for an axial 2D phase contrast image (repetition 
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time = 20 ms, echo time = 4 ms, field of view = 19 cm2, matrix = 256×160, flip angle = 8º, 
number of excitations = 8, bandwidth = 22.73 kHz, velocity encoding = 120 cm/sec, slice 
thickness = 5 mm).
 As previously described, we calculated flow from the phase-contrast images using 
interactive data language-based custom software (Cinetool version 4, General Electric 
Healthcare, Milwaukee, WI, USA).23 Regions of interest (ROIs), encompassing the entire 
lumen of the vessel, were drawn manually around both carotids and the basilar artery at the 
level of the clinoid segment on the phase-contrast images. The mean signal intensity in each 
ROI reflects the flow velocity in the vessel (cm/seconds). Flow (in mL/seconds) was calculated 
by multiplying the average velocity with the cross-sectional area of the vessel. To calculate 
tCBF (mL/min), flow rates for the carotid arteries and the basilar artery were summed and 
multiplied by 60 seconds/minute. Two independent, experienced technicians performed all 
manual ROI drawing and flow measurements (inter-rater correlations >0.94 for all vessels). 
 Total CBF strongly depends on the amount of brain tissue.26 To account for this, we 
calculated brain perfusion (in mL/min per 100 mL) by dividing tCBF (mL/min) by brain volume 
(mL) and multiplying the obtained result by 100. Brain volume was automatically obtained 
from three high-resolution axial MRI sequences that were acquired for each participant: (i) 
a T1-weighted three-dimensional fast radio frequency spoiled gradient recalled acquisition 
in steady state with an inversion recovery prepulse (FASTSPGR-IR); (ii) a proton density-
weighted sequence; and (iii) a fluid attenuated inversion recovery sequence (FLAIR). Pre-
processing steps and the classification algorithm that were used to extract total brain volume 
(TBV) from these three sequences have been described in detail elsewhere.27 In short, voxels 
were segmented into either: grey matter, white matter, cerebrospinal fluid, or background. The 
number of grey matter and white matter voxels were summed up and multiplied by the volume 
per voxel in mm3 to obtain total brain volume.
Demographics 
Information on potential confounders was collected for all participants. Body mass index 
(BMI) was calculated from height and weight measurements (kg/m2). Sitting diastolic and 
systolic blood pressures (mm Hg, average of two assessments) were measured on the right 
arm with a random-zero sphygmomanometer.26 Self-reported data on age at menopause, 
diabetes mellitus, smoking status (current, former, and never), and educational level (primary 
education, lower education [lower or intermediate general education, or lower vocational 
education], intermediate [intermediate vocational education or higher general education)], and 
higher [higher vocational education or university]) were obtained. In addition, information on 
use of antihypertensive medication, anticoagulant medication, and lipid-lowering medication 




Analysis of variance (ANOVA, continuous variables) and chi-square tests (categorical 
variables) were used to compare characteristics of breast cancer survivors and population-
based reference women.
 We used negative binomial regression to compare the distribution of plaque scores 
between groups (count variable, range 0 to 12), and linear regression models to compare 
groups on IMT (continuous), tCBF (continuous), and brain perfusion (continuous). Even though 
we matched the breast cancer survivors and controls on age at carotid artery ultrasound, we 
corrected all analyses for age to account for potential residual confounding by age. In addition, 
all analyses were corrected for BMI. In an extended model, Model II, we additionally corrected 
for prevalence of diabetes mellitus, smoking status, use of anticoagulant medication and lipid-
lowering medication, and educational level. We adjusted for educational level because of the 
different distribution of educational level between groups in the current study and its association 
with cardiovascular diseases in general.28 Note that all potential confounders were measured 
at time of assessment of the outcomes and not at time of cancer diagnosis and treatment. 
We therefore considered age at menopause, systolic and diastolic blood pressure, and use of 
antihypertensive medication as potential mediators rather than potential confounders, and did 
therefore not correct for these factors.29,30 Lastly, for the analyses on tCBF and brain perfusion 
we additionally corrected for total plaque score and total IMT in Model III to determine whether 
any association was explained by plaque score or IMT.
 Within the group of breast cancer survivors, we investigated if the degree to which the 
carotid artery was included in the radiation field was associated with plaque scores (negative 
binomial regression analysis), IMT, tCBF, or brain perfusion (linear regression analysis). We 
therefore classified field of radiotherapy in: (i) carotid artery was not in the radiation field (only 
axillary, breast, or chest wall radiation); (ii) a small part of the carotid artery was in the radiation 
field (internal mammary chain radiation, with or without axillary, breast, or chest wall radiation); 
and (iii) a large part of the carotid artery was in the radiation field (McWhirter or supraclavicular 
with or without internal mammary chain, axillary, breast, or chest wall radiation). For these 
analyses, we used the same models as used when comparing breast cancer survivors with 
cancer-free reference women. Survivors with a small part of the carotid artery in the radiation 
field were selected as the reference group because this was the most common type of 
treatment (see Table 1).
 We subsequently looked at the association of breast tumour side with plaque score by 
comparing carotid plaque scores of the left and right carotid artery within survivors. Here too, 
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we used negative binomial regression models to investigate differences in carotid plaque 
scores. Linear regression models were used to determine the difference in IMT (total, left, and 
right), tCBF, and brain perfusion.
 Statistical analyses were performed in R Version 3.3.2.
RESULTS
Characteristics of breast cancer survivors and population-based cancer-free reference 
women are presented in Table 1. Breast cancer survivors had been diagnosed on average 
(standard deviation [SD]) 21.1 years (4.4) before participation in this study, at a mean (SD) 
age of 42.6 years (5.4). They had a higher systolic and diastolic blood pressure, a younger 
age at menopause (mean age 44.1 versus 49.3 years), a higher educational level, and were 
less often current smokers than women from the reference group. 
 Breast cancer survivors had a similar total carotid plaque score (adjusted beta = -0.01 
[95% CI = -0.20 to 0.18]) and total IMT score (adjusted beta = 0.00 [95% CI = -0.02 to 0.03]) as 
cancer-free reference women (Table 2). Regarding brain perfusion, breast cancer survivors 
had a statistically significantly lower mean tCBF (adjusted beta = -19.6 mL/min [95% CI = 
-37.3 to -1.9]) and brain perfusion (adjusted beta = -2.5 mL/min per 100 mL [95% CI = -4.3 to 
-0.7]) than the cancer-free reference women (Table 2). Effect estimates for tCBF and brain 
perfusion hardly changed after including total mean IMT and total plaque score in the model 
(Table 2, Model III).
 Within the group of breast cancer survivors, no difference was found between participants 
with the carotid artery partly in the radiation field and those without the carotid artery in the 
radiation field (Table 3A). Survivors who underwent radiotherapy with a larger portion of the 
carotid artery in the radiation field had slightly higher carotid plaque scores, lower mean tCBF, 
and lower mean perfusion than those with a smaller portion of the carotid artery in the radiation 
field, albeit not statistically significant (Table 3B). Also, they had a statistically significantly 
higher total and right IMT score (adjusted beta for total IMT score = 0.05 [95% CI = 0.01 to 
0.09] and for right IMT score = 0.09 [95% CI = 0.01 to 0.16], Table 3B). Right-sided breast 
cancer survivors had a statistically significantly lower left carotid plaque score (adjusted beta 
= -0.31 [95% CI = -0.60 to -0.02]) and a higher brain perfusion (adjusted beta = 3.5 mL/min 
per 100 mL [95% CI = 0.7 to 6.2]) than participants who survived a left-sided tumor (Table 4). 
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Age, years, mean (SD) 63.8 (6.5) 61.7 (6.2) <.001
Body mass index, kg/m2, mean (SD) 26.7 (4.6) 27.4 (4.6) .11
Systolic blood pressure, mm Hg, mean (SD) 139 (19) 131 (19) <.001
Diastolic blood pressure, mm Hg, mean (SD) 84 (10) 81 (11) .03
Age at menopause, years, mean (SD) 44.1 (5.1) 49.3 (5.8) <.001
Diabetes mellitus, No. (%) 13 (7.5) 12 (3.5) .07
Smoker status, No. (%) .003
 Never 60 (34.7) 132 (38.2)
 Former 95 (54.9) 95 (41.4)
 Current 18 (10.4) 70 (20.3)
Antihypertensive medication, No. (%) 60 (34.7) 1 (0.3) <.001
Anticoagulant medication, No. (%) 16 (9.2) 39 (11.4) .54
Lipid-lowering medication, No. (%) 31 (17.9) 85 (24.9) .09
Educational level, No. (%) .002
 Primary 15 (8.7) 45 (13.0)
 Lower 67 (38.7) 172 (49.9)
 Intermediate 36 (20.8) 67 (19.4)
 Higher 15 (31.8) 61 (17.7)
Total brain volume, mL, mean (SD) 902 (76) 900 (80) .72
Age at cancer diagnosis, years, mean (SD) 42.6 (5.4)
Time since diagnosis in years, mean (SD) 21.1 (4.4)
Side of tumour, right side, No. (%) 89 (51.4)
Radiation field, No. (%)
 Carotid artery not in radiation field* 17 (9.9)
 Carotid artery partly in radiation field† 102 (59.6)
 Carotid artery in radiation field‡ 52 (30.4)
* Axillary, breast, or chest wall radiation. † Internal mammary chain radiation. ‡ McWhirter (supraclavicular 
and axillary) or supraclavicular radiation.
Side of tumour and radiation field was missing for one breast cancer survivor.
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Table 4 Association between tumour location (left or right-sided breast cancer) and carotid plaque 
















 Total 2.0 (1.0 to 3.5) 1.0 (0.0 to 3.0) -0.24 (-0.56 to 0.09) -0.15 (-0.36 to 0.05)
 Left 1.0 (0.0 to 2.0) 1.0 (0.0 to 2.0) -0.34 (-0.68 to -0.00) -0.31 (-0.60 to -0.02)




 Total 0.85 (0.13) 0.84 (0.15) -0.02 (-0.05 to 0.02) -0.01 (-0.05 to 0.03)
 Left 0.85 (0.15) 0.84 (0.15) -0.02 (-0.06 to 0.02) -0.01 (-0.05 to 0.04)
 Right 0.84 (0.14) 0.84 (0.17) -0.01 (-0.06 to 0.03) -0.01 (-0.06 to 0.03)
Cerebral blood flow, 
mL/min, mean (SD)
 Total 507 (84) 530 (92) 26.2 (0.29 to 52.1) 25.9 (-0.90 to 52.7)
Brain perfusion, 
mL/min per 100 mL, 
mean (SD)
 Total 56.0 (8.1) 59.0 (9.4) 3.2 (0.6 to 5.9) 3.5 (0.7 to 6.2)
Model I = adjusted for age and body mass index; Model II = as Model I, plus: age at menopause, 
prevalence of diabetes mellitus, smoking status, use of anticoagulant medication, use of lipid-lowering 
medication, and education. 
* Difference in median total plaque score, mean intima-media thickness, mean total cerebral blood flow, 
or mean brain perfusion between breast cancer survivors treated with left-sided cancer (reference group) 
and right-sided cancer.




This study shows that on average twenty years after treatment with chemotherapy and 
radiotherapy, breast cancer survivors have lower tCBF and brain perfusion than aged-matched 
cancer-free women. Our results within breast cancer survivors indicate that radiotherapy on a 
larger part of the carotid artery is associated with a greater IMT. Lastly, we found that plaque 
scores in the left carotid artery were significantly lower in participants with a right-sided tumour 
than in those with a left-sided tumour.
 We found that breast cancer survivors had lower tCBF and brain perfusion than cancer-free 
women, which was not completely explained by carotid pathology. In contrast, it has previously 
been shown that one year after completion of chemotherapy, brain perfusion was increased 
in breast cancer survivors, which might reflect a temporary compensatory mechanism for 
chemotherapy-induced damage.31 In addition, brain perfusion was decreased in the frontal 
and parietal parts of the brain, which was associated with lower grey matter density.32 The 
lower brain perfusion in our study might therefore underlie the cognitive deficits and alterations 
in brain volumes that we previously observed in this group of cancer survivors,19,20 and which 
are observed in breast cancer survivors who have completed chemotherapy in general.33 We 
have explored this hypothesis in post-hoc analyses and indeed found that the relation between 
global cognitive function and brain perfusion differed between breast cancer survivors and 
reference women (Supplementary Material). In addition, lower brain perfusion is associated 
with a higher risk of transient ischemic attack (TIA) in the general population.34 Although it 
has been shown that breast cancer survivors have a non-statistically significant higher risk of 
TIA,35 it might be relevant to focus on those survivors with altered brain perfusion.
 We did not find a difference in carotid pathology between the total group of breast cancer 
survivors and the cancer-free reference women. However, within breast cancer survivors, 
we found that more radiotherapy on the carotid artery was associated with a greater IMT. 
Carotid IMT is a marker for atherosclerosis. Although carotid plaques are a stronger predictor 
of cardiovascular disease than IMT in the general population,36 greater IMT is also associated 
with cardiovascular events independent of major cardiovascular risk factors including carotid 
plaques.37 Therefore, greater IMT in breast cancer survivors treated with radiotherapy on the 
carotid artery might explain the higher risk of cardiovascular events in those breast cancer 
survivors who were treated with radiotherapy.3 A potential explanation for the fact that we did 
not find differences between breast cancer survivors and cancer-free controls might be that 
cancer survivors had adopted a healthier lifestyle after their diagnosis and treatment. This may 
limit the damaging effects of chemotherapy and radiotherapy on the vascular system. This 
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hypothesis is supported by a higher rate of former smokers in our group of cancer survivors, 
which might suggest that these women stopped smoking after their cancer diagnosis.
 Our observation of higher left plaque score in breast cancer survivors with left-sided 
cancer than those with right-sided cancer may reflect an interaction between a generally 
higher rate of plaques in the left versus the right carotid artery and radiotherapy. In the general 
population, the prevalence of left-sided plaques is twice as high as right-sided plaques.38 
Also, left-sided plaques are predominantly composed of intraplaque haemorrhage and fibrous 
tissue and are therefore more vulnerable to plaque rupture and subsequent thromboembolic 
complications than right-sided plaques.38 In addition, the left carotid artery may be exposed to 
higher arterial pressure due to left-right differences in anatomy. For instance, the left carotid 
artery is directly connected to the aortic arch, whereas the right carotid artery is connected to 
the brachiocephalic artery.39 It is therefore possible that radiotherapy accelerates the number 
of plaques on the left side. Previously, our group has reported that breast cancer survivors 
who had received radiotherapy for left-sided breast cancer had higher risks for myocardial 
infarction (hazard ratio (HR) = 1.77) and congestive heart failure (HR = 1.41) than breast 
cancer survivors with right-sided tumours, although these effects were not significant.3 This 
higher risk might be explained by a higher radiation exposure of the heart in left-sided cancer 
patients. Together, these findings emphasise the importance of cardiovascular risk screening 
in breast cancer survivors, in particular in those with left-sided breast cancer.
 Strengths of our study are the sample of almost two hundred breast cancer survivors with 
a long interval since radiotherapy and chemotherapy, the homogeneous study population 
with regard to the cytotoxic agents received (regimen and cycles), and the comparison with 
population-based reference women without a history of cancer who underwent the same 
examinations as the breast cancer survivors. 
 CMF chemotherapy has a high likelihood of inducing early menopause. Age at menopause 
was therefore considered a mediating variable in the between-group analyses. Because of 
this, it is impossible to separate the direct effects of chemotherapy, and the effects through 
menopause. Samples with sufficient numbers of subjects who did and did not reach early 
menopause due to chemotherapy are necessary to separate the effects of chemotherapy and 
menopause on vascular pathology and brain perfusion. 
 A limitation is that the included breast cancer survivors did not receive endocrine therapy. 
Endocrine therapy was not part of the standard treatment for patients with breast cancer in the 
Netherlands until the mid-1990s. However, nowadays, patients frequently receive endocrine 
therapy, and it has been shown that this therapy is associated with the presence of carotid 
plaques.40 Also, the CMF regimen is no longer considered an optimal adjuvant chemotherapy 
regimen for breast cancer, but it has been the standard regimen worldwide up to the 1990s.39 
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It is therefore currently the only regimen that enables the investigation of the very late effects 
of chemotherapy in sufficiently large numbers of persons. Current regimens often include 
individual components of the CMF regimen, including cyclophosphamide and 5-fluorouracil. 
Therefore, the current findings may also be relevant for breast cancer survivors that are 
treated with contemporary chemotherapy regimens. Also, there is still a large group of women 
who have been treated with CMF in the past of whom some women may now experience the 
negative cerebral consequences. Lastly, the observed associations may be less pronounced 
in breast cancer patients who are currently treated with radiotherapy, as radiotherapy for 
breast cancer is usually given to more limited target volumes and radiotherapy techniques 
have improved leading to lower doses to the carotid arteries41 and the heart.42 
 Breast cancer survivors have lower brain perfusion on average twenty years post-
treatment which may be part of the mechanism underlying the well-known cognitive sequelae 
of chemotherapy. Radiotherapy on the carotid artery is associated with a larger IMT, which in 
turn might result in more cardiovascular disease. Therefore, cardiovascular risk management 
of breast cancer survivors is important.
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Cognitive function was assessed by a neuropsychological test battery administered at the 
research centre. The following cognitive tests were administrated: Letter-Digit Substitution 
Test, Word Fluency Test, Stroop Test (Reading, Naming, Interference), Purdue Pegboard 
Test (right, left, both hands), and 15-Word Learning Test (Immediate recall, Delayed recall, 
Recognition).1-5 
 Global cognitive function was assessed by the general cognitive factor based on Letter-
Digit Substitution Test, Word Fluency Test, Stroop Test: Interference, sum-score of individual 
Purdue Pegboard Tests, and Word Learning Test: Delayed recall. The general cognitive 
factor was identified as the first unrotated component of a principal component analysis, 
which explained at least 44.6% of the total variance in individual cognitive tests.6 The general 
cognitive factor was only computed if all five individual tests were completed. Therefore, the 
general cognitive factor could not be computed for 22 breast cancer survivors (12.7%) and 
39 reference women (11.3%). Excluded breast cancer survivors and reference women were 
slightly older than those who had all tests completed (mean age for breast cancer survivors 
was 65.7 versus 63.5 years, mean age for reference women was 63.1 versus 61.5 years). 
Most excluded breast cancer survivors had one missing test result (51.3%), 25.6% had two 
missing test results, and 23.1% had three or more missing test results. Of the excluded 
reference women, 68.1% had one missing test result, 22.7% had two missing test results, and 
9.1% had three or more missing test results.
Statistical analyses
In post-hoc analyses, we focused on the outcomes that were statistically significantly different 
between breast cancer survivors and reference women (i.e., total cerebral blood flow and brain 
perfusion). We explored whether the association between general cognitive function and total 
cerebral blood flow or brain perfusion differed between breast cancer survivors and reference 
women. In order to do so, we used linear regression models with the general cognitive factor 
as outcome and computed interaction terms between cancer status and total cerebral blood 
flow or brain perfusion. These models included the same covariates as Model II that we used 
to test differences in total cerebral blood flow and brain perfusion between breast cancer 
survivors and reference women, including: age, body mass index, prevalence of diabetes 





Results regarding the difference in total cerebral blood flow and brain perfusion between 
breast cancer survivors and reference women were similar in this smaller study population 
(n=458) to those obtained from the total study population (n=519). 
 We found that per mL/min increase in total cerebral blood flow, the general cognitive factor 
increased with 0.001 units. This association was stronger in breast cancer survivors than in 
reference women: per mL/min increase in total cerebral blood flow their general cognitive 
factor increased with an additional 0.002 units (95% confidence interval = 0.000 to 0.004, P 
for interaction = .03). 
 For each mL/min per 100 mL increase in brain perfusion, the general cognitive factor 
increased with 0.003 units. In breast cancer survivors, the general cognitive factor increased 
with an additional 0.025 units per mL/min per 100mL increase in brain perfusion (95% 
confidence interval = 0.006 to 0.044, P for interaction = .01). 
 Given the linear associations, a decrease in either total cerebral blood flow or brain 
perfusion will result in a stronger decrease in the general cognitive factor in breast cancer 
survivors than in reference women. These findings may indicate that the relation between 
changes in cerebral blood flow, brain perfusion, and general cognitive factor differ between 
breast cancer survivors and reference women.
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The aim of this thesis was to better understand the origin and course of cognitive decline 
in non-central nervous system (CNS) cancer patients and survivors, their risk of dementia, 
and the mechanisms underlying cognitive problems and dementia in cancer patients. In 
this last Part, I bring the main findings of this thesis together and place these findings in a 
broader perspective. Next, I discuss the methodological considerations, outline the clinical 
implications, and provide suggestions for future studies.
REVIEW AND INTERPRETATION OF MAIN FINDINGS
Part I - Cancer registration
The Netherlands Cancer Registry aims to register all cancers in the Netherlands and has 
nationwide coverage since 1989.1 Optimal cancer registration is necessary for studying 
cancer statistics and cancer aetiology. To improve the quality of cancer registration, different 
studies have determined the completeness and accuracy of national cancer registries.2-13 
For instance, completeness of cancer registration by the Netherlands Cancer Registry 
was estimated at 98.7% in 19902 and at 96.2% in 19933 based on linkage with data from 
general practitioners. The comparison of cancer registration by national cancer registries and 
population-based studies remains however scarce. In Chapter 2 we therefore determined 
the potential added value of population-based studies by linking participants in the Rotterdam 
Study to patients in the Netherlands Cancer Registry.14 Although there is no golden standard 
of cancer registration, we considered this comparison as the best alternative. Two findings 
stood out: (i) completeness of registered pathology-confirmed cancers was >95.0% in both 
registries, whereas completeness of cancers that were not confirmed by pathology was only 
40.0% in the Netherlands Cancer Registry compared to 97.7% in the Rotterdam Study; and 
(ii) the date of diagnosis was more often inaccurately registered by the Rotterdam Study 
(11.8% of the cancers) than by the Netherlands Cancer Registry (4.8% of the cancers).
 In Chapter 3, we took a closer look at the group of cancers that was often not registered by 
the Netherlands Cancer Registry, i.e., cancers that were not confirmed by pathology. Although 
we cannot rule out that non-pathology-confirmed tumours are in fact benign lesions, these 
patients have undergone the same diagnostic work-up – apart from pathological confirmation 
– as patients with pathology-confirmed cancer. Pathological confirmation of tumours can be 
omitted if patients are vulnerable, if they have other major health concerns, or if confirmation 
has no therapeutic consequences. We found that 11.7% of all cancers in the Rotterdam Study 
were not confirmed by pathology.15 Patients with non-pathology-confirmed cancers were older, 
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had more comorbidities, and had more aggressive cancer types than patients with pathology-
confirmed cancers. Importantly, the overall survival of patients with non-pathology-confirmed 
cancer (32.6% at one year after diagnosis) was substantially lower than that of patients with 
pathology-confirmed cancer (63.4% at one year after diagnosis). 
Main message Part I
The main message that emerges from this Part, is that combining multiple sources of cancer 
registration is necessary to improve the quality of cancer registration by population-based 
studies and national cancer registries. More effort is needed to register non-pathology-confirmed 
cancers, in particular as these cancers are related to patient and tumour characteristics. 
We therefore suggest to include non-pathology-confirmed cancers in sensitivity analyses to 
minimise bias. Implications for cancer registries will be discussed in the Implications section.
Part II - Cancer and cognition 
Several studies have shown that non-CNS cancer patients can have impaired cognitive 
function.16-22 Most of these studies have focused on the effects of chemotherapy on the 
brain. In addition, few studies have found that some patients have already impaired cognitive 
function before start of cancer treatment.23-28 Although psychological factors that accompany 
a cancer diagnosis cannot be completely ruled out, animal studies have confirmed these 
findings by showing that tumour-bearing, treatment-naive rodents can have impaired memory 
function.29,30,31 Together, these findings suggest that cancer treatment is not the only cause of 
cognitive problems in cancer patients and that cancer itself, psychological factors, or shared 
risk factors for both cancer and cognitive impairment may also affect cognitive function. 
 Before exploring the origin and course of cognitive function in cancer patients in a 
population-based setting, we first determined in Chapter 4 the trajectories of cognitive and 
motor function in the general population. Many studies have shown that cognitive and motor 
function decline during ageing,32-44 but the natural course of decline in these functions as well 
as their temporal relation in the general population is poorly understood. In a population free 
from neurodegenerative diseases, we found that cognitive and motor function declined linearly 
between the ages 45 and 65 years, followed by steeper decline. The decline in cognitive and 
motor function was similar – i.e., decline in cognitive function did not precede decline in motor 
function and vice versa – but there was a high variation in the rate of decline in individual tests. 
This indicates that some cognitive and motor functions, such as inhibition and psycho-motor 
speed, might be more vulnerable to normal ageing than for instance memory. 
 These established trajectories of cognitive and motor function could be used as standard 
to identify persons who deviate from the natural course of decline. I have illustrated this 
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application in Figure 1 by showing the cognitive trajectories of participants in the Rotterdam 
Study who were diagnosed with dementia during study follow-up and of those were diagnosed 
with cancer. Before dementia diagnosis, participants deviated from the expected natural 
course of decline, whereas before cancer diagnosis, participants followed the same course of 
decline as the general population. 
 Although Figure 1 suggests that persons who will be diagnosed with cancer do not deviate 
from the expected natural course of cognitive decline, it does not indicate whether their 
cognitive function deviates from this course more closely towards the clinical manifestation 
of cancer. To further elucidate the change in cognitive function before cancer diagnosis, we 
studied in Chapter 5 the trajectory of cognitive decline in participants who were diagnosed 
with cancer during study follow-up and compared this with the trajectory of cognitive decline 
in participants who remained free of cancer during follow-up.45 Instead of age, we used follow-
up time as underlying time scale to study the change in cognitive function towards diagnosis. 
This design enabled us to study purely the impact of cancer itself and shared risk factors on 
cognitive function while circumventing the potential effects of psychological factors and cancer 
treatment. We found that the trajectory of cognitive function in participants prior to cancer 
diagnosis was similar to that observed in participants who remained free of cancer.45 Although 
this study had some limitations such as the long interval between cognitive assessments and 
the limited number of assessments directly preceding cancer diagnosis, this finding suggests 
that – if anything – the effects of cancer itself and shared risk factors on cognitive function are 
limited before clinical manifestation of the disease. 
  Changes in cognitive function correlate moderately with changes in brain structure.46,47 
For instance, it has been shown that persons without cognitive impairment, but with lower 
volumes of the hippocampi or temporal lobes are at a higher risk of dementia than persons 
with normal brain tissue volumes.48 To further explore the potential impact of cancer itself and 
shared risk factors on the brain, we determined in Chapter 6 the relation between different 
measurements of brain structure and the risk of cancer. We found no association between brain 
structure and the risk of cancer, indicating that before cancer diagnosis, patients do not have 
more brain abnormalities than persons who remain free of cancer. Our findings therefore do 
not support that cancer affects the brain before clinical manifestation of the disease. Although 
we could not examine brain structure more closely towards cancer diagnosis, our findings 
indicate that, if anything, the impact of cancer and shared risk factors on brain structure before 
cancer diagnosis is very subtle.
 In Chapter 7 we further extended the trajectories of cognitive function in cancer patients by 
including cognitive assessments after cancer diagnosis to study the cognitive trajectories from 
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Figure 1 Trajectories of cognitive test scores.
The trajectories of the total population are shown in black. The trajectories of participants who were 
diagnosed with dementia during follow-up are shown in blue and of those who were diagnosed with 
cancer during follow-up are shown in yellow. The confidence intervals are not shown for clarity.
* Higher score indicates worse performance.
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has been extensively studied, clinical studies have not performed cognitive assessments prior 
to cancer diagnosis, have focused on a subgroup of cancer patients and intensive treatments, 
and may have been biased by selection of patients.49 Therefore, the course of cognitive 
function after cancer diagnosis and treatment in the general population of cancer patients 
is still poorly understood. We found that cognitive function in cancer patients from before 
to after cancer diagnosis declined with a similar rate as that in cancer-free persons. It must 
be noted that a large number of cancer patients was excluded from this study, because the 
majority of the patients (64.3%) did not have cognitive assessments after cancer diagnosis. 
Consequently, we have probably selected the healthiest patients with favourable cancer types. 
For instance, only 3.6% of the included patients had lung cancer – which is the second most 
common cancer type in the Netherlands when excluding non-melanoma skin cancers – and 
only 11.3% were treated with chemotherapy. Larger numbers are therefore needed to assess 
cognitive change in patients who underwent systemic treatments. Our findings indicate that 
in general, cognitive function in cancer patients changes similarly to that in persons without a 
history of cancer. This suggests that the effect of cancer itself on cognitive function is limited 
and underlines the necessity to identify high risk patients.
Main message Part II
In conclusion, the findings from the studies in this Part indicate that cognitive function and 
brain structure are not affected before cancer diagnosis. Also, at a population-level, the course 
of cognitive function in non-CNS cancer patients after diagnosis is similar to that in cancer-
free persons. These findings indicate that, if anything, effects of cancer itself and shared risk 
factors on cognitive function and brain structure are very subtle. The implications of these 
findings will be discussed in the Implications section.
Part III - Cancer and dementia
Having studied the change in cognitive function in cancer patients, we subsequently focused 
on their risk of dementia. At a population-level, we found that the change in cognitive function 
in the general population of cancer patients was similar to that in cancer-free persons. In 
addition, previous clinical studies have shown that patients with specific types of cancer or 
cancer treatment often have cognitive impairment. Against this background, we hypothesised 
that the risk of dementia in cancer patients is either similar or higher to the dementia risk 
in persons without a history of cancer. This hypothesis is supported by various biological 
processes that are involved in the pathogenesis of cancer and dementia, including 
inflammation, angiogenesis, oxidative stress, and DNA damage.50 In addition, a genome-
wide association study has found a positive genetic correlation between cancer and dementia 
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genes, implying that cancer and dementia share some genetic background.51
 In contrast to our hypothesis, studies have repeatedly shown that cancer patients have a 
lower risk of developing dementia than cancer-free persons.52-64 Interestingly, it has also been 
found that patients with dementia have a lower risk of developing cancer,59-67 suggesting an 
inverse link between cancer and dementia. This inverse link has been found for different cancer 
types, including non-melanoma skin cancer.54,55 Although different biological mechanisms 
underpinning this inverse link have been proposed,68-70 methodological issues including 
surveillance and survival bias as potential drivers of the inverse direction of this association 
have not been sufficiently investigated.71,72 The studies in this Part aimed to circumvent these 
biases in order to elucidate the biological relation between cancer and dementia.
 First, in Chapter 8, we studied Alzheimer’s disease (AD), the most common type of 
dementia, as a multistep process using multistage models that have originated from cancer 
research.73 The underlying theory is that a healthy stem cell transforms into a malignant cell 
through sequential mutations. Multistage models have established that seven successive 
mutations – equivalent to seven steps – are needed before a healthy cell becomes malignant.74 
We showed that AD complied with the multistep process and that 14 steps were required 
before clinical manifestation of the disease. Interestingly, genetically predisposed persons 
needed less steps before clinical manifestation, which was also observed in cancer.75 This 
indicates that these persons have already inherited one of the required steps, which can 
provide additional insight in the pathogenesis of dementia. These findings further support 
some biological similarity between cancer and AD.
 Next, we studied the preclinical stage of either cancer or dementia, and linked it to the 
other disease. We hypothesised that if there is a biological link between cancer and dementia, 
this would extent across all preclinical stages of the disease. By using this approach, we could 
limit the effects of surveillance and survival bias, because persons with a preclinical stage of 
a disease have often a longer life expectancy than those with clinically-manifested disease. 
Although not all persons with a preclinical stage of a disease will develop clinically-manifested 
disease, it may still be informative from a biological perspective.
 In Chapter 9 we first verified that patients with dementia have a lower risk of developing 
cancer than persons without dementia.76 Next, we determined the relation between mild 
cognitive impairment – a preclinical stage of dementia – and the risk of cancer. In contrast to 
patients with dementia, persons with mild cognitive impairment had a higher risk of developing 
cancer than cognitively normal persons. Mild cognitive impairment is defined as having both 
objective cognitive impairment and subjective memory complaints. In addition, persons have 
to be at least 60 years old. Therefore, although we found in Chapter 5 and 6 no relation 
between cognitive function and the risk of cancer, the association between mild cognitive 
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impairment and cancer might partly be explained by the combination of objective cognitive 
impairment and subjective memory complaints, rather than only deficits in objective cognitive 
function, or by the different study population (i.e., participants were aged at least 60 years 
when studying mild cognitive impairment). Subsequently, we studied in Chapter 10 the relation 
between plasma amyloid-β – one of the earliest detectable changes in preclinical dementia, 
even before the onset of mild cognitive impairment – and the risk of cancer and found that 
higher levels of plasma amyloid-β were related to a higher risk of cancer. Lastly, in Chapter 11 
we determined the relation between the tumour marker carcinoembryonic antigen and the risk 
of dementia and found that higher levels of carcinoembryonic antigen were associated with a 
higher risk of dementia.
 Although these associations might suggest a positive relation between cancer and 
dementia, one can argue the validity of using such markers as preclinical stages of a disease. 
Also, we cannot fully rule out methodological bias by studying preclinical stages of a disease. 
Therefore, we provided in Chapter 12 an alternative approach to deal with selection bias. 
 Since the date of cancer diagnosis is time-dependent, we first accounted for immortal time 
(Box 1 in Methodological considerations) by using the following three methods: (i) studying 
cancer as time-dependent variable; (ii) using inverse probability weights for the time until 
cancer diagnosis; and (iii) by cloning and censoring our dataset. Cancer is also related to death 
and therefore, part of the effect of cancer on dementia is through death. Censoring for death 
is informative and can result in spurious effect estimates. Figure 2 shows the corresponding 
directed acyclic graph. To deal with the competing risk of death and loss to follow-up, we used 
inverse probability weighting. Using this method, we found that cancer patients do not have a 
higher risk of dementia than persons without cancer. This emphasises the importance of using 
the correct statistical methods when studying an association in the presence of the competing 
risk of death.
Main message Part III
Taken together, the association between cancer and dementia remains complicated. A 
substantial amount of bias may influence the direction of this association. We have used 
different approaches to circumvent such bias. Our results do not support an inverse 
association between non-CNS cancer and dementia. In fact, cancer patients had a similar 
risk of developing dementia as persons without a history of cancer when using appropriate 
statistical models. If anything, our findings based on preclinical disease stages may stimulate 
future studies to explore a positive, biological relation between non-CNS cancer and dementia. 







Figure 2 Directed acyclic graph for the relation between cancer and the risk of dementia.
We were interested in the relation between cancer and the risk of dementia. Both cancer and dementia 
are strongly associated with death. Therefore, part of the effect of cancer on dementia goes through 
death (orange arrow). We must take the competing risk of death into account when studying this relation. 
In addition, confounders (grey arrows) for the relation between cancer and dementia, cancer and death, 
and dementia and death, might affect the relation between cancer and dementia and should therefore be 
taken into account. 
Part IV - Underlying mechanisms
Lastly, we investigated potential mechanisms underlying cognitive problems – and possibly 
dementia – in cancer patients. Different proposed mechanisms are the release of extracellular 
vesicles, inflammation, oxidative stress, vascular changes, mitochondrial dysfunction, 
changes in hormonal levels, and telomere shortening.77-79 The studies in this thesis focused 
on inflammation and vascular factors.
 In Chapter 13 and 16, we studied breast cancer survivors who were treated with surgery, 
radiotherapy, and chemotherapy on average twenty years before assessment. Although 
these breast cancer survivors did not participate in the Rotterdam Study, they underwent 
identical assessments in the same research centre as participants in the Rotterdam Study. 
This enabled us to use participants in the Rotterdam Study without a history of cancer as 
controls. We have previously shown that these breast cancer survivors have worse cognitive 
function, less grey matter volume, less white matter integrity, and more cerebral microbleeds 
than cancer-free controls.21,80,81 Note that, although we think that the effect of cancer itself on 
cognitive function is limited based on our findings in Part II, we cannot disentangle the effects 
of cancer and cancer treatment in these breast cancer survivors. I will therefore refer to the 
potential underlying mechanisms of both cancer and cancer treatment.
 In these breast cancer survivors, we investigated in Chapter 13 the association between 
cognitive function and inflammation by quantifying the granulocyte-to-lymphocyte ratio (GLR), 
platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII).82 These 
inflammatory ratios can broadly capture the balance between the two main components of 
the immune system: innate immunity, referring to the immune responses present at birth, 
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and adaptive immunity, reflecting the immune responses acquired during life.83 Granulocytes 
and platelets are primarily involved in innate immunity, whereas lymphocytes are related to 
adaptive immunity. Therefore, a higher GLR, PLR, and SII reflect an imbalance in the immune 
system towards innate immunity. 
 We found that breast cancer survivors had – twenty years after cancer treatment – 
higher inflammatory ratios than cancer-free controls. In addition, the relation between 
higher inflammatory ratios and lower general cognitive function was stronger in breast 
cancer survivors than in cancer-free controls. The SII may already be higher before cancer 
diagnosis.84 Therefore – and because of our study design – we could not determine causality. 
Nevertheless, these findings suggest that an imbalance in the immune system towards innate 
immunity may underlie late cognitive problems in cancer patients. Interestingly, we found in 
Chapter 14 that this imbalance may also be involved in the pathogenesis of dementia.85 It 
would therefore be interesting to further follow the breast cancer survivors and study their risk 
of dementia.
 Activation of the immune system can result in inflammation. Although we used the GLR, 
PLR, and SII as proxy for inflammation, it must be noted that we could not identify the 
phenotype of the underlying immune cell populations. Therefore, it is unknown if the underlying 
blood cells are functional and hence cause higher levels of pro-inflammatory cytokines. Few 
studies have tried to identify cytokines that may be involved in cognitive impairment in cancer 
patients, but findings are heterogeneous in terms of the involved cytokines and affected 
domains of cognitive function.25,86-90 Animal studies have further supported involvement of pro-
inflammatory cytokines and have shown that administration of low-dose aspirin in tumour-
bearing, treatment-naive mice resulted in improved memory function without affecting the 
tumour burden.91 If the higher inflammatory ratios truly reflect a higher production of pro-
inflammatory cytokines, these cytokines may cross the blood-brain barrier and activate 
microglial cells, thereby initiating the release of neuronal cytokines. This can result in 
neurotransmitter deregulation, decreased neurogenesis, and lower neuroplasticity.78,92,93 
Interestingly, it has been shown that amyloid-β may also activate microglial cells and thereby 
stimulate the production of pro-inflammatory cytokines in the brain.94 Given that higher levels 
of plasma amyloid-β are associated with a higher risk of cancer, amyloid-β might also have a 
role in cognitive problems in cancer patients. 
 Next, in Chapter 15 and 16 we focused on the potential role of vascular factors in cognitive 
problems in cancer patients. Cancer and cancer treatment are associated with vascular 
changes including hypercoagulable state, atherosclerosis, and injury to cardiac myocytes, 
resulting in a higher risk of cardiovascular diseases.95-99 Moreover, cancer and cardiovascular 
diseases share different pathways, including inflammation and oxidative stress,100,101 which may 
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also contribute to the higher risk of cardiovascular diseases in cancer patients. In Chapter 15, 
we studied presence of atherosclerotic calcification in the aortic arch before cancer diagnosis. 
We found that persons with the highest amount of aortic arch calcification had a higher risk of 
cancer than persons with the lowest amount of aortic arch calcification. Despite the fact that 
we cannot determine causality, this finding indicates that vascular changes can occur even 
before cancer diagnosis. In Chapter 16 we studied vascular factors after cancer diagnosis 
and treatment, and found no difference in presence of carotid plaques and intima-media 
thickness between breast cancer survivors and cancer-free controls. It is possible that cancer 
survivors adopt a healthier lifestyle,102 thereby limiting the potential damaging effects of cancer 
treatment. Also, cancer patients or survivors with the highest amount of atherosclerosis may 
have died of cardiovascular disease before study enrolment, resulting in survival bias. Within 
breast cancer survivors, radiotherapy on the carotid artery was associated with a greater 
intima-media thickness. In addition, breast cancer survivors had lower brain perfusion than 
cancer-free controls. In the general population, lower brain perfusion has been associated 
with an accelerated decline in cognitive function and with a higher risk of dementia.103 Lower 
brain perfusion can result in hypoxia, which is associated with microglial cell activiation.104 In 
turn, microglial cells can produce pro-inflammatory cytokines, resulting in neuronal damage.105 
In addition, hypoxia might result in accelerated amyloid-β production and less amyloid-β 
clearance.106 Therefore, our findings suggest that cancer and cancer treatment are related to 
vascular changes that might underlie cognitive problems in cancer patients.
Main message Part IV
In summary, our findings indicate that inflammation and vascular factors – which are also 
interrelated107 – may both contribute to cognitive problems and potentially dementia in non-
CNS cancer patients. Although these factors are also associated with cognitive problems and 
dementia in persons without a history of cancer, the impact might be different in non-CNS 
cancer patients and survivors potentially due to acceleration of ageing processes, differences 
in the involved immune cell populations, longer exposure to inflammation, or disruptions in the 





The shortcomings and strengths of the individual studies presented in this thesis have 
been discussed in the corresponding Chapters. In this section, I will elaborate on several 
methodological considerations that generally apply to the research described in this thesis.
Study setting
The majority of the studies in this thesis were embedded in the Rotterdam Study, a large 
prospective population-based cohort study.110 We chose to study cognitive function in cancer 
patients in a population-based setting, because of the following three advantages that will 
be discussed in more detail: (i) limiting selection of cancer patients; (ii) studying changes in 
cognitive function from before to after cancer diagnosis; and (iii) including a large population 
of cancer patients with different cancer types and treatments. 
 Firstly, the design of the Rotterdam Study increases generalisability of the findings to the 
general population and reduces the possibility of selection bias. We hypothesised that selection 
of participants in clinical settings might have unduly influenced the prevalence and severity 
of cognitive problems in cancer patients, because cancer patients with cognitive problems 
might be more willing to participate in a study on cognitive function. Therefore, despite the 
lack of ethnic and socioeconomic diversity in the Rotterdam Study, studying participants in a 
population-based setting increases the generalisability of findings to the general population. 
Nevertheless, also in population-based studies some selection is inevitable. For instance, 
persons with poorer health status are less likely to participate in observational studies.111 
Such selection may have resulted in the inclusion of relatively healthy participants and 
may therefore have affected the obtained effect estimates. For instance, in Chapter 7 we 
encountered selection of cancer patients that we did not anticipate. In this study, we included 
cancer patients with at least one cognitive assessment before cancer diagnosis and – as 
an extension of Chapter 5 – at least one cognitive assessment after diagnosis. We had to 
exclude 64.3% of the participants with cancer because they had no cognitive assessment 
after diagnosis. These cancer patients were older and had more aggressive cancer types than 
included patients, indicating that we selected the healthiest cancer patients. Almost half of the 
excluded cancer patients had died within five years after their last cognitive assessment. Due 
to the selection of the studied population, the effect estimates may have been underestimated. 
Because of the long interval between assessments, these patients would probably not have 
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Figure 3 Study design of the Rotterdam Study versus that of clinical studies.
A) Participants in the Rotterdam Study undergo a cognitive assessment every three to six years. During 
follow-up, some participants are diagnosed with cancer. Therefore, we can study cognitive assessments 
before and after cancer diagnosis. B) Some participants who are diagnosed with cancer die or are lost 
to follow-up before their first cognitive assessment after cancer diagnosis. These participants could not 
have been included in our study on cognitive function after cancer diagnosis, which may have resulted 
in selection bias. C) In clinical studies, cancer patients are assessed multiple times shortly after cancer 
diagnosis. Therefore, patients who die within two years after cancer diagnosis may still have participated 
in a clinical study. 
 Secondly, we were interested in the change in cognitive function from before to after 
cancer diagnosis. The population-based setting allowed us to study purely the effects of 
cancer itself and shared risk factors on cognitive function before cancer diagnosis by limiting 
the effects of psychological factors. Although our findings suggest that cognitive function is 
not affected before cancer diagnosis, the median time between the date of the last cognitive 
assessment before cancer diagnosis and the date of diagnosis ranged between 2.4 and 
3.7 years. Therefore, we cannot rule out that cognitive function is also not affected directly 
preceding cancer diagnosis. After cancer diagnosis, the median time between the date of 
diagnosis and the date of first cognitive assessment ranged between 2.7 and 3.8 years. These 
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findings provide insight in the overall trajectory of cognitive function from before to after cancer 
diagnosis in the general population of cancer patients, but are not directly comparable to 
clinical studies that have assessed cognitive function in a subgroup of cancer patients multiple 
times shortly after cancer diagnosis and treatment.
 Thirdly, we aimed to study the change in cognitive function in a large population of cancer 
patients with different cancer types and treatments to understand cognitive change in the 
general population of cancer patients. Although the number of included patients in clinical 
studies has been growing over the last years, the largest study – which has a follow-up 
duration shorter than one year – comprises 580 breast cancer patients.112 We included more 
cancer patients in our studies on cognitive function, but these cancer patients represented a 
heterogeneous group of cancer patients. This enabled us to draw conclusions about cancer 
patients in general, but not about subgroups of cancer patients and survivors. 
Ascertainment of cancer
Table 1 shows the total number of patients per cancer type for different age categories in 
the Rotterdam Study and in the Netherlands. The distribution of different cancer types in the 
Rotterdam Study is comparable to that in the Netherlands. In the Rotterdam Study, cancers 
are registered based on medical discharge letters and the general practitioner’s status in 
addition to linkage with the national hospital discharge registry, pathology databases, and 
the Netherlands Cancer Registry. Using these different sources, we can collect information 
about both pathology-confirmed and non-pathology-confirmed cancer diagnoses. To limit 
false positive findings, we included only pathology-confirmed cancers in our primary analyses 
and performed sensitivity analyses – results were not always shown – by including non-
pathology-confirmed cancers. Neglecting non-pathology-confirmed cancers might result 
in information bias, i.e., bias that occurs as a result of misclassification of the exposure or 
outcome. Information bias can be differential if misclassification of the disease is related to the 
exposure.113 For instance, persons with cognitive impairment or dementia might be less likely 
to undergo pathological confirmation of the tumour (surveillance bias). This can result in either 
an under- or an overestimation of the association. 
 Another important aspect in the diagnosis of cancer is the date of diagnosis. The date of 
cancer diagnosis is primarily based on the date of pathological confirmation of the cancer. 
In absence of pathological confirmation, we used the date of hospital admission or hospital 
discharge letter. We showed in Chapter 2 that the date of cancer diagnosis in the Rotterdam 
Study was often inaccurate (11.8% of the cancers). We have updated the date of diagnosis 
by evaluating the original medical files. Accuracy of the date of diagnosis is in particular 










































































































































































































































































































































































































































































































































































































































































































































































































































































cognitive function before cancer diagnosis, we would ideally have assessed cognition before 
start of the diagnostic work-up of cancer to fully exclude the effects of psychological factors 
such as stress. Although the date of cancer diagnosis marks a new phase in a person’s life, 
it does not reflect the origin of the cancer. The incipient phase of cancer varies between five 
to forty years for solid tumours. Against this background, it is challenging to study the causal 
effect of certain factors such as plasma amyloid-β (Chapter 10) and atherosclerosis (Chapter 
15) on cancer. This is furthermore complicated by the fact that latency periods – i.e., the 
period between biological initiation of cancer and cancer diagnosis – differ per cancer type. 
Unfortunately, data on latency periods is limited. Estimates of these periods can be obtained 
using statistical models, but – to reduce the effects of potential biases – these models can only 
be used for cancer types with high mortality rates and limited availability of effective treatment 
options to allow the disease to follow its natural course.114 Also, the obtained estimates can 
differ per statistical model and are probably not truly exact. For instance, the latency period for 
pancreatic cancer was estimated at 8.6 years using statistical models, whereas a biological 
study estimated its latency period between 18.5 and 21.2 years.115 Despite these limitations, 
the estimates obtained from statistical models may help to distinguish between cancers with 
short and long latency periods. The following latency periods have been estimated: a relatively 
short latency period for hepatic cancer (10.8 years), pancreatic cancer (8.6 years), and lung 
cancer (13.6 years), and a long latency period for acute myeloid leukaemia (25.8 years), 
stomach cancer (22.9 years), and brain cancer (21.9 years).114 Given these long latency 
periods, any association found in Chapter 10 and 15 may therefore also reflect reverse 
causation, i.e., cancer itself may cause higher levels of plasma amyloid-β and atherosclerosis.
 Lastly, we wanted to highlight the availability of detailed information about cancer stage 
and treatment. The Netherlands Cancer Registry provides information about the TNM 
Classification of Malignant Tumours, but this type of staging differs per cancer type. In 
addition, often one aspect of the TNM stage was missing. Due to these reasons, we were 
only able to classify patients into non-metastatic and metastatic disease at moment of cancer 
diagnosis. In addition, the Netherlands Cancer Registry collects information about cancer 
treatment, but only about the first-line therapy. Nowadays patients often receive second- or 
third-line therapies. To capture also these lines of therapy, we collected information about 
cancer treatment by evaluating the original medical files of the participants that were collected 
by the Rotterdam Study. This was not feasible for cancer stage, since this information was 
often missing in the medical files.
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Ascertainment of cognitive function 
Cognitive function in participants of the Rotterdam Study is assessed using a neuropsychological 
battery. Participants undergo cognitive screening during home interviews using the Mini-
Mental State Examination. From 1997 onwards, participants are assessed at the research 
centre using the Word Fluency Test, Letter-Digit Substitution Test, and Stroop Test. The test 
battery was further expanded with the Purdue Pegboard Test in 1999 and the Word Learning 
Test in 2002. Lastly, in 2006 the Design Organisation Test was added to the study protocol 
and in 2009 gait assessment. We did not include the Design Organisation Test and gait 
assessment in the studies on cancer and cognition due to the limited number of participants 
who completed these assessments before the end of complete cancer follow-up. Besides 
these objective measures of cognitive function, participants received three questions about 
memory complaints that may relate to subjective cognitive function. During home interviews, 
participants were asked the following three questions: (i) ‘Do you have more problems 
remembering things than before?’; (ii) ‘Has there been an increase in the times that you forgot 
what you were up to?’; and (iii) ‘Do you have more word-finding problems than before?’. 
 Together, the objective cognitive tests and measures of self-reported memory complaints 
can provide good insight in a person’s cognitive function. Although it has been shown that 
objective and subjective cognitive function correlate poorly,116 our findings on mild cognitive 
impairment and the risk of cancer might indicate that the combination of objective and subjective 
cognitive function is important. In this section on the ascertainment of cognitive function, I will 
elaborate on two concerns: (i) practice effects; and (ii) use of the general cognitive factor.
Practice effects
Repeated exposure to the same cognitive test can result in test-retest effects, including 
practice effects.117 Persons become more familiar with the tests and can develop strategies 
to deal with certain tests, such as clustering words during the Word Learning Test. Failure of 
accounting for practice effects can result in artificial improvement in cognitive function over 
time. Different studies have quantified the magnitude of practice effects, but most studies 
have determined these effects in a relatively short time period (ranging between six days to 
one year).117-121 
 In Chapter 4, we write the following limitation in the Discussion section: ‘Second, 
repetitive administering of cognitive tests can lead to learning effects, which could have led 
to overestimating performance with increasing age. However, these effects are expected to 
be limited, since the median test interval was 5.1 years for cognitive assessments and 5.4 
years for motor assessments.’. In the first sentence we acknowledged that practice effects 
might have influenced our findings. However, in the second sentence, we attenuated this 
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acknowledgement by speculating that the impact of practice effects is limited because of the 
long time period between assessments. The number of studies that has investigated practice 
effects over a long – i.e., multiple years – interval is very limited. One study has revealed that 
– depending on the administered cognitive test – up to seven to 13 years had to elapse before 
the advantage of the prior cognitive assessment was eliminated.122 This study, however, has 
investigated practice effects in persons between ages 18 and 58 years and may therefore not 
be generalisable to the population of the Rotterdam Study. Hence, I briefly explored if there 
were any indications of practice effects in the Rotterdam Study.
 I focused on the following four cognitive tests: Word Fluency Test, Letter-Digit Substitution 
Test, Stroop Test: Interference, and the Word Learning Test: Delayed recall. Next, I calculated 
the mean test score of participants who were aged 65 years at time of their first assessment, 
of those who were aged 65 years at their second assessment, and of participants who were 
aged 65 years at their third assessment, see Figure 4. The median (interquartile range) time 
between assessments was 5 years (4 to 6) for those with two assessments and 2 years (2 
to 2) for those with three assessments. Most participants who underwent three assessments 
participated in an additional examination round – the Rotterdam Scan Study – which took 
place between the original examination rounds. Therefore, their median time between 
assessments is lower than that of participants with only two assessments. I repeated this 
for the age of 70 years (Figure 4). Interestingly, persons who had undergone at least one 
cognitive test previously scored higher on that cognitive test than persons of the same age 
who were exposed to that cognitive test for the first time.
 These practice effects need to be further explored, including the impact of sex and 
education on these effects. Also, it has been shown that the magnitude of practice effects may 
differ between cognitively intact and cognitively impaired persons. For instance, in persons 
with amnestic mild cognitive impairment, loss of short-term practice effects was related to 
worse cognitive outcomes after one year.123 Furthermore, patients with dementia did not show 
practice effects.124 Against this background, it would be interesting to investigate if cancer 
patients and survivors show the same practice effects as cognitively intact persons without a 
history of cancer.
General cognitive function
The studies in this thesis primarily focused on individual cognitive tests. To evaluate general 
cognitive function, we additionally studied the general cognitive factor in the Chapters 5, 6, 
13, and 16. The general cognitive factor can be used as proxy of intelligence among young 
persons. In older persons, it is more related to general cognitive function as it decreases with 
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Figure 4 Practice effects in the Rotterdam Study.
Mean test scores and corresponding standard deviations are plotted for participants aged 65 or 70 years 
at their first, second, and third assessment. * Higher score indicates worse performance. † Only one 




the shared variance between cognitive tests.125 In other words, it explains that persons who 
are good at one cognitive test tend to be good at other types of cognitive tests. Part of the 
remaining variance is attributable to tests within a specific cognitive domain – persons who 
are good in a test related to a specific domain tend to be good in other tests related to that 
same domain – or to specific cognitive skills associated with individual cognitive tests. It has 
been shown that the general cognitive factor is independent from the cognitive tests used 
within the neuropsychological battery and may therefore be used to compare results with 
other studies.32
 The general cognitive factor can be calculated using principal component analysis. In 
this thesis, we included the following five individual cognitive tests to calculate the general 
cognitive factor: Word Fluency Test, Letter-Digit Substitution Test, Stroop Test: Interference, 
Purdue Pegboard Test, and Word Learning Test: Delayed recall. If a cognitive test consisted 
of multiple subtasks we included only one subtask to prevent distortion of the factor loadings 
due to correlation between subtasks. The general cognitive factor was identified as the 
first unrotated component of the principal component analysis and explained 53.4% of the 
variance in cognitive tests in the first assessment round in which all tests were administered 
(i.e., fourth assessment round of the first subcohort, second round of the second subcohort, 
and first round of the third subcohort).
 Despite multiple advantages such as reflecting general cognitive function, reducing 
the amount of data – and thereby the number of comparisons – and being comparable to 
other studies, it has also an important disadvantage. All individual cognitive tests have to 
be completed in order to calculate this factor. This results not only in a smaller, but also 
in a selected study population. Some of the included cognitive tests were included in the 
Rotterdam Study from 2002 onwards. Therefore, the general cognitive factor could only be 
calculated from 2002 onwards. Table 2 illustrates the problem of this selection. Participants 
who had completed all five cognitive tests were on average younger, had a higher educational 
level, and had higher cognitive test scores than participants with at least one, but not more 
than four of the cognitive test results. It is therefore important to keep this selection in mind 
when interpreting the results of the general cognitive factor.
Ascertainment of dementia
Whereas cognitive assessments – except for the Mini-Mental State Examination – take place in 
the research centre of the Rotterdam Study, potentially resulting in missing assessments after 
the diagnosis of cancer, information on a dementia diagnosis is continuously obtained through 
linkage with medical records from general practitioners and the regional institute for outpatient 
mental health care.126 In addition to this linkage, participants are screened for dementia during 
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the home interview with the Mini-Mental State Examination and the Geriatric Mental Schedule 
organic level. Using this combined approach, we aim to capture the majority of the dementia 
diagnoses. Some studies on cancer and dementia have relied on administrative claims data 
to identify dementia diagnoses, for instance through records of the health insurance program 
Medicare63,72,127-130 or through International Classification of Diseases codes.131 This approach 
is much less accurate and more sensitive to information bias due to potential misclassification. 
 Similar to cancer, dementia has a long incipient phase. Although many studies have tried 
to characterise this incipient phase by studying dynamic biomarkers such as amyloid-β, tau, 
and brain tissue volumes, it still is unknown how many years the pathophysiological process 
of dementia starts before clinical manifestation of the disease.132 Therefore, we cannot rule 
 
Table 2 Overview of characteristics and cognitive test scores of participants who had complete 












Age at cognitive assessment, years, mean (SD) 65.5 years (10.1) 67.9 years (10.8)
Women, No. (%) 4274 (57.7) 793 (55.3)
Educational level, No. (%)
 Primary 747 (10.1) 219 (15.3)
 Lower 2980 (40.2) 574 (40.1)
 Intermediate 2183 (29.4) 384 (26.8)
 Higher 1430 (19.3) 240 (16.7)
Cognitive test score
 Word Fluency Test, mean (SD) 22.2 (5.8) 20.5 (6.6)
 Letter-Digit Substitution Test, mean (SD) 29.2 (7.3) 26.6 (7.8)
 Stroop Test: Interference, seconds, median (IQR) 46.9 (38.7 to 59.7) 55.9 (43.5 to 78.9)
 Purdue Pegboard Test, mean (SD) 35.2 (5.4) 33.7 (6.1)
 Word Learning Test: Delayed recall, mean (SD) 7.2 (2.9) 6.1 (3)
Missing values are not imputed and therefore numbers do not always sum up to 100%. * Cognitive 
assessments took place at the fourth visit of the first subcohort, the second visit of the second subcohort, 
and the first visit of the third subcohort. Those with complete cognitive test scores had completed the Word 
Fluency Test, Letter-Digit Substitution Test, Stroop test: Interference subtask, Purdue Pegboard Test, 
and Word Learning Test: Delayed recall. Those with incomplete cognitive test scores had at least one 
of these tests complete. † 472 (32.9%) had missing Word Fluency Test score, 252 participants (17.6%) 
had missing Letter-Digit Substitution Test score, 834 (58.2%) had missing Stroop Test: Interference, 440 
(30.7%) had missing Purdue Pegboard Test score, and 823 (57.4%) had missing Word Learning Test: 
Delayed recall score. 
IQR = interquartile range, SD = standard deviation.
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out reverse causation when studying an exposure, for instance cancer (Chapter 12) or 
inflammation (Chapter 14), in relation to the risk of dementia. 
Statistical approach
Throughout this thesis, we used different statistical approaches to study our research questions. 
Regarding longitudinal data, we used the linear mixed model, Cox proportional hazards model, 
and joint model. The choice of these models primarily depended on the research question, but 
we could have used different models to analyse our data. For instance, we could have used 
joint models – which jointly model a time-to-event outcome with the longitudinal response – to 
determine the change in cognitive function in relation to the risk of cancer. We chose however 
the nested case-control setting with linear mixed models to fully control for age, and – if there 
was a difference in change in cognitive function between cancer patients and cancer-free 
controls – to determine the rate of cognitive decline towards cancer diagnosis. In this last part 
of Methodological considerations, I will briefly touch upon the shortcomings and merits of the 
used statistical models, methods to deal with the competing risk of death, and confounding. 
Statistical models to deal with longitudinal data
Longitudinal data poses several challenges.133 Measurements that are repeated over time 
within the same person are correlated. Furthermore, different persons are measured at 
different moments in time and measurements within persons are often missing, resulting in 
unbalanced data. For these reasons, simple statistical methods such as linear regression 
models are not optimal for analysing longitudinal data. We therefore used linear mixed models 
to analyse repeated measurements of cognitive function in Chapter 4, 5 and 7. To illustrate 
the unbalanced data, I have included the individual, raw trajectories of cognitive function in the 
plots of Chapter 7 in Figure 5. Each person has a unique trajectory, i.e., each person has a 
different intercept and slope of this trajectory. We assume that persons are randomly selected 
from the population. Therefore, the corresponding regression coefficients are sampled from 
a population of regression coefficients. Under this assumption, different persons share the 
same random effects, which accounts for the correlation between repeated measurements 
within one person. In addition, the linear mixed model can handle unbalanced data, enabling 
us to also include persons with only one measurement.
 In Chapter 6, 9, 10, 11, 12, and 15 we studied either cancer or dementia as an outcome. 
To deal with the time until the outcome of interest – i.e., the time that a person was at risk – we 
used Cox proportional hazards models. Simple statistical methods cannot be used to analyse 
such data because of censoring, i.e., persons who do not experience the outcome of interest 
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Figure 5 Trajectories of cognitive test scores in cancer patients from before to after diagnosis.
The trajectories estimated for the total population of cancer patients are shown in yellow. The trajectories 




censoring – in the Competing risk of death section. We further extended the traditional Cox 
proportional hazards model by studying dementia (Chapter 9) and cancer (Chapter 12) as 
time-dependent variable. This approach can account for immortal time (Box 1). We could 
not use this extended model to study the change in inflammatory ratios and the risk of 
dementia in Chapter 14, because the extended Cox proportional hazards model assumes 
that the trajectories of continuous, time-dependent variables are fully specified and measured 
without error. Inflammatory ratios are endogenous variables that were measured only during 
the research centre visits. Therefore, the complete trajectory of these variables is often 
unobserved, resulting in an unrealistic, step-wise trajectory. Furthermore, endogenous 
variables are often measured with error. To deal with endogenous, time-dependent variables, 
we used the joint model.
 Joint models link the survival model with repeated measurements of an endogenous 
variable. The linear mixed model can estimate the complete trajectory of the variable and can 
account for the measurement error or variability. Using joint models, we could estimate the 
difference in inflammatory ratios in relation to dementia by using all repeated measurements 
Box 1 Immortal time.
The date of cancer diagnosis usually differs from the date of study entry. Participants with 
a longer follow-up are more likely to be diagnosed with cancer during study follow-up than 
those with a shorter follow-up. Therefore, a cancer diagnosis is only observed when a 
participant survives up to the date of the potential cancer diagnosis. The time between 
study entry and cancer diagnosis is then referred to as immortal time, i.e., the follow-up 
time during which the outcome cannot occur. Note that immortal time bias differs from 
survival bias.134,135 Misclassification of immortal time can result in information bias, whereas 
exclusion of immortal time can result in selection bias.136 
 There are different ways to deal with immortal time of which three are presented in 
Figure 6.137 The first solution uses the time-dependent Cox proportional hazards model 
in which the time before cancer diagnosis is categorised as unexposed and the time after 
cancer diagnosis is categorised as exposed. The second solution uses inverse probability 
weights to account for the time until cancer diagnosis. The third solution emulates a trial 
by cloning each participant to a ‘cancer arm’ and a ‘non-cancer arm’. These arms are then 
identical at baseline. A participant with cancer will then be censored in the ‘non-cancer arm’ 
at time of cancer diagnosis, whereas a participant without cancer will be censored in the 
‘cancer arm’ after a specified time period. Subsequently, inverse probability weighting can 
be used to account for this informative censoring. 
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Figure 6 Illustration of immortal time.
The time between study entry and cancer diagnosis is referred to as immortal time, because death cannot 
have occurred before the cancer diagnosis. Immortal time can be solved by (1) using time-dependent Cox 
proportional hazards models in which immortal time is classified as time not exposed to cancer, (2) using 
inverse probability weights for the time until cancer diagnosis, or (3) using an emulated trial design. In this 
design, participants are cloned to a ‘non-cancer arm’ and a ‘cancer arm’. Participants who are diagnosed 
with cancer during follow-up are censored at the date of cancer diagnosis in the ‘non-cancer arm’. This 
figure has been adapted from Maringe et al. (2020).137
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of the inflammatory ratios while accounting for measurement error or variability of these ratios.
Competing risk of death
We minimised the effects of surveillance and survival bias by studying the preclinical stages of 
cancer and dementia. Nevertheless, death can preclude occurrence of the outcome of interest 
in participants who are at risk for the outcome. We tried to take the competing risk of death into 
account by using cause-specific Cox proportional hazards models. These models are often 
preferred when studying aetiological research questions.138,139 For aetiological associations, 
we are interested in the risk of the outcome of interest in participants who have not developed 
this outcome at certain time t (risk set at time t). When they experience the competing event of 
death, participants can be removed from the risk set at time t. Another approach to deal with 
competing risk is by using the subdistribution hazards model of Fine and Gray.140 This model 
is primarily used for predictive and prognostic research questions and calculates the absolute 
risk of the outcome by keeping persons in the risk set even after experiencing the competing 
risk of death. If the risk of death is different between participants with and without exposure, 
the risk set is artificially inflated in the group with the highest mortality rate. This results by 
definition in a lower subdistribution hazard. In predictive and prognostic studies, estimates 
can be influenced by having a reduced number of participants remaining at risk for the 
outcome due to an increased number of deaths. Therefore, it is more appropriate to keep the 
participants in the risk set after the competing event has occurred. Since the subdistribution 
hazard can provide information about the distribution of death between different groups of 
exposure, it can be used in combination with cause-specific Cox proportional hazards models 
to get insight in the problem of the competing risk of death in aetiological research questions. 
Note that the subdistribution hazards model of Fine and Gray can only be used for time-
independent exposures.141
 One of the assumptions of the cause-specific Cox proportional hazards model however 
is that censoring is non-informative.142 Censoring at any time during the follow-up must be 
independent of changing values of prognostic factors during follow-up.143 This assumption is 
unlikely to be met if competing events are defined as censoring events. Because cancer and 
dementia are strongly related to death, censoring for death is not non-informative. Therefore, 
censoring for death as competing event in the relation between cancer and dementia might 
result in biased hazard ratios. We have accounted for this informative censoring in Chapter 




Confounders are variables that are related to both the exposure of interest and the outcome 
of interest. Confounding is discussed in more detail in Box 2. In most studies in this thesis, 
we corrected and stratified for covariates that are associated with both cancer and cognitive 
impairment, i.e., age (either as covariate or as time scale), sex, educational level, body 
mass index, smoking status, and alcohol use. In few studies we also included the following 
covariates: psycholeptic drug use, Centre for Epidemiologic Studies Depression scale sum-
score, diabetes mellitus, hypercholesterolaemia, blood pressure, and hypertension. We 
selected these confounders based on existing knowledge. Another often used approach is to 
test whether a covariate is a confounder in the used dataset. This approach is not adequate, 
because statistics alone cannot make determinations about the temporal order. Also, statistical 
analyses cannot distinguish between confounders and mediators.144 It remains however 
challenging to select the optimal set of confounders when studying all cancer types, because 
the relation between a confounder and cancer differs per cancer type. In addition, we were not 
able to correct for other potential confounders due to missing or incomplete data, which might 
have resulted in residual confounding. Potential confounders are diet, physical activity, frailty, 
anxiety, and fatigue. For instance, it has been shown that before systemic cancer treatment, 
differences in cognitive function and white matter integrity between breast cancer patients 
and cancer-free controls were no longer statistically significant after correcting for fatigue, 
emphasising the importance of taking fatigue into account.145
IMPLICATIONS
The number of patients with cancer is increasing worldwide.146 About 20% to 30% of all non-
CNS cancer patients have cognitive problems, which can last up to more than twenty years 
after cessation of treatment in a subgroup of cancer survivors.16,81 Therefore, more insight in 
cognitive problems and the risk of dementia in cancer patients is necessary to inform patients 
and clinicians, and to develop prevention and intervention strategies. I will first discuss 
implications of our findings on cancer registration for cancer registries. Subsequently, I will 
focus on clinical implications. Implications for future research will be discussed separately in 




Confounding is a distortion that occurs when the exposure of interest is mixed together 
with the effect of another variable that is associated with the outcome.113 Let me illustrate 
confounding with the following example: the relation between carrying a cigarette lighter 
and the risk of lung cancer (Figure 7).147 Persons who carry a cigarette lighter have a 
higher risk of lung cancer than persons who do not carry a lighter. The cigarette lighter 
itself does not cause cancer. Carrying a cigarette lighter is mixed up with smoking, i.e., the 
relation between carrying a cigarette lighter and the risk of lung cancer is confounded by 
smoking. This results in a spurious association between carrying a cigarette lighter and the 
risk of lung cancer.
Carrying a 
cigarette lighter Lung cancerSmoking
Figure 7 Directed acyclic graph to illustrate confounding.
A variable is a confounder if it is a common cause of both the exposure and outcome.148 
Note that carrying a lighter itself is not a confounder in the relation between smoking and 
the risk of lung cancer, because carrying a lighter is the result of smoking, i.e., carrying a 
lighter does not cause smoking.149  
 There are several methods to deal with confounding. The following three methods can 
deal with confounding on the level of the study design. Firstly, you can prevent confounding 
by randomisation. The main advantage is that randomisation also controls for unknown 
confounders. Secondly, you can restrict the studied population, for instance by selecting 
only non-smokers. This method limits the generalisability. Thirdly, you can match two 
groups based on the confounding factor. On the level of data analysis, you can control for 
confounding by stratification, multi-variable modelling, or by using an instrumental variable. 




Cancers that are not confirmed by pathology were often missed by the Netherlands Cancer 
Registry. Of all registered cancers in the Rotterdam Study, 11.7% was non-pathology-
confirmed. Importantly, pathological confirmation was associated with tumour and patient 
characteristics, and survival. This underlines the necessity to continuously improve the quality 
of cancer registration and to combine multiple sources of cancer registration, for instance by 
standardised linkages between a population-based study and the national cancer registry. 
 A second implication – or recommendation – for cancer registries would be to collect 
follow-up data of cancer patients. The Netherlands Cancer Registry registers the first-line 
cancer treatment, but not the subsequent lines of treatment. This information is insufficient 
to address research questions after cancer diagnosis. Cancer registries could for instance 
update treatment-related information every six months.150,151 Given that not all cancers in the 
Rotterdam Study are registered by the Netherlands Cancer Registry, we should also consider 
to document details on cancer treatment in the Rotterdam Study. 
Patients and clinicians
At a population-level, cognitive function in cancer patients changes similarly to that in cancer-
free persons. Furthermore, we found no evidence that cancer patients have a higher risk of 
dementia. These findings may provide some reassurance to cancer patients, in particular 
those with favourable cancer types who received only local treatment. Patients treated with 
systemic treatments such as chemotherapy might have different cognitive trajectories. In 
addition, findings on a group-level are not always generalisable to the individual-level.152
 We therefore suggest using a personalised approach, rather than screening all cancer 
patients for cognitive problems. Patients and clinicians should be educated about cognitive 
problems in cancer patients in order to signal cognitive problems in an early stage. Patients 
can subsequently be referred to a neuropsychologist to undergo cognitive assessment and – 
if necessary – cognitive rehabilitation.153 This can result in improved quality of life and daily life 
functioning of cancer patients and survivors.
 Importantly, among the growing population of cancer patients and survivors the percentage 
of elderly patients and survivors will further increase,154 which poses several challenges for 
physicians, caregivers, and healthcare systems. Firstly, given that cancer treatment may 
accelerate ageing processes, elderly patients in particular may be more vulnerable to the 
effects of cancer treatment on the brain.155 Vulnerable elderly patients and survivors may be 
identified by comprehensive geriatric assessments before and following cancer treatment in 
order to start interventions such as cognitive rehabilitation in an early stage.156 Use of such 
geriatric assessments has also been associated with improved survival and physical state.157 
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Secondly, elderly patient care is often complex and requires involvement of caregivers.158 
Patients with comorbid cancer and dementia receive less often cancer treatment and have 
poorer survival than patients without dementia.159-164 In addition, comorbid cancer and dementia 
has been associated with agitation, depression, and sleep disturbances, but patients are often 
not able to report such symptoms.165 Therefore, care for patients with comorbid cancer and 
cognitive impairment or dementia should be further improved and healthcare professionals 
should pay close attention to this group of patients.
DIRECTIONS FOR FUTURE RESEARCH
The studies presented in this thesis have contributed to the understanding of the change in 
cognitive function and the risk of dementia in cancer patients. Many knowledge gaps in this 
field are still not filled. Furthermore, our work has generated several new questions that need 
to be answered. In this section, I will discuss some of these remaining knowledge gaps and 
new questions with regard to risk factors of cognitive problems in cancer patients, mechanisms 
underpinning these cognitive problems, and approaches to deal with the relation between 
cancer and dementia. During this discussion, I will also highlight some of our ongoing studies.
Identifying cancer patients at high risk of cognitive problems
At a population-level, we found that cognitive function in cancer patients declined similarly to 
that in persons without a history of cancer. In addition, previous clinical studies have shown 
that cancer patients with specific types of cancer or treatment have more often cognitive 
problems than cancer-free persons.16-28 This suggests that certain subgroups of cancer 
patients and survivors – that could not have been captured in our population-based study – 
might be vulnerable to develop cognitive problems. Identification of these high risk patients 
is necessary in order to minimise the negative impact of cognitive problems on quality of life.
 Several studies have focused on genetics to identify high risk patients.166 The most 
frequently studied genes are apolipoprotein E (APOE) and catechol-O-methyltransferase 
(COMT), which are associated with cognitive function and the risk of dementia irrespective 
of cancer status.167,168 Some studies have suggested that cancer patients who carry at least 
one APOE ε4 allele have more often cognitive impairment than non-carriers.19,169-171 This has 
also been supported by a preclinical study showing that mice who carried the APOE ε4 allele 
and were treated with chemotherapy performed worse than (i) mice with the APOE ε3 allele 
and (ii) untreated mice with the APOE ε4 allele.172 In addition, it has been shown that breast 
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cancer patients who were COMT-Val carriers had worse cognitive function than (i) breast 
cancer patients who were non-carriers and (ii) cancer-free controls who were also COMT-Val 
carriers.173 Nevertheless, findings across different studies are inconsistent.166 
 We have recently directed our attention to two other genes that are well known in the 
oncology field: BRCA1 and BRCA2. BRCA1 and BRCA2 are tumour suppressor genes that 
are involved in DNA double-strand break repair by homologous recombination.174,175 Persons 
with a germline BRCA1 or BRCA2 mutation have a strongly increased risk of developing 
cancer.176-178 Interestingly, recent evidence has highlighted the potential role of BRCA1 in 
impaired cognitive function and dementia.179-181 We have previously investigated cognitive 
function in breast cancer survivors with a germline BRCA1 mutation and found a higher 
prevalence of cognitive impairment in these survivors than in breast cancer survivors without 
such a mutation (21% cognitive impairment in patients without a mutation versus 36% in 
patients with a mutation, unpublished data). However, breast cancer survivors with a BRCA1 
mutation had received more intensive cancer treatment than patients without a mutation, 
which by itself can affect cognitive function.182,183 To study purely the effect of BRCA1 and 
BRCA2 on cognitive function, we are currently studying prevalence of cognitive problems and 
dementia in cancer-naive men with a germline BRCA1 or BRCA2 mutation. The risk of cancer 
in men with such a mutation is low compared to the risk of cancer in women, as well as the 
performance of risk-reducing surgeries, which may also affect cognitive health.
 Other interesting genes may be those linked to Lynch syndrome or Li-Fraumeni syndrome. 
In addition, epigenetic modifications including DNA methylation, histone modification, and 
microRNA regulation, may explain some of the shared aetiology between cancer and dementia 
and are worthwhile investigating.51
 Apart from genetic factors, it has been suggested that characteristics such as age and 
diabetes mellitus are associated with cognitive impairment in cancer patients.19 When starting 
this thesis, we aimed to identify risk factor profiles for cognitive decline in cancer patients. 
We realised however that part of the effect of risk factors on cognitive function is mediated 
by cancer. For instance, if we want to estimate the effect of smoking on cognitive decline 
in cancer patients, we need to estimate the direct effect of smoking on cognition and the 
indirect effect that is mediated through cancer (Figure 8). If we do not take this mediated 
effect into account and condition on cancer, we create a selection bias, resulting in a distorted 
association between smoking and cognitive decline in cancer patients.184 This effect could be 
taken into account by performing a mediation analysis. An alternative option is to apply existing 
prediction models for cognitive impairment or dementia to cancer patients,185 assuming that 
the effects of these risk factors on cognitive function and dementia in cancer patients are 




Smoking Cancer Cognitive decline
Figure 8 Directed acyclic graph to illustrate selection bias when conditioning on a collider.
When estimating the effect of smoking on cognitive function in cancer patients, we need to take the 
direct effect (effect of smoking on cognitive decline) and the indirect effect (effect of smoking on cognitive 
decline through cancer) into account. When conditioning on cancer, for instance by stratification, we open 
the path between confounders and smoking. This will result in selection bias.
 Certain cancer treatments such as chemotherapy are probably more harmful to cognitive 
function than local cancer treatments. Our study on cognitive function before and after cancer 
diagnosis included mainly cancer patients without treatment or who were treated with surgery 
or radiotherapy. In order to investigate effects of specific treatments, I would recommend 
researchers to include a large, homogenous population of cancer patients. For instance, 
combining multiple population-based cohort studies may result in a large number of cancer 
patients treated with systemic treatment and may therefore shed further light on the cognitive 
trajectory after systemic treatment. We will also further contribute to the understanding of the 
course of cognitive function after systemic treatment by inviting the breast cancer survivors 
in Chapter 13 and 16 for a follow-up study more than ten years after the original study. 
Importantly, many patients currently receive multiple years of different lines of cancer treatment 
to improve their survival. The potential synergistic or cumulative effects of such treatments 
on cognitive function have not been well established yet. Future longitudinal studies should 
therefore closely monitor cognitive effects of concurrent and sequential treatments.
Unravelling underlying mechanisms
We found that inflammation and changes in cerebral blood flow may underlie cognitive 
problems and possibly dementia in cancer patients. The effects of anti-inflammatory drugs 
on cognitive function have been investigated in tumour-bearing mice, showing that low-dose 
aspirin can result in improved memory function.91 It would be of great interest to further explore 
the effects of anti-inflammatory drugs and cardiovascular risk management in cancer patients 
and survivors using clinical trials. Also, given that our findings suggest that an imbalance of 
the immune system towards the innate immunity may underlie late cognitive problems in 
cancer patients, future studies should further investigate the effects of immunotherapy on 
cognitive function.186
 Inflammation and vascular factors are probably not the only mechanisms by which cancer 
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or cancer treatment can result in changes in cognitive function. Since it has been proposed 
that in particular cancer treatment leads to acceleration of ageing processes, other ageing 
pathways may also be related to impaired cognitive function in cancer patients.187,188 For 
instance, chemotherapy has been associated with shortened telomeres.189 In breast cancer 
survivors, lower telomerase – resulting in shorter telomeres – was associated with worse 
cognitive functioning, but longitudinal studies that include pre-treatment assessments are 
needed to assess if telomere length can be used as biomarker for cognitive decline in cancer 
patients and to determine causality of the relation.190 Aspirin has been shown to increase 
telomerase activity and might therefore maintain telomere length.191 If causally related, 
treatment with aspirin might prevent cognitive problems in cancer patients. Other ageing-
related markers that may be of interest are markers of cellular senescence or DNA damage, 
including senescence-associated cytokines such as interleukin-6 and interleukin-8, and 
expression of INK4a/ARF transcripts.187 Trajectories of such markers could be determined 
in large longitudinal studies that also incorporate assessments of cognitive function and 
neuroimaging.
 In addition to ageing-related processes, several studies have proposed a role for the gut 
microbiota in relation to cognitive impairment in cancer patients.192,193 The gut microbiota 
is an important modulator of the immune system that can influence brain function and 
behaviour.194 Disruption has been related to hepatic encephalopathy and psychiatric diseases. 
Chemotherapy and radiotherapy can induce changes in the composition of gut microbiota.195 
The impact of the gut microbiota on cognitive function could be investigated by studying the 
change in composition of the gut microbiota from pre- to post cancer treatment in relation 
to changes in cognitive function. If related to impaired cognitive function in cancer patients, 
the gut microbiota could be explored as therapeutic target through restoration of the gut 
microbiota. 
 Lastly, recent evidence has shown that cancer might not only affect the brain, but that the 
brain might also influence cancer initiation and progression. Several studies have reported a 
higher risk of cancer in patients with depression.196-199 We are currently investigating the relation 
between psychosocial factors including depression, anxiety, and grief in the PSYchosocial 
factors and Cancer (PSY-CA) consortium that is composed of 18 cohort studies. Also after 
clinical manifestation of cancer, psychosocial conditions might affect tumour biology.200 For 
instance, stress-induced activation of the sympathetic nervous system may stimulate tumour 
angiogenesis – and therefore tumour growth – via the release of noradrenaline.201 Unravelling 
the exact involved mechanisms and the physiological effects may help to further elucidate the 
link between cancer and the brain. 
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Studying the relation between cancer and dementia
We investigated the relation between cancer and dementia by studying preclinical stages of 
both diseases and using advanced statistical methods. Our results do not support an inverse 
association between these two diseases and – if anything – might point towards a positive, 
biological link. Nevertheless, each year several studies have been published that show an 
inverse link between cancer and dementia without using appropriate statistical methods to 
account for the competing risk of death. Moreover, several studies have extensively discussed 
the potential biological mechanisms underlying this inverse link, aiming to identify prevention 
and intervention targets for both diseases.68,69 Given our findings, I would challenge future 
studies to use different approaches in order to limit the effects of surveillance and survival bias 
on the relation between cancer and dementia. In line with our studies, it would be interesting 
to study trajectories of plasma amyloid-β levels in relation to the risk of cancer or to use 
amyloid positron emission tomography neuroimaging in cancer patients. In addition, one 
can investigate the trajectories of carcinoembryonic antigen levels in relation to the risk of 
dementia, or determine the risk of dementia in patients with carcinoma in situ. Regarding 
innovative statistical approaches, simulation studies might provide additional insight in the 
potential magnitude of bias in the link between cancer and dementia. Data could then be 
generated such that patients with cancer have a higher risk of dementia. Also causal inference 
frameworks may be used to clearly specify the research question and to estimate the causal 
relation between cancer and dementia.
Improving cognitive assessments
Lastly, I want to highlight an innovating strategy in the assessment of cognitive function. 
We have recently developed the Amsterdam Cognition Scan, which is an online cognitive 
assessment tool.202,203 Using this tool, participants can be assessed from home, which is time- 
and cost-efficient compared to traditional cognitive tests. Computer experience can easily be 
corrected for by using a measure of self-reported computer use per week.204 This strategy 
might be of particular interest in population-based studies, because we observed that many 
cancer patients did not have a cognitive assessment after cancer diagnosis. It is likely that 
also participants with other disabling diseases skip visits to the research centre after the 
diagnosis. Using an online tool, participants can be assessed more frequently and do not 
have to visit the research centre. In addition, data in the Amsterdam Cognition Scan is stored 
per mouse click, allowing to perform more sophisticated analyses that may capture more 
subtle changes in cognitive function by disentangle different cognitive subprocesses.205 This 
could provide more insight in the change in cognitive function during ageing in the general 




The link between cancer and the brain remains complex. In general, cognitive function in 
cancer patients does not change differently than cognitive function in persons without a 
history of cancer. In addition, we found that – at a population-level – cancer patients are not 
at increased risk of dementia, but there might be a positive, biological link between cancer 
and dementia. I challenge future studies to provide further insight in the link between these 
two diseases. Specific cancer types or systemic treatments may be related to accelerated 
cognitive decline, but single population-based studies are not the optimal setting to investigate 
those subgroups of patients and survivors. In such a subgroup of breast cancer survivors, 
we found that inflammation and cerebral blood flow may be related to late impaired cognitive 
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Great improvements in cancer screening and treatment have ensured prolonged survival of 
many cancer patients. In turn, this has resulted in a growing number of patients and survivors 
who have to deal with long-term and late side effects of the disease itself and its treatment. 
Cognitive problems are among the most frequently reported side effects that can negatively 
affect daily functioning and quality of life. Current studies have primarily studied subgroups 
of cancer patients and may therefore not be generalisable to other populations of cancer 
patients. Also, the origin of cognitive problems, the course of cognitive function, and the risk 
of dementia in non-central nervous system (CNS) cancer patients remain poorly understood. 
Such knowledge is of great importance to develop prevention and intervention strategies for 
cognitive problems in non-CNS cancer patients. This thesis focused on cognitive function 
from before to after cancer diagnosis in the general population of non-CNS cancer patients. In 
addition, this thesis investigated the association between cancer and dementia, and focused 
on potential mechanisms underlying cognitive problems and dementia in non-CNS cancer 
patients. The studies presented in this thesis were embedded in the Rotterdam Study, a large 
prospective population-based cohort study in the Netherlands.
 Part I discusses the quality of cancer registration. We first compared completeness and 
accuracy of cancer registration by the Rotterdam Study with that by the Netherlands Cancer 
Registry in Chapter 2. We found high completeness for pathology-confirmed cancers, but 
cancers without pathological confirmation were often not registered by the Netherlands 
Cancer Registry. In the Rotterdam Study, the date of cancer diagnosis was often inaccurately 
registered. In Chapter 3, we took a closer look at the non-pathology-confirmed cancers and 
found that these cancers were more present in older patients than in younger patients. Also, 
patients with non-pathology-confirmed cancer had a lower overall survival than patients 
with pathology-confirmed cancer. These findings indicate that combining multiple sources of 
cancer registration could improve the quality of cancer registration and that more effort should 
be put into capturing non-pathology-confirmed cancers. 
 Next, Part II focused on the change in cognitive function. We provided a standard of 
trajectories of cognitive and motor function during ageing in the general population in Chapter 
4. We subsequently studied in Chapter 5 the change in cognitive function in cancer patients 
prior to their cancer diagnosis. We found that cognitive function in persons who will be 
diagnosed with cancer changes similarly to that in persons who will remain free of cancer. 
Since changes in cognitive function correlate moderately with changes in brain structure, 
we investigated brain structure before cancer diagnosis in Chapter 6. We found no relation 
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between different measurements of brain structure and the risk of cancer, indicating that 
cancer patients do not have more brain abnormalities before clinical manifestation of cancer. 
Lastly, in Chapter 7, we extended our study on cognitive function prior to cancer diagnosis 
and visualised the trajectories of cognitive function after diagnosis. Also after diagnosis, 
cognitive function in cancer patients changed similarly to that in cancer-free persons. These 
findings indicate that in general, cognitive function in cancer patients changes similarly to 
that in cancer-free persons, thereby providing some reassurance to cancer patients. This 
suggests that the effect of cancer itself on cognitive function is limited. Larger numbers are 
needed to assess cognitive change in patients with specific types of cancer and systemic 
treatment, and to identify high risk patients. 
 Part III was dedicated to the relation between cancer and dementia. Previous studies have 
shown that cancer patients have a lower risk of dementia and vice versa, but the direction of 
this relation may be influenced by methodological bias. We shed light on the biological relation 
between these two diseases using alternative approaches to minimise effects of surveillance 
and survival bias. We first showed in Chapter 8 that Alzheimer’s disease, the most common 
type of dementia, followed a multistep process similar to the process of cancer. In Chapter 9, 
10, and 11, we studied the preclinical stage of either cancer or dementia and linked it to the 
other disease. We showed that patients with dementia have a lower risk of cancer, whereas 
persons with mild cognitive impairment, a preclinical stage of dementia, have a higher risk of 
cancer. Also, persons with higher levels of plasma amyloid-β – one of the earliest changes 
in preclinical dementia – had a higher risk of cancer. Lastly, we found that higher levels of 
the tumour marker carcinoembryonic antigen were related to a higher risk of dementia. In 
Chapter 12, we used alternative methods to account for selection bias to further study the 
risk of dementia in patients with cancer and found that they have a similar risk of dementia to 
that of persons without a history of cancer. Our findings indicate that patients with cancer are 
not at decreased risk of dementia. From a biological perspective, cancer and dementia may 
be positively related.
 Part IV investigated mechanisms underpinning cognitive problems and dementia in 
cancer patients. In Chapter 13 and 14, we focused on inflammatory ratios that can broadly 
capture the relation between innate and adaptive immunity. We found that breast cancer 
survivors – who were treated with chemotherapy on average twenty years ago – had higher 
inflammatory ratios than women without a history of cancer. Also, higher inflammatory ratios 
were associated with lower general cognitive function in breast cancer survivors and in 
cancer-free women, but the association was more pronounced in the breast cancer survivors. 
In addition, we found that higher levels of the same inflammatory ratios were related to a 
higher risk of dementia in the general population. These findings suggest that an imbalance in 
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the immune system towards innate immunity may underlie cognitive problems and potentially 
dementia in cancer patients. In Chapter 15 and 16 we determined the role of vascular factors. 
We showed that atherosclerosis can be present before clinical manifestation of cancer. After 
cancer, breast cancer survivors had lower cerebral perfusion than women without a history of 
cancer. Together, the findings from this Part suggest that inflammation and vascular factors 
may underlie cognitive problems – and potentially dementia – in cancer patients.
 Lastly, in Part V, I reviewed our findings in a broader perspective and discussed several 
methodological considerations, including the difference between population-based settings 
and clinical settings, the potential impact of practice effects, and methods to deal with 
competing risk of death. In addition, I discussed the implications of our research for cancer 
registries and for patients and clinicians. Lastly, I provided directions for future research 
to identify cancer patients at high risk of cognitive problems, to further unravel underlying 






Verbeteringen in kankerscreening en behandeling hebben geleid tot een betere overleving 
van vele patiënten met kanker. Echter heeft dit ook tot gevolg dat veel kankerpatiënten en 
overlevers te maken hebben met lange termijn en late bijwerkingen. Deze bijwerkingen 
kunnen het gevolg zijn van de kanker zelf of van de kankerbehandeling. Een van de 
meest gerapporteerde bijwerkingen zijn cognitieve klachten. Cognitieve klachten kunnen 
het dagelijks functioneren en de kwaliteit van leven negatief beïnvloeden. Eerdere studies 
naar het cognitief functioneren van kankerpatiënten hebben zich voornamelijk gericht op 
subgroepen van kankerpatiënten, waardoor de resultaten mogelijk niet generaliseerbaar 
zijn naar patiënten met andere soorten kanker of kankerbehandelingen. Daarnaast zijn de 
oorzaken van cognitieve problemen, het beloop van het cognitief functioneren en het risico op 
dementie bij patiënten met niet-centraal zenuwstelsel (CZS) kanker onduidelijk. Meer kennis 
over het ontstaan en het beloop van cognitieve problemen is nodig voor het ontwikkelen van 
preventie en interventie strategieën voor cognitieve problemen bij niet-CZS kankerpatiënten. 
Dit proefschrift is gericht op het beloop van het cognitief functioneren in de algemene populatie 
van kankerpatiënten van voor tot na de kankerdiagnose. Daarnaast bestudeert dit proefschrift 
de relatie tussen kanker en dementie, alsmede verschillende mechanismen die mogelijk ten 
grondslag liggen aan cognitieve problemen en dementie bij niet-CZS kankerpatiënten. De 
studies in dit proefschrift zijn gebaseerd op het Rotterdamse ERGO-onderzoek (Erasmus 
Rotterdam Gezondheid en Ouderen), een groot prospectief populatieonderzoek in Nederland.
 Deel I onderzocht de kwaliteit van kankerregistratie. In Hoofdstuk 2 hebben we de 
compleetheid en accuraatheid van kankerregistratie door het ERGO-onderzoek vergeleken 
met dat door de Nederlandse Kankerregistratie. We constateerden dat meer dan 95% van 
alle pathologisch bevestigde kankers was geregistreerd door beide registraties. Het aantal 
geregistreerde niet-pathologisch bevestigde kankers was daarentegen veel lager in de 
Nederlandse Kankerregistratie dan in het ERGO-onderzoek. Daarnaast vonden we dat 
de datum van kankerdiagnose vaak niet juist was geregistreerd in het ERGO-onderzoek. 
Vervolgens hebben we ons in Hoofdstuk 3 gericht op de niet-pathologisch bevestigde 
kankers. We vonden dat oude patiënten vaker een niet-pathologisch bevestigde kanker 
hadden dan jonge patiënten. Bovendien hadden patiënten met een niet-pathologisch 
bevestigde kanker een slechtere overleving dan patiënten met een pathologisch bevestigde 
kanker. Op basis van deze bevindingen hebben we geconcludeerd dat het belangrijk is om 
verschillende bronnen van kankerregistratie te combineren om de kwaliteit van registratie te 
waarborgen. Daarnaast is het belangrijk dat er meer inspanningen worden verricht om ook de 
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niet-pathologisch bevestigde kankers te registreren.
 Vervolgens richtte Deel II zich op de verandering van het cognitief functioneren over de tijd. 
In Hoofdstuk 4 hebben we een standaard gepresenteerd waarin het beloop van cognitieve 
en motorische functies in de algemene bevolking tijdens het ouder worden is weergegeven. 
Vervolgens hebben we in Hoofdstuk 5 het beloop van het cognitief functioneren bij 
kankerpatiënten voor de kankerdiagnose bestudeerd. We vonden dat het beloop van het 
cognitief functioneren van personen die in de toekomst met kanker worden gediagnosticeerd 
hetzelfde is als dat van personen die niet met kanker worden gediagnosticeerd. Gezien 
veranderingen in het cognitief functioneren niet een op een samenhangen met veranderingen 
in de structuur van de hersenen, hebben we in Hoofdstuk 6 de hersenstructuur onderzocht 
van personen die in de toekomst met kanker worden gediagnosticeerd. We vonden geen 
relatie tussen verschillende maten van de hersenstructuur en het risico op kanker, wat 
betekent dat kankerpatiënten geen veranderingen hebben in de hersenstructuur voordat 
zij worden gediagnosticeerd met kanker. Tot slot hebben we in Hoofdstuk 8 onze studie 
voor kankerdiagnose uitgebreid door tevens het beloop van het cognitief functioneren na 
kankerdiagnose in kaart te brengen. Ook na kankerdiagnose was het beloop van het 
cognitief functioneren bij kankerpatiënten hetzelfde als bij personen zonder kanker. Onze 
bevindingen geven aan dat in het algemeen het cognitief functioneren van kankerpatiënten 
hetzelfde verandert als dat van personen zonder kanker, wat enigszins geruststellend is voor 
kankerpatiënten. Dit betekent dat het effect van kanker zelf op de hersenen beperkt is. Grotere 
aantallen patiënten zijn nodig om de verandering van het cognitief functioneren te onderzoeken 
in patiënten met specifieke kankersoorten en na systemische kankerbehandeling. Daarnaast 
is het belangrijk om patiënten te identificeren die mogelijk wel een verhoogd risico hebben op 
het ontwikkelen van cognitieve problemen.
 Deel III was gewijd aan de relatie tussen kanker en dementie. Eerdere studies hebben 
laten zien dat kankerpatiënten een verlaagd risico hebben op dementie en dat patiënten met 
dementie een verlaagd risico hebben op kanker. De inverse richting van deze relatie kan 
echter beïnvloed worden door methodologische bias. We hebben in dit Deel verschillende 
alternatieve methoden toegepast om de effecten van methodologische bias te beperken. 
Hiermee hebben we geprobeerd ons inzicht in de biologische relatie tussen kanker 
en dementie te vergroten. Eerst hebben we in Hoofdstuk 8 laten zien dat de ziekte van 
Alzheimer, de meest voorkomende vorm van dementie, een vergelijkbaar stappen proces 
volgt als kanker. In Hoofdstuk 9, 10 en 11 hebben we het preklinische stadium van 
zowel kanker als dementie onderzocht en vervolgens gerelateerd aan de andere, klinisch 
gemanifesteerde ziekte. We hebben geconstateerd dat patiënten met dementie inderdaad 
een lager risico op kanker hebben, terwijl personen met een geringe cognitieve stoornis, een 
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preklinisch stadium van dementie, een hoger risico op kanker hebben. Bovendien hadden 
personen met hoge waarden van plasma amyloïd-β – een van de eerste veranderingen in 
preklinische dementie – een hoger risico op kanker. Als laatst vonden we dat hogere waarden 
van de tumormarker carcino-embryonaal antigeen gerelateerd waren aan een hoger risico 
op dementie. In Hoofdstuk 12 hebben we alternatieve methoden gebruikt om de gevolgen 
van selectie bias op de relatie tussen kanker en dementie te verminderen. We vonden dat 
het risico op dementie bij patiënten met kanker hetzelfde is als dat van personen zonder 
kanker. Dit betekent dat kankerpatiënten geen verlaagd risico hebben op dementie. Vanuit 
een biologisch perspectief zijn kanker en dementie mogelijk juist positief gerelateerd. 
 Deel IV onderzocht de mechanismen die mogelijk ten grondslag liggen aan cognitieve 
problemen en dementie bij kankerpatiënten. In Hoofdstuk 13 en 14 hebben we ons 
gericht op inflammatoire ratio’s die de verhouding tussen het aangeboren en het adaptief 
immuunsysteem weergeven. We vonden dat borstkanker overlevers – wie twintig jaar 
geleden behandeld waren met chemotherapie – hogere inflammatoire ratio’s hadden dan 
vrouwen zonder voorgeschiedenis van kanker. Daarnaast waren hogere inflammatoire 
ratio’s geassocieerd met een lager algemeen cognitief functioneren in zowel borstkanker 
overlevers als in vrouwen zonder kanker. Echter was deze associatie meer uitgesproken in 
de borstkanker overlevers. Verder vonden we dat hogere inflammatoire ratio’s in de algemene 
populatie waren gerelateerd aan een hoger risico op dementie. Deze bevindingen suggereren 
dat een disbalans van het immuunsysteem richting het aangeboren systeem mogelijk 
een rol kan spelen in de pathogenese van cognitieve problemen en mogelijk dementie bij 
kankerpatiënten. In Hoofdstuk 15 en 16 hebben we de rol van vasculaire factoren onderzocht. 
We hebben laten zien dat atherosclerose al aanwezig kan zijn voor klinische manifestatie 
van kanker. Na kankerdiagnose hadden overlevers van borstkanker een lagere doorbloeding 
van de hersenen dan vrouwen zonder kanker in de voorgeschiedenis. De resultaten van dit 
Deel suggereren dat inflammatie en vasculaire factoren mogelijk ten grondslag liggen aan 
cognitieve problemen – en mogelijk dementie – bij kankerpatiënten.
 Ten slotte heb ik in Deel V onze bevindingen in een breder perspectief geplaatst en 
heb ik verschillende methodologische overwegingen besproken, onder andere het verschil 
tussen populatieonderzoek en klinisch onderzoek, de mogelijke impact van leereffecten en 
methoden voor het omgaan met overlijden als concurrerend risico. Daarnaast heb ik de 
relevantie van dit onderzoek voor kankerregistraties, patiënten en clinici beschreven. Als 
laatste heb ik aanbevelingen gedaan voor toekomstig onderzoek zoals het identificeren van 
kankerpatiënten met een verhoogd risico op het ontwikkelen van cognitieve problemen, het 
verder onderzoeken van de onderliggende mechanismen, het bestuderen van de biologische 







Na vier jaar mag ik dan eindelijk beginnen met het schrijven van mijn dankwoord. Een van 
de leukste en meest gelezen hoofdstukken van elk boekje. Ik heb vaak naar dit moment 
uitgekeken. Tijdens het schrijven reflecteer ik op een bijzondere, mooie en bovenal leerzame 
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samen nog twee hele leuke projecten gedaan waarbij ik tijdens de Skype meetings meerdere 
keren prachtige natuurfoto’s van Utah ontving. 
Verder wil ik ook graag de mensen van het ERGO team bedanken en in het bijzonder 
Nano, Frank, en Jolande. Nano, dank voor al het oplossen van mijn computer problemen. 
Frank, bedankt voor alle datasets en voor alle hulp bij het koppelen met de Nederlandse 
Kankerregistratie. Jolande, als ik iets niet wist of niet kon vinden, dan wist jij het altijd. Jullie 
zijn onmisbaar voor ERGO.
Daarnaast wil ik alle deelnemers van ERGO danken. Zonder hen was dit onderzoek – en 
vele andere onderzoeken – er niet. Ik hoop dat iedere deelnemer ervan bewust is hoe erg 
hun inzet wordt gewaardeerd. Hier wil ik graag ook alle medewerkers van het ERGO-centrum 
bedanken voor hun inzet en toewijding voor het verzamelen van alle data. 
Collega’s van de Neuro-epi, ik ben erg blij dat ik deel uit heb mogen maken van deze groep. 
Mede door jullie heb ik het de afgelopen vier jaar erg naar mijn zin gehad. Ik mocht al snel 
in de ‘Drie Epi musketiers’-app groep van Pauline, Eline en Pınar. Pauline, jij was de eerste 
echte dr. van de nieuwe lichting. Met jouw enthousiasme en lach vrolijkte je altijd de afdeling 
op! Eline, jij was er altijd voor me op R- én persoonlijk gebied. Ik hoop dat we nog vaak (met 
Rutger erbij) gaan afspreken. Pınar, wij waren kamergenootjes vanaf dag 1 en hebben een 
prachtig paper samen. Ik wens je alle succes toe en hoop dat je snel richting de USA kan. 
Silvan, ook wij hebben een aantal mooie papers samen, we vulden elkaar goed aan. Zonder 
jou had dit boekje er anders uit gezien. Thom, inmiddels ben jij al gepromoveerd en hoop ik 
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dat je je droom bij de Neuro waar gaat maken! Alis en Noor, allebei al AIOS Neurologie, jullie 
hebben mijn laatste loodjes van dichtbij meegemaakt en hadden altijd een luisterend oor. 
Hopelijk kom ik jullie later tegen als (Interne Geneeskunde) collega in het EMC! Liefste MIJK, 
Maria, Isabelle, en Janine, wat een eer om met jullie het geweldige Neuro-epi Efteling uitje 
te organiseren. Wat een werk, maar vooral ook veel lol hebben we gehad! Ik hoop dat we in 
de toekomst nog een keer met elkaar naar de Efteling gaan! Janine, mocht er ooit nog een 
Whitestar 2 komen dan moeten we wel weer samen gaan. Joyce, ook mijn kamergenootje, 
ondanks dat jouw project vele tegenslagen heeft gekend, ben je altijd doorgegaan, keep 
going! Paloma, you are forming the bridge between Neuro-epi and causal inference, and I am 
lucky to have the opportunity to work with you on a great project! Sander, Jendé, Lisanne, 
Rowina, Amber, Tian, Sanne, Cevdet en Tosca, jullie wens ik nog heel veel succes met 
(voor sommigen ook al de laatste loodjes) jullie promotietraject. Postdocs Frank, Gena, 
Jeremy en Rebecca, dank voor jullie bereidheid om altijd te helpen. Daniel, jouw wil ik het in 
het bijzonder nog danken voor je mega snelle antwoorden op al mijn random vragen (avond, 
weekend, maakt niet uit!). Gabriëlle en Erica, dank voor al jullie hulp, geduld en geregel! 
Verder wil ik alle collega’s van de PSOE bedanken en in het bijzonder mijn collega’s van de 
cognitie groep. Emmie, ondanks dat ik bijna nooit mee ging lunchen, bleef je het altijd vragen. 
Je bent altijd vrolijk! Kete, de congres bezoeken waren leuker met jou! Ik heb het enorm naar 
mijn zin gehad! Philippe en Joost, mijn kamergenootjes in het NKI, dank voor de gezellige 
dagen (inclusief het leren van een paar woordjes Bengaals en Chinees). Elaine, jij begon 
net voor de coronatijd waardoor ik je niet vaak in ‘real’ life heb gezien, maar ik wens je veel 
succes met je onderzoek. Michiel, Marianne, en Jacobien, dank voor jullie begeleiding, 
samenwerking en gezelligheid! Lara, jij zit dan niet in de cognitie groep, maar verdient wel 
een apart plekje in dit dankwoord. We hebben samen hard gewerkt (inclusief vele brieven 
gevouwen). Er zijn er maar weinig die zo enthousiast zijn en alles voor elkaar kunnen krijgen 
als jij. Danielle en Karin, dank voor jullie behulpzaamheid!
Beste dr. de Jongh dank voor uw vertrouwen dat ik direct na mijn onderzoek als ANIOS mocht 
beginnen in het Ikazia Ziekenhuis. Beste collega’s van de afdeling Interne Geneeskunde, 
dank dat jullie mij het daar zo snel hebben laten thuis voelen. Het was erg wennen om na vier 
jaar weer ‘echt dokter’ te mogen zijn, zeker nu vanwege COVID-19. Ik kijk uit naar nog vele 
gezellige werkdagen met jullie!
Prof.dr. Berns en dr. Jansen, beste Els en Maurice, ook jullie wil ik hier in het bijzonder 
bedanken. Acht jaar geleden gaven jullie mij de kans om bij jullie in het laboratorium te 
Epilogue
442
beginnen als geneeskunde student. Ik leerde verschillende technieken die onmisbaar 
zijn voor het doen van onderzoek. Dit groeide uit tot mijn masteronderzoek wat prachtige 
resultaten heeft opgeleverd. Door jullie inzet en vertrouwen is mijn passie voor onderzoek 
enorm gegroeid. Heel veel dank daarvoor.
Lana, in mijn eerste week zaten we tijdens het uit eten gaan tegenover elkaar en hadden 
een instant klik. Sinds jouw officiële start een half jaar later hebben we héél véél Starbucks 
koffiemomentjes gehad. Tijdens deze momentjes werkten we ideeën uit, welke tot enkele 
prachtige papers van ons samen hebben geleid. Ik vind het zo bijzonder dat zonder jou, mijn 
boekje er anders uit had gezien. Onze momentjes mis ik wel, maar gelukkig hoef ik je niet 
helemaal te missen want momenteel zetten we ons avontuur en koffiemomentjes voort in 
het Ikazia ziekenhuis. Je bent enorm sociaal, intelligent en lief. Lieve Lana, ik ben blij dat jij 
vandaag naast me staat.
Charissa en Romy, inmiddels ken ik jullie al héél lang en daar ben ik erg blij mee. We 
hebben nog mooie herinneringen aan onze middelbare schooltijd. Inmiddels zijn jullie al een 
stuk verder (bijna getrouwd versus getrouwd en twee kleine lieverds). Ondanks die drukke 
leventjes vinden we gelukkig nog wel tijd in het weekend om af te spreken. Charissa en Romy, 
zo lief en zorgzaam als jullie zijn, dat zijn er maar weinig. Ik hoop dat we snel weer eens met 
elkaar uit eten en naar de bios kunnen gaan. Lieve Charissa en Romy, dank dat jullie vandaag 
bij mij zijn!
Annet, van Junior Med School naar dezelfde studiegroep in jaar 1 van Geneeskunde tot 
promotieonderzoek op dezelfde afdeling in het EMC. We hebben een lange weg afgelegd 
samen. Ik wens je heel veel succes met het afronden van je onderzoek en uiteindelijk met je 
opleiding tot oogarts. In de toekomst moeten we ons geannuleerde reisje naar München nog 
eens inhalen!
Michelle, ook jij verdient hier een apart plekje. De NAHHS reis naar Hong Kong en China was 
geweldig. Ik ben blij dat ik jouw vriendschap aan deze reis heb overgehouden. 
Lieve oma Sjanie en opa Koos, altijd als jullie bij een dokter zijn, vertellen jullie vol trots dat 
jullie kleindochter al oncoloog is. Zo ver is het nog niet, maar iedere dag is een stapje dichterbij. 
Dit boekje is een combinatie van de passies van pappa en mij. Lieve Raymond, Nadia en 
Joshua, dank voor jullie gezelligheid. Ik hoop dat we snel weer voor oma’s verjaardag uiteten 
kunnen en dat ik samen met Joshua weer een keer de stad in kan.
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Lieve opa en oma Terry, jullie hebben altijd met mij (als enig kleinkind) meegeleefd en staan 
altijd voor mij klaar. Opa spreek ik nog iedere avond via Whatsapp, wie kan dat nou zeggen?! 
Jullie zijn nog zo actief en leergierig, ik hoop dat ik later ook zo ben. René, als jouw kleine 
nichtje ben jij er altijd voor mij (en voor mamma). Je bent heel erg zorgzaam, creatief en leuk, 
en je hebt een heerlijke persoonlijkheid. Op nog vele etentjes bij opa en oma thuis!
Lieve pappa, zonder jou was dit boekje er niet. Je interesses zijn enorm breed, van 
rechtsgeleerdheid tot wiskunde, van sterrenkunde en natuurkunde tot biologie, van theosofie 
tot kunst. Ik heb veel van jou en onze gesprekken geleerd. Ik mis je. Lieve mamma, ik ben zo 
trots op jou. Hoe sterk jij bent, dat zijn er maar weinig. We halen geluk uit de kleinste dingen. 
Nog even, en dan kunnen we hopelijk weer veel tripjes naar Parijs maken samen met Jolie. 
Ik hou van jullie.
Lieve Atilla, mijn lieffie, dat ik jou tijdens mijn onderzoeksperiode heb leren kennen is het 
mooiste wat mij is overkomen. Jij was die jongen die ’s avonds op mijn computer in het EMC 
werkte waardoor ik niet vanuit thuis kon inloggen. Ik ken niemand die zo hard werkt als jij. Je 
bent heel goed in alles wat je doet en over een paar maandjes hoop ik ook jouw boekje te 
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